<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/css" href="gpml.css" ?>
<!DOCTYPE set SYSTEM "gpml.dtd">
<set>
<article>
<articleinfo>
<bibliomisc>MEDLINE:20233197</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic interactions between <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> and <cons lex="quinine" sem="G_DRUG">quinine</cons> in healthy volunteers following concurrent administration.</sentence>
</title>
<abstract>
<sentence>To evaluate the pharmacokinetic interactions between <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> and <cons lex="quinine" sem="G_DRUG">quinine</cons> in healthy volunteers.</sentence>
<sentence>Ten healthy volunteers were each given <cons sem="G_NUMBER">600-mg</cons> single oral doses of <cons lex="quinine" sem="G_DRUG">quinine</cons> alone, <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> alone (<cons sem="G_NUMBER">200 mg</cons> every 12 h for 9 days), and <cons lex="quinine" sem="G_DRUG">quinine</cons> in combination with <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, in a three-period pharmacokinetic nonrandomized sequential design study.</sentence>
<sentence><cons lex="quinine" sem="G_DRUG">Quinine</cons> was co-administered with the 15th dose of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
<sentence>Blood samples collected at predetermined time intervals were analysed for <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, <cons lex="quinine" sem="G_DRUG">quinine</cons> and its major metabolite, 3-hydroxyquinine, using a validated high-performance liquid chromatography method.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, quinine, DDI)">
<sentence>Concurrent <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> administration resulted in about <cons sem="G_NUMBER">fourfold</cons> <cons sem="G_CHANGE">increases</cons> in both the <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(T)</cons> [<cons sem="G_IVIVPARA">C(max)</cons> <cons sem="G_NUMBER">2.79 +/- 0.22 vs. 10.72 +/- 0.32 mg l(-1), 95% confidence interval (CI) 7.81, 8.04</cons>; <cons sem="G_IVIVPARA">AUC</cons> <cons sem="G_NUMBER">50.06 +/- 2.52 vs. 220.47 +/- 6.68 mg h(-1) l(-1), 95% CI 166.3, 175.3</cons>], a <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increase</cons> (<cons sem="G_NUMBER">P &lt; 0.01</cons>) in the <cons sem="G_IVIVPARA">elimination half-life</cons> <cons sem="G_NUMBER">(11.15 +/- 0.80 vs. 13.37 +/- 0.33 h, 95% CI 1.64, 2.77)</cons> and about a <cons sem="G_NUMBER">4.5-fold</cons> <cons sem="G_CHANGE">decrease</cons> in <cons sem="G_IVIVPARA">CL/F</cons> <cons sem="G_NUMBER">(12.01 +/- 0.61 vs. 2.71 +/- 0.09 l h(-1))</cons> of <cons lex="quinine" sem="G_DRUG" type="substrate_1">quinine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, quinine, DDI)">
<sentence>Also, with <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons>, there was a <cons sem = "G_CHANGE">pronounced</cons> <cons sem="G_CHANGE">reduction</cons> of <cons sem="G_IVIVPARA">AUC(metabolite)/AUC(unchanged drug) ratio</cons> of <cons lex="quinine" sem="G_DRUG" type="substrate_1">quinine</cons> (<cons sem="G_NUMBER">1.35 +/- 0.10 vs. 0.13 +/- 0.02</cons>) along with a <cons sem = "G_CHANGE">marked</cons> <cons sem="G_CHANGE">decrease</cons> in <cons sem="G_IVIVPARA">C(max)</cons> <cons sem="G_NUMBER">(1.80 +/- 0.12 vs. 0.96 +/- 0.09 mg l(-1))</cons> and <cons sem="G_IVIVPARA">AUC(0-48h)</cons> <cons sem="G_NUMBER">(62.80 +/- 6.30 vs. 25.61 +/- 2.44 mg h(-1) l(-1))</cons> of the metabolite.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, quinine, DDI)">
<sentence>Similarly, <cons lex="quinine" sem="G_DRUG" type="inhibitor_2">quinine</cons> caused <cons sem = "G_CHANGE">modest</cons> but <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> (<cons sem="G_NUMBER">P &lt; 0.01</cons>) in the <cons sem="G_IVIVPARA">C(max)</cons>, <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">elimination T((1/2))</cons> of <cons lex="ritonavir" sem="G_DRUG" type="substrate_2">ritonavir</cons>.</sentence>
</annotation>
<sentence>Downward dosage adjustment of <cons lex="quinine" sem="G_DRUG">quinine</cons> appears necessary when concurrently administered with <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:20209646</bibliomisc>
</articleinfo>
<title>
<sentence>Phase I study of <cons lex="valspodar" sem="G_DRUG">valspodar</cons> (PSC-833) with <cons lex="mitoxantrone" sem="G_DRUG">mitoxantrone</cons> and <cons lex="etoposide" sem="G_DRUG">etoposide</cons> in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.</sentence>
</title>
<abstract>
<sentence><cons lex="valspodar" sem="G_DRUG">Valspodar</cons>, a non-immunosuppressive analog of cylosporine, is a potent P-glycoprotein (MDR1) <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
<sentence>As MDR1-mediated efflux of chemotherapeutic agents from leukemic blasts <cons sem = "G_CHANGE">may</cons> contribute to drug resistance, a phase 1 study of <cons lex="valspodar" sem="G_DRUG">valspodar</cons> combined with <cons lex="mitoxantrone" sem="G_DRUG">mitoxantrone</cons> and <cons lex="etoposide" sem="G_DRUG">etoposide</cons> in pediatric patients with relapsed or refractory leukemias was performed.</sentence>
<sentence>Patients received a <cons lex="valspodar" sem="G_DRUG">valspodar</cons>-loading dose (<cons sem="G_NUMBER">2 mg/kg</cons>) followed by a 5-day continuous <cons lex="valspodar" sem="G_DRUG">valspodar</cons> infusion (<cons sem="G_NUMBER">8, 10, 12.5, or 15 mg/kg/day</cons>) combined with lower than standard doses of <cons lex="mitoxantrone" sem="G_DRUG">mitoxantrone</cons> and <cons lex="etoposide" sem="G_DRUG">etoposide</cons>.</sentence>
<sentence>The <cons lex="valspodar" sem="G_DRUG">valspodar</cons> dose was escalated using a standard 3 + 3 phase I design.</sentence>
<sentence>Twenty-one patients were evaluable for toxicity and 20 for response.</sentence>
<sentence>The maximum tolerated dose (MTD) of <cons lex="valspodar" sem="G_DRUG">valspodar</cons> was <cons sem="G_NUMBER">12.5 mg/kg/day</cons>, combined with <cons sem="G_NUMBER">50%</cons> dose-<cons sem="G_CHANGE">reduced</cons> <cons lex="mitoxantrone" sem="G_DRUG">mitoxantrone</cons> and <cons lex="etoposide" sem="G_DRUG">etoposide</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(valspodar, mitoxantrone, DDI)(valspodar, etoposide, DDI)">
<sentence>The <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="mitoxantrone" sem="G_DRUG" type="substrate_1">mitoxantrone</cons> and <cons lex="etoposide" sem="G_DRUG" type="substrate_2">etoposide</cons> was <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">64%</cons> and <cons sem="G_NUMBER">60%</cons>, respectively, when combined with <cons lex="valspodar" sem="G_DRUG" type="inhibitor_1">valspodar</cons>.</sentence>
</annotation>
<sentence>Dose-limiting toxicities included stomatitis, ataxia, and bone marrow aplasia.</sentence>
<sentence>Three of 11 patients with acute lymphoblastic leukemia (ALL) had complete responses while <cons sem="G_NEGATIVEEFFECT">no</cons> patient with acute myeloid leukemia (AML) had an objective response.</sentence>
<sentence>In vitro studies demonstrated P-glycoprotein expression on the blasts of 5 of 14 patients, although only 1 had <cons sem="G_MECHANISM">inhibition</cons> of rhodamine efflux by <cons lex="valspodar" sem="G_DRUG">valspodar</cons>.</sentence>
<sentence>While this regimen was tolerable, responses in this heavily pretreated population were limited to a subset of patients with ALL.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:20124517</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and <cons lex="rifampin" sem="G_DRUG">rifampin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affect</cons> the pharmacokinetics, but <cons sem="G_NEGATIVEEFFECT">not</cons> the safety or QTc interval, of <cons lex="casopitant" sem="G_DRUG">casopitant</cons>, a neurokinin-1 receptor antagonist.</sentence>
</title>
<abstract>
<sentence><cons lex="casopitant" sem="G_DRUG">Casopitant</cons>, an antiemetic, is a neurokinin-1 receptor antagonist <cons sem="G_MECHANISM">metabolized</cons> primarily by cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4 (CYP3A4)</cons>.</sentence>
<sentence>Three phase 1 studies with 131 healthy subjects examined the impact of a <cons sem="G_CHANGE">strong</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibitor</cons> (<cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>) and <cons sem="G_MECHANISM">inducer</cons> (<cons lex="rifampin" sem="G_DRUG">rifampin</cons>) on the pharmacokinetics and safety of <cons lex="casopitant" sem="G_DRUG">casopitant</cons>.</sentence>
<sentence>Oral <cons lex="casopitant" sem="G_DRUG">casopitant</cons> was administered alone (study 1, <cons sem="G_NUMBER">100-mg</cons> single dose; study 2, <cons sem="G_NUMBER">150 mg</cons> on day 1, <cons sem="G_NUMBER">50 mg</cons> on days 2 and 3; study 3, <cons sem="G_NUMBER">150-mg</cons> single dose) with either <cons sem="G_NUMBER">400 mg</cons> daily of oral <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> or <cons sem="G_NUMBER">600 mg</cons> daily of oral <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, casopitant, DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">Ketoconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">maximum observed plasma concentration (C(max))</cons> and <cons sem="G_IVIVPARA">area under the plasma concentration time curve</cons> to the last sampling time, t (<cons sem="G_IVIVPARA">AUC(0-t)</cons>) of single-dose <cons lex="casopitant" sem="G_DRUG" type="substrate_1">casopitant</cons> <cons sem="G_NUMBER">2.7-fold</cons> and <cons sem="G_NUMBER">12-fold</cons> and <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">C(max)</cons> of 3-day <cons lex="casopitant" sem="G_DRUG" type="substrate_1">casopitant</cons> <cons sem="G_NUMBER">2.5-fold</cons> on day 1 and <cons sem="G_NUMBER">2.9-fold</cons> on day 3, whereas <cons sem="G_IVIVPARA">AUC((0-tau))</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">4.3-fold</cons> on day 1 and <cons sem="G_NUMBER">5.8-fold</cons> on day 3.</sentence>
</annotation>
<sentence>Neither safety signals nor prolongation of Fredericia-corrected QT was observed at these <cons sem="G_CHANGE">increased</cons> exposures in study 2.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, casopitant, DDI)">
<sentence>Repeat-dose <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC((0-t))</cons> of <cons lex="casopitant" sem="G_DRUG" type="substrate_1">casopitant</cons> <cons sem="G_NUMBER">96%</cons> and <cons sem="G_NUMBER">90%</cons>, respectively.</sentence>
</annotation>
<sentence>These clinical studies confirmed the role of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> in the <cons sem="G_MECHANISM">metabolism</cons> and disposition of <cons lex="casopitant" sem="G_DRUG">casopitant</cons>.</sentence>
<sentence>Coadministration of <cons lex="casopitant" sem="G_DRUG">casopitant</cons> with <cons sem="G_CHANGE">strong</cons> <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> is likely to <cons sem="G_CHANGE">increase</cons> plasma exposure of <cons lex="casopitant" sem="G_DRUG">casopitant</cons>, whereas coadministration with <cons sem="G_CHANGE">strong</cons> <cons sem="G_MECHANISM">inducers</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> is likely to <cons sem="G_CHANGE">decrease</cons> <cons lex="casopitant" sem="G_DRUG">casopitant</cons> exposure and compromise efficacy.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:20091169</bibliomisc>
</articleinfo>
<title>
<sentence>A phase I dose escalation and pharmacokinetic study of <cons sem="G_DRUG">vatalanib (PTK787/ZK 222584)</cons> in combination with <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> in patients with advanced solid tumors.</sentence>
</title>
<abstract>
<sentence>To define the maximum-tolerated dose (MTD) for weekly <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> administered in combination with daily <cons sem="G_DRUG">vatalanib (PTK787/ZK 222584, PTK/ZK)</cons> and assess for a drug-drug interaction.</sentence>
<sentence>Patients were treated with escalating doses of weekly <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> (<cons sem="G_NUMBER">75-85 mg/m(2)</cons>), and daily <cons sem="G_DRUG">PTK/ZK</cons> (<cons sem="G_NUMBER">250-1,000 mg</cons>).</sentence>
<sentence>During the first cycle only, <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> was given on days 1 and 15, and <cons sem="G_DRUG">PTK/ZK</cons> on days 3-28.</sentence>
<sentence>Pharmacokinetic studies were conducted on cycle 1 days 1 and 15 for <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons>, and on cycle 1 day 15 for <cons sem="G_DRUG">PTK/ZK</cons>.</sentence>
<sentence>Therapy was given until disease progression.</sentence>
<sentence>Twenty-seven patients were accrued to four dose levels.</sentence>
<sentence>Two of five patients treated with <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> <cons sem="G_NUMBER">85 mg/m(2)</cons> and <cons sem="G_DRUG">PTK/ZK</cons> <cons sem="G_NUMBER">1,000 mg</cons> had Grade 3 transaminase elevation as dose-limiting toxicity.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(vatalanib, paclitaxel, DDI)">
<sentence>Paired PK analyses demonstrated a <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="paclitaxel" sem="G_DRUG" type="substrate_1">paclitaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> on day 15 <cons sem="G_NUMBER">(p = 0.006)</cons>.</sentence>
</annotation>
<sentence>Activity included one partial response and 11 patients with stable disease <cons sem="G_NUMBER">&gt; or =4 months</cons>, including patients previously treated with <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons>.</sentence>
<sentence>The MTD for weekly <cons lex="paclitaxel" sem="G_DRUG">paclitaxel</cons> plus daily <cons sem="G_DRUG">PTK/ZK</cons> is <cons sem="G_NUMBER">75 mg/m(2) and 750 mg</cons>.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(vatalanib, paclitaxel, DDI)">
<sentence>PK analysis revealed a <cons sem="G_CHANGE">significant</cons> drug-drug interaction, with an <cons sem="G_CHANGE">increase</cons> in <cons lex="paclitaxel" sem="G_DRUG" type="substrate_1">paclitaxel</cons> <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
</annotation>
<sentence>This combination was well tolerated with evidence of anti-cancer activity and provides guidance for phase 2 planning.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:20076952</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics and pharmacodynamics of intravenously and orally administered <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to investigate the effects of the cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4 (CYP34A)</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics and pharmacodynamics of orally and intravenously administered <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
<sentence>Twelve healthy subjects were administered <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo orally for 5 days in a four-session paired cross-over study.</sentence>
<sentence>On day 4, <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> was administered intravenously (<cons sem="G_NUMBER">0.1 mg/kg</cons>) in the first part of the study and orally (<cons sem="G_NUMBER">10 mg</cons>) in the second part.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> and its oxidative metabolites were measured for 48 h, and pharmacodynamic effects were evaluated.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, oxycodone, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">decreased</cons> plasma <cons sem="G_IVIVPARA">clearance (Cl)</cons> and <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC 0-infinity)</cons> of intravenous <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> by <cons sem="G_NUMBER">32</cons> and <cons sem="G_NUMBER">51%</cons>, respectively <cons sem="G_NUMBER">(P&lt;0.001)</cons> and <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of orally administrated <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> by <cons sem="G_NUMBER">144% (P&lt;0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, oxycodone, ADDI)">
<sentence>Most of the pharmacokinetic <cons sem ="G_CHANGE">changes</cons> in oral <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> were seen in the elimination phase, with <cons sem = "G_CHANGE">modest</cons> effects by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> on its  <cons sem="G_IVIVPARA">peak concentration</cons>, which was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">45% (P=0.009)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(oxymorphone, oxycodone, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC(0-48)</cons> of <cons lex="noroxycodone" sem="G_DRUG" type="M_1">noroxycodone</cons> was <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">49% (P&lt;0.001)</cons> and that of <cons lex="oxymorphone" sem="G_DRUG" type="M_2">oxymorphone</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">359% (P&lt;0.001)</cons> after the administration of oral <cons lex="oxycodone" sem="G_DRUG" type="inhibitor_1">oxycodone</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, oxycodone, ADDI)">
<sentence>The pharmacologic effects of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> were enhanced by <cons lex="itraconazole" sem="G_DRUG" type="inducer_1">itraconazole</cons> only <cons sem = "G_CHANGE">modestly</cons>.</sentence>
</annotation>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the exposure to <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated N-demethylation.</sentence>
<sentence>The clinical use of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> in patients receiving multiple doses of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> for pain relief <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">increase</cons> the risk of opioid-associated adverse effects.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:20012601</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic interaction between oral <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> and <cons lex="verapamil" sem="G_DRUG">verapamil</cons> in healthy subjects: role of P-glycoprotein <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="lovastatin" sem="G_DRUG">Lovastatin</cons> is an <cons sem="G_MECHANISM">inhibitor</cons> of P-glycoprotein (P-gp) and is <cons sem="G_MECHANISM">metabolized</cons> by the cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> isoenzyme.</sentence>
<sentence><cons lex="verapamil" sem="G_DRUG">Verapamil</cons> is a substrate of both P-gp and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>It is therefore likely that <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> can alter the absorption and <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="verapamil" sem="G_DRUG">verapamil</cons>.</sentence>
<sentence>The pharmacokinetic parameters of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and one of its metabolites, norverapamil, were compared in 14 healthy male Korean volunteers (age range 22-28 years) who had been administered <cons lex="verapamil" sem="G_DRUG">verapamil</cons> (<cons sem="G_NUMBER">60 mg</cons>) orally in the presence or absence of oral <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> (<cons sem="G_NUMBER">20 mg</cons>).</sentence>
<sentence>The design of the experiment was a standard 2 x 2 crossover model in random order.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(lovastatin, verapamil, DDI)">
<sentence>The pharmacokinetic parameters of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">altered</cons> by the co-administration of <cons lex="lovastatin" sem="G_DRUG" type="inhibitor_1">lovastatin</cons> compared to the control.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(lovastatin, verapamil, DDI)">
<sentence><cons sem="G_IVIVPARA">The area under the plasma concentration-time curve (AUC(0-infinity))</cons> and the <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">62.8 and 32.1%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(lovastatin, verapamil, DDI)">
<sentence>Consequently, the relative <cons sem="G_IVIVPARA">bioavailability</cons> of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> was also <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> (by <cons sem="G_NUMBER">76.5%</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(lovastatin, verapamil, NDDI)">
<sentence>The (<cons sem="G_IVIVPARA">AUC(0-infinity)</cons>) of <cons lex="verapamil" sem="G_DRUG" type="M_1">norverapamil</cons> and the <cons sem="G_IVIVPARA">terminal half-life</cons> of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">changed</cons> with <cons lex="lovastatin" sem="G_DRUG" type="inhibitor_1">lovastatin</cons> coadministration.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(lovastatin, verapamil, ADDI)">
<sentence>The metabolite-parent ratio was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> (<cons sem="G_NUMBER">29.2%</cons>) in the presence of <cons lex="lovastatin" sem="G_DRUG" type="inhibitor_1">lovastatin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(lovastatin, verapamil, DDI)">
<sentence><cons lex="lovastatin" sem="G_DRUG" type="inhibitor_1">Lovastatin</cons> <cons sem="G_CHANGE">increased</cons> the absorption of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> by <cons sem="G_MECHANISM">inhibiting</cons> P-gp and <cons sem="G_MECHANISM">inhibited</cons> the first-pass <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> by <cons sem="G_MECHANISM">inhibiting</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in the intestine and/or liver in humans.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:20002087</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_IVIVPARA">clearance</cons> by boosting doses of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, and by 4,4-dimethyl-benziso-(2H)-selenazine (<cons sem="G_DRUG">ALT-2074</cons>), an experimental catalytic mimic of glutathione oxidase.</sentence>
</title>
<abstract>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, midazolam, DDI)">
<sentence>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * The viral protease <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> is known to <cons sem="G_MECHANISM">inhibit</cons> <cons sem="G_IVIVPARA">clearance</cons> of intravenous <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons>.</sentence>
</annotation>
<sentence>* <cons sem="G_DRUG">ALT-2074</cons>, a catalytic mimic of glutathione oxidase, <cons sem="G_MECHANISM">inhibits</cons> human cytochrome P450 <cons lex="3a" sem="G_CYP">3A (CYP3A)</cons> isoforms in vitro.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, midazolam, DDI)">  
<sentence>* Short-term administration of low-dose <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">area under the plasma concentration curve</cons> following oral <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> by <cons sem="G_NUMBER">a factor of 28</cons>.</sentence>
</annotation>
<sentence>* Therefore <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> is an appropriate positive control <cons sem="G_MECHANISM">inhibitor</cons> for clinical drug interaction studies involving <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> substrates.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ALT-2074, midazolam, DDI)">  
<sentence>* <cons lex="midazolam" sem="G_DRUG" type="substrate_1">Midazolam</cons> <cons sem="G_IVIVPARA">clearance</cons> is weakly <cons sem="G_MECHANISM">inhibited</cons> by <cons sem="G_DRUG" type="inhibitor_2">ALT-2074</cons>, consistent with its in vitro profile.</sentence>
</annotation>
<sentence>We evaluated whether 'boosting' doses of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> can serve as a positive control <cons sem="G_MECHANISM">inhibitor</cons> for pharmacokinetic drug-drug interaction studies involving cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> (<cons lex="cyp3a" sem="G_CYP">CYP3A</cons>).</sentence>
<sentence>The study also determined whether 4,4-dimethyl-benziso-(2H)-selenazine (<cons sem="G_DRUG">ALT-2074</cons>), an investigational organoselenium compound that acts as a catalytic mimic of glutathione oxidase, <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">metabolism</cons> in vivo.</sentence>
<sentence>Thirteen healthy volunteers received single <cons sem="G_NUMBER">3-mg</cons> oral doses of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> on three occasions: in the control condition, during co-treatment with low-dose <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> (three oral doses of <cons sem="G_NUMBER">100 mg</cons> over 24 h), and during co-treatment with <cons sem="G_DRUG">ALT-2074</cons> (three oral doses of <cons sem="G_NUMBER">80 mg</cons> over 24 h).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, midazolam, DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">Ritonavir</cons> <cons sem="G_CHANGE">increased</cons> mean (+/-SE) total <cons sem="G_IVIVPARA">area under the curve (AUC)</cons> for <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> by a factor of <cons sem="G_NUMBER">28.4 +/- 4.2 (P &lt; 0.001)</cons>, and <cons sem="G_CHANGE">reduced</cons> <cons sem="G_IVIVPARA">oral clearance</cons> to <cons sem="G_NUMBER">4.2 +/- 0.5% of control (P &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ALT-2074, midazolam, ADDI)">    
<sentence>In contrast, <cons sem="G_DRUG" type="inhibitor_2">ALT-2074</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">AUC</cons> by <cons sem="G_NUMBER">1.25 +/- 0.11 (P &lt; 0.05)</cons>, and <cons sem="G_CHANGE">reduced</cons> <cons sem="G_IVIVPARA">oral clearance</cons> to <cons sem="G_NUMBER">88 +/- 8% of control</cons>.</sentence>
</annotation>
<sentence>Low-dose <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> produces extensive <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibition</cons> exceeding that of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (typically <cons sem="G_NUMBER">10- to 15-fold</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_IVIVPARA">AUC</cons> enhancement), and is a suitable positive control index <cons sem="G_MECHANISM">inhibitor</cons> for drug-drug interaction studies.</sentence>
<sentence><cons sem="G_DRUG">ALT-2074</cons> <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">metabolism</cons> to a small degree that is of uncertain clinical importance.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19940232</bibliomisc>
</articleinfo>
<title>
<sentence>Investigation of the pharmacokinetic interactions of <cons lex="deferasirox" sem="G_DRUG">deferasirox</cons>, a once-daily oral iron chelator, with <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="deferasirox" sem="G_DRUG">Deferasirox</cons>, a newly developed iron chelator, was coadministered orally with either a known <cons sem="G_MECHANISM">inducer</cons> of drug <cons sem="G_MECHANISM">metabolism</cons> or with cosubstrates for cytochrome P450 (CYP) to characterize the potential for drug-drug interactions.</sentence>
<sentence>In the <cons sem="G_MECHANISM">induction</cons> assessment, single-dose <cons lex="deferasirox" sem="G_DRUG">deferasirox</cons> pharmacokinetics were obtained in the presence and absence of a repeated-dose regimen of <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<sentence>In the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> interaction evaluation, <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and its active hydroxylated metabolite were assessed after single doses of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> in the presence and absence of steady-state concentrations of <cons lex="deferasirox" sem="G_DRUG">deferasirox</cons>.</sentence>
<sentence>To test for interaction at the level of <cons sem="G_CYP">CPY2C8</cons>, single-dose <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> pharmacokinetics/pharmacodynamics were determined with and <cons sem="G_NEGATIVEEFFECT">without</cons> repeated-dose administration of <cons lex="deferasirox" sem="G_DRUG">deferasirox</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, deferasirox, ADDI)">
<sentence>After <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>, a <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">reduction</cons> <cons sem="G_NUMBER">(44%)</cons> in plasma exposure (<cons sem="G_IVIVPARA">AUC</cons>) to <cons lex="deferasirox" sem="G_DRUG" type="substrate_1">deferasirox</cons> was observed.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(midazolam, deferasirox, ADDI)">
<sentence>Upon coadministration of <cons lex="midazolam" sem="G_DRUG" type="inducer_2">midazolam</cons>, there was a <cons sem = "G_CHANGE">modest</cons> <cons sem="G_CHANGE">reduction</cons> of up to <cons sem="G_NUMBER">22%</cons> in <cons lex="midazolam" sem="G_DRUG" type="inducer_2">midazolam</cons> exposure (<cons sem="G_IVIVPARA">AUC</cons>, <cons sem="G_IVIVPARA">C(max)</cons>), suggesting a <cons sem = "G_CHANGE">modest</cons> <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> by <cons lex="deferasirox" sem="G_DRUG" type="substrate_1">deferasirox</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Deferasirox, repaglinide, ADDI)">
<sentence><cons lex="deferasirox" sem="G_DRUG" type="inducer_3">Deferasirox</cons> caused <cons sem="G_CHANGE">increases</cons> in <cons lex="repaglinide" sem="G_DRUG" type="substrate_2">repaglinide</cons> plasma <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC</cons> of <cons sem="G_NUMBER">1.5-fold to over 2-fold</cons>, respectively, with <cons sem="G_CHANGE">little</cons> <cons sem = "G_CHANGE">change</cons> in blood glucose measures.</sentence>
</annotation>
<sentence>Specific patient prescribing recommendations were established when coadministering <cons lex="deferasirox" sem="G_DRUG">deferasirox</cons> with <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>, and <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<sentence>These recommendations <cons sem = "G_CHANGE">may</cons> also apply to other substrates of <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> or potent <cons sem="G_MECHANISM">inducers</cons> of glucuronidation.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19916995</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of the active principle of the weak opioid <cons sem="G_DRUG">tilidine</cons> by the triazole antifungal <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>.</sentence>
</title>
<abstract>
<sentence>To investigate in vivo the influence of the potent <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> on the pharmacokinetics and analgesic effects of <cons sem="G_DRUG">tilidine</cons>.</sentence>
<sentence>Sixteen healthy volunteers received <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> (<cons sem="G_NUMBER">400 mg</cons>) or placebo together with a single oral dose of <cons sem="G_DRUG">tilidine</cons> (<cons sem="G_NUMBER">100 mg</cons>).</sentence>
<sentence>Blood samples and urine were collected for 24 h and experimental pain was determined by using the cold pressor test.</sentence>
<sentence>Noncompartimental analysis was performed to determine pharmacokinetic parameters of <cons sem="G_DRUG">tilidine</cons>, nor<cons sem="G_DRUG">tilidine</cons> and <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>, whereas pharmacodynamic parameters were analysed by nonparametric repeated measures ANOVA (Friedman).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, tilidine, DDI)">
<sentence><cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">Voriconazole</cons> caused a <cons sem="G_NUMBER">20-fold</cons> <cons sem="G_CHANGE">increase</cons> in exposition of <cons lex="tilidine" sem="G_DRUG" type="substrate_1">tilidine</cons> in serum  [<cons sem="G_IVIVPARA">AUC</cons> <cons sem="G_NUMBER">1250.8 h*ng ml(-1), 95% confidence interval (CI) 1076.8, 1424.9 vs. 61 h*ng ml(-1), 95% CI 42.6, 80.9; P &lt; 0.0001</cons>], whereas the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="tilidine" sem="G_DRUG" type="M_1">nortilidine</cons> also <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">2.5-fold</cons>.</sentence>
</annotation>
<sentence>After <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> much lower serum concentrations of bisnor<cons sem="G_DRUG">tilidine</cons> were observed.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, tilidine, DDI)">
<sentence>The onset of analgesic activity occurred later with <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons>, which is in agreement with the prolonged <cons sem="G_IVIVPARA">t(max)</cons> of <cons lex="tilidine" sem="G_DRUG" type="M_1">nortilidine</cons> <cons sem="G_NUMBER">(0.78 h, 95% CI 0.63, 0.93 vs. 2.5 h, 95% CI 1.85, 3.18; P &lt; 0.0001)</cons> due to the additional <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="tilidine" sem="G_DRUG" type="M_1">nortilidine</cons> <cons sem="G_MECHANISM">metabolism</cons> to <cons lex="tilidine" sem="G_DRUG" type="M_2">bisnortilidine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, tilidine, ADDI)">
<sentence>After <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> the <cons sem="G_IVIVPARA">AUC under the pain withdrawal-time curve</cons> was <cons sem="G_CHANGE">reduced</cons> compared with placebo (<cons sem="G_NUMBER">149 s h(-1), 95% CI 112, 185 vs. 175 s h(-1), 95% CI 138, 213; P &lt; 0.016</cons>), mainly due to the shorter withdrawal time 0.75 h after <cons sem="G_DRUG" type="substrate_1">tilidine</cons> administration.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, tilidine, DDI)">
<sentence><cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">Voriconazole</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inhibited</cons> the sequential <cons sem="G_MECHANISM">metabolism</cons> of <cons sem="G_DRUG">tilidine</cons> with <cons sem="G_CHANGE">increased</cons> exposure of the active <cons lex="tilidine" sem="G_DRUG" type="M_1">nortilidine</cons>.</sentence>
</annotation>
<sentence>Furthermore, the incidence of adverse events was almost <cons sem = "G_CHANGE">doubled</cons> after <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons sem="G_DRUG">tilidine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19897389</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="clarithromycin" sem="G_DRUG">Clarithromycin</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increases</cons> exposure to oral S-<cons lex="ketamine" sem="G_DRUG">ketamine</cons>.</sentence>
</title>
<abstract>
<sentence>Oral <cons lex="ketamine" sem="G_DRUG">ketamine</cons> is used as an adjuvant in the treatment of refractory neuropathic and cancer-related pain.</sentence>
<sentence>Drug interactions <cons sem = "G_CHANGE">may</cons> alter the analgesic or other effects of <cons lex="ketamine" sem="G_DRUG">ketamine</cons>.</sentence>
<sentence>The aim of the study was to investigate the effect of cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> enzyme <cons sem="G_MECHANISM">inhibition</cons> with <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> on the pharmacokinetics and pharmacodynamics of oral S-<cons lex="ketamine" sem="G_DRUG">ketamine</cons> in a randomized controlled cross-over study with two phases.</sentence>
<sentence>Ten healthy subjects were pre-treated with oral <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> or placebo for 4 days.</sentence>
<sentence>On day 4, they ingested an oral dose of <cons sem="G_NUMBER">0.2mg/kg</cons> of S-<cons lex="ketamine" sem="G_DRUG">ketamine</cons> syrup.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="ketamine" sem="G_DRUG">ketamine</cons> and norketamine were measured for 24h.</sentence>
<sentence>Analgesic effects were evaluated in a cold pressor test and psychomotor effects were followed for 12h.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin, ketamine, DDI)">
<sentence><cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">Clarithromycin</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="ketamine" sem="G_DRUG" type="substrate_1">ketamine</cons> by <cons sem="G_NUMBER">3.6-fold (p&lt;0.001)</cons> and the mean <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="ketamine" sem="G_DRUG" type="substrate_1">ketamine</cons> by <cons sem="G_NUMBER">2.6-fold (p=0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin, norketamine, DDI)">
<sentence>The relative amount of the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> dependent metabolite <cons lex="ketamine" sem="G_DRUG" type="M_1">norketamine</cons> was <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">54%</cons> by <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> (<cons sem="G_NUMBER">p=0.004</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin, S-ketamine, DDI)">
<sentence>Self-rated drug effect of <cons lex="ketamine" sem="G_DRUG" type="substrate_2">S-ketamine</cons> was enhanced by <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> (<cons sem="G_NUMBER">p&lt;0.05</cons>) but other behavioral effects or cold pain scores were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affected</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin, S-ketamine, DDI)">
<sentence><cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">Clarithromycin</cons> <cons sem="G_CHANGE">strongly</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of oral <cons lex="ketamine" sem="G_DRUG" type="substrate_2">S-ketamine</cons> <cons sem = "G_CHANGE">probably</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-mediated N-demethylation.</sentence>
</annotation>
<sentence>This <cons sem="G_CHANGE">increase</cons> is reflected as <cons sem ="G_CHANGE">modest</cons> <cons sem ="G_CHANGE">changes</cons> in behavioral effects of oral <cons lex="ketamine" sem="G_DRUG">S-ketamine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19889885</bibliomisc>
</articleinfo>
<title>
<sentence>Time-dependent <cons sem="G_MECHANISM">inhibitory</cons> effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2- [(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo [22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (<cons sem="G_DRUG">FK1706</cons>), a novel nonimmunosuppressive immunophilin ligand, on <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> activity in humans in vivo and in vitro.</sentence>
</title>
<abstract>
<sentence>We investigated the <cons sem="G_MECHANISM">inhibitory</cons> effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1, 14-dihydroxy-12-(E)-2- [(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo  [22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (<cons sem="G_DRUG">FK1706</cons>), a novel nonimmunosuppressive immunophilin ligand, on <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> in in vitro and in vivo settings.</sentence>
<sentence>First, the <cons sem="G_MECHANISM">inhibitory</cons> effects of <cons sem="G_DRUG">FK1706</cons> (preincubation dependence, <cons sem="G_MECHANISM">inactivation</cons> rate estimation, and reversibility) were tested using human liver microsomes.</sentence>
<sentence>Second, the effect of repeated oral doses of <cons sem="G_DRUG">FK1706</cons> (<cons sem="G_NUMBER">60 mg q.d</cons>. for 14 days) on the pharmacokinetics of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> (single oral <cons sem="G_NUMBER">2-mg</cons> dose) was tested in healthy volunteers.</sentence>
<sentence>Finally, pharmacokinetic modeling and simulation were performed.</sentence>
<sentence>In vitro experiments showed that <cons sem="G_DRUG">FK1706</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> in a time-dependent and irreversible manner.</sentence>
<sentence>The in vitro maximum inactivation rate constant (<cons sem="G_IVIVPARA">k(inact)</cons>) and concentration of <cons sem="G_MECHANISM">inhibitor</cons> that gave half-maximal <cons sem="G_IVIVPARA">k(inact)</cons> (<cons sem="G_IVIVPARA">K(I)</cons>) were estimated to be <cons sem="G_NUMBER">10.1 h(-1)</cons> and <cons sem="G_NUMBER">2050 ng/ml</cons>, respectively.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(FK1706, midazolam, DDI)">
<sentence>In the clinical study, <cons sem="G_DRUG" type="inhibitor_1">FK1706</cons> produced a <cons sem="G_NUMBER">2-fold</cons> <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">area under the time-concentration curve (AUC)</cons> of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(FK1706, midazolam, DDI)">
<sentence>A pharmacokinetic model developed for this study, which described the time course of concentrations of both <cons sem="G_DRUG" type="inhibitor_1">FK1706</cons> and <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> and incorporated <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> <cons sem="G_MECHANISM">inactivation</cons> in the liver and intestine, successfully predicted the <cons sem = "G_CHANGE">change</cons> in the pharmacokinetics of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> using in vitro <cons sem="G_IVIVPARA">k(inact)</cons> and <cons sem="G_IVIVPARA">K(I)</cons> values <cons sem="G_NUMBER">(1.66- to 2.81-fold</cons> <cons sem="G_CHANGE">increases</cons> in <cons sem="G_IVIVPARA">AUC</cons> predicted) and estimated the in vivo <cons sem="G_MECHANISM">inactivation</cons> rate to be <cons sem="G_NUMBER">0.00404 to 0.0318 h(-1) x ml/ng</cons>.</sentence>
</annotation>
<sentence>In conclusion, <cons sem="G_DRUG"><cons sem="G_DRUG">FK1706</cons></cons> weakly or <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderately</cons></cons> <cons sem="G_MECHANISM">inhibited</cons> the activity of <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> in vitro and vivo at the tested dose.</sentence>
<sentence>The model developed here would be helpful in predicting drug-drug interactions and in the design of dose regimens that avoid drug-drug interactions.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19855315</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of the P-glycoprotein <cons sem="G_MECHANISM">inducer</cons> <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> on <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> pharmacokinetics.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to evaluate the possible effects of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons>, a P-glycoprotein <cons sem="G_MECHANISM">inducer</cons>, on <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> pharmacokinetics.</sentence>
<sentence>Twelve healthy Japanese volunteers (nine males and three females) were enrolled in this study after giving written informed consent.</sentence>
<sentence>This randomized open-label study consisted of two phases (control and 7-day treatment) with a 2-week washout period.</sentence>
<sentence>In the control phase, volunteers received <cons sem="G_NUMBER">60 mg</cons> <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> hydrochloride after an overnight fast.</sentence>
<sentence>In the treatment phase, <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> was dosed <cons sem="G_NUMBER">100 mg</cons> three times daily (for a total daily dose of <cons sem="G_NUMBER">300 mg</cons>) for 7 days, and on Day 7, a single <cons sem="G_NUMBER">60-mg</cons> dose of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> was coadministered with a <cons sem="G_NUMBER">100-mg</cons> dose of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons>.</sentence>
<sentence>The <cons sem="G_IVIVPARA">plasma concentrations</cons> and urinary excretion of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> were measured for 24 hours after dosing.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Carbamazepine, fexofenadine, ADDI)">
<sentence><cons lex="carbamazepine" sem="G_DRUG" type="inducer_1">Carbamazepine</cons> pretreatment <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">altered</cons> <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">fexofenadine</cons> pharmacokinetics, <cons sem="G_CHANGE">decreasing</cons> the mean (+/- standard deviation) <cons sem="G_IVIVPARA">peak plasma concentration</cons> from <cons sem="G_NUMBER">176.6 (+/- 82.1) ng/mL to 103.2 (+/- 33.6) ng/mL (P &lt; 0.01)</cons> and the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> from <cons sem="G_NUMBER">1058.4 (+/- 528.7) ng/h/mL to 604.8 (+/- 255.9) ng/h/mL (P &lt; 0.01)</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> <cons sem="G_CHANGE">changing</cons> the <cons sem="G_IVIVPARA">elimination half-life</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Carbamazepine, fexofenadine, DDI)">
<sentence>Relatively, <cons lex="carbamazepine" sem="G_DRUG" type="inducer_1">carbamazepine</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> the amount of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">fexofenadine</cons> excreted into the urine from <cons sem="G_NUMBER">8.1 (+/- 2.1) mg to 4.5 (+/- 1.4) mg (P &lt; 0.001)</cons>, although the <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">fexofenadine</cons> remained constant between the two study phases.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Carbamazepine, fexofenadine, DDI)">
<sentence>Thus, this study indicates that <cons lex="carbamazepine" sem="G_DRUG" type="inducer_1">carbamazepine</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreases</cons> <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">fexofenadine</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>, <cons sem = "G_CHANGE">probably</cons> as a result of P-glycoprotein <cons sem="G_MECHANISM">induction</cons> in the small intestine.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Carbamazepine, fexofenadine, ADDI)">
<sentence><cons lex="carbamazepine" sem="G_DRUG" type="inducer_1">Carbamazepine</cons> treatment, therefore, is of <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> clinical <cons sem = "G_CHANGE">significance</cons> for patients receiving <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">fexofenadine</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19792991</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons>-<cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> on cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> activity in healthy volunteers using <cons lex="midazolam" sem="G_DRUG">midazolam</cons> as a probe.</sentence>
</title>
<abstract>
<sentence>To investigate the <cons sem="G_MECHANISM">inhibitory</cons> potential of multiple doses of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>-boosted <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> on the pharmacokinetics of oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, a cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> model substrate.</sentence>
<sentence>Prospective, open-label, one-sequence, two-period crossover study.</sentence>
<sentence>Clinical pharmacology unit in the United Kingdom.</sentence>
<sentence>Eighteen healthy adult male and female volunteers (median age 37.5 yrs).</sentence>
<sentence>Intervention.</sentence>
<sentence>A single oral dose of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_NUMBER">7.5 mg</cons> was administered on day 1.</sentence>
<sentence>A second dose was administered on day 16, after 14 days of oral <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> <cons sem="G_NUMBER">1000 mg</cons>-<cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem="G_NUMBER">100 mg</cons> twice/day.</sentence>
<sentence>Serial blood samples were taken for measurement of <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and its metabolite, 1'-hydroxymidazolam.</sentence>
<sentence>Pharmacokinetic parameters of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and 1'-hydroxymidazolam were determined when <cons lex="midazolam" sem="G_DRUG">midazolam</cons> was given alone (day 1) and after coadministration with <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons>-<cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> for 14 days (day 16).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(saquinavir-ritonavir, midazolam, DDI)">
<sentence>Two weeks of treatment with <cons lex="saquinavir" sem="G_DRUG" type="inhibitor_1">saquinavir</cons>-<cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> resulted in a <cons sem="G_NUMBER">4.3-fold</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">maximum plasma concentration (C(max))</cons> and a <cons sem="G_NUMBER">12.4-fold</cons> <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC(0-infinity))</cons> for <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(saquinavir-ritonavir, midazolam, DDI)">
<sentence><cons lex="midazolam" sem="G_DRUG" type="substrate_1">Midazolam</cons>'s <cons sem="G_IVIVPARA">half-life</cons> <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">4.7 to 14.9 hours</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(saquinavir-ritonavir, midazolam, DDI)">
<sentence>Concomitant <cons sem="G_CHANGE">reduction</cons>s for <cons lex="midazolam" sem="G_DRUG" type="M_1">1'-hydroxymidazolam</cons> were approximately <cons sem="G_NUMBER">7-fold</cons> for <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_NUMBER">2-fold</cons> for <cons sem="G_IVIVPARA">AUC(0-infinity)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(saquinavir-ritonavir, midazolam, NDDI)">
<sentence>The <cons lex="midazolam" sem="G_DRUG" type="M_1">1'-hydroxymidazolam</cons> <cons sem="G_IVIVPARA">AUC(0-infinity):<cons sem="G_DRUG" type="substrate_1">midazolam</cons> AUC(0-infinity) ratio</cons> was only <cons sem="G_NUMBER">1%</cons> during coadministration of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> with <cons lex="saquinavir" sem="G_DRUG" type="inhibitor_1">saquinavir</cons>-<cons lex="ritonavir" sem="G_DRUG" type="inhibitor_2">ritonavir</cons> compared with <cons sem="G_NUMBER">33%</cons> for <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> alone.</sentence>
</annotation>
<sentence>Adverse-event reports indicated that the combination of <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons>, <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> was well tolerated but resulted in prolonged sedation.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(saquinavir-ritonavir, midazolam, DDI)">
<sentence>Administration of <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_2">ritonavir</cons>-boosted <cons lex="saquinavir" sem="G_DRUG" type="inhibitor_1">saquinavir</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increased</cons> the exposure of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its <cons sem="G_MECHANISM">metabolism</cons>, confirming that the combination of <cons lex="saquinavir" sem="G_DRUG" type="inhibitor_1">saquinavir</cons> and <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_2">ritonavir</cons> at steady state <cons sem="G_CHANGE">strongly</cons> <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19789372</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons>, a <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons>, on <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> pharmacokinetics and pharmacodynamics.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to determine whether <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons>, a <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons sem="G_CHANGE">altered</cons> the pharmacokinetics and pharmacodynamics of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>.</sentence>
<sentence>The pharmacokinetics of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> were examined in an open-label study in 12 healthy participants after a single dose of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> (<cons sem="G_NUMBER">2 mg</cons>) with and <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons> coadministration (<cons sem="G_NUMBER">50 mg</cons>, 3 times as a pretreatment for a day and 2 times on the study day).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(mexiletine, tizanidine, DDI)">
<sentence>Compared with <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> alone, <cons lex="mexiletine" sem="G_DRUG" type="inhibitor_1">mexiletine</cons> coadministration <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak plasma concentration</cons> <cons sem="G_NUMBER">(1.8 +/- 0.8 vs 5.3 +/- 1.8 ng/mL)</cons>, <cons sem="G_IVIVPARA">area under the curve</cons> <cons sem="G_NUMBER">(4.5 +/- 2.2 vs 15.4 +/- 6.5 ng x h/mL)</cons>, and the <cons sem="G_IVIVPARA">half-life</cons> <cons sem="G_NUMBER">(1.3 +/- 0.2 vs 1.8 +/- 0.7 h)</cons> of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons>, respectively <cons sem="G_NUMBER">(P &lt; .05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(mexiletine, tizanidine, DDI)">
<sentence><cons sem="G_CHANGE">Reduction</cons> in systolic blood pressure (<cons sem="G_NUMBER">-10 +/- 8 vs -24 +/- 7 mm Hg</cons>) and diastolic blood pressure (<cons sem="G_NUMBER">-10 +/- 7 vs -18 +/- 8 mm Hg</cons>) after <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> administration was also <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">enhanced</cons> by coadministration of <cons lex="mexiletine" sem="G_DRUG" type="inhibitor_1">mexiletine</cons> (<cons sem="G_NUMBER">P &lt; .01</cons>).</sentence>
</annotation>
<sentence>Of the 15 patients treated with <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> and <cons lex="mexiletine" sem="G_DRUG">mexiletine</cons>, 4 suffered <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>-<cons sem="G_MECHANISM">induced</cons> adverse effects such as drowsiness and dry mouth in the retrospective survey.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(mexiletine, tizanidine, DDI)">
<sentence>Present results suggested that coadministration of <cons lex="mexiletine" sem="G_DRUG" type="inhibitor_1">mexiletine</cons> <cons sem="G_CHANGE">increased</cons> blood <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> concentrations and enhanced <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> pharmacodynamics in terms of <cons sem="G_CHANGE">reduction</cons> in blood pressure and adverse symptoms.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19755414</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> on the pharmacokinetics and pharmacodynamics of oral <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
</title>
<abstract>
<sentence>The aim of this study is to determine whether the <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> enzyme activity with <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> affects the pharmacokinetics and pharmacodynamics of orally administered <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> in a randomized 2-phase crossover study.</sentence>
<sentence>Eleven healthy subjects were pretreated with <cons sem="G_NUMBER">800 mg</cons> of oral <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> or placebo for 4 days.</sentence>
<sentence>On day 3, they ingested <cons sem="G_NUMBER">10 mg</cons> of immediate-release <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> and its oxidative metabolites were measured for 48 hours, and pharmacodynamic effects were evaluated.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Telithromycin, oxycodone, ADDI)">
<sentence><cons lex="telithromycin" sem="G_DRUG" type="inhibitor_1">Telithromycin</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC(0-infinity))</cons> of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> by <cons sem="G_NUMBER">80% (P &lt; .001)</cons> and <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="oxycodone" sem="G_DRUG" type="M_1">noroxycodone</cons> by <cons sem="G_NUMBER">46% (P &lt; .001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Telithromycin, oxycodone, ADDI)">
<sentence>Most of the pharmacokinetic <cons sem ="G_CHANGE">changes</cons> were seen in the elimination phase, with <cons sem ="G_CHANGE">little</cons> effect by <cons lex="telithromycin" sem="G_DRUG" type="inhibitor_1">telithromycin</cons> on the <cons sem="G_IVIVPARA">peak concentration</cons> of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Telithromycin, oxycodone, ADDI)">
<sentence>Pharmacodynamic effects of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> were <cons sem = "G_CHANGE">modestly</cons> enhanced by <cons lex="telithromycin" sem="G_DRUG" type="inhibitor_1">telithromycin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Telithromycin, oxycodone, DDI)">
<sentence>In conclusion, <cons lex="telithromycin" sem="G_DRUG" type="inhibitor_1">telithromycin</cons> clearly <cons sem="G_CHANGE">reduces</cons> the N-demethylation of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> to <cons lex="oxycodone" sem="G_DRUG" type="M_1">noroxycodone</cons> by <cons sem="G_MECHANISM">inhibiting</cons> the CYP450 <cons lex="3a4" sem="G_CYP">3A4</cons> enzyme.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Telithromycin, oxycodone, DDI)">
<sentence>The use of <cons lex="telithromycin" sem="G_DRUG" type="inhibitor_1">telithromycin</cons> in patients receiving multiple doses of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> for pain relief <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">increase</cons> the risk of opioid adverse effects.</sentence>
</annotation>
<sentence><cons sem="G_CHANGE">Reduction</cons> of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> dose by <cons sem="G_NUMBER">25% to 50%</cons> followed by readjustment according to the clinical response <cons sem = "G_CHANGE">might</cons> be appropriate.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19637947</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetics of concurrent administration of <cons lex="fosamprenavir" sem="G_DRUG">fosamprenavir</cons> and <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> in human immunodeficiency virus-negative subjects.</sentence>
</title>
<abstract>
<sentence>To quantify the pharmacokinetics of <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> and <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons> (administered as the prodrug <cons lex="fosamprenavir" sem="G_DRUG">fosamprenavir</cons>) alone and in combination in human immunodeficiency virus (HIV)-negative subjects.</sentence>
<sentence>Randomized, open-label, three-way crossover study.</sentence>
<sentence>Research facility.</sentence>
<sentence>Eleven men and 10 women who were seronegative for HIV.</sentence>
<sentence>Subjects were randomized to 14-day treatment periods of <cons lex="fosamprenavir" sem="G_DRUG">fosamprenavir</cons> <cons sem="G_NUMBER">1400 mg once/day</cons>, <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons> <cons sem="G_NUMBER">400 mg once/day</cons>, or <cons lex="fosamprenavir" sem="G_DRUG">fosamprenavir</cons> <cons sem="G_NUMBER">1400 mg</cons> plus <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons> <cons sem="G_NUMBER">400 mg once/day</cons>; after a washout period of at least 21 days between each treatment, they received the other two treatments.</sentence>
<sentence>Subjects underwent 24-hour pharmacokinetic sampling at baseline and on day 14 of each treatment period.</sentence>
<sentence>Primary outcome measures were <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> and <cons sem="G_IVIVPARA">maximum concentration (C(max))</cons> for <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> and <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Atazanavir, amprenavir, DDI)">
<sentence><cons lex="atazanavir" sem="G_DRUG" type="inhibitor_1">Atazanavir</cons> <cons sem="G_CHANGE">significantly</cons> enhanced the exposure of <cons lex="amprenavir" sem="G_DRUG" type="substrate_1">amprenavir</cons>.</sentence>
</annotation>
<sentence>When <cons lex="fosamprenavir" sem="G_DRUG">fosamprenavir</cons> was given alone, the geometric mean of amprenavir's <cons sem="G_IVIVPARA">AUC</cons> was <cons sem="G_NUMBER">20.2 microg x hour/ml(95% confidence interval  [CI] 19.1-21.2 microg x hr/ml)</cons>.</sentence>
<sentence>When given in combination with <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons>, <cons lex="amprenavir" sem="G_DRUG">amprenavir</cons> had an <cons sem="G_IVIVPARA">AUC</cons> of <cons sem="G_NUMBER">39.8 microg x hour/ml (95% CI 38.7-40.9 microg x hr/ml)</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Atazanavir, amprenavir, DDI)">  
<sentence>Similarly, the <cons sem="G_IVIVPARA">C(max)</cons> for <cons lex="amprenavir" sem="G_DRUG" type="substrate_1">amprenavir</cons> <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">4193 ng/ml (95% CI 3927-4459 ng/ml) to 6621 ng/ml (95% CI 6427-6814 ng/ml)</cons> when given in combination with <cons lex="atazanavir" sem="G_DRUG" type="inhibitor_1">atazanavir</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fosamprenavir, atazanavir, DDI)">     
<sentence>In contrast, <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">C(max)</cons> for <cons lex="atazanavir" sem="G_DRUG" type="substrate_2">atazanavir</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> when <cons lex="atazanavir" sem="G_DRUG" type="substrate_2">atazanavir</cons> was coadministered with <cons sem="G_DRUG" type="inducer_1">fosamprenavir</cons>; <cons sem="G_IVIVPARA">AUC</cons> <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">17.6 microg x hour/ml (95% CI 16.6-18.7 microg x hr/ml) to 11.8 microg x hour/ml (95% CI 11.3-12.3 microg x hr/ml)</cons>, and <cons sem="G_IVIVPARA">C(max)</cons> <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">2507 ng/ml (95% CI 2379-2635 ng/ml) to 1832 ng/ml (95% CI 1752-1911 ng/ml)</cons>.</sentence>
</annotation>
<sentence>Adverse events were assessed at each study visit and 1 month after the subjects completed the three treatments.</sentence>
<sentence>Both drugs were well tolerated.</sentence>
<sentence>One serious adverse event (grade 3 acute pancreatitis) occurred and resolved <cons sem="G_NEGATIVEEFFECT">without</cons> further incident.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fosamprenavir, atazanavir, DDI)">  
<sentence><cons lex="atazanavir" sem="G_DRUG" type="substrate_2">Atazanavir</cons> <cons sem="G_NUMBER">400 mg/day</cons> plus <cons lex="fosamprenavir" sem="G_DRUG" type="inducer_1">fosamprenavir</cons> <cons sem="G_NUMBER">1400 mg/day</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> concentrations of <cons lex="atazanavir" sem="G_DRUG" type="substrate_2">atazanavir</cons> compared with standard dosing regimens of each drug alone.</sentence>
</annotation>
<sentence>This dosing scheme is <cons sem="G_NEGATIVEEFFECT">not</cons> a recommended combination of dual, fully active protease <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19623694</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of oral <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> on the pharmacokinetics of <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons> alone and with <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> or with <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> in healthy adult volunteers.</sentence>
</title>
<abstract>
<sentence>Patients with HIV/AIDS are at <cons sem="G_CHANGE">increased</cons> risk for opportunistic fungal infections.</sentence>
<sentence>These patients <cons sem = "G_CHANGE">may</cons> require concomitant treatment with antiretrovirals and azole antifungals, and interactions between these classes of drugs should be anticipated.</sentence>
<sentence>A phase 1, open-label, randomized, crossover, drug interaction study was conducted to assess the pharmacokinetic effects of coadministration of <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> (<cons sem="G_NUMBER">400 mg twice daily</cons>), with <cons lex="atazanavir" sem="G_DRUG">atazanavir (ATV)</cons> (<cons sem="G_NUMBER">300 mg/d alone</cons>) and with <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> (<cons sem="G_NUMBER">100 mg/d</cons>) or with <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> (<cons sem="G_NUMBER">400 mg/d</cons>) in healthy volunteers.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Posaconazole, ATV, DDI)">
<sentence><cons lex="posaconazole" sem="G_DRUG" type="inhibitor_1">Posaconazole</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">maximum observed plasma concentration (Cmax)</cons> and <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> of <cons lex="atazanavir" sem="G_DRUG" type="substrate_1">ATV</cons> by <cons sem="G_NUMBER">2.6-fold</cons> and <cons sem="G_NUMBER">3.7-fold</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Posaconazole+ ritonavir, ATV, DDI)">
<sentence><cons lex="posaconazole" sem="G_DRUG" type="inhibitor_1">Posaconazole</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="atazanavir" sem="G_DRUG" type="substrate_1">ATV</cons> <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUC</cons> when administered with <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_2">ritonavir</cons> by <cons sem="G_NUMBER">1.5-fold</cons> and <cons sem="G_NUMBER">2.5-fold</cons>, respectively.</sentence>
</annotation>
<sentence>Most subjects who received <cons lex="atazanavir" sem="G_DRUG">ATV</cons> (with and <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>) and <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> experienced clinically relevant <cons sem="G_CHANGE">increases</cons> in total bilirubin.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(efavirenz, posaconazole, DDI)">
<sentence>Coadministration of <cons lex="posaconazole" sem="G_DRUG" type="substrate_2">posaconazole</cons> and <cons lex="efavirenz" sem="G_DRUG" type="inducer_1">efavirenz</cons> resulted in clinically relevant <cons sem="G_CHANGE">decreases</cons> of <cons lex="posaconazole" sem="G_DRUG" type="substrate_2">posaconazole</cons> <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUC</cons> of approximately<cons sem="G_NUMBER">45%</cons> and <cons sem="G_NUMBER">50%</cons>, respectively.</sentence>
</annotation>
<sentence>Frequent monitoring of adverse events and toxicity related to antiviral exposure is recommended in the event of coadministration of <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> and <cons lex="atazanavir" sem="G_DRUG">ATV</cons> with or <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
<sentence>In addition, because of <cons sem="G_CHANGE">decreased</cons> <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> exposure, coadministration with <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> should be avoided unless the benefit to patients outweighs the risk.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19552748</bibliomisc>
</articleinfo>
<title>
<sentence>Enantioselective disposition of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> with the P-glycoprotein <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="verapamil" sem="G_DRUG">verapamil</cons>.</sentence>
</title>
<abstract>
<sentence>The aim was to compare possible effects of <cons lex="verapamil" sem="G_DRUG">verapamil</cons>, as a P-glycoprotein (P-gp) <cons sem="G_MECHANISM">inhibitor</cons>, on the pharmacokinetics of each <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> enantiomer, as a P-gp substrate.</sentence>
<sentence>Thirteen healthy Japanese volunteers (10 male and three female) were enrolled.</sentence>
<sentence>In a randomized, two-phase, crossover design, <cons lex="verapamil" sem="G_DRUG">verapamil</cons> was dosed <cons sem="G_NUMBER">80 mg</cons> three times daily (with total daily doses of <cons sem="G_NUMBER">240 mg</cons>) for 6 days, and on day 6, a single <cons sem="G_NUMBER">120-mg</cons> dose of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> was administered along with an <cons sem="G_NUMBER">80-mg</cons> dose of <cons lex="verapamil" sem="G_DRUG">verapamil</cons>.</sentence>
<sentence>Subsequently, <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> was administered alone after a 2-week wash-out period.</sentence>
<sentence>The <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> enantiomers were measured up to 24 h after dosing.</sentence>
<sentence>During the control phase, the mean <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of S(-)- and R(+)-<cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> was <cons sem="G_NUMBER">700 ng h(-1) ml(-1) [95% confidence interval (CI) 577, 823] and 1202 ng h(-1) ml(-1) (95% CI 1007, 1396)</cons>, respectively, with a <cons sem="G_CHANGE">significant</cons> difference (<cons sem="G_NUMBER">P &lt; 0.001</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Verapamil, S(-)-fexofenadine, DDI)(Verapamil, R(-)-fexofenadine, DDI)">
<sentence><cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">Verapamil</cons> had a <cons sem = "G_CHANGE">greater</cons> effect on the pharmacokinetic parameters of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">S(-)-fexofenadine</cons> compared with those of the R(+)-enantiomer, and <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">S(-)-fexofenadine</cons> and <cons lex="fexofenadine" sem="G_DRUG" type="substrate_2">R(+)-fexofenadine</cons> by <cons sem="G_NUMBER">3.5-fold (95% CI of differences 1.9, 5.1; P &lt; 0.001)</cons> and by <cons sem="G_NUMBER">2.2-fold (95% CI of differences 1.7, 3.0; P &lt; 0.001)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Verapamil, fexofenadine, DDI)">
<sentence>The R/S ratio for the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> was <cons sem="G_CHANGE">reduced</cons> from <cons sem="G_NUMBER">1.76 to 1.32 (P &lt; 0.001)</cons> by <cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">verapamil</cons> treatments.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Verapamil, fexofenadine, DDI)">
<sentence>This study indicates that P-gp plays a key role in the stereoselectivity of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_3">fexofenadine</cons> pharmacokinetics, since the pharmacokinetics of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_3">fexofenadine</cons> enantiomers were <cons sem="G_CHANGE">altered</cons> by the P-gp <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">verapamil</cons>, and this effect was <cons sem = "G_CHANGE">greater</cons> for <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">S-fexofenadine</cons> compared with <cons lex="fexofenadine" sem="G_DRUG" type="substrate_2">R-fexofenadine</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19486187</bibliomisc>
</articleinfo>
<title>
<sentence>Influence of <cons lex="darunavir" sem="G_DRUG">darunavir</cons> coadministration on <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> pharmacokinetics in HIV-infected patients: a population approach.</sentence>
</title>
<abstract>
<sentence>The influence of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>-boosted <cons lex="darunavir" sem="G_DRUG">darunavir</cons> coadministration on <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> pharmacokinetics was investigated in HIV-infected patients using a population-based approach.</sentence>
<sentence>The population was composed of 51 patients (89 samples; 42 patients treated with an antiretroviral regimen containing <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> and nucleoside/nucleotide reverse transcriptase <cons sem="G_MECHANISM">inhibitors</cons> and nine patients treated with a regimen containing a combination of <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> and <cons lex="darunavir" sem="G_DRUG">darunavir</cons>).</sentence>
<sentence>A one-compartment model with first-order absorption was fitted to the data using nonmem version V (GloboMax, Ellicott City, MD, USA).</sentence>
<sentence>Relationships were established between <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> <cons sem="G_IVIVPARA">clearance (Cl)</cons> and age (<cons sem="G_IVIVPARA">CL/F</cons>=<cons sem="G_NUMBER">2.42+47.2/age</cons>, where F denotes <cons sem="G_IVIVPARA">bioavailability</cons>) and between <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> volume of distribution (<cons sem="G_IVIVPARA">V(d)</cons>) and the presence of <cons lex="darunavir" sem="G_DRUG">darunavir</cons> in the antiretroviral regimen  [<cons sem="G_IVIVPARA">V(d)/F</cons>=<cons sem="G_NUMBER">38.0+75.0</cons> (1 - <cons lex="darunavir" sem="G_DRUG">darunavir</cons> coadministration), where <cons lex="darunavir" sem="G_DRUG">darunavir</cons> coadministration is 1 for patients treated with a combination of <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> and <cons lex="darunavir" sem="G_DRUG">darunavir</cons> and 0 for other patients].</sentence>
<annotation sem="INVIVOCDDIS" ddi="(darunavir, nevirapine, ADDI)">
<sentence>According to this final model, a <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">decrease</cons> in the means of <cons sem="G_IVIVPARA">CL/F</cons> <cons sem="G_NUMBER">(3.84 +/- 0.92 vs. 2.76 +/- 1.00 L/h; P&lt;0.05)</cons> and <cons sem="G_IVIVPARA">V(d)/F</cons> <cons sem="G_NUMBER">(93.2 +/- 31.10 vs. 39.8 +/- 6.97 L; P&lt;0.0001)</cons> and an <cons sem="G_CHANGE">increase</cons> in the mean of <cons lex="nevirapine" sem="G_DRUG" type="substrate_1">nevirapine</cons> through <cons sem="G_IVIVPARA">plasma concentrations</cons> <cons sem="G_NUMBER">(3.68 +/- 1.69 vs. 5.35 +/- 3.20 mg/L; P&lt;0.05)</cons> are observed if <cons lex="nevirapine" sem="G_DRUG" type="substrate_1">nevirapine</cons> is used in combination with <cons lex="darunavir" sem="G_DRUG" type="inhibitor_1">darunavir</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(darunavir, nevirapine, DDI)">
<sentence>These results suggest that <cons lex="nevirapine" sem="G_DRUG" type="inhibitor_1">nevirapine</cons> exposure is <cons sem="G_CHANGE">increased</cons> when <cons lex="nevirapine" sem="G_DRUG" type="substrate_1">nevirapine</cons> is administered in combination with <cons lex="darunavir" sem="G_DRUG" type="inhibitor_1">darunavir</cons> and that therapeutic drug monitoring of <cons lex="nevirapine" sem="G_DRUG" type="substrate_1">nevirapine</cons> should be performed if this antiretroviral regimen is considered.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19417618</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> <cons sem ="G_CHANGE">greatly</cons> <cons sem ="G_CHANGE">reduces</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of intravenous and oral <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="oxycodone" sem="G_DRUG">Oxycodone</cons> is a mu-opioid receptor agonist that is <cons sem="G_MECHANISM">metabolized</cons> mainly in the liver by cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> and <cons lex="2d6" sem="G_CYP">2D6</cons> enzymes.</sentence>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> is a <cons sem="G_CHANGE">strong</cons> <cons sem="G_MECHANISM">inducer</cons> of several drug-metabolizing enzymes.</sentence>
<sentence>The authors studied the interaction of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> with <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
<sentence>Their hypothesis was that <cons lex="rifampin" sem="G_DRUG">rifampin</cons> enhances the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> and attenuates its pharmacologic effect.</sentence>
<sentence>The protocol was a four-session, paired crossover.</sentence>
<sentence>Twelve volunteers were given <cons sem="G_NUMBER">600 mg</cons> oral <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or placebo once daily for 7 days.</sentence>
<sentence><cons lex="oxycodone" sem="G_DRUG">Oxycodone</cons> was given on day 6.</sentence>
<sentence>In the first part of the study, <cons sem="G_NUMBER">0.1 mg/kg</cons> <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> hydrochloride was given intravenously.</sentence>
<sentence>In the second part of the study, <cons sem="G_NUMBER">15 mg</cons> <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> hydrochloride was given orally.</sentence>
<sentence>Concentrations of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> and its metabolites noroxycodone, <cons lex="oxymorphone" sem="G_DRUG">oxymorphone</cons>, and noroxymorphone were determined for 48 h. Psychomotor effects were characterized for 12 h by several visual analog scales.</sentence>
<sentence>Analgesic effects were characterized by measuring the heat pain threshold and cold pain sensitivity.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, oxycodone, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">area under the <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> concentration-time curve</cons> of intravenous and oral <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> by <cons sem="G_NUMBER">53% and 86%</cons>, respectively <cons sem="G_NUMBER">(P &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Rifampin, oxycodone, DDI)">
<sentence><cons sem="G_IVIVPARA">Oral bioavailability</cons> of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> was <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">69% to 21% (P &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, oxycodone, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increased</cons> the plasma metabolite-to-parent drug ratios for <cons lex="oxycodone" sem="G_DRUG" type="M_1">noroxycodone</cons> and <cons lex="oxycodone" sem="G_DRUG" type="M_2">noroxymorphone</cons> <cons sem="G_NUMBER">(P &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Rifampin, oxycodone, DDI)">
<sentence>Pharmacologic effects of oral <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> were attenuated.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, oxycodone, DDI)">
<sentence><cons sem="G_MECHANISM">Induction</cons> of cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">area under the <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> concentration-time curve</cons> of intravenous and oral <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Rifampin, oxycodone, DDI)">
<sentence>The pharmacologic effects of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> were <cons sem = "G_CHANGE">modestly</cons> attenuated.</sentence>
</annotation>
<sentence>To maintain adequate analgesia, dose adjustment of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> <cons sem = "G_CHANGE">may</cons> be necessary, when used concomitantly with <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19371315</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> on <cons lex="lapatinib" sem="G_DRUG">lapatinib</cons> pharmacokinetics in healthy subjects.</sentence>
</title>
<abstract>
<sentence>To characterize the impact of potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> and <cons sem="G_MECHANISM">induction</cons> on <cons lex="lapatinib" sem="G_DRUG">lapatinib</cons> pharmacokinetics.</sentence>
<sentence>Two studies were conducted in healthy subjects.</sentence>
<sentence>One study examined the effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">200 mg b.i.d.</cons> for 7 days on a single <cons sem="G_NUMBER">100-mg</cons> dose of <cons lex="lapatinib" sem="G_DRUG">lapatinib</cons> in 22 healthy subjects.</sentence>
<sentence>The other study examined the effect of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> titrated up to <cons sem="G_NUMBER">200 mg b.i.d.</cons> over 20 days on a single <cons sem="G_NUMBER">250-mg</cons> dose of <cons lex="lapatinib" sem="G_DRUG">lapatinib</cons> in 24 healthy subjects.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, lapatinib, DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">Ketoconazole</cons> <cons sem="G_CHANGE">altered</cons> <cons lex="lapatinib" sem="G_DRUG" type="substrate_1">lapatinib</cons> <cons sem="G_IVIVPARA">AUC</cons>, <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">half-life</cons>, with geometric mean  [95% confidence interval (CI)] <cons sem="G_CHANGE">increases</cons> of <cons sem="G_NUMBER">3.57-fold (3.07, 4.15)</cons>, <cons sem="G_NUMBER">2.14-fold (1.74, 2.64)</cons> and <cons sem="G_NUMBER">1.66-fold (1.50, 1.84)</cons>, respectively, but had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on absorption rate.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Carbamazepine, lapatinib, DDI)">
<sentence><cons lex="carbamazepine" sem="G_DRUG" type="inducer_1">Carbamazepine</cons> <cons sem="G_CHANGE">altered</cons> <cons lex="lapatinib" sem="G_DRUG" type="substrate_1">lapatinib</cons> <cons sem="G_IVIVPARA">AUC</cons>, <cons sem="G_IVIVPARA">C(max)</cons> and absorption rate, with geometric mean (95% CI) <cons sem="G_CHANGE">decreases</cons> of <cons sem="G_NUMBER">72% (68, 77)</cons>, <cons sem="G_NUMBER">59% (49, 66)</cons> and <cons sem="G_NUMBER">28% (4, 46)</cons>, respectively, but had <cons sem="G_NEGATIVEEFFECT">no</cons> effect on <cons sem="G_IVIVPARA">half-life</cons>.</sentence>
</annotation>
<sentence>Systemic exposure to <cons lex="lapatinib" sem="G_DRUG">lapatinib</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">altered</cons> by potent <cons sem="G_MECHANISM">inhibition</cons> and <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Dose adjustments <cons sem = "G_CHANGE">may</cons> be required when <cons lex="lapatinib" sem="G_DRUG">lapatinib</cons> is administered with orally administered drugs that potently alter the activity of this enzyme.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19302901</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of oral <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> on the pharmacokinetic properties of oral and intravenous <cons sem="G_DRUG">midazolam</cons>: a phase I, randomized, open-label, crossover study in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>Like <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons>, a broad-spectrum oral triazole antifungal, <cons sem="G_MECHANISM">inhibits</cons> the activity of the cytochrome P450 (CYP) isozyme <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
<sentence><cons lex="midazolam" sem="G_DRUG">Midazolam</cons>, a short-acting benzodiazepine, is <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Potential drug interactions can be expected in patients who are concurrently receiving <cons sem="G_MECHANISM">inhibitors</cons> and substrates of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (eg, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons>) and benzodiazepines (eg, <cons lex="midazolam" sem="G_DRUG">midazolam</cons>).</sentence>
<sentence>Because of the potential for drug interactions, it is important to determine the effects of <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> on the pharmacokinetic properties of <cons lex="midazolam" sem="G_DRUG">midazolam</cons>.</sentence>
<sentence>The aim of this study was to compare the effects of oral administration of <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> versus <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the pharmacokinetic properties of orally and intravenously administered <cons lex="midazolam" sem="G_DRUG">midazolam</cons>.</sentence>
<sentence>This Phase I, randomized, open-label, crossover study was conducted at Swiss Pharma Contract Ltd., Allschwil, Switzerland.</sentence>
<sentence>Healthy volunteers were randomly assigned to 1 of 2 treatment arms.</sentence>
<sentence>Arm 1 received <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> <cons sem="G_NUMBER">200 mg BID</cons> for 7 days, <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> <cons sem="G_NUMBER">400 mg BID</cons> for 7 days, <cons sem="G_NEGATIVEEFFECT">no</cons> drugs during a 28-day washout, and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">400 mg</cons> once daily for 7 days.</sentence>
<sentence>Arm 2 received <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> in the reverse order, with a 28-day washout between treatments.</sentence>
<sentence>An oral/IV <cons lex="midazolam" sem="G_DRUG">midazolam</cons> sequence (oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_NUMBER">2 mg</cons> and IV <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_NUMBER">0.4 mg</cons>) was administered on days <cons sem="G_NUMBER">-2/-1, 6/7, 13/14 (arm 1), 36/17 (arm 2), 43/44, and 50/51</cons> in both treatment arms.</sentence>
<sentence>Blood samples were collected up to 24 hours after <cons lex="midazolam" sem="G_DRUG">midazolam</cons> administration.</sentence>
<sentence>Pharmacokinetic parameters, including <cons sem="G_IVIVPARA">C(max)</cons>, <cons sem="G_IVIVPARA">C(min) (before azole administration)</cons>, <cons sem="G_IVIVPARA">terminal-phase t(1/2) (t(1/2z))</cons>, and <cons sem="G_IVIVPARA">AUC</cons> to final measurable sampling time (<cons sem="G_IVIVPARA">AUC(tf)</cons>), were calculated using noncompartmental methods, and drug interactions were evaluated using analysis of variance.</sentence>
<sentence>Adverse events were collected using physical examination, including vital sign measurements; clinical laboratory analysis; electrocardiography; and direct questioning at predefined time points throughout the study to assess tolerability.</sentence>
<sentence>A total of 12 subjects were enrolled (11 men, 1 woman; all white; mean age, 42.8 years  [range, 28-53 years]; mean weight, <cons sem="G_NUMBER">80.6 kg</cons>; and mean body mass index, <cons sem="G_NUMBER">25.6 kg/m(2)</cons>).</sentence>
<sentence>All of the subjects completed the study.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(posaconazole, midazolam, DDI)">
<sentence>Based on point estimates of logarithm-transformed data, <cons lex="posaconazole" sem="G_DRUG" type="inhibitor_1">posaconazole</cons> <cons sem="G_NUMBER">200 and 400 mg BID</cons> were associated with <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> in <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">C(max)</cons> <cons sem="G_NUMBER">(up to 1.3- and 2.4-fold)</cons> and <cons sem="G_IVIVPARA">AUC(tf)</cons> values <cons sem="G_NUMBER">(up to 4.6- and 6.2-fold)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, midazolam, DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_2">Ketoconazole</cons> <cons sem="G_NUMBER">400 mg</cons> once daily was associated with <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(tf)</cons> (<cons sem="G_NUMBER">up to 2.8- and 8.2-fold</cons>, respectively).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(azole, midazolam, DDI)">
<sentence>When <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> was concurrently administered with either azole, <cons sem="G_IVIVPARA">t(1/2z)</cons> was prolonged.</sentence>
</annotation>
<sentence>Seven of 12 (<cons sem="G_NUMBER">58%</cons>) subjects reported <cons sem="G_NUMBER">&gt; or =1</cons> adverse event during the study (5 with <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> alone and 4 with <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> + <cons lex="midazolam" sem="G_DRUG">midazolam</cons>).</sentence>
<sentence>The most common adverse events were diarrhea (3 subjects  [<cons sem="G_NUMBER">25%</cons>] with <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> alone, 2  [<cons sem="G_NUMBER">17%</cons>] with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> alone, and 1  [<cons sem="G_NUMBER">8%</cons>] with <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> + <cons lex="midazolam" sem="G_DRUG">midazolam</cons>) and flatulence (1  [<cons sem="G_NUMBER">8%</cons>] with <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> alone and 1  [<cons sem="G_NUMBER">8%</cons>] with <cons lex="midazolam" sem="G_DRUG">midazolam</cons> alone).</sentence>
<sentence>The results from this study in a small, all-white population of healthy volunteers suggest that <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> was a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, but to a lesser extent than was <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
<sentence>Monitoring patients for adverse events, the need for dose adjustments, or both during coadministration with <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> <cons sem = "G_CHANGE">may</cons> be warranted in patients being treated with benzodiazepines that are predominantly <cons sem="G_MECHANISM">metabolized</cons> through <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (eg, <cons lex="midazolam" sem="G_DRUG">midazolam</cons>).</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19298689</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of concurrent administration of <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> on the disposition of <cons lex="quinine" sem="G_DRUG">quinine</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="nevirapine" sem="G_DRUG">Nevirapine</cons> and <cons lex="quinine" sem="G_DRUG">quinine</cons> are likely to be administered concurrently in the treatment of patients with HIV and malaria.</sentence>
<sentence>Both drugs are <cons sem="G_MECHANISM">metabolised</cons> to a <cons sem="G_CHANGE">significant</cons> extent by cytochrome P450 <cons sem="G_CYP">(CYP)3A4</cons> and <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> is also an <cons sem="G_MECHANISM">inducer</cons> of this enzyme.</sentence>
<sentence>This study therefore evaluated the effect of <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> on the pharmacokinetics of <cons lex="quinine" sem="G_DRUG">quinine</cons>.</sentence>
<sentence><cons lex="quinine" sem="G_DRUG">Quinine</cons> (<cons sem="G_NUMBER">600 mg</cons> single dose) was administered either alone or with the 17th dose of <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons> (<cons sem="G_NUMBER">200 mg</cons> every 12 h for 12 days) to 14 healthy volunteers in a crossover fashion.</sentence>
<sentence>Blood samples collected at predetermined time intervals were analysed for <cons lex="quinine" sem="G_DRUG">quinine</cons> and its major metabolite, 3-hydroxquinine, using a validated HPLC method.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(nevirapine, quinine, DDI)">
<sentence>Administration of <cons lex="quinine" sem="G_DRUG" type="substrate_1">quinine</cons> plus <cons lex="nevirapine" sem="G_DRUG" type="inducer">nevirapine</cons> resulted in <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">decreases</cons> (<cons sem="G_NUMBER">P &lt; 0.01</cons>) in the total <cons sem="G_IVIVPARA">area under the concentration-time curve (AUC(T))</cons>, <cons sem="G_IVIVPARA">maximum plasma concentration (C(max))</cons> and <cons sem="G_IVIVPARA">terminal elimination half-life (T((1/2)beta))</cons> of <cons lex="quinine" sem="G_DRUG" type="substrate_1">quinine</cons> compared with values with <cons lex="quinine" sem="G_DRUG" type="substrate_1">quinine</cons> dosing alone (<cons sem="G_IVIVPARA">AUC</cons>: <cons sem="G_NUMBER">53.29 +/- 4.01 vs 35.48 +/- 2.01 h mg/l</cons>; <cons sem="G_IVIVPARA">C(max)</cons>: <cons sem="G_NUMBER">2.83 +/- 0.16 vs 1.81 +/- 0.06 mg/l; T((1/2)beta): 11.35 +/- 0.72 vs 8.54 +/- 0.76 h)</cons>, while the <cons sem="G_IVIVPARA">oral plasma clearance</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">(11.32 +/- 0.84 vs 16.97 +/- 0.98 l/h)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(nevirapine, quinine, ADDI)">
<sentence>In the presence of <cons lex="nevirapine" sem="G_DRUG" type="inducer_1">nevirapine</cons> there was a <cons sem = "G_CHANGE">pronounced</cons> <cons sem="G_CHANGE">increase</cons> in the ratio of <cons sem="G_IVIVPARA">AUC(metabolite)/AUC (unchanged drug)</cons> and highly <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> in <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC</cons> of the metabolite (<cons sem="G_NUMBER">P &lt; 0.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(nevirapine, quinine, DDI)">
<sentence><cons lex="nevirapine" sem="G_DRUG" type="inducer_1">Nevirapine</cons> <cons sem="G_CHANGE">significantly</cons> alters the pharmacokinetics of <cons lex="quinine" sem="G_DRUG" type="substrate_1">quinine</cons>.</sentence>
</annotation>
<sentence>An <cons sem="G_CHANGE">increase</cons> in the dose of <cons lex="quinine" sem="G_DRUG">quinine</cons> <cons sem = "G_CHANGE">may</cons> be necessary when the drug is co-administered with <cons lex="nevirapine" sem="G_DRUG">nevirapine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19238656</bibliomisc>
</articleinfo>
<title>
<sentence>Mechanism of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem ="G_CHANGE">changes</cons> in <cons lex="methadone" sem="G_DRUG">methadone</cons> pharmacokinetics and pharmacodynamics: II. <cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> effects on <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and P-glycoprotein activities.</sentence>
</title>
<abstract>
<sentence><cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> diminishes <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>, an effect attributed to <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">induction</cons>, but the actual mechanisms are unknown.</sentence>
<sentence>We determined short-term (2-day) and steady-state (2-week) <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> effects on intestinal and hepatic <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> (probed with intravenous (IV) and oral <cons lex="alfentanil" sem="G_DRUG">alfentanil (ALF)</cons> and with miosis) and P-glycoprotein (P-gp) (<cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons>), and on <cons lex="methadone" sem="G_DRUG">methadone</cons> pharmacokinetics and pharmacodynamics in healthy volunteers.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Acute ritonavir, oral ALF, DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">Acute ritonavir</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the concentration-time curve (AUC)(0-infinity)</cons>/dose ratio (ritonavir/control) for <cons lex="alfentanil" sem="G_DRUG" type="substrate_1">oral ALF</cons> <cons sem="G_NUMBER">25-fold</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Steady-state ritonavir, IV ALF, DDI)(Steady-state ritonavir, oral ALF, DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inhibitor_2">Steady-state ritonavir</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC(0-Infinity)</cons>/dose ratio for <cons lex="alfentanil" sem="G_DRUG" type="substrate_2">IV</cons> and <cons lex="alfentanil" sem="G_DRUG" type="substrate_1">oral ALF</cons> <cons sem="G_NUMBER">4-</cons> and <cons sem="G_NUMBER">10-fold</cons>, respectively; <cons sem="G_CHANGE">reduced</cons> hepatic extraction (from <cons sem="G_NUMBER">0.26 to 0.07</cons>) and intestinal extraction (from <cons sem="G_NUMBER">0.51 to 0</cons>); and <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">bioavailability</cons> (from <cons sem="G_NUMBER">37 to 95%</cons>).</sentence>
</annotation>
<sentence>Acute <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem="G_MECHANISM">inhibits</cons> first-pass <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_NUMBER">&gt; 96%</cons>.</sentence>
<sentence>Chronic <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem="G_MECHANISM">inhibits</cons> hepatic <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> (<cons sem="G_NUMBER">&gt; 70%</cons>) and first-pass <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> (<cons sem="G_NUMBER">&gt; 90%</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, fexofenadine, ADDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">Acute</cons> and <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_2">steady-state ritonavir</cons> <cons sem="G_CHANGE">increased</cons> the <cons lex="fexofenadine" sem="G_DRUG" type="substrate_3">fexofenadine</cons> <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> <cons sem="G_NUMBER">2.8-</cons> and <cons sem="G_NUMBER">1.4-fold</cons>, respectively, suggesting P-gp <cons sem="G_MECHANISM">inhibition</cons>.</sentence>
</annotation>
<sentence>Steady-state compared with acute <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> caused mild apparent <cons sem="G_MECHANISM">induction</cons> of P-gp and hepatic <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, but net <cons sem="G_MECHANISM">inhibition</cons> still predominated.</sentence>
<sentence><cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> <cons sem="G_MECHANISM">inhibited</cons> both intestinal and hepatic <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and drug transport.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, ALF, DDI)">
<sentence><cons lex="alfentanil" sem="G_DRUG" type="substrate_4">ALF</cons> miosis noninvasively determined <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_3">ritonavir</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19238655</bibliomisc>
</articleinfo>
<title>
<sentence>Mechanism of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem ="G_CHANGE">changes</cons> in <cons lex="methadone" sem="G_DRUG">methadone</cons> pharmacokinetics and pharmacodynamics: I. Evidence against <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> mediation of <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> diminishes <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>, an effect attributed to <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">induction</cons>, but the actual mechanisms are unknown.</sentence>
<sentence>We determined <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> effects on stereoselective <cons lex="methadone" sem="G_DRUG">methadone</cons> pharmacokinetics and clinical effects (pupillary miosis) in healthy human immunodeficiency virus-negative volunteers.</sentence>
<sentence>Subjects received intravenous plus oral (deuterium-labeled) racemic <cons lex="methadone" sem="G_DRUG">methadone</cons> after <cons sem="G_NEGATIVEEFFECT">no</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, short-term (3-day) <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, and steady-state <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, R-methadone, DDI)(ritonavir, S-methadone, DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inducer_1">Acute</cons> and <cons lex="ritonavir" sem="G_DRUG" type="inducer_2">steady-state ritonavir</cons>, respectively, caused <cons sem="G_NUMBER">1.5-</cons> and <cons sem="G_NUMBER">2-fold</cons> <cons sem="G_MECHANISM">induction</cons> of systemic and apparent oral R- and S-<cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_IVIVPARA">clearances</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, methadone, DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inducer_3">Ritonavir</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">renal clearance</cons> <cons sem="G_NUMBER">40-50%</cons>, and stereoselectively (S &gt; R) <cons sem="G_CHANGE">increased</cons> hepatic <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> N-demethylation <cons sem="G_NUMBER">50-80%</cons>, extraction <cons sem="G_NUMBER">twofold</cons>, and <cons sem="G_IVIVPARA">clearance</cons> <cons sem="G_NUMBER">twofold</cons>.</sentence>
</annotation>
<sentence><cons sem="G_IVIVPARA">Bioavailability</cons> was unchanged despite <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inhibition</cons> of intestinal P-glycoprotein.</sentence>
<sentence>Intestinal and hepatic <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> was <cons sem="G_MECHANISM">inhibited</cons> <cons sem="G_NUMBER">&gt; 70%</cons>.</sentence>
<sentence><cons lex="ritonavir" sem="G_DRUG">Ritonavir</cons> shifted <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>-miosis curves leftward and upward.</sentence>
<sentence>Rapid <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem="G_MECHANISM">induction</cons> of <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_IVIVPARA">clearance</cons> results from <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">renal clearance</cons> and <cons sem="G_MECHANISM">induced</cons> hepatic <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence><cons sem="G_MECHANISM">Induction</cons> of <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_MECHANISM">metabolism</cons> occurred despite profound <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibition</cons>, suggesting <cons sem="G_NEGATIVEEFFECT">no</cons> role for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> in clinical <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_MECHANISM">metabolism</cons> and <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, methadone, ADDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inducer_3">Ritonavir</cons> <cons sem = "G_CHANGE">may</cons> alter <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> pharmacodynamics.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19232844</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> <cons sem="G_MECHANISM">metabolism</cons> and <cons sem="G_IVIVPARA">clearance</cons> are <cons sem="G_MECHANISM">induced</cons> by <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> despite <cons sem="G_MECHANISM">inhibition</cons> of cytochrome P4503A (<cons lex="cyp3a" sem="G_CYP">CYP3A</cons>) activity.</sentence>
</title>
<abstract>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> are <cons sem="G_CHANGE">decreased</cons> by <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>.</sentence>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> <cons sem="G_IVIVPARA">clearance</cons> and the drug interactions have been attributed to <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, but actual mechanisms of <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_IVIVPARA">clearance</cons> and the <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> interaction are unknown.</sentence>
<sentence>We assessed <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> effects on <cons lex="methadone" sem="G_DRUG">methadone</cons> pharmacokinetics and pharmacodynamics, intestinal and hepatic <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> activity, and intestinal P-glycoprotein transport activity.</sentence>
<sentence><cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> and transporters were assessed using <cons lex="alfentanil" sem="G_DRUG">alfentanil</cons> and <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons>, respectively.</sentence>
<sentence>Twelve healthy HIV-negative volunteers underwent a sequential crossover.</sentence>
<sentence>On three consecutive days they received oral <cons lex="alfentanil" sem="G_DRUG">alfentanil</cons> plus <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons>, intravenous <cons lex="alfentanil" sem="G_DRUG">alfentanil</cons>, and intravenous plus oral <cons lex="methadone" sem="G_DRUG">methadone</cons>.</sentence>
<sentence>This was repeated after <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons>.</sentence>
<sentence>Plasma and urine analytes were measured by mass spectrometry.</sentence>
<sentence>Opioid effects were measured by pupil diameter <cons sem = "G_CHANGE">change</cons> (miosis).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Nelfinavir, methadone, ADDI)">
<sentence><cons lex="nelfinavir" sem="G_DRUG" type="inducer_1">Nelfinavir</cons> <cons sem="G_CHANGE">decreased</cons> intravenous and oral <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> <cons sem="G_NUMBER">40-50%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Nelfinavir, S-methadone, DDI)(Nelfinavir, R-methadone, DDI)">
<sentence><cons sem="G_IVIVPARA">Systemic clearance</cons>, <cons sem="G_IVIVPARA">hepatic clearance</cons>, and hepatic extraction all <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">1.6-</cons> and <cons sem="G_NUMBER">2-fold</cons>, respectively, for <cons sem="G_DRUG" type="substrate_2">R-</cons> and <cons sem="G_DRUG" type="substrate_3">S-methadone</cons>; apparent <cons sem="G_IVIVPARA">oral clearance</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">1.7-</cons> and <cons sem="G_NUMBER">1.9-fold</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Nelfinavir, methadone, DDI)">
<sentence><cons lex="nelfinavir" sem="G_DRUG" type="inducer_1">Nelfinavir</cons> stereoselectively <cons sem="G_CHANGE">increased</cons> (S&gt;R) <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_MECHANISM">metabolism</cons> and metabolite <cons sem="G_MECHANISM">formation</cons> <cons sem="G_IVIVPARA">clearance</cons>, and <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_IVIVPARA">renal clearance</cons>.</sentence>
</annotation>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> <cons sem="G_IVIVPARA">bioavailability</cons> and P-glycoprotein activity were minimally <cons sem="G_CHANGE">affected</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Nelfinavir, alfentanil, DDI)">
<sentence><cons lex="nelfinavir" sem="G_DRUG" type="inhibitor_1">Nelfinavir</cons> <cons sem="G_CHANGE">decreased</cons> <cons lex="alfentanil" sem="G_DRUG" type="substrate_4">alfentanil</cons> systemic and apparent <cons sem="G_IVIVPARA">oral clearances</cons> <cons sem="G_NUMBER">50</cons> and <cons sem="G_NUMBER">76%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Nelfinavir, methadone, DDI)">
<sentence><cons lex="nelfinavir" sem="G_DRUG" type="inducer_1">Nelfinavir</cons> appeared to shift the <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>-effect (miosis) curve leftward and upward.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Nelfinavir, methadone, DDI)">
<sentence><cons lex="nelfinavir" sem="G_DRUG" type="inducer_1">Nelfinavir</cons> <cons sem="G_MECHANISM">induced</cons> <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> <cons sem="G_IVIVPARA">clearance</cons> by <cons sem="G_CHANGE">increasing</cons> <cons sem="G_IVIVPARA">renal clearance</cons>, and more so by stereoselectively <cons sem="G_CHANGE">increasing</cons> hepatic <cons sem="G_MECHANISM">metabolism</cons>, extraction and <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Induction</cons> occurred despite <cons sem="G_NUMBER">50%</cons> <cons sem="G_MECHANISM">inhibition</cons> of hepatic <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> activity and more than <cons sem="G_NUMBER">75%</cons> <cons sem="G_MECHANISM">inhibition</cons> of first-pass <cons lex="cyp3a4/5" sem="G_CYP">CYP3A4/5</cons> activity, suggesting <cons sem = "G_CHANGE">little</cons> or <cons sem="G_NEGATIVEEFFECT">no</cons> role for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> in clinical <cons lex="methadone" sem="G_DRUG">methadone</cons> disposition.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Nelfinavir, methadone, ADDI)">
<sentence><cons lex="nelfinavir" sem="G_DRUG" type="inducer_1">Nelfinavir</cons> <cons sem = "G_CHANGE">may</cons> alter <cons lex="methadone" sem="G_DRUG" type="substrate_1">methadone</cons> pharmacodynamics, increasing clinical effects.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19225389</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> pharmacokinetics are independent of cytochrome P4503A (<cons lex="cyp3a" sem="G_CYP">CYP3A</cons>) activity and gastrointestinal drug transport: insights from <cons lex="methadone" sem="G_DRUG">methadone</cons> interactions with ritonavir/indinavir.</sentence>
</title>
<abstract>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> <cons sem="G_IVIVPARA">clearance</cons> is highly variable, and drug interactions are problematic.</sentence>
<sentence>Both have been attributed to <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, but actual mechanisms are unknown.</sentence>
<sentence>Drug interactions can provide such mechanistic information.</sentence>
<sentence><cons sem="G_DRUG">Ritonavir</cons>/<cons sem="G_DRUG">indinavir</cons>, one of the earliest protease <cons sem="G_MECHANISM">inhibitor</cons> combinations, <cons sem = "G_CHANGE">may</cons> <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
<sentence>We assessed <cons sem="G_DRUG">ritonavir</cons>/<cons sem="G_DRUG">indinavir</cons> effects on <cons lex="methadone" sem="G_DRUG">methadone</cons> pharmacokinetics and pharmacodynamics, intestinal and hepatic <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity, and intestinal transporters (P-glycoprotein) activity.</sentence>
<sentence><cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and transporters were assessed with <cons lex="alfentanil" sem="G_DRUG">alfentanil</cons> and <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons>, respectively.</sentence>
<sentence>Twelve healthy human immunodeficiency virus-negative volunteers underwent a sequential three-part crossover.</sentence>
<sentence>On three consecutive days, they received oral <cons sem="G_DRUG">alfentanil</cons>/<cons sem="G_DRUG">fexofenadine</cons>, intravenous <cons lex="alfentanil" sem="G_DRUG">alfentanil</cons>, and intravenous plus oral (deuterium-labeled) <cons lex="methadone" sem="G_DRUG">methadone</cons>, repeated after acute (3 days) and steady-state (2 weeks) ritonavir/indinavir.</sentence>
<sentence>Plasma and urine analytes were measured by mass spectrometry.</sentence>
<sentence>Opioid effects were assessed by miosis.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir/indinavir, Alfentanil, DDI)">
<sentence><cons lex="alfentanil" sem="G_DRUG" type="substrate_1">Alfentanil</cons> apparent <cons sem="G_IVIVPARA">oral clearance</cons> was <cons sem="G_MECHANISM">inhibited</cons> more than <cons sem="G_NUMBER">97%</cons> by both acute and steady-state <cons sem="G_DRUG" type="substrate_1">ritonavir</cons>/<cons sem="G_DRUG" type="substrate_2">indinavir</cons>, and systemic <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_MECHANISM">inhibited</cons> more than <cons sem="G_NUMBER">90%</cons> due to diminished hepatic and intestinal extraction.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir/indinavir, fexofenadine, DDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">Ritonavir</cons>/<cons sem="G_DRUG" type="inhibitor_2">indinavir</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="fexofenadine" sem="G_DRUG" type="substrate_2">fexofenadine</cons> <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> <cons sem="G_NUMBER">four- to five-fold</cons>, suggesting <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inhibition</cons> of gastrointestinal P-glycoprotein.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir/indinavir, methadone N-demethylation, NDDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">Ritonavir</cons>/<cons sem="G_DRUG" type="inhibitor_2">indinavir</cons> <cons sem="G_CHANGE">slightly</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="methadone" sem="G_DRUG" type="substrate_3">methadone</cons> N-demethylation, but it had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effects on <cons lex="methadone" sem="G_DRUG" type="substrate_3">methadone</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> or on systemic or apparent <cons sem="G_IVIVPARA">oral clearance</cons>, <cons sem="G_IVIVPARA">renal clearance</cons>, hepatic extraction or <cons sem="G_IVIVPARA">clearance</cons>, or <cons sem="G_IVIVPARA">bioavailability</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir/indinavir, methadone, NDDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">Ritonavir</cons>/<cons sem="G_DRUG" type="inhibitor_2">indinavir</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effects on <cons lex="methadone" sem="G_DRUG" type="substrate_3">methadone</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>-effect relationships.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of both hepatic and intestinal <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity is responsible for <cons sem="G_DRUG">ritonavir</cons>/<cons sem="G_DRUG">indinavir</cons> drug interactions.</sentence>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> disposition was unchanged, despite profound <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity, suggesting <cons sem = "G_CHANGE">little</cons> or <cons sem="G_NEGATIVEEFFECT">no</cons> role for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> in clinical <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_MECHANISM">metabolism</cons> and <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
<sentence><cons lex="methadone" sem="G_DRUG">Methadone</cons> <cons sem="G_IVIVPARA">bioavailability</cons> was unchanged, despite <cons sem="G_MECHANISM">inhibition</cons> of gastrointestinal P-glycoprotein activity, suggesting that this transporter does <cons sem="G_NEGATIVEEFFECT">not</cons> limit <cons lex="methadone" sem="G_DRUG">methadone</cons> intestinal absorption.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19223624</bibliomisc>
</articleinfo>
<title>
<sentence>Model-based approach to characterize <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> autoinduction and concurrent enzyme <cons sem="G_MECHANISM">induction</cons> with <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons>.</sentence>
</title>
<abstract>
<sentence>Characterization of the time course and magnitude of enzyme <cons sem="G_MECHANISM">induction</cons> due to multiple <cons sem="G_MECHANISM">inducers</cons> is important for interpretation of clinical data from drug-drug interaction studies.</sentence>
<sentence>A population interaction model was developed to quantify <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> autoinduction and further <cons sem="G_MECHANISM">induction</cons> with concurrent <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> coadministration.</sentence>
<sentence><cons lex="efavirenz" sem="G_DRUG">Efavirenz</cons> concentration data in the absence and presence of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> following single- and multiple-dose oral administrations in healthy subjects were used for model development.</sentence>
<sentence>The proposed model was able to describe the time-dependent <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> autoinduction and the further <cons sem="G_MECHANISM">induction</cons> with <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> when the agents were combined.</sentence>
<sentence>The estimated population averages of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> <cons sem="G_IVIVPARA">oral clearance</cons> were <cons sem="G_NUMBER">5.5, 9.4, 14.4, and 16.7 liters/h</cons> on days 1, 14, and 35 and at steady state for the interaction, respectively, for <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> monotherapy for 2 weeks followed by the coadministration of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> for 3 weeks.</sentence>
<sentence>The estimated times to <cons sem="G_NUMBER">50%</cons> of the steady state for <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> autoinduction and for the <cons sem="G_MECHANISM">induction</cons> resulting from the concurrent administration of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> and <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> were similar (around 10 to 12 days).</sentence>
<sentence>With this model-based analysis, <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> exposures can be projected prior to and at the steady state of <cons sem="G_MECHANISM">induction</cons>, allowing a better understanding of the time course and magnitude of enzyme <cons sem="G_MECHANISM">induction</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19172254</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="allicin" sem="G_DRUG">allicin</cons> on <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in healthy volunteers with different <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes.</sentence>
</title>
<abstract>
<sentence>To investigate the interaction between <cons lex="allicin" sem="G_DRUG">allicin</cons> and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and to observe the effects of allicin on <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in healthy Chinese male volunteers with different <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes.</sentence>
<sentence>Eighteen subjects (six <cons sem="G_CYP">CYP2C19*1/CYP2C19*1</cons>, four <cons sem="G_CYP">CYP2C19*1/CYP2C19*2</cons>, two <cons sem="G_CYP">CYP2C19*1/ CYP2C19*3</cons>, and six <cons sem="G_CYP">CYP2C19*2/ CYP2C19*2</cons>) were enrolled in a two-phase randomized crossover trial.</sentence>
<sentence>In each phase, all subjects received placebo or a <cons sem="G_NUMBER">180 mg</cons> <cons lex="allicin" sem="G_DRUG">allicin</cons> capsule once daily for 14 consecutive days.</sentence>
<sentence>The pharmacokinetics of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> (<cons sem="G_NUMBER">20 mg</cons> orally on day 15) was determined for up to 12 h following administration by high-performance liquid chromatography.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(allicin, omeprazole, ADDI)">
<sentence>In carriers of the <cons sem="G_CYP">CYP2C19*1/CYP2C19*1</cons> and <cons sem="G_CYP">CYP2C19*1/CYP2C19*2 or *3</cons> genotype, <cons lex="allicin" sem="G_DRUG" type="inhibitor_1">allicin</cons> treatment <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak plasma concentration (C(max))</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> by <cons sem="G_NUMBER">49.7 +/- 7.2 (p &lt; 0.001)</cons> and <cons sem="G_NUMBER">54.2 +/- 9.2% (p &lt; 0.001)</cons>, and <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the plasma time-concentration curve (AUC(0-infinity))</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> by <cons sem="G_NUMBER">48.1 +/- 9.0 (p = 0.001)</cons> and <cons sem="G_NUMBER">73.6 +/- 26.7% (p &lt; 0.001)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(allicin, omeprazole, DDI)">
<sentence>The ratio of <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of 5-hydroxyomeprazole to <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> (a marker for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity) <cons sem="G_CHANGE">decreased</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">p &lt; 0.001 and p = 0.001</cons>, respectively).</sentence>
</annotation>
<sentence>However, <cons sem="G_NEGATIVEEFFECT">no</cons> pharmacokinetic parameters were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">changed</cons> by <cons lex="allicin" sem="G_DRUG">allicin</cons> in <cons sem="G_CYP">CYP2C19*2/CYP2C19*2</cons>.</sentence>
<sentence>The <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulfone were unchanged in all three genotypes.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(allicin, omeprazole, DDI)">
<sentence><cons lex="allicin" sem="G_DRUG" type="inhibitor_1">Allicin</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> by <cons sem="G_MECHANISM">inhibiting</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity in individuals with the <cons sem="G_CYP">CYP2C19*1/CYP2C19*1</cons> and <cons sem="G_CYP">CYP2C19*1/CYP2C19*2 or *3</cons> genotypes, but <cons sem="G_NEGATIVEEFFECT">not</cons> in those with the <cons sem="G_CYP">CYP2C19*2/ CYP2C19*2</cons> genotype.</sentence>
</annotation>
<sentence><cons lex="allicin" sem="G_DRUG">Allicin</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affect</cons> the activity of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in all subjects.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19057238</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons sem="G_DRUG">desvenlafaxine</cons> on the cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6</cons> enzyme system.</sentence>
</title>
<abstract>
<sentence>The cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6 (CYP2D6)</cons> enzyme is responsible for <cons sem="G_MECHANISM">metabolizing</cons> approximately <cons sem="G_NUMBER">25%</cons> of pharmaceutical agents.</sentence>
<sentence>Individuals with impaired <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">metabolism</cons> and those concomitantly receiving agents that <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> can have variations in concentrations of such medications and their metabolites.</sentence>
<sentence>Five studies assessing the interaction between <cons sem="G_DRUG">desvenlafaxine</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> are reviewed.</sentence>
<sentence>Study 1 compared <cons sem="G_DRUG">desvenlafaxine</cons> <cons sem="G_IVIVPARA">area under the plasma concentration-versus-time curve (AUC)</cons> in <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> extensive <cons sem="G_MECHANISM">metabolizers</cons> (EMs) and poor <cons sem="G_MECHANISM">metabolizers</cons> (PMs) after administration of <cons sem="G_NUMBER">100 mg</cons> of <cons sem="G_DRUG">desvenlafaxine</cons> or <cons sem="G_NUMBER">75 mg</cons> of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> extended release (ER).</sentence>
<sentence>Studies 2 to 5 assessed the effect of concomitant administration of <cons sem="G_DRUG">desvenlafaxine</cons> <cons sem="G_NUMBER">100 mg</cons> (studies 2, 4, and 5) or <cons sem="G_NUMBER">400 mg</cons> (study 3), <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> (<cons sem="G_NUMBER">20 mg</cons>, study 4), and <cons lex="duloxetine" sem="G_DRUG">duloxetine</cons> (<cons sem="G_NUMBER">30 mg</cons> twice daily; study 5) on the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> probe <cons lex="desipramine" sem="G_DRUG">desipramine</cons>.</sentence>
<sentence>In study 1, there was <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> difference in mean <cons sem="G_DRUG">desvenlafaxine</cons> <cons sem="G_IVIVPARA">AUC</cons> between the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> EMs and PMs <cons sem="G_NUMBER">(-11%; P=0.641)</cons> who were administered <cons sem="G_DRUG">desvenlafaxine</cons>.</sentence>
<sentence>However, PMs receiving <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> ER had <cons sem="G_CHANGE">significantly</cons> higher <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> and lower <cons sem="G_DRUG">desvenlafaxine</cons> <cons sem="G_IVIVPARA">AUC</cons>s compared with EMs (<cons sem="G_NUMBER">+350% and -74%</cons>, respectively; <cons sem="G_NUMBER">P&lt;0.001</cons> for each).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(desvenlafaxine, desipramine, DDI)">
<sentence>In studies 2, 4, and 5, the mean <cons sem="G_CHANGE">increases</cons> in <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> <cons sem="G_IVIVPARA">AUC</cons> with concomitant administration of <cons sem="G_DRUG" type="inhibitor_1">desvenlafaxine</cons> <cons sem="G_NUMBER">100 mg</cons> ranged from <cons sem="G_NUMBER">17% to 36%</cons>; the <cons sem="G_CHANGE">increase</cons> with concomitant administration of <cons sem="G_DRUG" type="inhibitor">desvenlafaxine</cons> <cons sem="G_NUMBER">400 mg</cons> (study 3) was <cons sem="G_NUMBER">90%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Paroxetine, desipramine, DDI)(duloxetine, desipramine, DDI)">
<sentence><cons lex="paroxetine" sem="G_DRUG" type="inhibitor_2">Paroxetine</cons> and <cons lex="duloxetine" sem="G_DRUG" type="inhibitor_3">duloxetine</cons> produced <cons sem="G_CHANGE">increases</cons> in mean <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> <cons sem="G_IVIVPARA">AUC</cons> of <cons sem="G_NUMBER">419%</cons> and <cons sem="G_NUMBER">122%</cons>, respectively, which were <cons sem="G_CHANGE">significantly</cons> <cons sem = "G_CHANGE">greater</cons> than the <cons sem="G_CHANGE">increases</cons> seen with <cons sem="G_DRUG" type="inhibitor_1">desvenlafaxine</cons> <cons sem="G_NUMBER">100 mg</cons> (<cons sem="G_NUMBER">P&lt;0.001</cons> for each comparison).</sentence>
</annotation>
<sentence>Based on the findings presented here, <cons sem="G_DRUG">desvenlafaxine</cons> is expected to have a low risk for variability in efficacy and safety/tolerability resulting from <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> polymorphisms or drug-drug interactions when coadministered with <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> substrates or <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19025521</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of P-glycoprotein, <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderately</cons></cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of oral <cons lex="morphine" sem="G_DRUG">morphine</cons>.</sentence>
</title>
<abstract>
<sentence>Individual variation in opioid response is considerable, partly due to pharmacokinetic factors.</sentence>
<sentence>Transporter proteins are becoming increasingly interesting also in the pharmacokinetics of opioids.</sentence>
<sentence>The efflux transporter P-glycoprotein can <cons sem="G_CHANGE">affect</cons> gastrointestinal absorption and tissue distribution, particularly brain access of many opioids.</sentence>
<sentence>The aim of this study was to evaluate whether <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, which is a potent <cons sem="G_MECHANISM">inhibitor</cons> of P-glycoprotein and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, would <cons sem = "G_CHANGE">change</cons> the pharmacokinetics or the pharmacodynamics of oral <cons lex="morphine" sem="G_DRUG">morphine</cons>.</sentence>
<sentence>Twelve healthy male volunteers ingested, in a randomized crossover study, once daily <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo for 4 days.</sentence>
<sentence>On day 4, 1 h after the last pre-treatment dose, the subjects ingested <cons sem="G_NUMBER">0.3 mg/kg</cons> <cons lex="morphine" sem="G_DRUG">morphine</cons>.</sentence>
<sentence>Blood samples for the determination of plasma <cons lex="morphine" sem="G_DRUG">morphine</cons>, <cons lex="morphine" sem="G_DRUG">morphine</cons>-3-glucuronide (M3G), <cons lex="morphine" sem="G_DRUG">morphine</cons>-6-glucuronide (M6G) and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> concentrations were drawn up to 48 h after <cons lex="morphine" sem="G_DRUG">morphine</cons> ingestion.</sentence>
<sentence>Pharmacodynamic effects were evaluated using a questionnaire, visual analogue scales, a reaction time test, the Digit Symbol Substitution Test and the Critical Flicker Fusion Test.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, morphine, ADDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curve  [AUC(0-9)]</cons> of <cons lex="morphine" sem="G_DRUG" type="substrate_1">morphine</cons> by <cons sem="G_NUMBER">29%(P=0.002)</cons>, its <cons sem="G_IVIVPARA">AUC(0-48)</cons> by <cons sem="G_NUMBER">22% (P=0.013)</cons> and its <cons sem="G_IVIVPARA">peak plasma concentration</cons> by <cons sem="G_NUMBER">28% (P=0.035)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, M3G, NDDI)(Itraconazole, M6G, NDDI)(Itraconazole, morphine, NDDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affect</cons> the pharmacokinetic variables of M3G or M6G or the pharmacodynamic effects of <cons lex="morphine" sem="G_DRUG" type="substrate_1">morphine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, morphine, ADDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderately</cons></cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of oral <cons lex="morphine" sem="G_DRUG" type="substrate_1">morphine</cons>, <cons sem = "G_CHANGE">probably</cons> by enhancing its absorption by <cons sem="G_MECHANISM">inhibiting</cons> intestinal wall P-glycoprotein.</sentence>
</annotation>
<sentence>A possible improvement of <cons lex="morphine" sem="G_DRUG">morphine</cons> penetration to the brain could <cons sem="G_NEGATIVEEFFECT">not</cons> be observed.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:19015346</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="voriconazole" sem="G_DRUG">Voriconazole</cons> <cons sem="G_CHANGE">increases</cons> while <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem="G_CHANGE">decreases</cons> plasma <cons lex="meloxicam" sem="G_DRUG">meloxicam</cons> concentrations.</sentence>
</title>
<abstract>
<sentence>This study investigated the effect of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 <cons lex="2c9" sem="G_CYP">2C9 (CYP2C9)</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, on the pharmacokinetics and pharmacodynamics of <cons lex="meloxicam" sem="G_DRUG">meloxicam</cons>.</sentence>
<sentence>Twelve healthy volunteers in a crossover study ingested <cons sem="G_NUMBER">15 mg</cons> of <cons lex="meloxicam" sem="G_DRUG">meloxicam</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> pretreatment (control), after <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> pretreatment, and after <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> pretreatment.</sentence>
<sentence>The <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="meloxicam" sem="G_DRUG">meloxicam</cons>, <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, and <cons sem="G_DRUG">thromboxane B(2) (TxB(2))</cons> generation were monitored.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, meloxicam, ADDI)">
<sentence>Compared to the control phase, <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curve from 0 to 72 h (AUC(0-72))</cons> of <cons lex="meloxicam" sem="G_DRUG" type="substrate_1">meloxicam</cons> by <cons sem="G_NUMBER">47% (P &lt; 0.001)</cons> and prolonged its mean <cons sem="G_IVIVPARA">half-life(t(1/2))</cons> by <cons sem="G_NUMBER">51% (P &lt; 0.01)</cons>, <cons sem="G_NEGATIVEEFFECT">without</cons> affecting its mean <cons sem="G_IVIVPARA">peak concentration (C(max))</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, meloxicam, ADDI)">
<sentence>In contrast, <cons lex="itraconazole" sem="G_DRUG" type="inducer_1">itraconazole</cons> <cons sem="G_CHANGE">decreased</cons> the mean <cons sem="G_IVIVPARA">AUC(0-72)</cons> and <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="meloxicam" sem="G_DRUG" type="substrate_1">meloxicam</cons> by <cons sem="G_NUMBER">37% (P &lt; 0.001)</cons> and by <cons sem="G_NUMBER">64% (P &lt; 0.001)</cons>, respectively, and prolonged its <cons sem="G_IVIVPARA">t(1/2)</cons> and time to <cons sem="G_IVIVPARA">C(max)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, meloxicam, NDDI)(itraconazole, meloxicam, NDDI)">
<sentence>The plasma protein unbound fraction of <cons lex="meloxicam" sem="G_DRUG" type="substrate_1">meloxicam</cons> was <cons sem="G_NEGATIVEEFFECT">unchanged</cons> by <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inducer_1">itraconazole</cons>.</sentence>
</annotation>
<sentence>Lowered plasma <cons lex="meloxicam" sem="G_DRUG">meloxicam</cons> concentrations during the <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> phase were associated with <cons sem="G_CHANGE">decreased</cons> pharmacodymic effects of <cons lex="meloxicam" sem="G_DRUG">meloxicam</cons>, as observed by weaker <cons sem="G_MECHANISM">inhibition</cons> of <cons sem="G_DRUG">TxB(2)</cons> synthesis compared to the control and <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> phases.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, meloxicam, DDI)(itraconazole, meloxicam, DDI)">
<sentence><cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">Voriconazole</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="meloxicam" sem="G_DRUG" type="substrate_1">meloxicam</cons>, whereas <cons lex="itraconazole" sem="G_DRUG" type="inducer_1">itraconazole</cons>, unexpectedly, <cons sem="G_CHANGE">decreases</cons> plasma <cons lex="meloxicam" sem="G_DRUG" type="substrate_1">meloxicam</cons> concentrations, possibly by impairing its absorption.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18989234</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="efavirenz" sem="G_DRUG">Efavirenz</cons> induces <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons>-mediated hydroxylation of <cons lex="bupropion" sem="G_DRUG">bupropion</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence>To characterize the effect of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> on <cons lex="bupropion" sem="G_DRUG">bupropion</cons> hydroxylation as a marker of cytochrome P450 (CYP) <cons lex="2b6" sem="G_CYP">2B6</cons> activity in healthy subjects.</sentence>
<sentence>Thirteen subjects received a single oral dose of <cons lex="bupropion" sem="G_DRUG">bupropion</cons> SR <cons sem="G_NUMBER">150 mg</cons> before and after 2 weeks of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> administration for comparison of <cons lex="bupropion" sem="G_DRUG">bupropion</cons> and hydroxybupropion pharmacokinetics.</sentence>
<sentence><cons lex="efavirenz" sem="G_DRUG">Efavirenz</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> were also assessed.</sentence>
<sentence>Subjects were genotyped for <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> (G516T, C1459T, and A785G), <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (A-392G), <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> (A6986G), and multidrug resistance protein 1 (C3435T).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(efavirenz, bupropion, DDI)">
<sentence>The <cons sem="G_IVIVPARA">area under the concentration vs. time curve ratio</cons> of <cons lex="bupropion" sem="G_DRUG" type="M_1">hydroxybupropion</cons>:<cons lex="bupropion" sem="G_DRUG" type="substrate_1">bupropion</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">2.3-fold</cons> after <cons lex="efavirenz" sem="G_DRUG" type="inducer_1">efavirenz</cons> administration (<cons sem="G_NUMBER">P=0.0001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(efavirenz, bupropion, DDI)">
<sentence><cons lex="bupropion" sem="G_DRUG" type="substrate_1">Bupropion</cons> <cons sem="G_IVIVPARA">area under the concentration vs. time curve</cons> and <cons sem="G_IVIVPARA">Cmax</cons> <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">55%</cons> and <cons sem="G_NUMBER">34%</cons>, respectively (<cons sem="G_NUMBER">P&lt;0.002</cons>).</sentence>
</annotation>
<sentence>None of the <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> or <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> genotypes evaluated were associated with a difference in <cons lex="bupropion" sem="G_DRUG">bupropion</cons> or <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
<sentence>The 2 individuals homozygous for multidrug resistance protein 1 3435-T/T had <cons sem="G_NUMBER">2.5-</cons> and <cons sem="G_NUMBER">1.8-fold</cons> <cons sem = "G_CHANGE">greater</cons> <cons lex="bupropion" sem="G_DRUG">bupropion</cons> and <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> <cons sem="G_IVIVPARA">clearance</cons>, respectively, relative to C/C and C/T individuals (<cons sem="G_NUMBER">P&lt;0.05</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(efavirenz, bupropion, DDI)">
<sentence>Our results confirm that <cons lex="efavirenz" sem="G_DRUG" type="inducer_1">efavirenz</cons> <cons sem="G_MECHANISM">induces</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> enzyme activity in vivo, as demonstrated by an <cons sem="G_CHANGE">increase</cons> in <cons lex="bupropion" sem="G_DRUG" type="substrate_1">bupropion</cons> hydroxylation after 2 weeks of <cons lex="efavirenz" sem="G_DRUG" type="inducer_1">efavirenz</cons> administration.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18836708</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="voriconazole" sem="G_DRUG">Voriconazole</cons> drastically <cons sem="G_CHANGE">increases</cons> exposure to oral <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
</title>
<abstract>
<sentence>We investigated the effect of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
<sentence>Twelve healthy subjects ingested either <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> or placebo for 4 days in a randomized, cross-over study.</sentence>
<sentence>On day 3, they ingested <cons sem="G_NUMBER">10 mg</cons> <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
<sentence>Timed plasma samples were collected for the measurement of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>, noroxycodone, <cons lex="oxymorphone" sem="G_DRUG">oxymorphone</cons>, noroxymorphone and <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> up to 48 h, and pharmacodynamic effects were recorded.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, oxycodone, DDI)">
<sentence>When <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> was taken at the same time as <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons>, the mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC(0-infinity))</cons> of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">3.6-fold (range <cons sem="G_NUMBER">2.7- to 5.6-fold</cons>)</cons>, <cons sem="G_IVIVPARA">peak plasma concentration</cons> <cons sem="G_NUMBER">1.7-fold</cons> and <cons sem="G_IVIVPARA">elimination half-life</cons> <cons sem="G_NUMBER">2.0-fold (p &lt; 0.001)</cons> when compared to placebo.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(voriconazole, oxycodone, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC(0-infinity) ratio</cons> of <cons lex="oxycodone" sem="G_DRUG" type="M_1">noroxycodone</cons> to <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> was <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">92% (p &lt; 0.001)</cons>, and that of <cons lex="oxymorphone" sem="G_DRUG" type="M_2">oxymorphone</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">108% (p &lt; 0.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, oxycodone, ADDI)">
<sentence>Pharmacodynamic effects of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons> were <cons sem = "G_CHANGE">modestly</cons> <cons sem="G_CHANGE">increased</cons> by <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, oxycodone, DDI)">
<sentence><cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">Voriconazole</cons> <cons sem="G_MECHANISM">inhibits</cons> the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-mediated N-demethylation of <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons>, drastically increasing exposure to oral <cons lex="oxycodone" sem="G_DRUG" type="substrate_1">oxycodone</cons>.</sentence>
</annotation>
<sentence>Clinically, lower doses of <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons> <cons sem = "G_CHANGE">may</cons> be needed during <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> treatment to avoid opioid-related adverse effects especially after repeated dosing.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18728241</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetics of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> when co-administered with <cons lex="rifampin" sem="G_DRUG">rifampin</cons> in TB/HIV co-infected patients: pharmacogenetic effect of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> variation.</sentence>
</title>
<abstract>
<sentence>The goal of this study was to determine the effect of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> genetic variation on the steady-state pharmacokinetics of <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> (<cons sem="G_NUMBER">600 mg/d</cons>) in TB/HIV co-infected patients receiving concomitant <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, a potent CYP <cons sem="G_MECHANISM">inducer</cons>.</sentence>
<sentence>In the 26 patients studied, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> c.516GG, GT, and TT genotype frequencies were <cons sem="G_NUMBER">0.27, 0.50, and 0.23</cons>, respectively.</sentence>
<sentence>Mean plasma <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> <cons sem="G_IVIVPARA">area under the curve</cons> was <cons sem="G_CHANGE">significantly</cons> higher in patients with <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> c.516TT than in those with GT (<cons sem="G_NUMBER">107 vs 27.6 microg x h/mL, P&lt; .0001</cons>) or GG genotype (<cons sem="G_NUMBER">107 vs 23.0 microg x h/mL, P&lt; .0001</cons>).</sentence>
<sentence>Apparent <cons sem="G_IVIVPARA">oral clearance</cons> (<cons sem="G_IVIVPARA">CL/F</cons>) was <cons sem="G_CHANGE">significantly</cons> lower in patients with <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> c.516TT than in those with GT genotype (<cons sem="G_NUMBER">2.1 vs 8.4 mL/min/kg, P&lt;0.0001</cons>) and GG genotype (<cons sem="G_NUMBER">2.1 vs 9.9 mL/min/kg, P&lt; .0001</cons>).</sentence>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> differences in <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> exposure or <cons sem="G_IVIVPARA">CL/F</cons> existed between patients with <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> c.516GT and GG genotypes.</sentence>
<sentence>Our results indicate that <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> c.516TT genotype can be used to identify <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> poor <cons sem="G_MECHANISM">metabolizers</cons> in patients co-treated with <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18537963</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetics of intravenous and oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> in plasma and saliva in humans: usefulness of saliva as matrix for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> phenotyping.</sentence>
</title>
<abstract>
<sentence>To compare <cons lex="midazolam" sem="G_DRUG">midazolam</cons> kinetics between plasma and saliva and to find out whether saliva is suitable for <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> phenotyping.</sentence>
<sentence>This was a two way cross-over study in eight subjects treated with <cons sem="G_NUMBER">2 mg</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> IV or <cons sem="G_NUMBER">7.5 mg</cons> orally under basal conditions and after <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">induction</cons> with <cons sem="G_DRUG">rifampicin</cons>.</sentence>
<sentence>Under basal conditions and IV administration, <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and 1'-hydroxymidazolam (plasma, saliva), 4-hydroxymidazolam and 1'-hydroxymidazolam-glucuronide (plasma) were detectable.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, midazolam, DDI)">
<sentence>After <cons sem="G_DRUG" type="inducer_1">rifampicin</cons>, the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons>  [mean differences plasma <cons sem="G_NUMBER">53.7 (95% CI 4.6, 102.9)</cons> and saliva <cons sem="G_NUMBER">0.83 (95% CI 0.52, 1.14) ng ml(-1) h</cons>] and <cons lex="midazolam" sem="G_DRUG" type="M_1">1'-hydroxymidazolam</cons>  [mean difference plasma <cons sem="G_NUMBER">11.8 (95% CI 7.9 , 15.7) ng ml(-1) h]</cons> had <cons sem="G_CHANGE">decreased</cons> <cons sem="G_CHANGE">significantly</cons>.</sentence>
</annotation>
<sentence>There was a <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlation</cons> between the <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> concentrations in plasma and saliva (basal conditions: <cons sem="G_NUMBER">r = 0.864, P &lt; 0.0001</cons>; after <cons sem="G_DRUG" type="inducer">rifampicin</cons>: <cons sem="G_NUMBER">r = 0.842, P &lt; 0.0001</cons>).</sentence>
<sentence>After oral administration and basal conditions, <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, 1'-hydroxymidazolam and 4-hydroxymidazolam were detectable in plasma and saliva.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, midazolam, DDI)">
<sentence>After treatment with <cons sem="G_DRUG" type="inducer_1">rifampicin</cons>, the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons>  [mean difference plasma <cons sem="G_NUMBER">104.5 (95% CI 74.1, 134.9) ng ml(-1) h]</cons> and <cons lex="midazolam" sem="G_DRUG" type="M_1">1'-hydroxymidazolam</cons>  [mean differences plasma <cons sem="G_NUMBER">51.9 (95% CI 34.8, 69.1)</cons> and saliva <cons sem="G_NUMBER">2.3 (95% CI 1.9, 2.7) ng ml(-1) h</cons>] had <cons sem="G_CHANGE">decreased</cons> <cons sem="G_CHANGE">significantly</cons>.</sentence>
</annotation>
<sentence>The parameters separating best between basal conditions and post-<cons sem="G_DRUG">rifampicin</cons> were: (1'-hydroxymidazolam + 1'-hydroxymidazolam-glucuronide)/midazolam at 20-30 min (plasma) and the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> (saliva) after IV, and the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> (plasma) and of 1'-hydroxymidazolam (plasma and saliva) after oral administration.</sentence>
<sentence>Saliva appears to be a suitable matrix for non-invasive <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> phenotyping using <cons lex="midazolam" sem="G_DRUG">midazolam</cons> as a probe drug, but sensitive analytical methods are required.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18520598</bibliomisc>
</articleinfo>
<title>
<sentence>The role of cytochrome P2C19 in R-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> pharmacokinetics and its interaction with <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>.</sentence>
</title>
<abstract>
<sentence>Previous studies reported <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> to be an <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 (CYP) <cons lex="2c19" sem="G_CYP">2C19</cons> and suggested the pharmacokinetic interaction of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> with R-<cons lex="warfarin" sem="G_DRUG">warfarin</cons>.</sentence>
<sentence>The aim of this study was to compare possible effects of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> on the stereoselective pharmacokinetics and pharmacodynamics of <cons lex="warfarin" sem="G_DRUG">warfarin</cons> between <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes.</sentence>
<sentence>Seventeen subjects, of whom 10 were homozygous extensive <cons sem="G_MECHANISM">metabolizers</cons> (hmEMs) and seven were poor <cons sem="G_MECHANISM">metabolizers</cons> (PMs) for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, were enrolled in this randomized crossover study, and they ingested <cons sem="G_NUMBER">20 mg</cons> <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> or placebo once daily for 11 days.</sentence>
<sentence>On day 7, they administered a single dose of <cons sem="G_NUMBER">10 mg</cons> racemic <cons lex="warfarin" sem="G_DRUG">warfarin</cons>.</sentence>
<sentence>The <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="warfarin" sem="G_DRUG">warfarin</cons> enantiomers and prothrombin time expressed as international normalized ratio were monitored up to 120 hours.</sentence>
<sentence>During the placebo phase, <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> and <cons sem="G_IVIVPARA">elimination half-life (t1/2)</cons> of R-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> in PMs was <cons sem="G_CHANGE">significantly</cons> <cons sem = "G_CHANGE">greater</cons> than those in hmEMs (<cons sem="G_IVIVPARA">AUC[0-infinity]</cons>, <cons sem="G_NUMBER">42,938/34,613 ng h/mL  [PM/hmEM], P = 0.004</cons>; <cons sem="G_IVIVPARA">t1/2</cons>, <cons sem="G_NUMBER">48.8/40.8 hours  [PM/hmEM], P = 0.013</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Omeprazole, R-warfarin, DDI)">
<sentence><cons lex="omeprazole" sem="G_DRUG" type="inhibitor_1">Omeprazole</cons> treatment <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> <cons sem="G_NUMBER">(41,387 ng h/mL, P = 0.004)</cons> and <cons sem="G_IVIVPARA"><cons sem="G_IVIVPARA">t1/2</cons></cons> <cons sem="G_NUMBER">(46.4 hours, P = 0.017)</cons> of <cons lex="warfarin" sem="G_DRUG" type="substrate_1">R-warfarin</cons> in hmEMs to levels comparable to those in the PMs.</sentence>
</annotation>
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> differences in S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> pharmacokinetics between the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes (<cons sem="G_IVIVPARA">AUC[0-infinity]</cons>, <cons sem="G_NUMBER">15,851/16,968 ng*h/mL</cons>  [PM/hmEM]; <cons sem="G_IVIVPARA">t1/2</cons>, <cons sem="G_NUMBER">22.7/25.4 h</cons>  [PM/hmEM]), or between the two treatment phases (<cons sem="G_IVIVPARA">AUC[0-infinity]</cons>, <cons sem="G_NUMBER">14,756/18,166 ng h/mL</cons>  [PM/hmEM]; <cons sem="G_IVIVPARA">t1/2</cons>, <cons sem="G_NUMBER">27.0/25.4 hours</cons>  [PM/hmEM] in the <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> phase) as well as anticoagulant effects.</sentence>
<sentence>These results indicate that <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity was one of determinants on the R-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> disposition because the pharmacokinetics of <cons lex="warfarin" sem="G_DRUG">warfarin</cons> enantiomers were different between the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes and the <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_CHANGE">affected</cons> the R-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> pharmacokinetics of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> in only hmEMs.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Omeprazole, R-warfarin, DDI)">
<sentence>However, the phamacodynamic effect of the interaction of <cons lex="warfarin" sem="G_DRUG" type="substrate_2">warfarin</cons> with <cons lex="omeprazole" sem="G_DRUG" type="inhibitor_1">omeprazole</cons> would be of <cons sem = "G_CHANGE">minor</cons> clinical <cons sem = "G_CHANGE">significance</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18399713</bibliomisc>
</articleinfo>
<title>
<sentence>Determinants of steady-state <cons lex="torasemide" sem="G_DRUG">torasemide</cons> pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.</sentence>
</title>
<abstract>
<sentence><cons lex="torasemide" sem="G_DRUG">Torasemide</cons> is frequently used for the treatment of hypertension and heart failure.</sentence>
<sentence>However, the determinants of <cons lex="torasemide" sem="G_DRUG">torasemide</cons> pharmacokinetics in patients during steady-state conditions are largely unknown.</sentence>
<sentence>We therefore explored the impact of genetic polymorphisms of cytochrome P450 (CYP) <cons lex="2c9" sem="G_CYP">2C9 (CYP2C9)</cons> and <cons lex="1b1" sem="G_CYP">organic anion transporting polypeptide (OATP) 1B1 (SLCO1B1)</cons>, gender, and the effects of <cons lex="losartan" sem="G_DRUG">losartan</cons> and <cons lex="irbesartan" sem="G_DRUG">irbesartan</cons> comedication on the interindividual variability of steady-state pharmacokinetics of <cons lex="torasemide" sem="G_DRUG">torasemide</cons>.</sentence>
<sentence>Twenty-four patients receiving stable medication with <cons lex="torasemide" sem="G_DRUG">torasemide</cons> <cons sem="G_NUMBER">10 mg</cons> once daily and with an indication for additional angiotensin II receptor blocker (ARB) treatment to control hypertension or to treat heart failure were selected.</sentence>
<sentence>Blood samples were taken before <cons lex="torasemide" sem="G_DRUG">torasemide</cons> administration and 0.5, 1, 2, 4, 8, 12 and 24 hours after administration.</sentence>
<sentence>After this first study period, patients received either <cons lex="irbesartan" sem="G_DRUG">irbesartan</cons> <cons sem="G_NUMBER">150 mg</cons> (five female and seven male patients aged 69+/-8 years) or <cons lex="losartan" sem="G_DRUG">losartan</cons> <cons sem="G_NUMBER">100 mg</cons> (two female and ten male patients aged 61+/-8 years) once daily.</sentence>
<sentence>After 3 days of ARB medication, eight blood samples were again collected at the timepoints indicated above.</sentence>
<sentence>The patients' long-term medications, which did <cons sem="G_NEGATIVEEFFECT">not</cons> include known <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons sem="G_MECHANISM">inhibitors</cons>, were maintained at a constant dose during the study.</sentence>
<sentence>All patients were genotyped for <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> (*1/*1  [n=15]; *1/*2  [n = 4]; *1/*3  [n=5]) as well as for <cons sem="G_CYP">SLCO1B1 (c.521TT  [n=13]; c.521TC  [n=11])</cons>.</sentence>
<sentence>Factorial ANOVA revealed an independent impact of the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> genotype (dose-normalized <cons sem="G_IVIVPARA">area under the plasma concentration-time curve during the 24-hour dosing interval at steady state  [AUC(24,ss)/D]</cons>: <cons sem="G_NUMBER">*1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001</cons>), the <cons sem="G_CYP">SLCO1B1</cons> genotype (<cons sem="G_IVIVPARA">AUC(24,ss)/D</cons>: <cons sem="G_NUMBER">TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p&lt;0.05</cons>) and gender (<cons sem="G_IVIVPARA">AUC(24,ss)/D</cons>: males <cons sem="G_NUMBER">359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p&lt;0.01</cons>) on disposition of <cons lex="torasemide" sem="G_DRUG">torasemide</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(irbesartan, torasemide, ADDI)(losartan, torasemide, NDDI)">
<sentence>Coadministration of <cons lex="irbesartan" sem="G_DRUG" type="inhibitor_1">irbesartan</cons> caused a <cons sem="G_NUMBER">13%</cons> <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">AUC(24,ss)/D</cons> of <cons lex="torasemide" sem="G_DRUG" type="substrate_1">torasemide</cons> (<cons sem="G_NUMBER">p=0.002</cons>), whereas <cons lex="losartan" sem="G_DRUG" type="inhibitor_2">losartan</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> effect.</sentence>
</annotation>
<sentence>This study shows that the <cons sem="G_CYP">CYP2C9*3</cons> and <cons sem="G_CYP">SLCO1B1 c.521TC</cons> genotype and female gender are <cons sem="G_CHANGE">significant</cons> and independent predictors of the pharmacokinetics of <cons lex="torasemide" sem="G_DRUG">torasemide</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(irbesartan, torasemide, ADDI)">
<sentence>Coadministration of <cons lex="irbesartan" sem="G_DRUG" type="inhibitor_1">irbesartan</cons> yields <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> but <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> in the <cons lex="torasemide" sem="G_DRUG" type="substrate_1">torasemide</cons> <cons sem="G_IVIVPARA">plasma concentration</cons> and <cons sem="G_IVIVPARA">elimination half-life</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18333864</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inducers</cons> with and <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> on the pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>To assess the potential of known <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inducers</cons>, with and <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>, to alter the pharmacokinetic profile of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons>.</sentence>
<sentence>Two separate, open, randomized, placebo-controlled studies were conducted in healthy subjects.</sentence>
<sentence>Study 1 was a 28-day parallel-group study with three treatment groups of 12 subjects each.</sentence>
<sentence>On days 1-7, all subjects received <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> <cons sem="G_NUMBER">100 mg b.i.d.</cons>; on days 8-21, subjects received <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> <cons sem="G_NUMBER">100 mg b.i.d.</cons> plus either <cons sem="G_DRUG">rifampicin</cons> <cons sem="G_NUMBER">600 mg q.d.</cons>, <cons lex="efavirenz" sem="G_DRUG">efavirenz (EFV)</cons> <cons sem="G_NUMBER">600 mg q.d.</cons>, or placebo q.d. as assigned; on days 22-28, the <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> dose was <cons sem="G_CHANGE">increased</cons> to <cons sem="G_NUMBER">200 mg b.i.d.</cons> for patients receiving either <cons sem="G_DRUG">rifampicin</cons> or <cons lex="efavirenz" sem="G_DRUG">EFV</cons>.</sentence>
<sentence>Study 2 was a 21-day, two-way crossover study with three cohorts (12 subjects per cohort).</sentence>
<sentence>On days 1-21, subjects received <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> <cons sem="G_NUMBER">300 mg b.i.d.</cons> and boosted <cons lex="lopinavir" sem="G_DRUG">lopinavir</cons> (LPV/r, <cons lex="lopinavir" sem="G_DRUG">lopinavir</cons> <cons sem="G_NUMBER">400 mg</cons> + <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem="G_NUMBER">100 mg</cons>) or placebo b.i.d. in cohort 1, <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> <cons sem="G_NUMBER">100 mg b.i.d.</cons> and boosted <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> (SQV/r, <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> <cons sem="G_NUMBER">1000 mg</cons> + <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem="G_NUMBER">100 mg</cons>) or placebo b.i.d. in cohort 2, and <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> <cons sem="G_NUMBER">100 mg b.i.d. and 1000 mg</cons> <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> + LPV/r (<cons sem="G_NUMBER">400 mg/100 mg</cons>) or placebo b.i.d. in cohort 3.</sentence>
<sentence>On days 8-21, subjects in all three cohorts also received <cons lex="efavirenz" sem="G_DRUG">EFV</cons> <cons sem="G_NUMBER">600 mg</cons> or placebo q.d. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, Maraviroc, DDI)(EFV, Maraviroc, DDI)">
<sentence><cons lex="maraviroc" sem="G_DRUG" type="substrate_1">Maraviroc</cons> (<cons sem="G_NUMBER">100 mg b.i.d.</cons>) exposure (<cons sem="G_IVIVPARA">AUC(12)</cons> and <cons sem="G_IVIVPARA">C(max)</cons>) was <cons sem="G_CHANGE">reduced</cons> in the presence of <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> and <cons lex="efavirenz" sem="G_DRUG" type="inducer_2">EFV</cons> by approximately <cons sem="G_NUMBER">70%</cons> and <cons sem="G_NUMBER">50%</cons>, respectively.</sentence>
</annotation>
<sentence><cons lex="maraviroc" sem="G_DRUG">Maraviroc</cons> <cons sem="G_IVIVPARA">AUC(12)</cons> and <cons sem="G_IVIVPARA">C(max)</cons> approached preinduction values when the <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> dose was <cons sem="G_CHANGE">increased</cons> to <cons sem="G_NUMBER">200 mg b.i.d.</cons> for both the <cons sem="G_DRUG">rifampicin</cons>-treated and <cons lex="efavirenz" sem="G_DRUG">EFV</cons>-treated groups.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(LPV/r, Maraviroc, DDI)(EFV, Maraviroc, DDI)">
<sentence>Co-administration of <cons sem="G_DRUG" type="inhibitor_1">LPV/r</cons> with <cons lex="maraviroc" sem="G_DRUG" type="substrate_1">maraviroc</cons> (<cons sem="G_NUMBER">300 mg b.i.d.</cons>) resulted in geometric mean ratios (GMRs) of <cons sem="G_NUMBER">395%</cons> and <cons sem="G_NUMBER">197%</cons> for <cons lex="maraviroc" sem="G_DRUG" type="substrate_1">maraviroc</cons> <cons sem="G_IVIVPARA">AUC(12)</cons> and <cons sem="G_IVIVPARA">C(max)</cons>, respectively, compared with placebo; addition of <cons lex="efavirenz" sem="G_DRUG" type="inhibitor_2">EFV</cons> resulted in GMRs of <cons sem="G_NUMBER">253%</cons> and <cons sem="G_NUMBER">125%</cons> for <cons sem="G_IVIVPARA">AUC(12)</cons> and <cons sem="G_IVIVPARA">C(max)</cons>, respectively.</sentence>  
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(SQV/r, Maraviroc, DDI)(EFV, Maraviroc, DDI)">
<sentence>Co-administration of <cons sem="G_DRUG" type="inhibitor_3">SQV/r</cons> with <cons lex="maraviroc" sem="G_DRUG" type="substrate_1">maraviroc</cons> (<cons sem="G_NUMBER">100 mg b.i.d.</cons>) resulted in GMRs of <cons sem="G_NUMBER">977%</cons> and <cons sem="G_NUMBER">478%</cons> for <cons lex="maraviroc" sem="G_DRUG" type="substrate_1">maraviroc</cons> <cons sem="G_IVIVPARA">AUC(12)</cons> and <cons sem="G_IVIVPARA">C(max)</cons>, respectively, compared with placebo; addition of <cons lex="efavirenz" sem="G_DRUG" type="inhibitor_2">EFV</cons> resulted in GMRs of <cons sem="G_NUMBER">500%</cons> and <cons sem="G_NUMBER">226%</cons> for <cons sem="G_IVIVPARA">AUC(12)</cons> and <cons sem="G_IVIVPARA">C(max)</cons>, respectively.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> pharmacokinetic data are reported for cohort 3 because all subjects were discontinued during period 1 due to poor toleration of the drug regimen.</sentence>
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> serious adverse events reported in either study, and most adverse events were mild or <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> in severity and resolved <cons sem="G_NEGATIVEEFFECT">without</cons> intervention.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, Maraviroc, DDI)(EFV, Maraviroc, DDI)">
<sentence>As expected with a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrate, <cons lex="maraviroc" sem="G_DRUG" type="substrate_1">maraviroc</cons> exposure (<cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(12)</cons>) was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> by the known <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inducers</cons>, <cons sem="G_DRUG" type="inducer">rifampicin</cons> and <cons lex="efavirenz" sem="G_DRUG" type="inducer_1">EFV</cons>, by approximately <cons sem="G_NUMBER">70%</cons> and <cons sem="G_NUMBER">50%</cons>, respectively.</sentence>
</annotation>
<sentence>Upward adjustment of the <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> dose during co-administration with <cons sem="G_DRUG">rifampicin</cons> or <cons lex="efavirenz" sem="G_DRUG">EFV</cons> appears to compensate for this <cons sem ="G_CHANGE">reduction</cons>.</sentence>
<sentence>Protease <cons sem="G_MECHANISM">inhibitors</cons> (PIs) <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> exposure; however, the addition of <cons lex="efavirenz" sem="G_DRUG">EFV</cons> to the <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> + PI regimens <cons sem="G_CHANGE">reduced</cons> the magnitude of PI-mediated <cons sem="G_CHANGE">increase</cons> in <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> exposure (by approximately <cons sem="G_NUMBER">50%</cons>), but the net effect was still <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18333863</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> on the pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>To evaluate the influence of cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> on the clinical pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons>, a novel CCR5 antagonist.</sentence>
<sentence>Four open-label, randomized, placebo-controlled studies were conducted in healthy subjects to assess the effect of separate and distinct combinations of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> on the steady-state pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons>.</sentence>
<sentence>Study 1 was a two-way crossover study investigating the influence of <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> (SQV; <cons sem="G_NUMBER">1200 mg t.i.d.</cons>) and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">400 mg q.d.</cons>) on the pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> (<cons sem="G_NUMBER">100 mg b.i.d.</cons>).</sentence>
<sentence>All subjects received <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> for 7 days in both study periods.</sentence>
<sentence>Cohort 1 subjects also received <cons sem="G_DRUG">SQV</cons> or placebo and cohort 2 subjects also received <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> or placebo.</sentence>
<sentence>Study 2 was a parallel-group study including four treatment groups investigating the effects of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>-boosted <cons lex="lopinavir" sem="G_DRUG">lopinavir</cons> (LPV/r; <cons sem="G_NUMBER">400 mg/100 mg b.i.d.</cons>), <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>-boosted <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> (SQV/r; <cons sem="G_NUMBER">1000 mg/100 mg b.i.d.</cons>), and low-dose <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> (RTV; <cons sem="G_NUMBER">100 mg b.i.d.</cons>) on the steady-state pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> (<cons sem="G_NUMBER">100 mg b.i.d.</cons>), and exploring whether <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> dose adjustment can compensate for interaction effects.</sentence>
<sentence>Treatment lasted 28 days and comprised three distinct phases: (i) <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> alone on days 1-7; (ii) <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> + interactant on days 8-21; and (iii) <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> (adjusted dose) + interactant on days 22-28.</sentence>
<sentence>Study 3 was a two-way crossover study investigating the effects of <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons> (ATZ; <cons sem="G_NUMBER">400 mg q.d.</cons>) and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>-boosted <cons lex="atazanavir" sem="G_DRUG">atazanavir</cons> (ATZ/r; <cons sem="G_NUMBER">300 mg/100 mg b.i.d.</cons>) on the pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> (<cons sem="G_NUMBER">300 mg b.i.d.</cons>).</sentence>
<sentence>All subjects received <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> on days 1-14 of both study periods.</sentence>
<sentence>Subjects also received ATZ on days 1-7 and ATZ/r on days 8-14 of one treatment period, and placebo on days 1-14 of the other treatment period.</sentence>
<sentence>Study 4 was a two-way crossover study investigating the effects of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>-boosted <cons lex="tipranavir" sem="G_DRUG">tipranavir</cons> (TPV/r; <cons sem="G_NUMBER">500 mg/200 mg b.i.d.</cons>) on the pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> (<cons sem="G_NUMBER">150 mg b.i.d.</cons>).</sentence>
<sentence>Subjects received <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> plus TPV/r or placebo on days 1-8.</sentence>
<sentence>All of the drugs/drug combinations tested (except for TPV/r) <cons sem="G_CHANGE">increased</cons> <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> exposure, albeit to different degrees of magnitude.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(SQV/r, Maraviroc, DDI)(RTV, Maraviroc, DDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">SQV/r</cons> caused the largest <cons sem="G_CHANGE">increase</cons> in <cons lex="maraviroc" sem="G_DRUG" type="substrate_1">maraviroc</cons> exposure (<cons sem="G_NUMBER">8.3-fold</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">AUC(tau)</cons>), whereas <cons sem="G_DRUG" type="inhibitor_2">RTV</cons> caused the smallest <cons sem="G_CHANGE">increase</cons> in <cons lex="maraviroc" sem="G_DRUG" type="substrate_1">maraviroc</cons> exposure (<cons sem="G_NUMBER">2.6-fold</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">AUC(tau)</cons>).</sentence>
</annotation>
<sentence>Downward adjustment of the <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> dose in study 2 during co-administration of HIV protease <cons sem="G_MECHANISM">inhibitors</cons> was able to compensate for the interactions.</sentence>
<sentence>TPV/r had <cons sem="G_NEGATIVEEFFECT">no</cons> clinically relevant effect on <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> exposure at steady state.</sentence>
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> treatment-related serious adverse events or discontinuations due to adverse events in any of the studies, and most adverse events were mild or <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> in severity and resolved <cons sem="G_NEGATIVEEFFECT">without</cons> intervention.</sentence>
<sentence>Potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>, including <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and protease <cons sem="G_MECHANISM">inhibitors</cons> (except TPV/r), <cons sem="G_CHANGE">increase</cons> <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> exposure.</sentence>
<sentence>Downward adjustment of the <cons lex="maraviroc" sem="G_DRUG">maraviroc</cons> dose during co-administration with protease <cons sem="G_MECHANISM">inhibitors</cons> can compensate for the interaction.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(TPV/r, Maraviroc, NDDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_3">TPV/r</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affect</cons> the steady-state pharmacokinetics of <cons lex="maraviroc" sem="G_DRUG" type="substrate_1">maraviroc</cons>, and hence <cons sem="G_NEGATIVEEFFECT">no</cons> dose adjustment would be warranted.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18294330</bibliomisc>
</articleinfo>
<title>
<sentence>The different effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> enantiomers.</sentence>
</title>
<abstract>
<sentence>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Recently, we have shown that the <cons sem="G_IVIVPARA">plasma concentration</cons> of R-<cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> is <cons sem = "G_CHANGE">greater</cons> than that of the S-enantiomer.</sentence>
<sentence>Although <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> co-administration is known to <cons sem="G_CHANGE">increase</cons> the <cons sem="G_IVIVPARA">bioavailability</cons> of a racemic mixture of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons>, <cons sem = "G_CHANGE">little</cons> is known about the stereoselective <cons sem="G_MECHANISM">inhibition</cons> of P-gp activity by <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
<sentence>This study indicates that the stereoselective pharmacokinetics of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> are due to P-gp-mediated transport and its stereoselectivity is <cons sem="G_CHANGE">altered</cons> by <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, a an <cons sem="G_MECHANISM">inhibitor</cons> of P-gp.</sentence>
<sentence>The aim of this study was to determine the <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, a P-glycoprotein (P-gp) <cons sem="G_MECHANISM">inhibitor</cons>, on the stereoselective pharmacokinetics of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons>.</sentence>
<sentence>A two-way double-blind, placebo-controlled crossover study was performed with a 2-week washout period.</sentence>
<sentence>Twelve healthy volunteers received either <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem="G_NUMBER">200 mg</cons> or matched placebo in a randomized fashion with a single oral dose of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> <cons sem="G_NUMBER">60 mg</cons> simultaneously.</sentence>
<sentence>The <cons sem="G_IVIVPARA">plasma concentrations</cons> and the amount of <cons sem="G_IVIVPARA">urinary excretion (Ae)</cons> of <cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> enantiomers were measured up to 24 h after dosing.</sentence>
<sentence>After placebo administration, mean <cons sem="G_IVIVPARA">AUC(0,24 h)</cons> of S- and R-<cons lex="fexofenadine" sem="G_DRUG">fexofenadine</cons> was <cons sem="G_NUMBER">474 ng ml(-1) h (95% CI 311, 638) and 798 ng ml(-1) h (95% CI 497, 1101)</cons>, respectively.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, S-fexofenadine, DDI)(Itraconazole, R-fexofenadine, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">affected</cons> the pharmacokinetic parameters of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">S-fexofenadine</cons> more, and <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">AUC(0,24 h)</cons> of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">S-fexofenadine</cons> and <cons lex="fexofenadine" sem="G_DRUG" type="substrate_2">R-fexofenadine</cons> by <cons sem="G_NUMBER">4.0-fold (95% CI of differences 2.8, 5.3; P &lt; 0.001)</cons> and by <cons sem="G_NUMBER">3.1-fold (95% CI of differences 2.2, 4.0; P = 0.014)</cons>, respectively, and <cons sem="G_IVIVPARA">Ae(0,24 h)</cons> of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_1">S-fexofenadine</cons> and <cons lex="fexofenadine" sem="G_DRUG" type="substrate_2">R-fexofenadine</cons> by <cons sem="G_NUMBER">3.6-fold (95% CI of differences 2.6, 4.5; P &lt; 0.001)</cons> and by <cons sem="G_NUMBER">2.9-fold (95% CI of differences 2.1, 3.8; P &lt; 0.001)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Itraconazole, S-fexofenadine, DDI)(Itraconazole, R-fexofenadine, DDI)">
<sentence>Additionally, the R : S ratio for <cons sem="G_IVIVPARA">AUC(0,24 h)</cons> and <cons sem="G_IVIVPARA">Ae(0,24 h)</cons> were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> in the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phase, while <cons sem="G_IVIVPARA">t(max)</cons>, <cons sem="G_IVIVPARA">t(1/2)</cons> and <cons sem="G_IVIVPARA">renal clearance</cons> were constant during the study.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, fexofenadine, DDI)">
<sentence>This study indicates that the stereoselective pharmacokinetics of <cons lex="fexofenadine" sem="G_DRUG" type="substrate_3">fexofenadine</cons> are due to P-gp-mediated transport and its stereoselectivity is <cons sem="G_CHANGE">altered</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>, a P-gp <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
</annotation>
<sentence>However, further study will be needed because the different affinities of the two enantiomers for P-gp have <cons sem="G_NEGATIVEEFFECT">not</cons> been supported by in vitro studies.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18193210</bibliomisc>
</articleinfo>
<title>
<sentence>Drug interaction between oral <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> and <cons lex="verapamil" sem="G_DRUG">verapamil</cons> in healthy subjects: effects of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> on the pharmacokinetics of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and norverapamil.</sentence>
</title>
<abstract>
<sentence>It has been reported that <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> are <cons sem="G_MECHANISM">inhibitors</cons> of both P-glycoprotein (P-gp) and microsomal cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>, and <cons lex="verapamil" sem="G_DRUG">verapamil</cons> is a substrate of both P-gp and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Thus, it could be expected that <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> would alter the absorption and <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="verapamil" sem="G_DRUG">verapamil</cons>.</sentence>
<sentence>The pharmacokinetic parameters of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and one of its metabolites, norverapamil, were compared after oral administration of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> (<cons sem="G_NUMBER">60 mg</cons>) in the presence or absence of oral <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> (<cons sem="G_NUMBER">40 mg</cons>) in 12 healthy volunteers.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(atorvastatin, verapamil, DDI)">
<sentence>Pharmacokinetics of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">altered</cons> by the coadministration of <cons lex="atorvastatin" sem="G_DRUG" type="inhibitor_1">atorvastatin</cons> compared with those of <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="atorvastatin" sem="G_DRUG" type="inhibitor_1">atorvastatin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(atorvastatin, verapamil, ADDI)">
<sentence>For example, the total <cons sem="G_IVIVPARA">area under the plasma-concentration time curve to the last measured time, 24 h, in plasma (AUC(0-24) (h))</cons> of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_CHANGE">significantly</cons> by <cons sem="G_NUMBER">42.8%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(atorvastatin, verapamil, ADDI)">
<sentence>Thus, the relative <cons sem="G_IVIVPARA">bioavailability</cons> <cons sem="G_CHANGE">increased</cons> by the same magnitude with <cons lex="atorvastatin" sem="G_DRUG" type="inhibitor_1">atorvastatin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(atorvastatin, verapamil, ADDI)">
<sentence>Although the <cons sem="G_IVIVPARA">AUC(0-24) (h)</cons> of <cons lex="verapamil" sem="G_DRUG" type="M_1">norverapamil</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> different between two groups of humans, the <cons sem="G_IVIVPARA">AUC(0-24) (h, norverapamil)/ AUC(0-24) (h, <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons>) ratio</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> (<cons sem="G_NUMBER">27.5%</cons> <cons sem="G_CHANGE">decrease</cons>) with <cons lex="atorvastatin" sem="G_DRUG" type="inhibitor_1">atorvastatin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(atorvastatin, verapamil, DDI)">
<sentence>The above data suggest that <cons lex="atorvastatin" sem="G_DRUG" type="inhibitor_1">atorvastatin</cons> could <cons sem="G_MECHANISM">inhibit</cons> the absorption of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> via <cons sem="G_MECHANISM">inhibition</cons> of P-gp and/or the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in humans.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18094221</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, an <cons sem="G_MECHANISM">inducer</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and P-glycoprotein, on the pharmacokinetics of <cons lex="risperidone" sem="G_DRUG">risperidone</cons>.</sentence>
</title>
<abstract>
<sentence>The authors studied the effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, a dual <cons sem="G_MECHANISM">inducer</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of <cons lex="risperidone" sem="G_DRUG">risperidone</cons> in humans.</sentence>
<sentence>Ten healthy male subjects were treated daily for 7 days with <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or with placebo.</sentence>
<sentence>On day 6, a single dose of <cons sem="G_NUMBER">1 mg</cons> <cons lex="risperidone" sem="G_DRUG">risperidone</cons> was administered.</sentence>
<sentence>Plasma <cons lex="risperidone" sem="G_DRUG">risperidone</cons> and 9-hydroxyrisperidone concentrations were measured.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, risperidone, ADDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> the mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> by <cons sem="G_NUMBER">51%</cons> for <cons lex="risperidone" sem="G_DRUG" type="substrate_1">risperidone</cons>, by <cons sem="G_NUMBER">43%</cons> for <cons lex="risperidone" sem="G_DRUG" type="M_1">9-hydroxyrisperidone</cons>, and by <cons sem="G_NUMBER">45%</cons> for the active moieties (<cons lex="risperidone" sem="G_DRUG" type="substrate_1">risperidone</cons> + <cons lex="risperidone" sem="G_DRUG" type="M_1">9-hydroxyrisperidone</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, risperidone, ADDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> also <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="risperidone" sem="G_DRUG" type="substrate_1">risperidone</cons> by <cons sem="G_NUMBER">38%</cons>, 9-hydroxyrisperidone by <cons sem="G_NUMBER">46%</cons>, and the active moieties by <cons sem="G_NUMBER">41%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, risperidone, DDI)">
<sentence>The apparent <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="risperidone" sem="G_DRUG" type="substrate_1">risperidone</cons> approximately <cons sem = "G_CHANGE">doubled</cons> after <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> treatment.</sentence>
</annotation>
<sentence>Thus, <cons lex="rifampin" sem="G_DRUG">rifampin</cons> <cons sem="G_CHANGE">reduced</cons> the exposure to <cons lex="risperidone" sem="G_DRUG">risperidone</cons>, <cons sem = "G_CHANGE">probably</cons> because of a <cons sem="G_CHANGE">decrease</cons> in its <cons sem="G_IVIVPARA">bioavailability</cons> through the <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and <cons sem = "G_CHANGE">probably</cons> P-glycoprotein.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18043911</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> <cons sem="G_MECHANISM">metabolism</cons> and potentiation of its effects by <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> in routinely treated patients with acute myocardial infarction (AMI).</sentence>
</title>
<abstract>
<sentence>To investigate the influence of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> on <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> concentrations and its effect in patients treated for acute myocardial infarction (AMI) who are routinely given <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> as a co-treatment of depression.</sentence>
<sentence>We recruited 17 depressed AMI patients who received <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> as a routine part of their therapy (mean dose <cons sem="G_NUMBER">75 +/- 39 mg/day</cons>).</sentence>
<sentence>Patients were genotyped for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> 3, 4 and gene duplication.</sentence>
<sentence><cons lex="metoprolol" sem="G_DRUG">Metoprolol</cons> and alpha-hydroxy-<cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> were analyzed in plasma 0, 2, 6 and 12 h post-dose.</sentence>
<sentence>Heart rates (HR) at rest were registered after each sampling.</sentence>
<sentence><cons lex="paroxetine" sem="G_DRUG">Paroxetine</cons> <cons sem="G_NUMBER">20 mg</cons> daily was then administered, and all measurements were repeated on day 8.</sentence>
<sentence>All patients were genotypically extensive <cons sem="G_MECHANISM">metabolizers</cons> (EMs) (nine with 1/1 and eight with 1/3 or 4).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(paroxetine, metoprolol, DDI)">
<sentence>Following the administration of <cons lex="paroxetine" sem="G_DRUG" type="inhibitor_1">paroxetine</cons>, mean <cons lex="metoprolol" sem="G_DRUG" type="substrate_1">metoprolol</cons> <cons sem="G_IVIVPARA">areas under the concentration-time curve (AUC)</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">( 1064 +/- 1213 to 4476 +/- 2821 nM x h/mg per kg, P = 0.0001)</cons>, while metabolite <cons sem="G_IVIVPARA">AUC</cons>s <cons sem="G_CHANGE">decreased</cons> <cons sem="G_NUMBER">(1492 +/- 872 to 348 +/- 279 n M x h/mg per kg, P &lt; 0.0001)</cons>, with an <cons sem="G_CHANGE">increase</cons> of metabolic ratios (MR) <cons sem="G_NUMBER">(0.9 +/- 1.3 to 26 +/- 29; P &lt; 0.0001)</cons>.</sentence>
</annotation>
<sentence>Mean HRs were <cons sem="G_CHANGE">significantly</cons> lower after the study week at each time point.</sentence>
<sentence>Mean <cons sem="G_IVIVPARA">area under the HR versus time curve (AUEC)</cons> <cons sem="G_CHANGE">decreased</cons> (<cons sem="G_NUMBER">835 +/- 88 to 728 +/- 84 beats x h/min; P = 0.0007</cons>).</sentence>
<sentence><cons lex="metoprolol" sem="G_DRUG">Metoprolol</cons> <cons sem="G_IVIVPARA">AUC</cons>s <cons sem="G_MECHANISM">correlated</cons> with patients' <cons sem="G_IVIVPARA">AUECs</cons> at the baseline (Spearman <cons sem="G_NUMBER">r = -0.64, P &lt; 0.01</cons>), but <cons sem="G_NEGATIVEEFFECT">not</cons> on the eighth day of the study.</sentence>
<sentence>A <cons sem ="G_CHANGE">reduction</cons> of <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> dose was required in two patients due to excessive bradycardia and severe orthostatic hypotension.</sentence>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> other adverse effects of the drugs were identified.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(paroxetine, metoprolol, DDI)">
<sentence>A <cons sem = "G_CHANGE">pronounced</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="metoprolol" sem="G_DRUG" type="substrate_1">metoprolol</cons> <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="paroxetine" sem="G_DRUG" type="inhibitor_1">paroxetine</cons> was observed in AMI patients, but <cons sem="G_NEGATIVEEFFECT">without</cons> serious adverse effects.</sentence>
</annotation>
<sentence>We suggest, however, that the <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> dose is controlled upon initiation and withdrawal of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18034666</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> on the pharmacokinetics of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>.</sentence>
</title>
<abstract>
<sentence>The nonsteroidal anti-inflammatory drug <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> is extensively <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 (CYP) enzymes, mainly by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>Our objective was to study the effect of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of several CYP enzymes, on the pharmacokinetics of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>.</sentence>
<sentence>This study had a two-way, open, crossover design and included 10 healthy caucasian male subjects.</sentence>
<sentence>In the control phase, the subjects ingested a single <cons sem="G_NUMBER">50-mg</cons> oral dose of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons>.</sentence>
<sentence>In the <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> phase, the subjects ingested <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> <cons sem="G_NUMBER">400 mg</cons> twice daily on the first day and <cons sem="G_NUMBER">200 mg</cons> twice daily on the second day, and <cons sem="G_NUMBER">50 mg</cons> <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> was given 1 h after the last dose of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>.</sentence>
<sentence>Plasma <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> concentrations were determined for up to 24 h post-dose.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, diclofenac, DDI)">
<sentence>In the <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> phase, the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> of <cons lex="diclofenac" sem="G_DRUG" type="substrate_1">diclofenac</cons> was <cons sem="G_NUMBER">178% (95% CI 143-212%; P &lt; 0.001)</cons> and the <cons sem="G_IVIVPARA">peak plasma concentration</cons> was <cons sem="G_NUMBER">214% (95% CI 128-300%; P &lt; 0.05)</cons> of the respective control value.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, diclofenac, NDDI)">
<sentence><cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">Voriconazole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affect</cons> <cons sem="G_CHANGE">significantly</cons> the <cons sem="G_IVIVPARA">elimination half-life</cons> or <cons sem="G_IVIVPARA">time to maximum concentration</cons> of <cons lex="diclofenac" sem="G_DRUG" type="substrate_1">diclofenac</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, diclofenac, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="diclofenac" sem="G_DRUG" type="substrate_1">diclofenac</cons> was <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">47% (95% CI -76% to -16%; P &lt; 0.01</cons>) by <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, diclofenac, DDI)">
<sentence>In conclusion, <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> <cons sem="G_CHANGE">increased</cons> exposure to <cons lex="diclofenac" sem="G_DRUG" type="substrate_1">diclofenac</cons>, <cons sem = "G_CHANGE">probably</cons> mainly by <cons sem="G_MECHANISM">inhibition</cons> of its cytochrome P450 (CYP)-mediated <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, and to some extent that of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> enzymes during the first-pass <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> seems to be involved in the interaction.</sentence>
<sentence>The clinical importance of the interaction between <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> remains to be studied, but lower doses of <cons lex="diclofenac" sem="G_DRUG">diclofenac</cons> <cons sem = "G_CHANGE">may</cons> be adequate for patients receiving <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18025525</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic interaction between <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> at steady state in healthy male subjects.</sentence>
</title>
<abstract>
<sentence>A randomized, placebo-controlled (with respect to <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>), 2-period, multiple-dose intragroup fixed-dose sequence study was conducted in 34 healthy male subjects to evaluate the interactions between <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> (triazole antifungal agent) and <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> (reverse transcriptase <cons sem="G_MECHANISM">inhibitor</cons>).</sentence>
<sentence>In period 1, subjects received <cons sem="G_NUMBER">200 mg</cons> twice-daily (bid) <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> (n = 17) or placebo (n = 17) for 3 days (<cons sem="G_NUMBER">400-mg</cons> bid loading doses on day 1).</sentence>
<sentence>In period 2, following a 7-day washout, subjects received <cons sem="G_NUMBER">400 mg</cons> once-daily (qd) <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> alone for 10 days (days 11-20).</sentence>
<sentence>Then <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> was coadministered with <cons sem="G_NUMBER">200 mg</cons> bid <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> or placebo for the next 9 days (days 21-29).</sentence>
<sentence>Serial plasma <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> concentrations were measured on days 3, 19, and 29, and the safety data were collected throughout the study.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(efavirenz, voriconazole, DDI)">
<sentence>The <cons sem="G_NUMBER">400-mg qd</cons> <cons lex="efavirenz" sem="G_DRUG" type="inducer_1">efavirenz</cons> dose substantially <cons sem="G_CHANGE">reduced</cons> the steady-state mean <cons lex="voriconazole" sem="G_DRUG" type="substrate_1">voriconazole</cons> <cons sem="G_IVIVPARA">area under the curve over the dosing interval (AUC0-12)</cons> by <cons sem="G_NUMBER">80% (90% confidence interval  [CI], 75%-84%)</cons> and <cons sem="G_IVIVPARA">peak concentration (Cmax)</cons> by <cons sem="G_NUMBER">66%(90% CI, 57%-73%)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(efavirenz, voriconazole, DDI)">
<sentence>The <cons sem="G_CHANGE">decrease</cons> in <cons lex="voriconazole" sem="G_DRUG" type="substrate_1">voriconazole</cons> exposure during coadministration is <cons sem = "G_CHANGE">probably</cons> mainly due to the <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> by <cons lex="efavirenz" sem="G_DRUG" type="inducer_1">efavirenz</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, efavirenz, ADDI)">
<sentence>The <cons sem="G_NUMBER">200 mg bid</cons> <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> <cons sem="G_CHANGE">increased</cons> the steady-state mean <cons sem="G_IVIVPARA">AUC0-24</cons> and <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="efavirenz" sem="G_DRUG" type="substrate_2">efavirenz</cons> by <cons sem="G_NUMBER">43% (90% CI, 36%-51%)</cons> and <cons sem="G_NUMBER">37% (90% CI, 29%-46%)</cons>, respectively.</sentence>
</annotation>
<sentence>The <cons sem="G_CHANGE">increase</cons> in <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> exposure during coadministration is <cons sem = "G_CHANGE">probably</cons> due to the <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> by <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(efavirenz, voriconazole, DDI)">
<sentence>Coadministration of <cons sem="G_NUMBER">200 mg bid</cons> <cons lex="voriconazole" sem="G_DRUG" type="substrate_1">voriconazole</cons> with <cons sem="G_NUMBER">400 mg</cons> (or higher) qd <cons lex="efavirenz" sem="G_DRUG" type="inhibitor_1">efavirenz</cons> is contraindicated due to the clinically <cons sem="G_CHANGE">significant</cons> effect of <cons lex="efavirenz" sem="G_DRUG" type="inhibitor_1">efavirenz</cons> on <cons lex="voriconazole" sem="G_DRUG" type="substrate_1">voriconazole</cons> pharmacokinetics.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:18021336</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic interaction between <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="praziquantel" sem="G_DRUG">Praziquantel</cons>, a broad-spectrum anthelminthic, has been reported to undergo extensive first-pass <cons sem="G_MECHANISM">metabolism</cons> by cytochrome P450 (CYP) enzymes in vivo.</sentence>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons>, a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, is known to <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increase</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of many co-administered drugs.</sentence>
<sentence>However, <cons sem="G_NEGATIVEEFFECT">no</cons> data are available on the potential pharmacokinetic drug interaction between <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> in humans.</sentence>
<sentence>To investigate the potential pharmacokinetic interaction of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> with <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> in healthy adult Thai male volunteers.</sentence>
<sentence>In an open-label, randomized two-phase crossover study, separated by a 2-week period, 10 healthy adult Thai male volunteers ingested a single dose of <cons sem="G_NUMBER">20 mg/kg</cons> <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> alone or with co-administration of <cons sem="G_NUMBER">400-mg</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> orally daily for 5 days.</sentence>
<sentence>Venous blood samples were collected at specific times for a 24-h period.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> were determined using high-performance liquid chromatography.</sentence>
<sentence>A non-compartmental model was applied for pharmacokinetic parameter analysis of <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, praziquantel, DDI)">
<sentence>Concurrent administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> with <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">area under the curve from time zero to infinity (AUC(0-alpha))</cons> and <cons sem="G_IVIVPARA">maximum plasma concentration (Cmax)</cons> of <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> by <cons sem="G_NUMBER">93% (955.94 +/- 307.74 vs. 1843.10 +/- 336.39 ng h/mL; P &lt; 0.01)</cons> and <cons sem="G_NUMBER">102% (183.38 +/- 43.90 vs. 371.31 +/- 44.63 ng/mL; P &lt; 0.01)</cons>, respectively, whereas the mean total <cons sem="G_IVIVPARA">clearance (CL/F)</cons> of <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">58% (2.65 +/- 0.64 vs. 1.11 +/- 0.35 mL/h/kg; P &lt; 0.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, praziquantel, ADDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">Ketoconazole</cons> co-administration alters the pharmacokinetics of <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons> in humans, possibly through <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, particularly <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, first-pass <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="praziquantel" sem="G_DRUG" type="substrate_1">praziquantel</cons>.</sentence>
</annotation>
<sentence>Our data suggest that when <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> is co-administered with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, the dose of <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> could be <cons sem="G_CHANGE">reduced</cons> to half the standard dose of <cons lex="praziquantel" sem="G_DRUG">praziquantel</cons> to <cons sem="G_CHANGE">reduce</cons> the cost of therapy.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17987285</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> on the pharmacokinetics of intravenous <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="fentanyl" sem="G_DRUG">Fentanyl</cons> is a widely used opioid analgesic, which is extensively <cons sem="G_MECHANISM">metabolized</cons> by hepatic cytochrome P450 (CYP) <cons lex="3a" sem="G_CYP">3A</cons>.</sentence>
<sentence>Recent reports suggest that concomitant administration of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibitors</cons> with <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> <cons sem = "G_CHANGE">may</cons> lead to dangerous drug interactions.</sentence>
<sentence>The potential interactions of <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> with triazole antifungal agents <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> were studied in a randomized crossover study in three phases.</sentence>
<sentence>Twelve healthy volunteers were given <cons sem="G_NUMBER">5 microg/kg</cons> of intravenous <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> pretreatment (control), after oral <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> (<cons sem="G_NUMBER">400 mg</cons> twice on the first day and <cons sem="G_NUMBER">200 mg</cons> twice on the second day), or after oral <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> (<cons sem="G_NUMBER">400 mg</cons> once on the first day and <cons sem="G_NUMBER">200 mg</cons> once on the second day).</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons>, norfentanyl, <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons>, and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> were determined up to 24 h. Pharmacokinetic parameters were calculated using compartmental methods.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, fentanyl, ADDI)(fluconazole, fentanyl, ADDI)">
<sentence>The mean plasma <cons sem="G_IVIVPARA">clearance</cons> of intravenous <cons lex="fentanyl" sem="G_DRUG" type="substrate_1">fentanyl</cons> was <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">23% (range -22 to 48%; p &lt; 0.05)</cons> and <cons sem="G_NUMBER">16% (-34 to 53%; p &lt; 0.05)</cons> after <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_2">fluconazole</cons> administration, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, fentanyl, ADDI)">
<sentence><cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">Voriconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the <cons lex="fentanyl" sem="G_DRUG" type="substrate_1">fentanyl</cons> plasma concentration-time curve</cons> by <cons sem="G_NUMBER">1.4-fold (p &lt; 0.05)</cons>.</sentence>
</annotation>
<sentence>The initial <cons sem="G_IVIVPARA">plasma concentrations</cons> and volume of distribution of <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> differ <cons sem="G_CHANGE">significantly</cons> between phases.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, fentanyl, DDI)(fluconazole, fentanyl, DDI)">
<sentence>Both <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_2">fluconazole</cons> delay the elimination of <cons lex="fentanyl" sem="G_DRUG" type="substrate_1">fentanyl</cons> <cons sem="G_CHANGE">significantly</cons>.</sentence>
</annotation>
<sentence>Caution should be exercised, especially in patients who are given <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> or <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> during long-lasting <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> treatment, because insidiously elevated <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> concentration <cons sem = "G_CHANGE">may</cons> lead to respiratory depression.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17913794</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="trimethoprim" sem="G_DRUG">Trimethoprim</cons> and the <cons sem="G_CYP">CYP2C8*3 allele</cons> have opposite effects on the pharmacokinetics of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>.</sentence>
</title>
<abstract>
<sentence>We studied the effects of the <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> genotype on the pharmacokinetics of the antidiabetic <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>.</sentence>
<sentence>In a randomized crossover study, 16 healthy volunteers with the <cons sem="G_CYP">CYP2C8(*)1/(*)1</cons> (n = 8), (*)1/(*)3 (n = 5), or (*)3/(*)3 (n = 3) genotype ingested <cons sem="G_NUMBER">160 mg</cons> of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> or placebo twice daily for 6 days.</sentence>
<sentence>On day 3, they ingested <cons sem="G_NUMBER">15 mg</cons> of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>.</sentence>
<sentence>The effects of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> on <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons> were characterized in vitro.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Trimethoprim, pioglitazone, ADDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> <cons sem="G_CHANGE">raised</cons> the <cons sem="G_IVIVPARA">area under the plasma <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> concentration-time curve (AUC(0-infinity))</cons> by <cons sem="G_NUMBER">42% (p &lt; 0.001)</cons> and <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_MECHANISM">formation</cons> rates of <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> metabolites M-IV and M-III (<cons sem="G_NUMBER">p &lt; 0.001</cons>).</sentence>
</annotation>
<sentence>During the placebo phase, the weight-adjusted <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons> was <cons sem="G_NUMBER">34%</cons> smaller in the <cons sem="G_CYP">CYP2C8(*)3/(*)3</cons> group and <cons sem="G_NUMBER">26%</cons> smaller in the <cons sem="G_CYP">CYP2C8(*)1/(*)3</cons> group than in the <cons sem="G_CYP">CYP2C8(*)1/(*)1</cons> group (<cons sem="G_NUMBER">p &lt; 0.05</cons>).</sentence>
<annotation sem="INVIVOVDDIS" ddi="(Trimethoprim, pioglitazone, DDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> <cons sem="G_MECHANISM">inhibited</cons> M-IV <cons sem="G_MECHANISM">formation</cons> in vitro (<cons sem="G_MECHANISM">inhibition</cons> constant <cons sem="G_NUMBER">38.2 muM</cons>), predicting the in vivo interaction.</sentence>
</annotation>
<sentence>In conclusion, drug interactions and pharmacogenetics affecting the <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> enzyme <cons sem = "G_CHANGE">may</cons> <cons sem = "G_CHANGE">change</cons> the safety of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17909805</bibliomisc>
</articleinfo>
<title>
<sentence>A phase I study of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> modulation in patients with advanced cancers.</sentence>
</title>
<abstract>
<sentence>The aims were to determine the maximum tolerable dose (MTD) of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> with <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, and to <cons sem="G_MECHANISM">correlate</cons> the pharmacokinetics of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> with <cons lex="midazolam" sem="G_DRUG">midazolam</cons> phenotyping of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity.</sentence>
<sentence>Forty-one patients with refractory metastatic cancers were treated with an escalating dose of intravenous <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> once in every 3 week of <cons sem="G_NUMBER">10 mg/m(2)</cons>, concurrently with oral <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">200 mg</cons> twice daily for 3 days starting 2 days before the administration of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence>
<sentence><cons lex="midazolam" sem="G_DRUG">Midazolam</cons> phenotyping test with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> modulation was performed before the first cycle of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence>
<sentence><cons lex="docetaxel" sem="G_DRUG">Docetaxel</cons> and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> pharmacokinetics were compared to our previous study of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> treatment <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> modulation.</sentence>
<sentence>Neutropenia was the dose-limiting toxicity.</sentence>
<sentence>The maximum tolerated dose was <cons sem="G_NUMBER">70 mg</cons> with mean <cons sem="G_IVIVPARA">AUC</cons> at <cons sem="G_NUMBER">70 mg</cons> similar to <cons sem="G_NUMBER">75 mg/m(2)</cons> of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, docetaxel, DDI)(ketoconazole, midazolam, DDI)">
<sentence>The plasma <cons sem="G_IVIVPARA">clearances</cons> of <cons lex="docetaxel" sem="G_DRUG" type="substrate_1">docetaxel</cons> and <cons lex="midazolam" sem="G_DRUG" type="substrate_2">midazolam</cons> were <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">1.7-</cons> and <cons sem="G_NUMBER">6-folds</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, docetaxel, DDI)(ketoconazole, midazolam, DDI)">
<sentence>The variability of <cons lex="midazolam" sem="G_DRUG" type="substrate_2">midazolam</cons> <cons sem="G_IVIVPARA">AUC</cons> was <cons sem="G_CHANGE">reduced</cons> from <cons sem="G_NUMBER">157 to 67%</cons>, but variability of <cons lex="docetaxel" sem="G_DRUG" type="substrate_1">docetaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">reduced</cons> by <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibition</cons>.</sentence>
</annotation>
<sentence><cons lex="docetaxel" sem="G_DRUG">Docetaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> <cons sem="G_MECHANISM">correlated</cons> with renal function and maximum concentration of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_IVIVPARA">clearance</cons> or other variables of hepatic function.</sentence>
<sentence>Fixed dosing was found to be feasible, <cons sem="G_NEGATIVEEFFECT">without</cons> <cons sem="G_CHANGE">increased</cons> variability of <cons sem="G_IVIVPARA">clearance</cons> or neutrophil toxicity compared to BSA-based dosing.</sentence>
<sentence>With <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> modulation, <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> <cons sem="G_MECHANISM">correlated</cons> with renal function but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> phenotype.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17687273</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="terbinafine" sem="G_DRUG">terbinafine</cons> and <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> on the pharmacokinetics of the antidepressant <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons>.</sentence>
</title>
<abstract>
<sentence>This study investigated the effect of <cons lex="terbinafine" sem="G_DRUG">terbinafine</cons> and <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> on the pharmacokinetics of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> in healthy volunteers.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> and <cons sem="G_DRUG">O-desmethylvenlafaxine (ODV)</cons> were measured after ingestion of <cons sem="G_NUMBER">75 mg</cons> <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> pretreatment (control), after <cons lex="terbinafine" sem="G_DRUG">terbinafine</cons> pretreatment, or after <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> pretreatment.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(terbinafine, venlafaxine, DDI)">
<sentence>During the <cons lex="terbinafine" sem="G_DRUG" type="inhibitor_1">terbinafine</cons> phase, the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC(0-infinity))</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> was on average <cons sem="G_NUMBER">490% (P&lt;0.001)</cons> and that of <cons lex="venlafaxine" sem="G_DRUG" type="M_1">ODV</cons> <cons sem="G_NUMBER">57% (P&lt;0.001)</cons> of the corresponding control value.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(terbinafine, venlafaxine, DDI)">
<sentence><cons lex="terbinafine" sem="G_DRUG" type="inhibitor_1">Terbinafine</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity) ratio</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="M_1">ODV</cons> over <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> by <cons sem="G_NUMBER">82% (P&lt;0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Voriconazole, venlafaxine, ADDI)">
<sentence><cons lex="voriconazole" sem="G_DRUG" type="inhibitor_2">Voriconazole</cons> <cons sem="G_CHANGE">slightly</cons> <cons sem="G_CHANGE">increased</cons> the sum of <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> plus <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="M_1">ODV</cons> (active moiety) by <cons sem="G_NUMBER">31% (P&lt;0.001)</cons>.</sentence>
</annotation>
<sentence>The most likely mechanism for the interaction between <cons lex="terbinafine" sem="G_DRUG">terbinafine</cons> and <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> is the <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated O-demethylation of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons>, whereas the <cons sem = "G_CHANGE">minor</cons> effects of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> are <cons sem = "G_CHANGE">probably</cons> due to the <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-, or <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17676319</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="voriconazole" sem="G_DRUG">Voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> <cons sem="G_CHANGE">increase</cons> the exposure to oral <cons lex="diazepam" sem="G_DRUG">diazepam</cons>.</sentence>
</title>
<abstract>
<sentence>We assessed the effect of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="diazepam" sem="G_DRUG">diazepam</cons>.</sentence>
<sentence>Twelve healthy volunteers took <cons sem="G_NUMBER">5 mg</cons> of oral <cons lex="diazepam" sem="G_DRUG">diazepam</cons> in a randomised order on three study sessions: <cons sem="G_NEGATIVEEFFECT">without</cons> pretreatment, after oral <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> <cons sem="G_NUMBER">400 mg</cons> twice daily on the first day and <cons sem="G_NUMBER">200 mg</cons> twice daily on the second day, or after oral <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> <cons sem="G_NUMBER">400 mg</cons> on the first day and <cons sem="G_NUMBER">200 mg</cons> on the second day.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="diazepam" sem="G_DRUG">diazepam</cons> and N-desmethyldiazepam were determined for up to 48 h. Pharmacodynamic variables were measured for 12 h.</sentence> 
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, diazepam, DDI)">
<sentence>In the <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> phase, the <cons sem="G_IVIVPARA">area under the plasma concentration time curve (AUC 0-infinity)</cons> of <cons lex="diazepam" sem="G_DRUG" type="substrate_1">diazepam</cons> was <cons sem="G_CHANGE">increased</cons> (geometric mean ratio) <cons sem="G_NUMBER">2.2-fold (p &lt; 0.05; 90% confidence interval  [CI] 1.56 to 2.82</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(voriconazole, diazepam, DDI)">
<sentence>This was associated with the prolongation of the mean <cons sem="G_IVIVPARA">elimination half-life (t(1/2))</cons> from <cons sem="G_NUMBER">31 h to 61 h (p &lt; 0.01)</cons> after <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluconazole, diazepam, DDI)">
<sentence>In the <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_2">fluconazole</cons> phase, the <cons sem="G_IVIVPARA">AUC 0-infinity</cons> of <cons lex="diazepam" sem="G_DRUG" type="substrate_1">diazepam</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">2.5-fold (p &lt; 0.01; 90% CI 1.94 to 3.40)</cons>, and the <cons sem="G_IVIVPARA">t(1/2)</cons> was <cons sem="G_CHANGE">prolonged</cons> from <cons sem="G_NUMBER">31 h to 73 h (p &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, diazepam, NDDI)(fluconazole, diazepam, NDDI)">
<sentence>The <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="diazepam" sem="G_DRUG" type="substrate_1">diazepam</cons> was practically <cons sem="G_NEGATIVEEFFECT">unchanged</cons> by <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_2">fluconazole</cons>.</sentence>
</annotation>
<sentence>The pharmacodynamics of <cons lex="diazepam" sem="G_DRUG">diazepam</cons> were <cons sem="G_CHANGE">changed</cons> only <cons sem = "G_CHANGE">modestly</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(voriconazole, diazepam, DDI)(fluconazole, diazepam, DDI)">
<sentence>Both <cons lex="voriconazole" sem="G_DRUG" type="inhibitor_1">voriconazole</cons> and <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_2">fluconazole</cons> considerably <cons sem="G_CHANGE">increase</cons> the exposure to <cons lex="diazepam" sem="G_DRUG" type="substrate_1">diazepam</cons>.</sentence>
</annotation>
<sentence>Recurrent administration of <cons lex="diazepam" sem="G_DRUG">diazepam</cons> <cons sem="G_CHANGE">increases</cons> the risk of clinically <cons sem="G_CHANGE">significant</cons> interactions during <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> or <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> treatment, because the elimination of <cons lex="diazepam" sem="G_DRUG">diazepam</cons> is impaired <cons sem="G_CHANGE">significantly</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17652181</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies.</sentence>
</title>
<abstract>
<sentence><cons lex="cinacalcet" sem="G_DRUG">Cinacalcet</cons> hydrochloride (<cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons>) is a positive allosteric modulator of the calcium-sensing receptor indicated for the treatment of secondary hyperparathyroidism in dialysis patients.</sentence>
<sentence>In vitro study has demonstrated that <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 (CYP) <cons lex="2d6" sem="G_CYP">2D6</cons> with a <cons sem="G_IVIVPARA">K(i)</cons> value of <cons sem="G_NUMBER">0.087 micromol/L</cons>, which is comparable to the well-known potent <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons lex="quinidine" sem="G_DRUG">quinidine</cons> (<cons sem="G_NUMBER">0.064 micromol/L</cons>).</sentence>
<sentence>A clinical study was conducted to assess the <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> substrates in healthy volunteers.</sentence>
<sentence>Each subject received <cons sem="G_NUMBER">50 mg</cons> of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> or a matched placebo orally once daily for 8 days with <cons sem="G_NUMBER">30 mg</cons> of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> coadministered on day 8.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(cinacalcet, dextromethorphan, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> and <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="dextromethorphan" sem="G_DRUG" type="substrate_1">dextromethorphan</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">11-</cons> and <cons sem="G_NUMBER">7-fold</cons>, respectively, in extensive <cons sem="G_MECHANISM">metabolizers</cons> when coadministered with <cons lex="cinacalcet" sem="G_DRUG" type="inhibitor_1">cinacalcet</cons> versus placebo.</sentence>
</annotation>
<sentence>Therefore, during concomitant treatment with <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons>, it <cons sem = "G_CHANGE">may</cons> be necessary to consider making dose adjustments for drugs with a narrow therapeutic index that are mainly <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17646413</bibliomisc>
</articleinfo>
<title>
<sentence>Steady-state pharmacokinetic and safety profiles of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> in healthy male subjects.</sentence>
</title>
<abstract>
<sentence>Since there is a likelihood of coadministration of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, two studies were conducted to evaluate the potential of drug interaction.</sentence>
<sentence>Study A was a randomized, placebo-controlled, two-period, parallel-group trial (n = 34).</sentence>
<sentence>Study B had the same design <cons sem="G_NEGATIVEEFFECT">without</cons> the placebo group (n = 17).</sentence>
<sentence>In period 1, subjects received <cons sem="G_NUMBER">200 mg</cons> <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> or placebo twice daily (BID) for 3 days (<cons sem="G_NUMBER">400 mg BID</cons> on day 1).</sentence>
<sentence>In period 2, following a 7-day washout, subjects received <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> alone at <cons sem="G_NUMBER">400 mg BID</cons> (study A) or <cons sem="G_NUMBER">100 mg BID</cons> (study B) for 10 days (days 11 to 20), and then <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> was coadministered with <cons sem="G_NUMBER">200 mg BID</cons> <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> or placebo for the next 10 days (days 21 to 30).</sentence>
<sentence>Serial plasma samples were collected on days 3, 20, and 30, and safety data were collected throughout the study.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, voriconazole, DDI)">
<sentence>High-dose (<cons sem="G_NUMBER">400 mg BID</cons>) <cons lex="ritonavir" sem="G_DRUG" type="inducer_1">ritonavir</cons> substantially <cons sem="G_CHANGE">reduced</cons> the steady-state mean <cons lex="voriconazole" sem="G_DRUG" type="substrate_1">voriconazole</cons> exposure (<cons sem="G_IVIVPARA">area under the concentration-time curve from 0 to 12 h  [AUC(0-12)]</cons>, <cons sem="G_NUMBER">-82%</cons>; maximum concentration  [<cons sem="G_IVIVPARA">C(max)</cons>], <cons sem="G_NUMBER">-66%</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ritonavir, voriconazole, DDI)">
<sentence>However, the effect of low-dose (<cons sem="G_NUMBER">100 mg BID</cons>) <cons lex="ritonavir" sem="G_DRUG" type="inducer_1">ritonavir</cons> was <cons sem = "G_CHANGE">less</cons> <cons sem = "G_CHANGE">pronounced</cons> (<cons sem="G_IVIVPARA">AUC(0-12)</cons>, <cons sem="G_NUMBER">-39%</cons>; <cons sem="G_IVIVPARA">C(max)</cons>, <cons sem="G_NUMBER">-24%</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, voriconazole, ADDI)">
<sentence>The <cons sem="G_CHANGE">decrease</cons> in <cons lex="voriconazole" sem="G_DRUG" type="substrate_1">voriconazole</cons> exposure was <cons sem = "G_CHANGE">probably</cons> due to the <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> by <cons lex="ritonavir" sem="G_DRUG" type="inducer_1">ritonavir</cons>.</sentence>
</annotation>
<sentence>It is interesting that one subject in each study exhibited the opposite effect of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> on <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> exposure <cons sem="G_NUMBER">(a 2.5- to 3-fold</cons> <cons sem="G_CHANGE">increase</cons>), <cons sem = "G_CHANGE">probably</cons> due to lack of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Voriconazole, ritonavir, NDDI)">
<sentence><cons lex="voriconazole" sem="G_DRUG" type="inducer_2">Voriconazole</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> apparent effect on the exposure of high-dose <cons lex="ritonavir" sem="G_DRUG" type="substrate_2">ritonavir</cons> but <cons sem="G_CHANGE">slightly</cons> <cons sem="G_CHANGE">decreased</cons> the exposure of low-dose <cons lex="ritonavir" sem="G_DRUG" type="substrate_2">ritonavir</cons> (<cons sem="G_IVIVPARA">AUC(0-12)</cons>,<cons sem="G_NUMBER">-14%</cons>; <cons sem="G_IVIVPARA">C(max)</cons>, <cons sem="G_NUMBER">-24%</cons>).</sentence>
</annotation>
<sentence>The safety profile of combination therapy was <cons sem="G_NEGATIVEEFFECT">not</cons> notably different from that of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> or <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> alone.</sentence>
<sentence>Due to the <cons sem="G_CHANGE">significant</cons> effect of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> on <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> exposure, coadministration of <cons lex="voriconazole" sem="G_DRUG">voriconazole</cons> with <cons sem="G_NUMBER">400 mg BID</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> is contraindicated; coadministration with <cons sem="G_NUMBER">100 mg BID</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> should be avoided, unless an assessment of the benefit/risk to the patient justifies the use.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17559737</bibliomisc>
</articleinfo>
<title>
<sentence>Drug interaction assessment following concomitant administration of <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> in healthy men.</sentence>
</title>
<abstract>
<sentence><cons lex="posaconazole" sem="G_DRUG">Posaconazole</cons> is an extended-spectrum triazole antifungal agent for the treatment and prophylaxis of invasive fungal infections.</sentence>
<sentence>This randomized, open-label, parallel-group, multiple-dose study was conducted in healthy adult volunteers to assess the potential for a drug interaction between <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> and the <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> tablet formulation.</sentence>
<sentence>Subjects were randomly assigned for 10 days to one of the following treatments: <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> (<cons sem="G_NUMBER">200 mg</cons> once daily), <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> (<cons sem="G_NUMBER">200 mg</cons> once daily), or <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> (<cons sem="G_NUMBER">200 mg</cons> once daily) and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> (<cons sem="G_NUMBER">200 mg</cons> once daily).</sentence>
<sentence>Blood samples were collected on days 1 and 10 for pharmacokinetic evaluation of <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons> and <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> concentrations.</sentence>
<sentence>A total of 36 healthy men enrolled in the study.</sentence>
<sentence>On day 1, the <cons sem="G_IVIVPARA">maximum plasma concentration (C(max))</cons> and <cons sem="G_IVIVPARA">area under the concentration-time curve calculated from time 0-24 h post-dose (AUC(0-24))</cons> were <cons sem="G_NEGATIVEEFFECT">unchanged</cons> upon co-administration.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(phenytoin, posaconazole, DDI)">
<sentence>At steady state (day 10), co-administration of <cons lex="posaconazole" sem="G_DRUG" type="substrate_1">posaconazole</cons> with <cons lex="phenytoin" sem="G_DRUG" type="inducer_1">phenytoin</cons> resulted in <cons sem="G_NUMBER">44% (p = 0.012)</cons> and <cons sem="G_NUMBER">52% (p = 0.007)</cons> <cons sem="G_CHANGE">decreases</cons> in <cons lex="posaconazole" sem="G_DRUG" type="substrate_1">posaconazole</cons> <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(0-24)</cons>, respectively.</sentence>
</annotation>
<sentence>These <cons sem="G_CHANGE">decreases</cons> in exposure corresponded with a <cons sem="G_NUMBER">90%</cons> <cons sem="G_CHANGE">increase</cons> in steady-state <cons sem="G_IVIVPARA">clearance</cons> of orally administered <cons lex="posaconazole" sem="G_DRUG">posaconazole</cons>.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(posaconazole, phenytoin, ADDI)">
<sentence><cons lex="phenytoin" sem="G_DRUG" type="substrate_2">Phenytoin</cons> <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(0-24)</cons> were <cons sem="G_NEGATIVEEFFECT"><cons sem="G_NEGATIVEEFFECT">not</cons></cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">altered</cons> upon co-administration of the two agents, <cons sem="G_NUMBER">24%</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">C(max)</cons> (<cons sem="G_NUMBER">p = 0.196</cons>) and <cons sem="G_NUMBER">25%</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">AUC(0-24)</cons> (<cons sem="G_NUMBER">p = 0.212</cons>) values, although inter-subject variability was observed within this group.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(phenytoin, posaconazole, DDI)">
<sentence>Because co-administration of <cons lex="phenytoin" sem="G_DRUG" type="substrate_1">phenytoin</cons> and <cons lex="posaconazole" sem="G_DRUG" type="inducer_1">posaconazole</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem ="G_CHANGE">reduces</cons> <cons lex="posaconazole" sem="G_DRUG" type="inducer_1">posaconazole</cons> exposure and <cons sem="G_CHANGE">increases</cons> <cons lex="phenytoin" sem="G_DRUG" type="substrate_1">phenytoin</cons> levels in some subjects, concomitant use of these agents should be avoided unless the benefit outweighs the risk.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17518508</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetics of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> hydrochloride when administered with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
</title>
<abstract>
<sentence>The calcimimetic <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> hydrochloride (<cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons>) is used for treatment of patients with chronic kidney disease with secondary hyperparathyroidism, a population that commonly receives multiple concurrent medications.</sentence>
<sentence><cons lex="cinacalcet" sem="G_DRUG">Cinacalcet</cons> is eliminated primarily via oxidative <cons sem="G_MECHANISM">metabolism</cons> mediated, in part, through cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
<sentence>Thus, the potential for an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> to alter the pharmacokinetics of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> is of clinical importance.</sentence>
<sentence>The objective of this study was to evaluate the pharmacokinetics of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> during treatment with a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
<sentence>Twenty-four healthy subjects were enrolled in an open-label, crossover, phase I study to receive a single oral dose of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> (<cons sem="G_NUMBER">90 mg</cons>) alone and with 7 days of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">200 mg</cons> twice daily).</sentence>
<sentence>Blood samples for pharmacokinetics were collected for up to 72 hours postdose.</sentence>
<sentence><cons lex="cinacalcet" sem="G_DRUG">Cinacalcet</cons> plasma concentration-time data were analysed by noncompartmental methods.</sentence>
<sentence>Pharmacokinetic parameters were analysed using a crossover ANOVA model that included subjects who completed both treatment arms.</sentence>
<sentence>Twenty subjects completed both treatment arms.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, cinacalcet, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> of <cons lex="cinacalcet" sem="G_DRUG" type="substrate_1">cinacalcet</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">2.3-fold (90% CI 1.92, 2.67)  [range 1.15- to 7.12-fold]</cons> and the mean <cons sem="G_IVIVPARA">maximum plasma concentration</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">2.2-fold (90% CI 1.67, 2.78)  [range 0.904- to 10.8-fold]</cons> when administered with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>, relative to when administered alone.</sentence>
</annotation>
<sentence>The time to reach the <cons sem="G_IVIVPARA">maximum plasma concentration</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affected</cons>, and the terminal <cons sem="G_IVIVPARA">elimination half-lives</cons> were similar between treatments.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, cinacalcet, ADDI)">
<sentence>Co-administration of a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderately</cons></cons> <cons sem="G_CHANGE">increased</cons> <cons lex="cinacalcet" sem="G_DRUG" type="substrate_1">cinacalcet</cons> exposure in study subjects.</sentence>
</annotation>
<sentence>This suggests that clinicians should monitor parathyroid hormone and calcium concentrations when a patient receiving <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> initiates or discontinues therapy with a <cons sem="G_CHANGE">strong</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:17503755</bibliomisc>
</articleinfo>
<title>
<sentence>Does <cons lex="tenofovir" sem="G_DRUG">tenofovir</cons> influence <cons lex="efavirenz" sem="G_DRUG">efavirenz</cons> pharmacokinetics?</sentence>
</title>
<abstract>
<sentence>A recent report described a possible interaction between <cons lex="tenofovir" sem="G_DRUG">tenofovir (TFV)</cons> and <cons lex="efavirenz" sem="G_DRUG">efavirenz (EFV)</cons>.</sentence>
<sentence>Patients developed neuropsychiatric manifestations upon introduction of <cons lex="tenofovir" sem="G_DRUG">TFV</cons> on a stable <cons lex="efavirenz" sem="G_DRUG">EFV</cons>-containing regimen.</sentence>
<sentence>We evaluated the possibility of a pharmacokinetic interaction between <cons lex="tenofovir" sem="G_DRUG">TFV</cons> and <cons lex="efavirenz" sem="G_DRUG">EFV</cons> by assessing cross-sectional and longitudinal data in 169 individuals receiving <cons lex="efavirenz" sem="G_DRUG">EFV</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(TFV, EFV, ADDI)">
<sentence><cons lex="efavirenz" sem="G_DRUG" type="substrate_1">EFV</cons> <cons sem="G_IVIVPARA">plasma area-under-the-curve (AUC)</cons> levels were comparable among individuals receiving (n=18) or <cons sem="G_NEGATIVEEFFECT">not</cons> receiving <cons lex="tenofovir" sem="G_DRUG" type="inducer_1">TFV</cons> (n=151); <cons sem="G_NUMBER">57,962 versus 52,293 ng*h/ml</cons>.</sentence>
</annotation>
<sentence>However, under conditions of limited <cons lex="efavirenz" sem="G_DRUG">EFV</cons> <cons sem="G_MECHANISM">metabolism</cons>, that is, the group of 23 individuals carrying two copies of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> loss/diminished-function alleles, plasma <cons sem="G_IVIVPARA">AUC</cons> values were <cons sem="G_CHANGE">highest</cons> among individuals receiving <cons lex="tenofovir" sem="G_DRUG">TFV</cons> (n=5, <cons sem="G_NUMBER">353,031 ng*h/ml</cons>), compared with those <cons sem="G_NEGATIVEEFFECT">not</cons> receiving <cons lex="tenofovir" sem="G_DRUG">TFV</cons> (n=18, <cons sem="G_NUMBER">180,689 ng*h/ml</cons>).</sentence>
<sentence>Statistical analysis identified both a global, sixfold effect of <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> loss/diminished function (<cons sem="G_NUMBER">P &lt; 0.0001</cons>) and a <cons sem="G_CHANGE">significant</cons> interaction between the number of loss/diminished-function alleles and the co-medication with <cons lex="tenofovir" sem="G_DRUG">TFV</cons> (<cons sem="G_NUMBER">P = 0.009</cons>).</sentence>
<sentence>Although there is <cons sem="G_NEGATIVEEFFECT">no</cons> clear evidence for a pharmacokinetic interaction between <cons lex="tenofovir" sem="G_DRUG">TFV</cons> and <cons lex="efavirenz" sem="G_DRUG">EFV</cons>, we cannot rule out an interaction between these drugs restricted to individuals who are slow EFV <cons sem="G_MECHANISM">metabolizers</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16867168</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on <cons lex="solifenacin" sem="G_DRUG">solifenacin</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="solifenacin" sem="G_DRUG">Solifenacin</cons> succinate (YM905) is a new, once-daily, orally administered muscarinic receptor antagonist designed to treat overactive bladder.</sentence>
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="solifenacin" sem="G_DRUG">solifenacin</cons> involves hepatic cytochrome P450 (CYP) <cons sem="G_CYP">3A4</cons>; therefore, the pharmacokinetics of <cons lex="solifenacin" sem="G_DRUG">solifenacin</cons> <cons sem = "G_CHANGE">may</cons> be <cons sem="G_CHANGE">affected</cons> by drugs that <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>This study aimed to examine the effects of co-administration of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, on the pharmacokinetics of <cons lex="solifenacin" sem="G_DRUG">solifenacin</cons> in healthy volunteers.</sentence>
<sentence>In a single-site, open-label, monosequence, crossover study, 17 healthy men and women aged 18 to 65 years received a single <cons sem="G_NUMBER">10 mg</cons> oral dose of <cons lex="solifenacin" sem="G_DRUG">solifenacin</cons>, which is is the <cons sem="G_CHANGE">highest</cons> available dose.</sentence>
<sentence>After a 14-day wash-out period, they began 20 days of oral <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> at a dose of <cons sem="G_NUMBER">200 mg</cons> once daily.</sentence>
<sentence>A single 10 mg dose of <cons lex="solifenacin" sem="G_DRUG">solifenacin</cons> was administered again on day 7 of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> treatment.</sentence>
<sentence>Pharmacokinetics was assessed using the standard measurements of <cons sem="G_IVIVPARA">maximum plasma concentration (Cmax)</cons>, time to <cons sem="G_IVIVPARA">Cmax</cons>, <cons sem="G_IVIVPARA">area under the curve (AUC)</cons>, and <cons sem="G_IVIVPARA">elimination half-life (t1/2)</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, solifenacin, DDI)">
<sentence>Co-administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> resulted in a <cons sem="G_NUMBER">1.43</cons> times <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="solifenacin" sem="G_DRUG" type="substrate_1">solifenacin</cons> and an approximately <cons sem="G_NUMBER">2 times</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">AUC</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, solifenacin, ADDI)">
<sentence>The mean <cons sem="G_IVIVPARA">t1/2</cons> of <cons lex="solifenacin" sem="G_DRUG" type="substrate_1">solifenacin</cons> was extended from <cons sem="G_NUMBER">49.3 to 77.5 hr</cons> whereas time to <cons sem="G_IVIVPARA">Cmax</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem = "G_CHANGE">change</cons>.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> substantial <cons sem="G_CHANGE">increase</cons> in the overall rate of adverse events, and <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effects on vital signs, electrocardiography, clinical laboratory values, or physical examinations were noted.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, solifenacin, DDI)">
<sentence>Administration of <cons sem="G_NUMBER">200 mg</cons> <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> once daily in healthy male volunteers resulted in a 2 times <cons sem="G_CHANGE">increase</cons> in exposure of a single <cons sem="G_NUMBER">10 mg</cons> dose of <cons lex="solifenacin" sem="G_DRUG" type="substrate_1">solifenacin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, solifenacin, DDI)">    
<sentence>Since <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> is one of the strongest <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, it is expected that co-administration of other <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> will <cons sem="G_NEGATIVEEFFECT">not</cons> result in a stronger <cons sem="G_CHANGE">increase</cons> in <cons lex="solifenacin" sem="G_DRUG" type="substrate_1">solifenacin</cons> exposure.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16832679</bibliomisc>
</articleinfo>
<title>
<sentence>The <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">increase</cons> the plasma concentrations of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="zopiclone" sem="G_DRUG">Zopiclone</cons> is a short acting hypnotic, which is <cons sem="G_MECHANISM">metabolised</cons> by cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="2c8" sem="G_CYP">2C8</cons> in vitro.</sentence>
<sentence>We studied the possible effect of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, on the pharmacokinetics and pharmacodynamics of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>.</sentence>
<sentence>In a randomised 2-phase crossover study, 10 healthy volunteers took <cons sem="G_NUMBER">600 mg</cons> <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> or placebo orally twice daily for 3 days.</sentence>
<sentence>On day 3, each ingested a <cons sem="G_NUMBER">7.5 mg</cons> dose of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> and urinary excretion of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> and its two primary metabolites, plasma <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, and psychomotor performance were measured.</sentence>
<sentence>The effects of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> on the depletion of <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> (<cons sem="G_NUMBER">500 nM</cons>) were studied in vitro in human liver microsomes.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(gemfibrozil, zopiclone, NDDI)">
<sentence>The pharmacokinetic variables of the parent <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affected</cons> by <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(gemfibrozil, zopiclone, DDI)">
<sentence>However, <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> <cons sem="G_CHANGE">raised</cons> the mean <cons sem="G_IVIVPARA">peak plasma concentration (C(max))</cons> of <cons lex="zopiclone" sem="G_DRUG" type="M_1">N-oxide-zopiclone</cons> (<cons sem="G_NUMBER">1.6-fold; P&lt;0.001</cons>) and that of <cons lex="zopiclone" sem="G_DRUG" type="M_2">N-desmethyl-zopiclone</cons> (<cons sem="G_NUMBER">1.2-fold; P&lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(gemfibrozil, zopiclone, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC(0)-infinity)</cons> values of <cons lex="zopiclone" sem="G_DRUG" type="M_1">N-oxide-zopiclone</cons> and <cons lex="zopiclone" sem="G_DRUG" type="M_2">N-desmethyl-zopiclone</cons> were <cons sem="G_CHANGE">raised</cons> <cons sem="G_NUMBER">2-fold (P&lt;0.001)</cons> and <cons sem="G_NUMBER">1.2-fold (P&lt;0.01)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(gemfibrozil, zopiclone, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="zopiclone" sem="G_DRUG" type="M_1">N-oxide-zopiclone</cons> was <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">48%</cons> by <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> (<cons sem="G_NUMBER">P&lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(gemfibrozil, zopiclone, NDDI)">
<sentence>The pharmacodynamic effects of <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons>, measured using psychometric tests, were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affected</cons> by <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(gemfibrozil, zopiclone, DDI)">    
<sentence>In vitro, <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_2">ketoconazole</cons> (<cons sem="G_NUMBER">1 microM</cons>) and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_3">itraconazole</cons> (<cons sem="G_NUMBER">8 microM</cons>) <cons sem="G_CHANGE">decreased</cons> the elimination rate of <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons> enantiomers by about <cons sem="G_NUMBER">65-95%</cons>, while <cons lex="montelukast" sem="G_DRUG" type="inhibitor_4">montelukast</cons> (<cons sem="G_NUMBER">16 microM</cons>), <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> (<cons sem="G_NUMBER">200 microM</cons>) and <cons sem="G_DRUG" type="inhibitor_5">sulfaphenazole</cons> (<cons sem="G_NUMBER">10 microM</cons>) had <cons sem="G_NEGATIVEEFFECT">no</cons> appreciable effect.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(gemfibrozil, zopiclone, NDDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">increase</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of the parent <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons>.</sentence>
</annotation>
<sentence>Accordingly, <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">metabolise</cons> <cons lex="zopiclone" sem="G_DRUG">zopiclone</cons> in vivo.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(gemfibrozil, zopiclone, NDDI)">
<sentence>However, as <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> <cons sem="G_CHANGE">raises</cons> the concentrations of two potentially active metabolites of <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons>, <cons sem="G_CHANGE">slightly</cons> enhanced effects of <cons lex="zopiclone" sem="G_DRUG" type="substrate_1">zopiclone</cons> by <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> can <cons sem="G_NEGATIVEEFFECT">not</cons> be excluded.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16815319</bibliomisc>
</articleinfo>
<title>
<sentence>Cytochrome P450 <cons lex="2b6" sem="G_CYP">2B6</cons> activity as measured by <cons lex="bupropion" sem="G_DRUG">bupropion</cons> hydroxylation: effect of <cons sem="G_MECHANISM">induction</cons> by <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and ethnicity.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to investigate the activity of the drug-metabolizing enzyme cytochrome P450 (CYP) <cons lex="2b6" sem="G_CYP">2B6</cons> before and after in vivo <cons sem="G_MECHANISM">induction</cons> by <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (INN, <cons sem="G_DRUG">rifampicin</cons>) in white subjects and Chinese subjects by use of the probe drug <cons lex="bupropion" sem="G_DRUG">bupropion</cons> (INN, amfebutamone).</sentence>
<sentence>Healthy male white subjects (n = 9) and Chinese subjects (n = 9) (age range, 19-34 years) of known <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> genotype received orally administered <cons lex="bupropion" sem="G_DRUG">bupropion</cons> (Zyban SR, <cons sem="G_NUMBER">150 mg</cons>) alone and during daily treatment with <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (<cons sem="G_NUMBER">600 mg</cons>).</sentence>
<sentence>Blood samples were taken for up to 72 hours after each <cons lex="bupropion" sem="G_DRUG">bupropion</cons> dose, and <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="bupropion" sem="G_DRUG">bupropion</cons> and its active metabolites, hydroxybupropion, threohydrobupropion, and erythrohydrobupropion, were measured by HPLC.</sentence>
<sentence>The subjects' <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> genotype was determined by use of a matrix-assisted laser desorption /ionization-time of flight (MALDI-TOF) mass spectrometry assay.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, bupropion, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> treatment <cons sem="G_CHANGE">increased</cons> the apparent <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="bupropion" sem="G_DRUG" type="substrate_1">bupropion</cons> in Chinese subjects and white subjects combined (n = 16) from <cons sem="G_NUMBER">2.6 L x h(-1) x kg(-1) (95% confidence interval  [CI], 2.3-3.0 L x h(-1) x kg(-1))</cons> after <cons lex="bupropion" sem="G_DRUG" type="substrate_1">bupropion</cons> alone to <cons sem="G_NUMBER">7.9 L x h(-1) x kg(-1) (95% CI, 6.8-10.1 L x h(-1) x kg(-1))</cons> during <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> treatment.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, bupropion, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> treatment <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">half-life</cons> of <cons lex="bupropion" sem="G_DRUG" type="substrate_1">bupropion</cons> from <cons sem="G_NUMBER">15.9 hours (95% CI, 13.5-20.4 hours) to 8.2 hours (95% CI, 6.7-12.4 hours)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, bupropion, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> treatment <cons sem="G_CHANGE">increased</cons> the <cons lex="bupropion" sem="G_DRUG" type="M_1">hydroxybupropion</cons> <cons sem="G_IVIVPARA">maximum concentration</cons> from <cons sem="G_NUMBER">395 ng/mL (95% CI, 341-497 ng/mL) to 548 ng/mL (95% CI, 490-638 ng/mL)</cons>, <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">area under the concentration-time curve extrapolated to infinity</cons> of <cons lex="bupropion" sem="G_DRUG" type="M_1">hydroxybupropion</cons> from <cons sem="G_NUMBER">14.7 microg x h/mL (95% CI, 12.7-18.4 microg x h/mL) to 8.4 microg x h/mL (95% CI, 7.4-10.2 microg x h/mL)</cons>, and <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="bupropion" sem="G_DRUG" type="M_1">hydroxybupropion</cons> from <cons sem="G_NUMBER">21.9 hours (95% CI, 20.3-24.0 hours) to 10.7 hours (95% CI, 8.6-14.5 hours)</cons>.</sentence>
</annotation>
<sentence>There was <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> difference in the pharmacokinetics of <cons lex="bupropion" sem="G_DRUG">bupropion</cons> or hydroxybupropion between white subjects and Chinese subjects before and after treatment with <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, once corrected for body weight.</sentence>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inducers</cons> <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> activity in vivo, and the clinical consequences of potential interactions between <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> substrates deserve further investigation.</sentence>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> appears to <cons sem="G_MECHANISM">induce</cons> the elimination of hydroxybupropion.</sentence>
<sentence>Differences in <cons lex="bupropion" sem="G_DRUG">bupropion</cons> pharmacokinetics that were observed between white subjects and Chinese subjects can be attributed to differences in body weight, suggesting that, for a given subject weight, <cons lex="cyp2b6" sem="G_CYP">CYP2B6</cons> activity is similar in white subjects and Chinese subjects.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16775418</bibliomisc>
</articleinfo>
<title>
<sentence>Influence of high-dose <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the pharmacokinetics of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence>
</title>
<abstract>
<sentence>The pharmacokinetics (PK) of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> are characterized by large inter-individual variability in systemic drug exposure (<cons sem="G_IVIVPARA">AUC</cons>) and drug <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
<sentence>The PK variability is thought to be largely related to differences in the catalytic function of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, involved in <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_MECHANISM">metabolism</cons> and elimination.</sentence>
<sentence>As variability in efficacy and toxicity is associated with variability in <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">clearance</cons>, <cons sem ="G_CHANGE">reducing</cons> inter-individual PK variability <cons sem = "G_CHANGE">may</cons> help improve the risk-benefit ratio of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> therapy.</sentence>
<sentence>We investigated if high-dose <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a potent <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> <cons sem="G_MECHANISM">inhibitor</cons>, could result in a uniform <cons sem ="G_CHANGE">reduction</cons> of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> and <cons sem="G_CHANGE">reduce</cons> the inter-individual variability in <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
<sentence>Seven patients were treated in a randomized-cross over design with intravenous <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> (<cons sem="G_NUMBER">100 mg/m(2)</cons>) followed 3 weeks later by <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> (<cons sem="G_NUMBER">15 mg/m(2)</cons>) given in combination with orally administered <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">400 mg</cons> 3 times daily, up to 47 hours after <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> infusion) or vice versa.</sentence>
<sentence><cons lex="docetaxel" sem="G_DRUG">Docetaxel</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>-time data were described by a three-compartment PK model.</sentence>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> <cons sem="G_IVIVPARA">plasma concentration</cons>-time data were described by a one-compartment PK model.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, Docetaxel, DDI)">
<sentence><cons lex="docetaxel" sem="G_DRUG" type="substrate_1">Docetaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">50% (P = .018)</cons> from <cons sem="G_NUMBER">32.8 +/- 13.7 L/hr to 16.5 +/- 8.15 L/hr</cons> upon <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> coadministration, albeit with large inter-individual variability (fractional <cons sem = "G_CHANGE">change</cons> in <cons sem="G_IVIVPARA">clearance</cons>, range <cons sem="G_NUMBER">0.31 - 0.66</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, Docetaxel, DDI)">
<sentence>In the presence of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>, inter-individual variability in <cons sem="G_IVIVPARA">clearance</cons> and <cons sem="G_IVIVPARA">AUC</cons>, expressed as coefficient of variation, was <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">41.6 to 49.5%</cons> and from <cons sem="G_NUMBER">28.0 to 35.1%</cons>, respectively, and <cons sem="G_NEGATIVEEFFECT">not</cons>, as we had hypothesized, <cons sem="G_CHANGE">reduced</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, Docetaxel, NDDI)">    
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> by concomitant high-dose <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> administration does <cons sem="G_NEGATIVEEFFECT">not</cons> result in a uniform <cons sem ="G_CHANGE">reduction</cons> of <cons lex="docetaxel" sem="G_DRUG" type="substrate_1">docetaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> and does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">reduce</cons> the inter-individual variability in <cons lex="docetaxel" sem="G_DRUG" type="substrate_1">docetaxel</cons> <cons sem="G_IVIVPARA">AUC</cons> or <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
</annotation>
<sentence>This approach is unsuitable as method to achieve a uniform <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> PK profile.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16680561</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetics of <cons lex="desipramine" sem="G_DRUG">desipramine</cons> HCl when administered with <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> HCl.</sentence>
</title>
<abstract>
<sentence>In vitro work has demonstrated that <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> is a <cons sem="G_CHANGE">strong</cons> <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 isoenzyme (CYP) <cons lex="2d6" sem="G_CYP">2D6</cons>.</sentence>
<sentence>The purpose of this study was to evaluate the effect of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity, using <cons lex="desipramine" sem="G_DRUG">desipramine</cons> as a probe substrate, in healthy subjects.</sentence>
<sentence>Seventeen subjects who were genotyped as <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> extensive <cons sem="G_MECHANISM">metabolizers</cons> were enrolled in this randomized, open-label, crossover study to receive a single oral dose of <cons lex="desipramine" sem="G_DRUG">desipramine</cons> (<cons sem="G_NUMBER">50 mg</cons>) on two separate occasions, once alone and once after multiple doses of <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> (<cons sem="G_NUMBER">90 mg</cons> for 7 days).</sentence>
<sentence>Blood samples were obtained predose and up to 72 h postdose.</sentence>
<sentence>Fourteen subjects completed both treatment arms.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(cinacalcet, desipramine, DDI)">
<sentence>Relative to <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> alone, mean <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">3.6-</cons> and <cons sem="G_NUMBER">1.8-fold</cons> when coadministered with <cons lex="cinacalcet" sem="G_DRUG" type="inhibitor_1">cinacalcet</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(cinacalcet, desipramine, DDI)">
<sentence>The <cons sem="G_IVIVPARA">t (1/2,z)</cons> of <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> was longer when <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> was coadministered with <cons lex="cinacalcet" sem="G_DRUG" type="inhibitor_1">cinacalcet</cons> (<cons sem="G_NUMBER">21.0 versus 43.3 hs</cons>).</sentence>
</annotation>
<sentence>The <cons sem="G_IVIVPARA">t (max)</cons> was similar between the regimens.</sentence>
<sentence>Fewer subjects reported adverse events following treatment with <cons lex="desipramine" sem="G_DRUG">desipramine</cons> alone than when receiving <cons lex="desipramine" sem="G_DRUG">desipramine</cons> with <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> (<cons sem="G_NUMBER">33 versus 86%</cons>), the most frequent of which (nausea and headache) have been reported for patients treated with either <cons lex="desipramine" sem="G_DRUG">desipramine</cons> or <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons>.</sentence>
<sentence>This study demonstrates that <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons> is a <cons sem="G_CHANGE">strong</cons> <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>These data suggest that during concomitant treatment with <cons lex="cinacalcet" sem="G_DRUG">cinacalcet</cons>, dose adjustment <cons sem = "G_CHANGE">may</cons> be necessary for drugs that demonstrate a narrow therapeutic index and are <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16633141</bibliomisc>
</articleinfo>
<title>
<sentence>Combined effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and <cons sem="G_CYP">CYP2D6*10</cons> genetic polymorphism on the pharmacokinetics and pharmacodynamics of <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence>This study was to evaluate the combined effects of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and the <cons sem="G_CYP">CYP2D6*10</cons> genotype on the pharmacokinetics and pharmacodynamics of <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons>, a substrate of both <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, in healthy subjects.</sentence>
<sentence>Nineteen healthy volunteers whose <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> genotypes were predetermined were enrolled (9 for <cons sem="G_CYP">CYP2D6*1/*1</cons> and 10 for <cons sem="G_CYP">CYP2D6*10/*10</cons>).</sentence>
<sentence>Four subjects (1 for <cons sem="G_CYP">CYP2D6*1/*1</cons> and 3 for <cons sem="G_CYP">CYP2D6*10/*10</cons>) did <cons sem="G_NEGATIVEEFFECT">not</cons> complete the study because of adverse events.</sentence>
<sentence>The pharmacokinetics of <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> and its pharmacodynamic effects measured for QTc prolongation and neurologic side effects were evaluated after a single dose of <cons sem="G_NUMBER">5 mg</cons> <cons lex="haloperidol" sem="G_DRUG">haloperidol</cons> following a pretreatment of placebo or <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> at <cons sem="G_NUMBER">200 mg/d</cons> for 10 days in a randomized crossover manner.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, haloperidol, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> pretreatment <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">area under the time-concentration curves (AUCs)</cons> of <cons lex="haloperidol" sem="G_DRUG" type="substrate_1">haloperidol</cons> by <cons sem="G_NUMBER">55%</cons> compared to placebo pretreatment <cons sem="G_NUMBER">(21.7 +/- 11.3 vs 33.5 +/- 29.3 ng h/mL)</cons>.</sentence>
</annotation>
<sentence>The subjects with <cons sem="G_CYP">CYP2D6*10/*10</cons> genotype showed <cons sem="G_NUMBER">81%</cons> higher <cons sem="G_IVIVPARA">AUC</cons> compared to that of subjects with <cons sem="G_CYP">CYP2D6*1/*1</cons> genotype (<cons sem="G_NUMBER">27.6 +/- 22.2 vs 50.2 +/- 47.1 ng h/mL</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, haloperidol, DDI)">
<sentence>In the presence of <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>, subjects with <cons sem="G_CYP">CYP2D6*10/*10</cons> showed <cons sem="G_NUMBER">3-fold</cons> higher <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="haloperidol" sem="G_DRUG" type="substrate_1">haloperidol</cons> compared to that of placebo pretreated subjects with <cons sem="G_CYP">CYP2D6*1/*1</cons> genotype (<cons sem="G_NUMBER">21.7 +/- 11.3 vs 66.7 +/- 62.1 ng h/mL; P &lt; 0.05</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, haloperidol, ADDI)">
<sentence>The <cons sem="G_CYP">CYP2D6*10</cons> genotype and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> pretreatment <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="haloperidol" sem="G_DRUG" type="substrate_1">haloperidol</cons> by <cons sem="G_NUMBER">24%</cons> and <cons sem="G_NUMBER">25%</cons>, respectively, but <cons sem="G_NEGATIVEEFFECT">without</cons> a statistical <cons sem = "G_CHANGE">significance</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Itraconazole, haloperidol, ADDI)">
<sentence>In the subjects with both <cons sem="G_CYP">CYP2D6*10</cons> genotype and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> pretreatment, however, the <cons sem="G_IVIVPARA">oral clearance</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> to <cons sem="G_NUMBER">42%</cons> of subjects with wild genotype in the placebo pretreatment (<cons sem="G_NUMBER">4.7 +/- 3.6 vs 2.0 +/- 1.9 L/h/kg; P &lt; 0.05</cons>).</sentence>
</annotation>
<sentence>Barnes Akathisia Rating Scale (BARS) of subjects with <cons sem="G_CYP">CYP2D6*10/*10</cons> in the presence of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> pretreatment was <cons sem="G_CHANGE">significantly</cons> higher than that of subjects with <cons sem="G_CYP">CYP2D6*1/*1</cons> genotype in the period of placebo pretreatment.</sentence>
<sentence>Except for this, all other pharmacodynamic estimations did <cons sem="G_NEGATIVEEFFECT">not</cons> reach to statistical <cons sem = "G_CHANGE">significance</cons> although each <cons sem="G_CYP">CYP2D6*10</cons> genotype and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> pretreatment caused higher value of UKU side effect and BARS scores.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, haloperidol, ADDI)">
<sentence>The <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> effect of <cons sem="G_CYP">CYP2D6*10</cons> genotype on the pharmacokinetics and pharmacodynamics of <cons lex="haloperidol" sem="G_DRUG" type="substrate_1">haloperidol</cons> seems to be augmented by the presence of <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> pretreatment.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16487224</bibliomisc>
</articleinfo>
<title>
<sentence>Different effects of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> on <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> pharmacokinetics in relation to <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotype status.</sentence>
</title>
<abstract>
<sentence><cons lex="rabeprazole" sem="G_DRUG">Rabeprazole</cons> is known to be a substrate of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence>Our objective was to evaluate the possible effect of an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>, and compare the <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> on the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> between <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes.</sentence>
<sentence>A two-way randomized double-blind, placebo-controlled crossover study was performed.</sentence>
<sentence>Twenty-one volunteers, of whom seven were homozygous extensive <cons sem="G_MECHANISM">metabolizers</cons> (EMs), eight were heterozygous EMs and six were poor <cons sem="G_MECHANISM">metabolizers</cons> (PMs) for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, received two 6-day courses of either <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> 50 mg or placebo daily in a randomized fashion with a single oral dose of <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> <cons sem="G_NUMBER">20 mg</cons> on day 6 in all cases.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> and its metabolite <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> thioether were monitored up to 24 h after dosing.</sentence>
<sentence>During placebo administration, the mean <cons sem="G_IVIVPARA">AUC</cons>s(0,infinity) of <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> in homozygous EMs, heterozygous EMs and PMs were <cons sem="G_NUMBER">882 (95% CI, 602, 1162) ng ml-1h , 1214 (975, 1453) ng ml-1 h and 2762 (2482, 3042) ng ml-1 h (P&lt;0.001)</cons>, respectively.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, rabeprazole, DDI)">
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> treatment <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">AUC(0,infinity)</cons> of <cons lex="rabeprazole" sem="G_DRUG" type="substrate_1">rabeprazole</cons> and <cons lex="rabeprazole" sem="G_DRUG" type="M_1">rabeprazole thioether</cons> by <cons sem="G_NUMBER">2.8-fold (P&lt;0.001)</cons> and <cons sem="G_NUMBER">5.1-fold (P&lt;0.01)</cons> in homozygous EMs, and by <cons sem="G_NUMBER">1.7-fold (P&lt;0.01)</cons> and <cons sem="G_NUMBER">2.6-fold (P&lt;0.01)</cons> in heterozygous EMs, and <cons sem="G_CHANGE">significantly</cons> prolonged the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="rabeprazole" sem="G_DRUG" type="substrate_1">rabeprazole</cons> and <cons lex="rabeprazole" sem="G_DRUG" type="M_1">rabeprazole thioether</cons> in homozygous EMs and in heterozygous EMs, whereas <cons sem="G_NEGATIVEEFFECT">no</cons> difference in any pharmacokinetic parameters was found in PMs.</sentence>
</annotation>
<sentence>There was a <cons sem="G_CHANGE">significant</cons> difference in <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>-mediated percentage <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">AUC</cons>(0,infinity) of <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> and <cons lex="rabeprazole" sem="G_DRUG">rabeprazole thioether</cons> between <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, rabeprazole, DDI)">
<sentence>The present study indicates that there are <cons sem="G_CHANGE">significant</cons> drug interactions between <cons lex="rabeprazole" sem="G_DRUG" type="substrate_1">rabeprazole</cons> and <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> in EMs of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
</annotation>
<sentence>It is predominantly involved in <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> and <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> thioether <cons sem="G_MECHANISM">metabolism</cons> in EMs.</sentence>
<sentence>Therefore, <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> is the key determinant of <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> disposition in EMs.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16433874</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetics of ruboxistaurin are <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">altered</cons> by <cons sem="G_DRUG">rifampicin</cons>-mediated <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">induction</cons>.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to evaluate the effect of <cons sem="G_DRUG">rifampicin</cons> co-administration on the pharmacokinetics of ruboxistaurin and its active metabolite, N-desmethyl ruboxistaurin and, in addition, to compare the <cons sem ="G_CHANGE">changes</cons> in pharmacokinetics of ruboxistaurin and N-desmethyl ruboxistaurin with the urinary 6beta-hydroxycortisol : <cons lex="cortisol" sem="G_DRUG">cortisol</cons> ratio.</sentence>
<sentence>Ruboxistaurin is a specific protein-kinase-C beta <cons sem="G_MECHANISM">inhibitor</cons> in clinical development for the treatment of diabetic microvascular complications.</sentence>
<sentence>This was a two-period, one-sequence study.</sentence>
<sentence>Sixteen healthy male subjects completed both study periods.</sentence>
<sentence>In period one, a single <cons sem="G_NUMBER">64 mg</cons> oral dose of ruboxistaurin was administered.</sentence>
<sentence>In period two, <cons sem="G_NUMBER">600 mg</cons> <cons sem="G_DRUG">rifampicin</cons> was administered daily for 9 days, during which another single <cons sem="G_NUMBER">64 mg</cons> ruboxistaurin dose was administered on day 7.</sentence>
<sentence>Blood samples were collected and assayed for ruboxistaurin and N-desmethyl ruboxistaurin.</sentence>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">induction</cons> was assessed by ratios of urinary 6beta-hydroxycortisol : <cons lex="cortisol" sem="G_DRUG">cortisol</cons> (6beta-OHC : C) obtained via 24 h and morning-spot sampling techniques.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, ruboxistaurin, DDI)">
<sentence>Results Following repeated doses of <cons sem="G_DRUG" type="inducer_1">rifampicin</cons>, both the mean <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC(0,infinity)</cons> of <cons sem="G_DRUG" type="substrate_1">ruboxistaurin</cons> were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> by approximately <cons sem="G_NUMBER">95% (P &lt; or = 0.001)</cons>.</sentence>
</annotation>
<sentence>For the metabolite, the mean <cons sem="G_IVIVPARA">C(max)</cons> <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">68% (P &lt; or = 0.001)</cons>, and <cons sem="G_IVIVPARA">AUC(0,infinity)</cons> <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">77% (P &lt; or = 0.001)</cons>.</sentence>
<sentence>The <cons sem="G_IVIVPARA">t(max)</cons> values did <cons sem="G_NEGATIVEEFFECT">not</cons> appear <cons sem="G_CHANGE">affected</cons>.</sentence>
<sentence>The 6beta-OHC : C ratios from both 24 h and morning spot methods <cons sem="G_CHANGE">increased</cons> <cons sem="G_CHANGE">significantly</cons>, consistent with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">induction</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, ruboxistaurin, DDI)">
<sentence>The effect of <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> co-administration on the exposure of <cons sem="G_DRUG" type="substrate_1">ruboxistaurin</cons> is consistent with <cons sem="G_DRUG" type="substrate_1">ruboxistaurin</cons> being a substrate of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<sentence>Therefore, co-administration with known <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inducing</cons> agents (<cons sem="G_DRUG">rifampicin</cons>, <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons>, <cons lex="phenobarbital" sem="G_DRUG">phenobarbital</cons>, etc.) <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">decrease</cons> the concentrations of ruboxistaurin and N-desmethyl-ruboxistaurin.</sentence>
<sentence>In this study, 6beta OHC : C ratios substantially underestimated the impact of <cons sem="G_DRUG">rifampicin</cons> on ruboxistaurin.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16410677</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> on the pharmacokinetics of <cons lex="cabergoline" sem="G_DRUG">cabergoline</cons> in healthy controls and in patients with Parkinson's disease.</sentence>
</title>
<abstract>
<sentence><cons lex="cabergoline" sem="G_DRUG">Cabergoline</cons> is used in the treatment of Parkinson's disease (PD).</sentence>
<sentence><cons lex="clarithromycin" sem="G_DRUG">Clarithromycin</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and P-glycoprotein and is often co-administered with <cons lex="cabergoline" sem="G_DRUG">cabergoline</cons> in usual clinical practice.</sentence>
<sentence>We studied the effect of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> co-administration on the blood concentration of <cons lex="cabergoline" sem="G_DRUG">cabergoline</cons> in healthy male volunteers and in PD patients.</sentence>
<sentence>Study 1: Ten healthy male volunteers were enrolled and were randomized to take a single oral dose of <cons lex="cabergoline" sem="G_DRUG">cabergoline</cons> (<cons sem="G_NUMBER">1 mg/day</cons>) for 6 days or a single oral dose of <cons lex="cabergoline" sem="G_DRUG">cabergoline</cons> plus <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> (<cons sem="G_NUMBER">400 mg/day</cons>) for 6 days.</sentence>
<sentence>Study 2: Seven PD patients receiving stable <cons lex="cabergoline" sem="G_DRUG">cabergoline</cons> doses were enrolled.</sentence>
<sentence>They were evaluated for the plasma <cons lex="cabergoline" sem="G_DRUG">cabergoline</cons> concentration before and after the addition of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> <cons sem="G_NUMBER">400 mg/day</cons> for 6 days, and again 1 month after discontinuation of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons>.</sentence>
<sentence>The dose and duration of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> were decided according to usual clinical practice.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, cabergoline, DDI)">
<sentence>In healthy male volunteers, mean <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUC(0-10 h)</cons> of <cons lex="cabergoline" sem="G_DRUG" type="substrate_1">cabergoline</cons> <cons sem="G_CHANGE">increased</cons> to a similar degree during co-administration of <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, cabergoline, DDI)">
<sentence>Mean <cons sem="G_IVIVPARA">plasma <cons lex="cabergoline" sem="G_DRUG" type="substrate_1">cabergoline</cons> concentration</cons> over 10 h post-dosing <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">2.6-fold</cons> with <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> co-administration.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, cabergoline, DDI)">
<sentence>In PD patients, <cons sem="G_IVIVPARA">plasma <cons lex="cabergoline" sem="G_DRUG" type="substrate_1">cabergoline</cons> concentration</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">1.7-fold</cons> during <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> co-administration.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, cabergoline, ADDI)">
<sentence>Co-administration with <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">increase</cons> the blood concentration of <cons lex="cabergoline" sem="G_DRUG" type="substrate_1">cabergoline</cons> in healthy volunteers and in PD patients.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16390353</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons sem="G_DRUG">rifampicin</cons> on the pharmacokinetics of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>.</sentence>
</title>
<abstract>
<sentence>The effect of enzyme <cons sem="G_MECHANISM">induction</cons> on the pharmacokinetics of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>, a thiazolidinedione antidiabetic drug that is <cons sem="G_MECHANISM">metabolized</cons> primarily by <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, is <cons sem="G_NEGATIVEEFFECT">not</cons> known.</sentence>
<sentence><cons sem="G_DRUG">rifampicin</cons> is a potent <cons sem="G_MECHANISM">inducer</cons> of several CYP enzymes and our objective was to study its effects on the pharmacokinetics of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons> in humans.</sentence>
<sentence>In a randomized, two-phase crossover study, ten healthy subjects ingested either <cons sem="G_NUMBER">600 mg</cons> <cons sem="G_DRUG">rifampicin</cons> or placebo once daily for 6 days.</sentence>
<sentence>On the last day, they received a single oral dose of <cons sem="G_NUMBER">30 mg</cons> <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>.</sentence>
<sentence>The <cons sem="G_IVIVPARA">plasma concentrations</cons> and cumulative excretion of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons> and its active metabolites M-IV and M-III into urine were measured up to 48 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampicin, pioglitazone, DDI)">
<sentence><cons sem="G_DRUG" type="inducer_1">Rifampicin</cons> <cons sem="G_CHANGE">decreased</cons> the mean total <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC(0-infinity))</cons> of <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> by <cons sem="G_NUMBER">54% (range 20-66%; P = 0.0007; 95% confidence interval -78 to -30%)</cons> and shortened its dominant <cons sem="G_IVIVPARA">elimination half-life (t(1/2))</cons> from <cons sem="G_NUMBER">4.9 to 2.3 h (P = 0.0002)</cons>.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem="G_CHANGE">significant</cons> effect on <cons sem="G_IVIVPARA">peak concentration (C(max))</cons> or time to peak (<cons sem="G_IVIVPARA">t(max)</cons>) was observed.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampicin, pioglitazone, DDI)">
<sentence><cons sem="G_DRUG" type="inducer_1">Rifampicin</cons> <cons sem="G_CHANGE">increased</cons> the apparent <cons sem="G_MECHANISM">formation</cons> rate of <cons lex="pioglitazone" sem="G_DRUG" type="M_1">M-IV</cons> and shortened its <cons sem="G_IVIVPARA">t(max)</cons> (<cons sem="G_NUMBER">P &lt; 0.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampicin, pioglitazone, DDI)">    
<sentence>It also <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="pioglitazone" sem="G_DRUG" type="M_1">M-IV</cons> (by <cons sem="G_NUMBER">34%; P = 0.0055</cons>) and <cons lex="pioglitazone" sem="G_DRUG" type="M_2">M-III</cons> (by <cons sem="G_NUMBER">39%; P = 0.0026</cons>), shortened their <cons sem="G_IVIVPARA">t1/2</cons> (<cons lex="pioglitazone" sem="G_DRUG" type="M_1">M-IV</cons> by <cons sem="G_NUMBER">50%; P = 0.0008</cons>, and <cons lex="pioglitazone" sem="G_DRUG" type="M_2">M-III</cons> by <cons sem="G_NUMBER">55%; P = 0.0016</cons>) and <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> ratios of <cons lex="pioglitazone" sem="G_DRUG" type="M_1">M-IV</cons> and <cons lex="pioglitazone" sem="G_DRUG" type="M_2">M-III</cons> to <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> by <cons sem="G_NUMBER">44% (P = 0.0011)</cons> and <cons sem="G_NUMBER">32% (P = 0.0027)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampicin, pioglitazone, DDI)">        
<sentence><cons sem="G_DRUG" type="inducer_1">Rifampicin</cons> <cons sem="G_CHANGE">increased</cons> the <cons lex="pioglitazone" sem="G_DRUG" type="M_1">M-IV</cons>/<cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> and <cons lex="pioglitazone" sem="G_DRUG" type="M_2">M-III</cons>/<cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> ratios in urine by <cons sem="G_NUMBER">98% (P = 0.0015)</cons> and <cons sem="G_NUMBER">95% (P = 0.0024)</cons>.</sentence>
</annotation>
<sentence>A previously unrecognized metabolite M-XI, tentatively identified as a dihydroxy metabolite, was detected in urine during both phases, and <cons sem="G_DRUG">rifampicin</cons> <cons sem="G_CHANGE">increased</cons> the ratio of <cons lex="pioglitazone" sem="G_DRUG" type="M_2">M-XI</cons> to <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> by <cons sem="G_NUMBER">240% (P = 0.0020)</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampicin, pioglitazone, DDI)">
<sentence><cons sem="G_DRUG" type="inducer_1">rifampicin</cons> caused a substantial <cons sem="G_CHANGE">decrease</cons> in the <cons sem="G_IVIVPARA">plasma concentration</cons> of <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons>, <cons sem = "G_CHANGE">probably</cons> by <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampicin, pioglitazone, DDI)">    
<sentence>Concomitant use of <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> with <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">decrease</cons> the efficacy of the latter drug.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16390352</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of cytochrome P450 <cons lex="3a" sem="G_CYP">3A</cons> modulators <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> on <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> pharmacokinetics.</sentence>
</title>
<abstract>
<sentence>To explore the potential for drug interactions on <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> pharmacokinetics using in vitro and in vivo assessments.</sentence>
<sentence>The CYP enzymes responsible for <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> metabolite <cons sem="G_MECHANISM">formation</cons> were assessed using recombinant expressed CYPs and CYP-selective <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
<sentence>P-glycoprotein (Pgp) transport was tested in MDCK cells expressing the human MDR1 gene.</sentence>
<sentence>The effects of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> were evaluated clinically in 12 healthy volunteers that received <cons sem="G_NUMBER">25 mg</cons> <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> before and after 4 days of treatment with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">200 mg</cons> daily.</sentence>
<sentence>To assess <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">induction</cons> in vivo, 18 patients with psychiatric disorders were titrated to steady-state <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> levels (<cons sem="G_NUMBER">300 mg</cons> twice daily), then titrated to <cons sem="G_NUMBER">600 mg</cons> daily <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> for 2 weeks.</sentence>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> was found to be responsible for <cons sem="G_MECHANISM">formation</cons> of <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons> sulfoxide and N- and O-desalkylquetiapine and <cons sem="G_NEGATIVEEFFECT">not</cons> a Pgp substrate.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, quetiapine, DDI)">
<sentence>In the clinical studies, <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> <cons sem="G_CHANGE">increased</cons> mean <cons lex="quetiapine" sem="G_DRUG" type="substrate_1">quetiapine</cons> plasma <cons sem="G_IVIVPARA">C(max)</cons> by <cons sem="G_NUMBER">3.35-fold, from 45 to 150 ng ml(-1) (mean <cons sem="G_IVIVPARA">C(max)</cons> ratio 90% CI 2.51, 4.47)</cons> and <cons sem="G_CHANGE">decreased</cons> its <cons sem="G_IVIVPARA">clearance (CL/F)</cons> by <cons sem="G_NUMBER">84%, from 138 to 22 l h(-1) (mean ratio 90% CI 0.13, 0.20)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(carbamazepine, quetiapine, DDI)">
<sentence><cons lex="carbamazepine" sem="G_DRUG" type="inhibitor_2">Carbamazepine</cons> <cons sem="G_CHANGE">decreased</cons> <cons lex="quetiapine" sem="G_DRUG" type="substrate_1">quetiapine</cons> plasma <cons sem="G_IVIVPARA">C(max)</cons> by <cons sem="G_NUMBER">80%, from 1042 to 205 ng ml(-1) (mean <cons sem="G_IVIVPARA">C(max)</cons> ratio 90% CI 0.14, 0.28)</cons> and <cons sem="G_CHANGE">increased</cons> its <cons sem="G_IVIVPARA">clearance</cons> <cons sem="G_NUMBER">7.5-fold, from 65 to 483 l h(-1) (mean ratio 90% CI 6.04, 9.28)</cons>.</sentence>
</annotation>
<sentence>Cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> is a primary enzyme responsible for the metabolic <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="quetiapine" sem="G_DRUG">quetiapine</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, quetiapine, DDI)(carbamazepine, quetiapine, DDI)">
<sentence><cons lex="quetiapine" sem="G_DRUG" type="substrate_1">Quetiapine</cons> pharmacokinetics were <cons sem="G_CHANGE">affected</cons> by concomitant administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> and <cons lex="carbamazepine" sem="G_DRUG" type="inhibitor_2">carbamazepine</cons>, and therefore other drugs and ingested natural products that <cons sem="G_CHANGE">strongly</cons> modulate the activity or expression of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> would be predicted to <cons sem = "G_CHANGE">change</cons> exposure to <cons lex="quetiapine" sem="G_DRUG" type="substrate_1">quetiapine</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16338282</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of low-dose <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> (<cons sem="G_NUMBER">100 mg</cons> twice daily) on the activity of cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>In the treatment of human immunodeficiency virus infection, the protease <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> is used in a low dose (<cons sem="G_NUMBER">100 mg</cons> twice daily) to <cons sem="G_MECHANISM">inhibit</cons> cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> and thereby <cons sem="G_CHANGE">increase</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of coadministered protease <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
<sentence>When applied in a therapeutic dose (<cons sem="G_NUMBER">600 mg</cons> twice daily), <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> also <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>The effect of low-dose <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is unknown and was investigated in this study.</sentence>
<sentence>This was a 1-arm, 2-period, fixed-order study in 13 healthy male volunteers who were extensive <cons sem="G_MECHANISM">metabolizers</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>The first period examined baseline <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity by evaluating the pharmacokinetics of a single dose of <cons lex="desipramine" sem="G_DRUG">desipramine</cons> and by metabolic phenotyping with <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>.</sentence>
<sentence>During the second period, participants took <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, <cons sem="G_NUMBER">100 mg</cons> twice daily, for 2 weeks, followed by repeat assessment of <cons lex="desipramine" sem="G_DRUG">desipramine</cons> pharmacokinetics and the <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> metabolic phenotype in the presence of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, desipramine, ADDI)">
<sentence>Low-dose <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> (<cons sem="G_NUMBER">100 mg</cons> twice daily) <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the exposure to single-dose <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons>, as reflected in a geometric mean ratio (with <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons>/<cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons>) of <cons sem="G_NUMBER">1.26 (95% confidence interval, 1.13-1.40)</cons> for the <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> <cons sem="G_IVIVPARA">area under the concentration versus time curve from time 0 to infinity</cons> (<cons sem="G_NUMBER">P &lt; .001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, dextrorphan , NDDI)">
<sentence>Coadministration of low-dose <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> did <cons sem="G_NUMBER"><cons sem="G_NEGATIVEEFFECT">not</cons></cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affect</cons> the <cons lex="dextromethorphan" sem="G_DRUG" type="M_1">dextromethorphan</cons>/<cons lex="dextromethorphan" sem="G_DRUG" type="substrate_2">dextrorphan</cons> urinary metabolic ratio and did <cons sem="G_NEGATIVEEFFECT">not</cons> convert any extensive <cons sem="G_MECHANISM">metabolizer</cons> to a poor <cons sem="G_MECHANISM">metabolizer</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ritonavir, desipramine, ADDI)">
<sentence>Low-dose <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> (<cons sem="G_NUMBER">100 mg</cons> twice daily) exerts a <cons sem = "G_CHANGE">modest</cons> <cons sem="G_MECHANISM">inhibitory</cons> effect on the activity of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in extensive <cons sem="G_MECHANISM">metabolizers</cons>, as assessed with <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> as the index substrate.</sentence>
</annotation>
<sentence>This effect was <cons sem="G_NEGATIVEEFFECT">not</cons> apparent with the dextromethorphan/dextrorphan metabolic ratio as an indicator for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity.</sentence>
<sentence>It is expected that the effect of low-dose <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> will <cons sem="G_NEGATIVEEFFECT">not</cons> require standard dose <cons sem ="G_CHANGE">reduction</cons>s for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> substrates.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16283275</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> on the pharmacokinetics of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>.</sentence>
</title>
<abstract>
<sentence>Our objective was to study the effects of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> on the pharmacokinetics of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons> and the active compounds, which are all the substrates of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>In a randomized, two-phase crossover study, 10 healthy volunteers were pretreated for 2 days with either <cons sem="G_NUMBER">600 mg</cons> oral <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> or placebo twice daily.</sentence>
<sentence>On day 3, they received a single dose of <cons sem="G_NUMBER">600 mg</cons> <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> or placebo, and 1 h later they received a single oral dose of <cons sem="G_NUMBER">30 mg</cons> <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="pioglitazone" sem="G_DRUG">pioglitazone</cons> and both active metabolites M-III and M-IV were measured for up to 120 h. </sentence> 
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, pioglitazone, DDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> <cons sem="G_CHANGE">raised</cons> the mean total <cons sem="G_IVIVPARA">area under the concentration-time curve (AUC)</cons> of parent <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> <cons sem="G_NUMBER">3.4-fold (P&lt;0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, pioglitazone, NDDI)">
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> statistically <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> were seen in the total <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="pioglitazone" sem="G_DRUG" type="M_1">M-III</cons> or <cons lex="pioglitazone" sem="G_DRUG" type="M_2">M-IV</cons> after <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> pretreatment.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, pioglitazone, DDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> <cons sem="G_CHANGE">reduced</cons> the <cons lex="pioglitazone" sem="G_DRUG" type="M_1">M-III</cons>/<cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> and <cons lex="pioglitazone" sem="G_DRUG" type="M_2">M-IV</cons>/<cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> ratio by <cons sem="G_NUMBER">71% (P&lt;0.001)</cons> and <cons sem="G_NUMBER">65%(P&lt;0.001)</cons>, strikingly prolonging their <cons sem="G_IVIVPARA">t((1/2))</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, pioglitazone, DDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">plasma concentration</cons> of parent <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> and also <cons sem="G_MECHANISM">inhibited</cons> the further <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="pioglitazone" sem="G_DRUG" type="M_1">M-III</cons> and <cons lex="pioglitazone" sem="G_DRUG" type="M_2">M-IV</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, pioglitazone, DDI)">
<sentence>Careful blood glucose monitoring and dosage adjustments are suggested during coadministration of <cons lex="pioglitazone" sem="G_DRUG" type="substrate_1">pioglitazone</cons> and <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16282844</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="fluvoxamine" sem="G_DRUG">Fluvoxamine</cons> affects <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> kinetics and dynamics.</sentence>
</title>
<abstract>
<sentence><cons lex="sildenafil" sem="G_DRUG">Sildenafil</cons> used as oral drug treatment for erectile dysfunction is predominantly <cons sem="G_MECHANISM">metabolized</cons> by the cytochrome P450 isozyme <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
<sentence>The antidepressant <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> is an <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
<sentence>In a randomized, double-blind, placebo-controlled, crossover study, we evaluated the effects of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> dosed to steady state on the pharmacokinetics and pharmacodynamics of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons>.</sentence>
<sentence>Twelve healthy men received oral <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> or placebo for 10 days (<cons sem="G_NUMBER">50 mg</cons> every day on days 1-3; <cons sem="G_NUMBER">100 mg</cons> every day on days 4-10).</sentence>
<sentence>On day 11, all participants received a single, oral, open-label dose of <cons sem="G_NUMBER">50 mg</cons> <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons>, and blood samples were collected for analysis of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> by liquid chromatography/mass spectrometry.</sentence>
<sentence>Concurrently, the effect of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> on venodilation <cons sem="G_MECHANISM">induced</cons> by a constant dose of sodium <cons lex="nitroprusside" sem="G_DRUG">nitroprusside</cons> was assessed using the dorsal hand vein compliance technique.</sentence>
<sentence><cons lex="sildenafil" sem="G_DRUG">Sildenafil</cons> was well tolerated in the presence of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, sildenafil, ADDI)">
<sentence>During <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons>, <cons lex="sildenafil" sem="G_DRUG" type="substrate_1">sildenafil</cons> exposure (<cons sem="G_IVIVPARA">area under the curve</cons>) <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">40% (P &lt; 0.001)</cons>, and its <cons sem="G_IVIVPARA">half-life</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">19% (P = 0.034)</cons>.</sentence>
</annotation>
<sentence>Concurrently, sodium <cons lex="nitroprusside" sem="G_DRUG">nitroprusside</cons>-<cons sem="G_MECHANISM">induced</cons> venodilation was <cons sem="G_CHANGE">significantly</cons> augmented by <cons sem="G_NUMBER">59%</cons> during <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> compared to placebo (<cons sem="G_NUMBER">P = 0.012</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, sildenafil, ADDI)">
<sentence>In conclusion, <cons lex="sildenafil" sem="G_DRUG" type="substrate_1">sildenafil</cons> kinetics are mildly <cons sem="G_CHANGE">affected</cons> by <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> which translates into an <cons sem="G_CHANGE">increase</cons> in vascular <cons lex="sildenafil" sem="G_DRUG" type="substrate_1">sildenafil</cons> effects.</sentence>
</annotation>
<sentence>Whereas the pharmacokinetic <cons sem ="G_CHANGE">changes</cons> do <cons sem="G_NEGATIVEEFFECT">not</cons> suggest a large clinically relevant interaction, it <cons sem = "G_CHANGE">may</cons> be prudent to consider a starting dose of <cons sem="G_NUMBER">25 mg</cons> in patients concurrently treated with <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16272957</bibliomisc>
</articleinfo>
<title>
<sentence>Interaction magnitude, pharmacokinetics and pharmacodynamics of <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> in relation to <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypic status.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to investigate the impact of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> polymorphism on the extent of the interaction and on the pharmacokinetics and pharmacodynamics of <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons>.</sentence>
<sentence>Homozygous (hmEMs) and heterozygous extensive <cons sem="G_MECHANISM">metabolizers</cons> (htEMs), and poor <cons sem="G_MECHANISM">metabolizers</cons> (PMs, n = 6 each) took an oral dose (<cons sem="G_NUMBER">20 mg</cons>) of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>.</sentence>
<sentence>After a 1-week washout period, each subject received <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> (<cons sem="G_NUMBER">200 mg</cons>) for 8 days, and <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> pharmacokinetics were studied on days 1 and 7.</sentence>
<sentence>On day 8, <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> was given again and its kinetic disposition was compared with that in the first dose.</sentence>
<sentence>ADP-<cons sem="G_MECHANISM">induced</cons> platelet aggregation was measured as a pharmacodynamic index.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ticlopidine, omeprazole, DDI)">
<sentence>In contrast to the PMs, whose mean kinetic parameters were <cons sem="G_NEGATIVEEFFECT"><cons sem="G_NEGATIVEEFFECT">not</cons></cons> <cons sem="G_CHANGE">altered</cons> by the repeated dosings of <cons lex="ticlopidine" sem="G_DRUG" type="inhibitor_1">ticlopidine</cons>, an <cons sem="G_NUMBER">eight- to 10-fold</cons> <cons sem="G_CHANGE">increase</cons> in the mean <cons sem="G_IVIVPARA">AUC</cons> ratio of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> to <cons lex="omeprazole" sem="G_DRUG" type="M_1">5-hydroxyomeprazole</cons> was observed in both the EM groups.</sentence>
</annotation>
<sentence>No <cons sem="G_CHANGE">significant</cons> intergenotypic differences in the pharmacokinetic parameters of <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> were observed, although the accumulation ratio tended to be <cons sem = "G_CHANGE">greater</cons> in hmEMs than in PMs (<cons sem="G_NUMBER">2.4 +/- 0.2 versus 1.7 +/- 0.2</cons>).</sentence>
<sentence>A <cons sem="G_CHANGE">significantly</cons> positive <cons sem="G_MECHANISM">correlation</cons> (<cons sem="G_NUMBER">P = 0.031</cons>) was observed between the individual percent <cons sem="G_MECHANISM">inhibition</cons> of platelet aggregation and <cons sem="G_IVIVPARA">AUC0-24</cons> of <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> regardless of the <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> polymorphism.</sentence>
<sentence><cons lex="ticlopidine" sem="G_DRUG">Ticlopidine</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons sem = "G_CHANGE">may</cons> be associated with the phenocopy when <cons sem="G_CYP">CYPC19</cons> substrates are co-administered to EMs.</sentence>
<sentence>Whether and to what extent <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> would be involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="ticlopidine" sem="G_DRUG">ticlopidine</cons> remain unanswered from the present in-vivo study.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16236038</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="fluvoxamine" sem="G_DRUG">Fluvoxamine</cons> impairs single-dose <cons lex="caffeine" sem="G_DRUG">caffeine</cons> <cons sem="G_IVIVPARA">clearance</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> altering <cons lex="caffeine" sem="G_DRUG">caffeine</cons> pharmacodynamics.</sentence>
</title>
<abstract>
<sentence>Coadministration of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> impairs the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> and prolongs its <cons sem="G_IVIVPARA">elimination half-life</cons>, which is attributable to <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> by <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>.</sentence>
<sentence>The clinical importance of this interaction is <cons sem="G_NEGATIVEEFFECT">not</cons> established.</sentence>
<sentence>To evaluate the effects of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> on the kinetics and dynamics of single doses of <cons lex="caffeine" sem="G_DRUG">caffeine</cons>.</sentence>
<sentence>Seven healthy subjects received single <cons sem="G_NUMBER">250 mg</cons> doses of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> (or matching placebo) together with <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> (four doses of <cons sem="G_NUMBER">100 mg</cons> over 2 days) or with matching placebo in a double-blind, four-way crossover study.</sentence>
<sentence>For 24 h after <cons lex="caffeine" sem="G_DRUG">caffeine</cons> or placebo administration, plasma <cons lex="caffeine" sem="G_DRUG">caffeine</cons> and <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> concentrations were determined.</sentence>
<sentence>Psychomotor performance, sedation, and electroencephalographic (EEG) "beta" frequency activity were also assessed.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, caffeine, DDI)">
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> apparent <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="caffeine" sem="G_DRUG" type="substrate_1">caffeine</cons> <cons sem="G_NUMBER">(105 vs. 9.1 mL min(-1), P &lt; 0.01; mean difference: 95.7 mL min(-1), 95% CI: 54.9-135.6)</cons>, and prolonged its <cons sem="G_IVIVPARA">elimination half-life</cons> <cons sem="G_NUMBER">(4.9 vs. 56 h, P &lt; 0.01; mean difference: 51 h, 95% CI: 26-76)</cons>.</sentence>
</annotation>
<sentence><cons lex="caffeine" sem="G_DRUG">Caffeine</cons> produced CNS-stimulating effects compared with placebo.</sentence>
<sentence>However, psychomotor performance, alertness, or EEG effects attributable to <cons lex="caffeine" sem="G_DRUG">caffeine</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> augmented by coadministration of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, caffeine, ADDI)">
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem = "G_CHANGE">impaired</cons> <cons lex="caffeine" sem="G_DRUG" type="substrate_1">caffeine</cons> <cons sem="G_IVIVPARA">clearance</cons>, but <cons sem="G_NEGATIVEEFFECT">without</cons> detectable <cons sem ="G_CHANGE">changes</cons> in <cons lex="caffeine" sem="G_DRUG" type="substrate_1">caffeine</cons> pharmacodynamics.</sentence>
</annotation>
<sentence>However, this study does <cons sem="G_NEGATIVEEFFECT">not</cons> rule out possible adverse effects due to extensive accumulation of <cons lex="caffeine" sem="G_DRUG">caffeine</cons> with daily ingestion in <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>-treated individuals.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16176119</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic drug interactions of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> with <cons sem="G_DRUG">rifampicin</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="gefitinib" sem="G_DRUG">Gefitinib</cons> (IRESSA, ZD1839), an epidermal growth factor receptor tyrosine kinase <cons sem="G_MECHANISM">inhibitor</cons>, has been approved in several countries for the treatment of advanced non-small-cell lung cancer.</sentence>
<sentence>Preclinical studies were conducted to determine the cytochrome P450 (CYP) isoenzymes involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> and to evaluate the potential of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> to cause drug interactions through <cons sem="G_MECHANISM">inhibition</cons> of CYP isoenzymes.</sentence>
<sentence>Based on these findings, three clinical studies were carried out to investigate pharmacokinetic drug interactions in vivo with <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons>.</sentence>
<sentence>In preclinical studies radiolabelled <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> was incubated with: (i) hepatic microsomal protein in the presence of selective CYP inhibitors; and (ii) expressed CYP enzymes.</sentence>
<sentence>Human hepatic microsomal protein was incubated with selective CYP substrates in the presence of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons>.</sentence>
<sentence>Clinical studies were all phase I, open-label, single-centre studies; two had a randomised, two-way crossover design and the third was nonrandomised.</sentence>
<sentence>The first and second studies investigated the pharmacokinetics of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> in the presence of a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inducer</cons> (<cons sem="G_DRUG">rifampicin</cons>  [<cons lex="rifampin" sem="G_DRUG">rifampin</cons>]) or <cons sem="G_MECHANISM">inhibitor</cons> (<cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>) in healthy male volunteers.</sentence>
<sentence>The third study investigated the effects that <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> had on the pharmacokinetics of <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons>, a <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> substrate, in patients with solid tumours.</sentence>
<sentence>The results of preclinical studies demonstrated that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is involved in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> and that <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> is a weak <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, gefitinib, DDI)">
<sentence>In clinical studies when <cons lex="gefitinib" sem="G_DRUG" type="inducer_1">gefitinib</cons> was administered in the presence of <cons lex="rifampicin" sem="G_DRUG" type="substrate_1">rifampicin</cons>, geometric mean (gmean) <cons sem="G_IVIVPARA">maximum concentration</cons> and <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> were <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">65%</cons> and <cons sem="G_NUMBER">83%</cons>, respectively; these <cons sem ="G_CHANGE">changes</cons> were statistically <cons sem="G_CHANGE">significant</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, gefitinib, DDI)">
<sentence>When <cons lex="gefitinib" sem="G_DRUG" type="inhibitor_1">gefitinib</cons> was administered in the presence of <cons lex="itraconazole" sem="G_DRUG" type="substrate_2">itraconazole</cons>, gmean <cons sem="G_IVIVPARA">AUC</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">78%</cons> and <cons sem="G_NUMBER">61%</cons> at <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> doses of <cons sem="G_NUMBER">250</cons> and <cons sem="G_NUMBER">500 mg</cons>, respectively; these <cons sem ="G_CHANGE">changes</cons> also being statistically <cons sem="G_CHANGE">significant</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(metoprolol, gefitinib, ADDI)">
<sentence>Coadministration of <cons lex="metoprolol" sem="G_DRUG" type="substrate_3">metoprolol</cons> with <cons lex="gefitinib" sem="G_DRUG" type="inhibitor_1">gefitinib</cons> resulted in a <cons sem="G_NUMBER">35%</cons> <cons sem="G_CHANGE">increase</cons> in the <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> <cons sem="G_IVIVPARA">area under plasma concentration-time curve from time zero to the time of the last quantifiable concentration</cons>; this <cons sem = "G_CHANGE">change</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> statistically <cons sem="G_CHANGE">significant</cons>.</sentence>
</annotation>
<sentence>There was <cons sem="G_NEGATIVEEFFECT">no</cons> apparent <cons sem = "G_CHANGE">change</cons> in the safety profile of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> as a result of coadministration with other agents.</sentence>
<sentence>Although <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inducers</cons> <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">reduce</cons> exposure to <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons>, further work is required to define any resultant effect on the efficacy of <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons>.</sentence>
<sentence>Exposure to <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> is <cons sem="G_CHANGE">increased</cons> by coadministration with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>, but since <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> is known to have a good tolerability profile, a dosage <cons sem ="G_CHANGE">reduction</cons> is <cons sem="G_NEGATIVEEFFECT">not</cons> recommended.</sentence>
<sentence><cons lex="gefitinib" sem="G_DRUG">Gefitinib</cons> is unlikely to exert a clinically relevant effect on the pharmacokinetics of drugs that are dependent on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> for their <cons sem="G_IVIVPARA">clearance</cons>, but the potential to <cons sem="G_CHANGE">increase</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> should be considered if <cons lex="gefitinib" sem="G_DRUG">gefitinib</cons> is coadministered with <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> substrates that have a narrow therapeutic index or are individually dose titrated.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16122280</bibliomisc>
</articleinfo>
<title>
<sentence>Clinical pharmacokinetics of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons>, the first ketolide antibacterial.</sentence>
</title>
<abstract>
<sentence><cons lex="telithromycin" sem="G_DRUG">Telithromycin</cons> is the first ketolide, which is a new class of antibacterial agents related to the macrolides that have structural modifications permitting dual binding to bacterial ribosomal RNA so that activity is retained against Streptococcus pneumoniae with macrolide-lincosamide-streptogramin(B) resistance.</sentence>
<sentence>Clinical experience in infectious patients has shown that oral <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> <cons sem="G_NUMBER">800mg</cons> once daily for 5-10 days is effective for the treatment of community-acquired upper and lower respiratory tract infections.</sentence>
<sentence>Absorption of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> in humans is estimated to be <cons sem="G_NUMBER">&gt; or = 90%</cons>.</sentence>
<sentence>Prior to entering the systemic circulation, <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> undergoes first-pass <cons sem="G_MECHANISM">metabolism</cons> (mainly by the liver).</sentence>
<sentence>Its absolute <cons sem="G_IVIVPARA">bioavailability</cons> is <cons sem="G_NUMBER">57%</cons> and is <cons sem="G_NEGATIVEEFFECT">unaffected</cons> by food.</sentence>
<sentence>The volume of distribution of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> after intravenous infusion is <cons sem="G_NUMBER">2.9 L/kg</cons>.</sentence>
<sentence><cons lex="telithromycin" sem="G_DRUG">Telithromycin</cons> is <cons sem="G_NUMBER">60-70%</cons> bound to serum proteins and has extensive diffusion into a range of target biological tissues, achieving concentrations above its minimum <cons sem="G_MECHANISM">inhibitory</cons> concentration (MIC) against key respiratory pathogens throughout the dosing interval.</sentence>
<sentence>After entering the systemic circulation, <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> is eliminated by multiple pathways (<cons sem="G_NUMBER">7%</cons> by biliary and/or intestinal excretion, <cons sem="G_NUMBER">13%</cons> by renal excretion and <cons sem="G_NUMBER">37%</cons> by hepatic <cons sem="G_MECHANISM">metabolism</cons>).</sentence>
<sentence><cons lex="telithromycin" sem="G_DRUG">Telithromycin</cons> is <cons sem="G_MECHANISM">metabolised</cons> via cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> and non-CYP pathways.</sentence>
<sentence>The identified metabolites show minimal antibacterial activity compared with the parent drug.</sentence>
<sentence>In healthy subjects receiving <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> <cons sem="G_NUMBER">800 mg</cons> once daily, the <cons sem="G_IVIVPARA">peak plasma concentration</cons> achieved is <cons sem="G_NUMBER">2.27 microg/mL</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> show a biphasic <cons sem="G_CHANGE">decrease</cons> over time, with an initial disposition <cons sem="G_IVIVPARA">half-life</cons> of <cons sem="G_NUMBER">2.9 hours</cons> and a <cons sem="G_IVIVPARA">terminal elimination half-life</cons> of approximately <cons sem="G_NUMBER">10 hours</cons> after multiple dose administration.</sentence>
<sentence>Steady-state <cons sem="G_IVIVPARA">plasma concentrations</cons> are achieved within 2-3 days of once-daily administration.</sentence>
<sentence>Owing to elimination by multiple pathways there is a small <cons sem="G_CHANGE">increase</cons> in exposure when one of these elimination pathways is impaired, as indicated by the results of studies in special patient populations (e.g. those with hepatic or renal impairment).</sentence>
<sentence>Dosage <cons sem ="G_CHANGE">reduction</cons>s <cons sem = "G_CHANGE">may</cons> be recommended in patients with severe renal impairment.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, telithromycin, DDI)(ketoconazole, telithromycin, DDI)">
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> by potent <cons sem="G_MECHANISM">inhibitors</cons> such as <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> and <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_2">ketoconazole</cons> results in a <cons sem="G_NUMBER">54%</cons> and <cons sem="G_NUMBER">95%</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="telithromycin" sem="G_DRUG" type="substrate_1">telithromycin</cons> <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons>, respectively.</sentence>
</annotation>
<sentence>The potential for <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> to <cons sem="G_MECHANISM">inhibit</cons> the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> pathway is similar to that of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons>.</sentence>
<sentence>The once-daily administration of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> is likely to limit the potential for drug interactions and clinically <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> in exposure.</sentence>
<sentence>In phase III clinical trials, the <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> <cons sem="G_NUMBER">800 mg</cons> once-daily dose has been shown to provide close to the maximum antimicrobial activity against S. pneumoniae, Haemophilus influenzae and Staphylococcus aureus in patients with community-acquired pneumonia.</sentence>
<sentence>In conclusion, <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> has a well characterised and reproducible pharmacokinetic profile, with pharmacokinetic/pharmacodynamic relationships supporting an oral dosage regimen of <cons sem="G_NUMBER">800 mg</cons> once daily.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16097365</bibliomisc>
</articleinfo>
<title>
<sentence>Interaction between <cons lex="amlodipine" sem="G_DRUG">amlodipine</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> in patients with hypercholesterolemia and hypertension.</sentence>
</title>
<abstract>
<sentence>3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase <cons sem="G_MECHANISM">inhibitors</cons> are often prescribed in association with antihypertensive agents, including calcium antagonists.</sentence>
<sentence><cons lex="simvastatin" sem="G_DRUG">Simvastatin</cons> is an HMG-CoA reductase <cons sem="G_MECHANISM">inhibitor</cons> that is <cons sem="G_MECHANISM">metabolized</cons> by the cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
<sentence>The calcium antagonist <cons lex="amlodipine" sem="G_DRUG">amlodipine</cons> is also <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>The purpose of this study was to investigate drug interactions between <cons lex="amlodipine" sem="G_DRUG">amlodipine</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>.</sentence>
<sentence>Eight patients with hypercholesterolemia and hypertension were enrolled.</sentence>
<sentence>They were given 4 weeks of oral <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> (<cons sem="G_NUMBER">5 mg/day</cons>), followed by 4 weeks of oral <cons lex="amlodipine" sem="G_DRUG">amlodipine</cons> (<cons sem="G_NUMBER">5 mg/day</cons>) co-administered with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> (5 mg/day).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(simvastatin , amlodipine, ADDI)">
<sentence>Combined treatment with <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> and <cons lex="amlodipine" sem="G_DRUG" type="inhibitor_1">amlodipine</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak concentration (C(max))</cons> of HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons> from <cons sem="G_NUMBER">9.6 +/- 3.7 ng/ml to 13.7 +/- 4.7 ng/ml (p &lt; 0.05)</cons> and the <cons sem="G_IVIVPARA">area under the concentration-time curve (AUC)</cons> from <cons sem="G_NUMBER">34.3 +/- 16.5 ng h/ml to 43.9 +/- 16.6 ng h/ml (p &lt; 0.05)</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> affecting the <cons lex="cholesterol" sem="G_DRUG">cholesterol</cons>-lowering effect of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(simvastatin , amlodipine, ADDI)">
<sentence>This study is the first to determine prospectively the pharmacokinetic and pharmacodynamic interaction between <cons lex="amlodipine" sem="G_DRUG" type="inhibitor_1">amlodipine</cons> and <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:16084850</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">decreases</cons> and <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> <cons sem="G_CHANGE">increases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> and its metabolites.</sentence>
</title>
<abstract>
<sentence>The pharmacokinetic interactions of the widely used statin <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> with fibrates and enzyme <cons sem="G_MECHANISM">inducers</cons> are <cons sem="G_NEGATIVEEFFECT">not</cons> known.</sentence>
<sentence>Therefore we studied the effects of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (INN, <cons sem="G_DRUG">rifampicin</cons>) and <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> on the pharmacokinetics of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons>.</sentence>
<sentence>Two randomized crossover studies were conducted.</sentence>
<sentence>In study 1, 10 healthy volunteers took <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or placebo once daily for 5 days.</sentence>
<sentence>On day 6, they ingested a single <cons sem="G_NUMBER">40-mg</cons> dose of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons>.</sentence>
<sentence>In study 2, 10 healthy volunteers took <cons sem="G_NUMBER">600 mg</cons> <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> or placebo twice daily for 5 days.</sentence>
<sentence>On day 3, they ingested a single <cons sem="G_NUMBER">20-mg</cons> dose of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> (in nanograms per milliliter) and its metabolites (in arbitrary units) were measured by liquid chromatography-tandem mass spectrometry up to 48 to 72 hours after dosing.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, atorvastatin, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">reduced</cons> the total <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> of <cons sem="G_NEGATIVEEFFECT">unchanged</cons> <cons lex="atorvastatin" sem="G_DRUG" type="substrate_1">atorvastatin</cons> (acid) by <cons sem="G_NUMBER">80% (95% confidence interval  [CI], 73% to 84%; P &lt; .001)</cons>, that of the active metabolites <cons lex="atorvastatin" sem="G_DRUG" type="M_1">2-hydroxyatorvastatin acid</cons> by <cons sem="G_NUMBER">43% (95% CI, 29% to 51%; P &lt; .001)</cons> and <cons lex="atorvastatin" sem="G_DRUG" type="M_2">4-hydroxyatorvastatin acid</cons> by <cons sem="G_NUMBER">81% (95% CI, 74% to 84%; P &lt; .001)</cons>, and that of their <cons lex="atorvastatin" sem="G_DRUG" type="M_3">lactones</cons> by <cons sem="G_NUMBER">93% (95% CI, 90% to 95%), by 61% (95% CI, 50% to 69%)</cons>, and by <cons sem="G_NUMBER">76% (95% CI, 70% to 81%), respectively (P &lt; .001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, atorvastatin, DDI)">
<sentence>The <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="M_1">2-hydroxyatorvastatin acid</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">68% (95% CI, 21% to 127%; P = .005)</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, atorvastatin, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">shortened</cons> (<cons sem="G_NUMBER">P &lt; .001</cons>) the <cons sem="G_IVIVPARA">half-lives</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_1">atorvastatin</cons> (by <cons sem="G_NUMBER">74%; 95% CI, 67% to 81%</cons>) and its metabolites, for example, <cons lex="atorvastatin" sem="G_DRUG" type="M_3">atorvastatin lactone</cons> (by <cons sem="G_NUMBER">82%; 95% CI, 80% to 85%</cons>) and <cons lex="atorvastatin" sem="G_DRUG" type="M_1">2-hydroxyatorvastatin acid</cons> (by <cons sem="G_NUMBER">70%; 95% CI, 64% to 78%</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, atorvastatin, DDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_1">atorvastatin</cons> <cons sem="G_NUMBER">(by 24%; 95% CI, -1% to 50%; P =.059)</cons>, <cons lex="atorvastatin" sem="G_DRUG" type="M_1">2-hydroxyatorvastatin acid</cons> <cons sem="G_NUMBER">(by 51%; 95% CI, 28% to 70%; P &lt; .001)</cons> and its <cons lex="atorvastatin" sem="G_DRUG" type="M_3">lactone</cons> <cons sem="G_NUMBER">(by 29%; 95% CI, 13% to 53%; P =.003)</cons>, and <cons lex="atorvastatin" sem="G_DRUG" type="M_2">4-hydroxyatorvastatin acid</cons> <cons sem="G_NUMBER">(by 82%; 95% CI, 60% to 126%; P &lt; .001)</cons> and its lactone <cons sem="G_NUMBER">(by 28%; 95% CI, 15% to 51%; P =.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, atorvastatin, NDDI)">
<sentence>The <cons sem="G_IVIVPARA">half-lives</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_1">atorvastatin</cons> and its lactone metabolites were <cons sem="G_CHANGE">slightly</cons> <cons sem="G_CHANGE">shortened</cons> by <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> (<cons sem="G_NUMBER">P &lt; .05</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, atorvastatin, DDI)(Gemfibrozil, atorvastatin, ADDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">decreases</cons> and <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderately</cons></cons> <cons sem="G_CHANGE">increases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_1">atorvastatin</cons> and its metabolites.</sentence>
</annotation>
<sentence>It is advisable to <cons sem="G_CHANGE">increase</cons> the dosage of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> and preferable to administer it in the evening to guarantee adequate concentrations during the nighttime rapid <cons lex="cholesterol" sem="G_DRUG">cholesterol</cons> synthesis when <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or other potent <cons sem="G_MECHANISM">inducers</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> are coadministered.</sentence>
<sentence>Care is warranted, and only low doses of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> should be used if coadministration with <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> is needed.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15915352</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="probenecid" sem="G_DRUG">probenecid</cons> on the pharmacokinetics of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence><cons lex="carbamazepine" sem="G_DRUG">Carbamazepine (CBZ)</cons> undergoes biotransformation by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, and glucuronide conjugation.</sentence>
<sentence>There has been <cons sem="G_NEGATIVEEFFECT">no</cons> clear demonstration to reveal the role of glucuronidation in the disposition of <cons lex="carbamazepine" sem="G_DRUG">CBZ</cons>.</sentence>
<sentence>We evaluated the effect of <cons lex="probenecid" sem="G_DRUG">probenecid</cons>, a UDP-glucuronosyltransferase <cons sem="G_MECHANISM">inhibitor</cons>, on the pharmacokinetics of <cons lex="carbamazepine" sem="G_DRUG">CBZ</cons> in humans.</sentence>
<sentence>In a randomized, open-label, two-way crossover study, ten healthy male subjects were treated twice daily for 10 days with <cons sem="G_NUMBER">500 mg</cons> <cons lex="probenecid" sem="G_DRUG">probenecid</cons> or with a matched placebo.</sentence>
<sentence>On day 6, a single dose of <cons sem="G_NUMBER">200 mg</cons> <cons lex="carbamazepine" sem="G_DRUG">CBZ</cons> was administered orally.</sentence>
<sentence>Concentrations of <cons lex="carbamazepine" sem="G_DRUG">CBZ</cons> and <cons lex="carbamazepine" sem="G_DRUG">CBZ 10,11-epoxide (CBZ-E)</cons> in plasma and urine were measured.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Probenecid, CBZ, ADDI)">
<sentence><cons lex="probenecid" sem="G_DRUG" type="inducer_1">Probenecid</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> of <cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ</cons> from <cons sem="G_NUMBER">1253.9 micromol h/l to 1020.7 micromol h/l (P &lt; 0.001)</cons> while <cons sem="G_CHANGE">increasing</cons> that of <cons lex="carbamazepine" sem="G_DRUG" type="M_1">CBZ-E</cons> from <cons sem="G_NUMBER">137.6 micromol h/l to 183.5 micromol h/l (P = 0.033)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Probenecid, CBZ, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ</cons> was <cons sem="G_CHANGE">increased</cons> by <cons lex="probenecid" sem="G_DRUG" type="inducer_1">probenecid</cons> by <cons sem="G_NUMBER">26% (90% confidence interval, 17-34%; P &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Probenecid, CBZ, ADDI)">
<sentence><cons lex="probenecid" sem="G_DRUG" type="inducer_1">Probenecid</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC ratio</cons> of <cons lex="carbamazepine" sem="G_DRUG" type="M_1">CBZ-E</cons>/<cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ</cons> from <cons sem="G_NUMBER">0.11 to 0.16 (P &lt; 0.001)</cons>.</sentence>
</annotation>
<sentence>However, <cons lex="probenecid" sem="G_DRUG">probenecid</cons> had minimal effect on the recovery of the conjugated and free forms of <cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ</cons> and <cons lex="carbamazepine" sem="G_DRUG" type="M_1">CBZ-E</cons> in urine.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Probenecid, CBZ, ADDI)">
<sentence>Although <cons lex="probenecid" sem="G_DRUG" type="inducer_1">probenecid</cons> showed a minimal effect on the glucuronidation of <cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ</cons> and <cons lex="carbamazepine" sem="G_DRUG" type="M_1">CBZ-E</cons>, it <cons sem="G_CHANGE">increased</cons> <cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ</cons> biotransformation to <cons lex="carbamazepine" sem="G_DRUG" type="M_1">CBZ-E</cons>, most likely reflecting the <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> activities, in humans.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Probenecid, CBZ, DDI)">
<sentence>These results demonstrate that glucuronide conjugation plays a <cons sem = "G_CHANGE">minor</cons> role in the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ</cons> and <cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ-E</cons> in humans, and that <cons lex="probenecid" sem="G_DRUG" type="inducer_1">probenecid</cons> has an <cons sem="G_MECHANISM">inducing</cons> effect on the disposition of <cons lex="carbamazepine" sem="G_DRUG" type="substrate_1">CBZ</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15896247</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of antimalarial <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> in healthy human volunteers.</sentence>
</title>
<abstract>
<sentence>Antimalarial <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> has a structure related to <cons lex="quinine" sem="G_DRUG">quinine</cons>.</sentence>
<sentence>The major metabolite of <cons lex="quinine" sem="G_DRUG">quinine</cons> is 3-hydroxyquinine <cons sem="G_MECHANISM">formed</cons> by cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4 (CYP3A4)</cons>.</sentence>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, is known to <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increase</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of various co-administered drugs including <cons lex="quinine" sem="G_DRUG">quinine</cons>.</sentence>
<sentence>To assess the effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> in healthy Thai male volunteers.</sentence>
<sentence>In an open, randomized two-phase crossover study separated by a 1-month period, eight healthy Thai male volunteers received a single oral dose of <cons sem="G_NUMBER">500 mg</cons> <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> alone or co-administration with <cons sem="G_NUMBER">400 mg/day</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> orally for 10 days.</sentence>
<sentence>Serial blood samples were collected at specific time points for a 56-day period.</sentence>
<sentence>Plasma <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> and <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> carboxylic metabolite concentrations during 56 days were measured by a modified and validated high-performance liquid chromatographic method with UV detection.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, mefloquine, DDI)">
<sentence>Co-administration with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increased</cons> the mean values of <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> <cons sem="G_IVIVPARA">AUC0-t</cons>, <cons sem="G_IVIVPARA">t(1/2)</cons>, and <cons sem="G_IVIVPARA">Cmax</cons> when compared with <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> alone by <cons sem="G_NUMBER">79% (P &lt; 0.001)</cons>, <cons sem="G_NUMBER">39% (P &lt; 0.05)</cons> and <cons sem="G_NUMBER">64% (P &lt; 0.001)</cons> respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, mefloquine, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC0-t</cons> , and <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="mefloquine" sem="G_DRUG" type="M_1">mefloquine carboxylic acid</cons> metabolite were <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">28% (P &lt; 0.05) and 31% (P &lt; 0.05)</cons>, respectively when compared with <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> alone.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, mefloquine, DDI)">
<sentence>Co-administration with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> <cons sem="G_CHANGE">increased</cons> plasma <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> concentrations in healthy human volunteers.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, mefloquine, ADDI)">
<sentence>One of possible mechanisms of the <cons sem="G_CHANGE">increase</cons> in plasma <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> concentrations <cons sem = "G_CHANGE">may</cons> be the result of the <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> by <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>.</sentence>
</annotation>
<sentence>In case of <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> is co-administered with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, drug-drug interactions should be recognized and the dose of <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> should be adjusted to maximize the therapeutic efficacy and to <cons sem="G_CHANGE">reduce</cons> the cost of therapy.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15845683</bibliomisc>
</articleinfo>
<title>
<sentence>The effect of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> on the pharmacokinetics of intravenous <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_MECHANISM">Inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4 (cytochrome P450 3A4)</cons> have a <cons sem = "G_CHANGE">minor</cons> effect on <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons> pharmacokinetics.</sentence>
<sentence>We studied the effect of coadministration of the antidepressant <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> (<cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons>) and antimicrobial drug <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>) on <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons> pharmacokinetics in a double-blind, randomized, three-way crossover study.</sentence>
<sentence>Nine volunteers ingested daily <cons sem="G_NUMBER">100 mg</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and placebo, <cons sem="G_NUMBER">100 mg</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and <cons sem="G_NUMBER">1500 mg</cons> <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, or their corresponding placebos for 5 days.</sentence>
<sentence>On day 6, <cons sem="G_NUMBER">1.5 mg/kg</cons> <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons> was administered IV over 60 min.</sentence>
<sentence>Concentrations of <cons lex="lidocaine" sem="G_DRUG">lidocaine</cons> and its major metabolite monoethylglycinexylidide were measured for 10 h.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, lidocaine, ADDI)">
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> alone <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> by <cons sem="G_NUMBER">41% (P &lt; 0.001)</cons> and prolonged its <cons sem="G_IVIVPARA">elimination half-life</cons> from <cons sem="G_NUMBER">2.6 to 3.5 h (P &lt; 0.01)</cons>2.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine + erythromycin, lidocaine, DDI)">
<sentence>During the combination of <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> and <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_2">erythromycin</cons>, <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_NUMBER">53%</cons> smaller than during placebo (<cons sem="G_NUMBER">P &lt; 0.001</cons>) and <cons sem="G_NUMBER">21%</cons> smaller than during <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> alone (<cons sem="G_NUMBER">P &lt; 0.05</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Fluvoxamine + erythromycin, lidocaine, DDI)">
<sentence>During the combination phase the <cons sem="G_IVIVPARA">half-life</cons> of <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> (<cons sem="G_NUMBER">4.3 h</cons>) was longer than during the placebo (<cons sem="G_NUMBER">2.6 h; P &lt; 0.001</cons>) or <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> (<cons sem="G_NUMBER">3.5 h; P &lt; 0.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, lidocaine, ADDI)">
<sentence>We conclude that <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> by <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> considerably <cons sem ="G_CHANGE">reduces</cons> elimination of <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> and <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">increase</cons> the risk of <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> toxicity.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine + erythromycin, lidocaine, DDI)">
<sentence>Concomitant use of both <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> and a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> such as <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_2">erythromycin</cons> can further <cons sem="G_CHANGE">increase</cons> plasma <cons lex="lidocaine" sem="G_DRUG" type="substrate_1">lidocaine</cons> concentrations by <cons sem="G_CHANGE">decreasing</cons> its <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15801938</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> on the pharmacokinetics and pharmacodynamics of racemic <cons lex="warfarin" sem="G_DRUG">warfarin</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence>Case reports suggest that gemfobrozil can <cons sem="G_CHANGE">increase</cons> the anticoagulant effect of <cons lex="warfarin" sem="G_DRUG">warfarin</cons>.</sentence>
<sentence>Because <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> in vitro, we studied its effects on the pharmacokinetics and pharmacodynamics of racemic <cons lex="warfarin" sem="G_DRUG">warfarin</cons>.</sentence>
<sentence>In a randomized cross-over study, 10 healthy subjects ingested <cons sem="G_NUMBER">600 mg</cons> <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> or placebo twice daily for 8 days.</sentence>
<sentence>On day 3, they were administered a single dose of <cons sem="G_NUMBER">10 mg</cons> racemic R-S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> orally.</sentence>
<sentence>The concentrations of R- and S-<cons lex="warfarin" sem="G_DRUG">warfarin</cons> in plasma and thromboplastin time were monitored up to 168 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, S-warfarin, ADDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inducer_1">Gemfibrozil</cons> <cons sem="G_CHANGE">decreased</cons> the mean (+/-SD) <cons sem="G_IVIVPARA">area under the plasma concentration-time curve  [AUC((0-infinity))]</cons> of <cons lex="warfarin" sem="G_DRUG" type="substrate_2">S-warfarin</cons> by <cons sem="G_NUMBER">11%, from 19.9 +/- 5.2 mg l(-1) h to 17.6 +/- 4.7 mg l(-1) h (95% CI on the difference -3.7, -0.78; P &lt; 0.01)</cons> and that of <cons lex="warfarin" sem="G_DRUG" type="substrate_3">R-warfarin</cons> by <cons sem="G_NUMBER">6% from 31.3 +/- 7.5 mg l(-1) h</cons> during the <cons lex="gemfibrozil" sem="G_DRUG" type="inducer_1">gemfibrozil</cons> phase to <cons sem="G_NUMBER">29.5 +/- 6.9 mg l(-1) h during the placebo phase (95% CI -3.3, -0.33; P &lt; 0.05)</cons>.</sentence>
</annotation>
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> differences in the <cons sem="G_IVIVPARA">elimination half-lives</cons> of <cons lex="warfarin" sem="G_DRUG">S-</cons> or <cons lex="warfarin" sem="G_DRUG">R-warfarin</cons> between the phases.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, warfarin, NDDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inducer_1">Gemfibrozil</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> alter the anticoagulant effect of <cons lex="warfarin" sem="G_DRUG" type="substrate_1">warfarin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, R-warfarin, ADDI)(Gemfibrozil, S-warfarin, ADDI)">
<sentence>Unexpectedly, <cons lex="gemfibrozil" sem="G_DRUG" type="inducer_1">gemfibrozil</cons> <cons sem="G_CHANGE">slightly</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="warfarin" sem="G_DRUG" type="substrate_3">R-</cons> and <cons lex="warfarin" sem="G_DRUG" type="substrate_2">S-warfarin</cons>.</sentence>
</annotation>
<sentence>Displacement of <cons lex="warfarin" sem="G_DRUG">warfarin</cons> from plasma albumin by <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> or its interference with the absorption of <cons lex="warfarin" sem="G_DRUG">warfarin</cons> could explain the present findings.</sentence>
<sentence>Usual therapeutic doses of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> seem to have limited effects on the pharmacokinetics and pharmacodynamics of single dose <cons lex="warfarin" sem="G_DRUG">warfarin</cons> in healthy subjects.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15770075</bibliomisc>
</articleinfo>
<title>
<sentence>Influence of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> co-administration and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> genotype on the pharmacokinetics of the new antipsychotic <cons lex="aripiprazole" sem="G_DRUG">ARIPIPRAZOLE</cons>.</sentence>
</title>
<abstract>
<sentence>The results of in vitro studies indicated that <cons lex="aripiprazole" sem="G_DRUG">ARIPIPRAZOLE</cons>, a newly developed antipsychotic, is mainly <cons sem="G_MECHANISM">metabolized</cons> by the human cytochrome P450 isozymes <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>The objective of the present study was to investigate the influence of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> (hereafter referred to as ITZ) co-administration (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons>) on the pharmacokinetics of <cons lex="aripiprazole" sem="G_DRUG">ARIPIPRAZOLE</cons> administered to 24 healthy adult male volunteers in a fasting condition.</sentence>
<sentence>The influence of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> was also examined by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> genotype.</sentence>
<sentence>All subjects were administered a single oral dose of <cons lex="aripiprazole" sem="G_DRUG">ARIPIPRAZOLE</cons> alone in Period I and a single oral dose of <cons lex="aripiprazole" sem="G_DRUG">ARIPIPRAZOLE</cons> following administration of <cons lex="itraconazole" sem="G_DRUG">ITZ</cons> at <cons sem="G_NUMBER">100 mg/day</cons> for 7 consecutive days in Period II.</sentence>
<sentence>The pharmacokinetic parameters of <cons lex="aripiprazole" sem="G_DRUG">ARIPIPRAZOLE</cons> and its main metabolite OPC-14857 were determined.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ITZ, ARIPIPRAZOLE, ADDI)">
<sentence>Co-administration of <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">ITZ</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">Cmax</cons>, <cons sem="G_IVIVPARA">AUC</cons>336 hr, and <cons sem="G_IVIVPARA">t1/2</cons>,z of <cons lex="aripiprazole" sem="G_DRUG" type="substrate_1">ARIPIPRAZOLE</cons> and <cons lex="aripiprazole" sem="G_DRUG" type="M_1">OPC-14857</cons> by <cons sem="G_NUMBER">19.4%</cons>, <cons sem="G_NUMBER">48.0%</cons>, and <cons sem="G_NUMBER">18.6%</cons> and by <cons sem="G_NUMBER">18.6%</cons>, <cons sem="G_NUMBER">38.8%</cons>, and <cons sem="G_NUMBER">53.4%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ITZ, ARIPIPRAZOLE, ADDI)">
<sentence>By co-administration of <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">ITZ</cons>, the <cons sem="G_IVIVPARA">CL/F</cons> of <cons lex="aripiprazole" sem="G_DRUG" type="substrate_1">ARIPIPRAZOLE</cons> in extensive <cons sem="G_MECHANISM">metabolizers</cons> was <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">26.6%</cons>, with an even <cons sem = "G_CHANGE">greater</cons> <cons sem="G_CHANGE">decrease</cons> (<cons sem="G_NUMBER">47.3%,</cons>.) in intermediate <cons sem="G_MECHANISM">metabolizers</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ITZ, ARIPIPRAZOLE, ADDI)">
<sentence>For the co-administration period, the <cons sem="G_IVIVPARA">CL/F</cons> of <cons lex="aripiprazole" sem="G_DRUG" type="substrate_1">ARIPIPRAZOLE</cons> in intermediate <cons sem="G_MECHANISM">metabolizers</cons> was about <cons sem="G_NUMBER">half</cons> of that in extensive <cons sem="G_MECHANISM">metabolizers</cons>.</sentence>
</annotation>
<sentence>For <cons sem="G_IVIVPARA">Cmax</cons>, there was <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> difference between extensive <cons sem="G_MECHANISM">metabolizers</cons> and intermediate <cons sem="G_MECHANISM">metabolizers</cons>, and the percent <cons sem = "G_CHANGE">change</cons> by co-administration of <cons lex="itraconazole" sem="G_DRUG">ITZ</cons> was less than <cons sem="G_NUMBER">20%</cons> in both extensive <cons sem="G_MECHANISM">metabolizers</cons> and intermediate <cons sem="G_MECHANISM">metabolizers</cons>.</sentence>
<sentence>For OPC-14857, the <cons sem="G_IVIVPARA">t(max)</cons> in intermediate <cons sem="G_MECHANISM">metabolizers</cons> was longer than that in extensive <cons sem="G_MECHANISM">metabolizers</cons>, with the difference being amplified by co-administration of <cons lex="itraconazole" sem="G_DRUG">ITZ</cons>.</sentence>
<sentence>The <cons sem="G_IVIVPARA">AUC</cons>336 hr showed similar <cons sem="G_CHANGE">increases</cons> by co-administration of <cons lex="itraconazole" sem="G_DRUG">ITZ</cons> in all genotypes.</sentence>
<sentence>The urinary 6beta-hydroxycortisol/cortisol concentration ratio following <cons lex="itraconazole" sem="G_DRUG">ITZ</cons> administration for 7 consecutive days was about half of that before the start of ITZ administration, indicating that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> metabolic activity was <cons sem="G_MECHANISM">inhibited</cons> by administration of ITZ.</sentence>
<sentence>The influence of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> on the pharmacokinetics of <cons lex="aripiprazole" sem="G_DRUG">ARIPIPRAZOLE</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> considered to be clinically <cons sem="G_CHANGE">significant</cons>.</sentence>
<sentence>On the other hand, definite differences in pharmacokinetics were observed between <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> genotypes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15767219</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or <cons sem="G_DRUG">grapefruit juice</cons> on the pharmacokinetics of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons>.</sentence>
</title>
<abstract>
<sentence>To determine whether coadministration of the cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4 (CYP3A4)</cons> <cons sem="G_MECHANISM">inhibitors</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or <cons sem="G_DRUG">grapefruit juice</cons> will modify the pharmacokinetic profile of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons>, and to assess the safety of <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons>.</sentence>
<sentence>Two single-center, open-label studies; the <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> study was nonrandomized, sequential, and multiple dose, and the <cons sem="G_DRUG">grapefruit juice</cons> study was randomized, two-period crossover, and single dose.</sentence>
<sentence>Two clinical investigative centers in the United States.</sentence>
<sentence>Thirty-four healthy, nonsmoking male volunteers aged 18-45 years.</sentence>
<sentence>All patients received <cons lex="telithromycin" sem="G_DRUG">telithromycin</cons> <cons sem="G_NUMBER">800 mg/day</cons>; 18 patients received concomitant <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem="G_NUMBER">200 mg/day</cons>, and 16 received concomitant single-dose, single-strength <cons sem="G_DRUG">grapefruit juice</cons>.</sentence>
<sentence>Standard pharmacokinetic and safety measurements were performed.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, telithromycin, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> given concomitantly with <cons lex="telithromycin" sem="G_DRUG" type="substrate_1">telithromycin</cons> <cons sem="G_CHANGE">increased</cons> the steady-state <cons sem="G_IVIVPARA">area under the plasma concentration-time curve from 0-24 hours</cons> of <cons lex="telithromycin" sem="G_DRUG" type="substrate_1">telithromycin</cons> by <cons sem="G_NUMBER">53.8% (p&lt;0.0001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice, telithromycin, NDDI)">
<sentence>Coadministration of <cons sem="G_DRUG" type="inhibitor_2">grapefruit juice</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affect</cons> <cons lex="telithromycin" sem="G_DRUG" type="substrate_1">telithromycin</cons> pharmacokinetic parameters, and <cons lex="telithromycin" sem="G_DRUG" type="substrate_1">telithromycin</cons> was well tolerated in both studies.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, telithromycin, ADDI)">
<sentence>Only <cons sem = "G_CHANGE">modest</cons> <cons sem ="G_CHANGE">changes</cons> in the pharmacokinetics of <cons lex="telithromycin" sem="G_DRUG" type="substrate_1">telithromycin</cons> were seen with concomitant administration of <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice, telithromycin, NDDI)">
<sentence><cons lex="telithromycin" sem="G_DRUG">Telithromycin</cons> pharmacokinetics were <cons sem="G_NEGATIVEEFFECT">unaffected</cons> by concomitant administration of <cons sem="G_DRUG" type="inhibitor_2">grapefruit juice</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15606443</bibliomisc>
</articleinfo>
<title>
<sentence>The effect of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> on <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> mediated <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> <cons sem="G_MECHANISM">metabolism</cons> in human liver microsomes and healthy subjects.</sentence>
</title>
<abstract>
<sentence><cons lex="rosiglitazone" sem="G_DRUG">Rosiglitazone</cons>, a thiazolidinedione antidiabetic medication used in the treatment of Type 2 diabetes mellitus, is predominantly <cons sem="G_MECHANISM">metabolized</cons> by the cytochrome P450 (CYP) enzyme <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
<sentence>The anti-infective drug <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> has been shown in vitro to be a selective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
<sentence>The purpose of this study was to evaluate the effect of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> on the <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> in vivo and in vitro.</sentence>
<sentence>The effect of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> on the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> in vitro was assessed in pooled human liver microsomes.</sentence>
<sentence>The effect in vivo was determined by evaluating <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> pharmacokinetics in the presence and absence of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons>.</sentence>
<sentence>Eight healthy subjects (four men and four women) completed a randomized, cross-over study.</sentence>
<sentence>Subjects received single dose <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> (<cons sem="G_NUMBER">8 mg</cons>) in the presence and absence of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> <cons sem="G_NUMBER">200 mg</cons> given twice daily for 5 days.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(trimethoprim, rosiglitazone, DDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> <cons sem="G_MECHANISM">inhibited</cons> <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> <cons sem="G_MECHANISM">metabolism</cons> both in vitro and in vivo.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(trimethoprim, rosiglitazone, DDI)">
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="M_1">rosiglitazone para-hydroxylation</cons> by <cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">trimethoprim</cons> in vitro was found to be competitive with apparent <cons sem="G_IVIVPARA">K(i)</cons> and <cons sem="G_IVIVPARA">IC(50)</cons> values of <cons sem="G_NUMBER">29 microm</cons> and <cons sem="G_NUMBER">54.5 microm</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(trimethoprim, rosiglitazone, ADDI)">
<sentence>In the presence of <cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">trimethoprim</cons>, <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> plasma <cons sem="G_IVIVPARA">AUC</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">31% (P = 0.01) from 2774 +/- 645 microg l(-1) h to 3643 +/- 1051 microg l(-1) h (95% confidence interval (CI) for difference 189, 1549)</cons>, and <cons sem="G_IVIVPARA">half-life</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">27% (P = 0.006) from 3.3 +/- 0.5 to 4.2 +/- 0.8 h (95% CI for difference 0.36, 1.5)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(trimethoprim, rosiglitazone, DDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> <cons sem="G_CHANGE">reduced</cons> the <cons lex="rosiglitazone" sem="G_DRUG" type="M_2">para-O-sulphate rosiglitazone</cons>/<cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> and the <cons lex="rosiglitazone" sem="G_DRUG" type="M_3">N-desmethylrosiglitazone</cons>/<cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> <cons sem="G_IVIVPARA">AUC(0-24) ratios</cons> by <cons sem="G_NUMBER">22%</cons> and <cons sem="G_NUMBER">38%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(trimethoprim, rosiglitazone, DDI)">
<sentence>These results indicate that <cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">trimethoprim</cons> is a competitive <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>-mediated <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> <cons sem="G_MECHANISM">metabolism</cons> in vitro and that <cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">trimethoprim</cons> administration <cons sem="G_CHANGE">increases</cons> plasma <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> concentrations in healthy subjects.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15592331</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="ciprofloxacin" sem="G_DRUG">Ciprofloxacin</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increases</cons> concentrations and hypotensive effect of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its cytochrome P450 <cons lex="1a2" sem="G_CYP">1A2</cons>-mediated presystemic <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="tizanidine" sem="G_DRUG">Tizanidine</cons>, a centrally acting skeletal muscle relaxant, is <cons sem="G_MECHANISM">metabolized</cons> mainly by cytochrome P450 (CYP) <cons lex="1a2" sem="G_CYP">1A2</cons> and has a low <cons sem="G_IVIVPARA">oral bioavailability</cons>.</sentence>
<sentence>The fluoroquinolone antibiotic <cons lex="ciprofloxacin" sem="G_DRUG">ciprofloxacin</cons> is only a <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderately</cons></cons> potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence>Our objective was to study the extent and mechanism of a possible interaction of <cons lex="ciprofloxacin" sem="G_DRUG">ciprofloxacin</cons> with <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>.</sentence>
<sentence>In a double-blind, randomized, 2-phase crossover study, 10 healthy volunteers ingested <cons sem="G_NUMBER">500 mg</cons> <cons lex="ciprofloxacin" sem="G_DRUG">ciprofloxacin</cons> or placebo twice daily for 3 days.</sentence>
<sentence>On day 3, a single dose of <cons sem="G_NUMBER">4 mg</cons> <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> was ingested 1 hour after the morning dose of <cons lex="ciprofloxacin" sem="G_DRUG">ciprofloxacin</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> and <cons lex="ciprofloxacin" sem="G_DRUG">ciprofloxacin</cons> and pharmacodynamic variables were measured.</sentence>
<sentence>A <cons lex="caffeine" sem="G_DRUG">caffeine</cons> test was used as a marker for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ciprofloxacin, tizanidine, DDI)">
<sentence><cons lex="ciprofloxacin" sem="G_DRUG" type="inhibitor_1">Ciprofloxacin</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve from time 0 to infinity  [AUC(0-infinity)]</cons> of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> by <cons sem="G_NUMBER">10-fold (range, 6-fold to 24-fold; P &lt; .001)</cons>and its <cons sem="G_IVIVPARA">peak concentration</cons> by <cons sem="G_NUMBER">7-fold (range, 4-fold to 21-fold; P &lt; .001)</cons>, whereas its <cons sem="G_IVIVPARA">elimination half-life</cons> was only prolonged from <cons sem="G_NUMBER">1.5 to 1.8 hours (P = .007)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ciprofloxacin, tizanidine, DDI)">
<sentence>The pharmacodynamic effects of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> were much stronger during the <cons lex="ciprofloxacin" sem="G_DRUG" type="inhibitor_1">ciprofloxacin</cons> phase than during the placebo phase with regard to <cons sem ="G_CHANGE">changes</cons> in systolic blood pressure (<cons sem="G_NUMBER">-35 mm Hg versus -15 mm Hg, P = .001</cons>), diastolic blood pressure (<cons sem="G_NUMBER">-24 mm Hg versus -11 mm Hg, P &lt; .001</cons>), Digit Symbol Substitution Test (<cons sem="G_NUMBER">P = .02</cons>), subjective drug effect (<cons sem="G_NUMBER">P = .002</cons>), and subjective drowsiness (<cons sem="G_NUMBER">P = .009</cons>).</sentence>
</annotation>
<sentence>The <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> and its <cons sem = "G_CHANGE">change</cons> <cons sem="G_MECHANISM">correlated</cons> (<cons sem="G_NUMBER">P &lt; .01</cons>) with the caffeine/paraxanthine ratio and its <cons sem = "G_CHANGE">change</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ciprofloxacin, tizanidine, DDI)">
<sentence><cons lex="ciprofloxacin" sem="G_DRUG" type="inhibitor_1">Ciprofloxacin</cons> <cons sem = "G_CHANGE">greatly</cons> elevates <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> and dangerously potentiates its hypotensive and sedative effects, mainly by <cons sem="G_MECHANISM">inhibiting</cons> its <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons>, at least when administered 1 hour before <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons>.</sentence>
</annotation>
<sentence><cons lex="tizanidine" sem="G_DRUG">Tizanidine</cons> seems to be a useful probe drug for measuring presystemic <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence>Care should be exercised when <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> is used concomitantly with <cons lex="ciprofloxacin" sem="G_DRUG">ciprofloxacin</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15518608</bibliomisc>
</articleinfo>
<title>
<sentence>Comparative pharmacokinetic interaction profiles of <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons>, <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>, and <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> when coadministered with cytochrome P450 <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</title>
<abstract>
<sentence>Three-hydroxy-3-methylglutaryl coenzyme-A reductase <cons sem="G_MECHANISM">inhibitors</cons> (statins) are first-line treatments for hypercholesterolemia.</sentence>
<sentence>Although exceedingly well tolerated, treatment with statins incurs a small risk of myopathy or potentially fatal rhabdomyolysis, particularly when coadministered with medications that <cons sem="G_CHANGE">increase</cons> their systemic exposure.</sentence>
<sentence>Studies compared the multiple-dose pharmacokinetic interaction profiles of <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons>, <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>, and <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> when coadministered with 4 <cons sem="G_MECHANISM">inhibitors</cons> of cytochrome P450-<cons lex="3a4" sem="G_CYP">3A4</cons> isoenzymes in healthy subjects.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(verapamil, pravastatin, NDDI)(mibefradil, pravastatin, NDDI)(itraconazole, pravastatin, NDDI)">
<sentence>Compared with <cons lex="pravastatin" sem="G_DRUG" type="substrate_1">pravastatin</cons> alone, coadministration of <cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">verapamil</cons>, <cons sem="G_DRUG" type="inhibitor_2">mibefradil</cons>, or <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_3">itraconazole</cons> with <cons lex="pravastatin" sem="G_DRUG" type="substrate_1">pravastatin</cons> was associated with <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> in <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> pharmacokinetics.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(verapamil, simvastatin, DDI)">
<sentence>However, concomitant <cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">verapamil</cons> <cons sem="G_CHANGE">increased</cons> the <cons lex="simvastatin" sem="G_DRUG" type="substrate_2">simvastatin</cons> <cons sem="G_IVIVPARA">area under the concentration:time curve (AUC)</cons> approximately <cons sem="G_NUMBER">fourfold</cons>, the <cons sem="G_IVIVPARA">maximum serum concentration (C(max))</cons> <cons sem="G_NUMBER">fivefold</cons>, and the active metabolite <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">C(max)</cons> approximately <cons sem="G_NUMBER">four-</cons> and <cons sem="G_NUMBER">threefold</cons>, respectively (all comparisons <cons sem="G_NUMBER">p &lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(mibefradil, atorvastatin, DDI)">
<sentence>Similar (<cons sem = "G_CHANGE">greater</cons> than <cons sem="G_NUMBER">fourfold</cons>) important <cons sem="G_CHANGE">increases</cons> in these parameters and a <cons sem="G_NUMBER">&gt;60%</cons><cons sem="G_CHANGE">increase</cons> in the serum <cons sem="G_IVIVPARA">half-life</cons> (<cons sem="G_NUMBER">p = 0.03</cons>) of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_3">atorvastatin</cons> were observed when coadministered with <cons sem="G_DRUG" type="inhibitor_2">mibefradil</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, atorvastatin, ADDI)">  
<sentence>The <cons sem="G_IVIVPARA">half-life</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_3">atorvastatin</cons> also <cons sem="G_CHANGE">increased</cons> by approximately <cons sem="G_NUMBER">60% (p = 0.052)</cons> when coadministered with <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_3">itraconazole</cons>, which elicited a <cons sem="G_NUMBER">2.4-fold</cons> <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="atorvastatin" sem="G_DRUG" type="substrate_3">atorvastatin</cons> and a <cons sem="G_NUMBER">47%</cons> <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">AUC</cons> (<cons sem="G_NUMBER">p &lt;0.001</cons> for <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Clarithromycin, simvastatin, DDI)(Clarithromycin, atorvastatin, DDI)(Clarithromycin, pravastatin, DDI)">  
<sentence><cons lex="clarithromycin" sem="G_DRUG">Clarithromycin</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">p &lt;0.001</cons>) <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC</cons> (and <cons sem="G_IVIVPARA">C(max)</cons>) of all 3 statins, most <cons sem = "G_CHANGE">markedly</cons> <cons lex="simvastatin" sem="G_DRUG" type="substrate_2">simvastatin</cons> ( approximately <cons sem="G_NUMBER">10-fold</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">AUC</cons>) and <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> (<cons sem="G_NUMBER">12-fold</cons>), followed by <cons lex="atorvastatin" sem="G_DRUG" type="substrate_3">atorvastatin</cons> (<cons sem = "G_CHANGE">greater</cons> than <cons sem="G_NUMBER">fourfold</cons>) and then <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> (almost <cons sem="G_NUMBER">twofold</cons>).</sentence>
</annotation>
<sentence><cons lex="pravastatin" sem="G_DRUG">Pravastatin</cons> has a neutral drug interaction profile relative to cytochrome P450-<cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>, but these substrates <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increase</cons> systemic exposure to <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15373932</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the pharmacokinetics of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence>Fungal infection is a <cons sem="G_CHANGE">significant</cons> comorbidity in patients with diabetes mellitus, and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, an antifungal agent, causes a number of drug interactions with coadministered drugs.</sentence>
<sentence><cons lex="rosiglitazone" sem="G_DRUG">Rosiglitazone</cons> is a novel thiazolidinedione antidiabetic drug, mainly <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and to a lesser extent <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence>We investigated the possible effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the pharmacokinetics of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> in humans.</sentence>
<sentence>Ten healthy Korean male volunteers were treated twice daily for 5 days with <cons sem="G_NUMBER">200 mg</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> or with placebo, using a randomized, open-label, two-way crossover study.</sentence>
<sentence>On day 5, a single dose of <cons sem="G_NUMBER">8 mg</cons> <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> was administered orally, and plasma <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> concentrations were measured.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, rosiglitazone, ADDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">Ketoconazole</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> for <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> by <cons sem="G_NUMBER">47% [P = 0.0003; 95% confidence interval (CI) 23, 70]</cons> and the mean <cons sem="G_IVIVPARA">elimination half-life</cons> from <cons sem="G_NUMBER">3.55 to 5.50 h (P = 0.0003; 95% CI in difference 1.1, 2.4)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, rosiglitazone, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> was <cons sem="G_CHANGE">increased</cons> by <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> treatment by <cons sem="G_NUMBER">17% (P = 0.03; 95% CI 5, 29)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, rosiglitazone, ADDI)">
<sentence>The apparent <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">28%</cons> after <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> treatment (<cons sem="G_NUMBER">P = 0.0005; 95% CI 18, 38</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, rosiglitazone, DDI)">
<sentence>This study revealed that <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> <cons sem="G_CHANGE">affected</cons> the disposition of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> in humans, <cons sem = "G_CHANGE">probably</cons> by the <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> and <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, leading to <cons sem="G_CHANGE">increasing</cons> <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> concentrations that could <cons sem="G_CHANGE">increase</cons> the efficacy of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> or its adverse events.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15371985</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics of the cytochrome P450 <cons lex="2c8" sem="G_CYP">2C8</cons> substrate <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="trimethoprim" sem="G_DRUG">Trimethoprim</cons> is a relatively selective <cons sem="G_MECHANISM">inhibitor</cons> of the cytochrome P450 (CYP) <cons lex="2c8" sem="G_CYP">2C8</cons> enzyme in vitro.</sentence>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> (INN, <cons sem="G_DRUG">rifampicin</cons>) is a potent <cons sem="G_MECHANISM">inducer</cons> of several CYP enzymes, and in vitro studies have suggested that it also <cons sem="G_MECHANISM">induces</cons> <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
<sentence>Our aims were to investigate possible effects of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> and <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> activity by use of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons>, a thiazolidinedione antidiabetic drug <cons sem="G_MECHANISM">metabolized</cons> primarily by <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>, as an in vivo probe.</sentence>
<sentence>Two separate randomized crossover studies with 2 phases were conducted.</sentence>
<sentence>In study 1, 10 healthy volunteers took <cons sem="G_NUMBER">160 mg</cons> <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> or placebo orally twice daily for 4 days.</sentence>
<sentence>On day 3, they ingested a single <cons sem="G_NUMBER">4-mg</cons> dose of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons>.</sentence>
<sentence>In study 2, 10 healthy volunteers took <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or placebo orally once daily for 5 days.</sentence>
<sentence>On day 6, they ingested a single <cons sem="G_NUMBER">4-mg</cons> dose of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons>.</sentence>
<sentence>In both studies, plasma <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> and N -desmethylrosiglitazone concentrations were measured for up to 48 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(trimethoprim, rosiglitazone, ADDI)">
<sentence>Results In study 1, <cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">trimethoprim</cons> <cons sem="G_CHANGE">raised</cons> the <cons sem="G_IVIVPARA">area under the plasma <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> concentration-time curve  [AUC(0- infinity )]</cons> by <cons sem="G_NUMBER">37% (range, 16% to 51%; P &lt;.0001)</cons> and the <cons sem="G_IVIVPARA">peak plasma <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> concentration (C max)</cons> by <cons sem="G_NUMBER">14% (range, -3% to 38%; P =.0014)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(trimethoprim, rosiglitazone, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">elimination half-life (t1/2)</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> was prolonged from <cons sem="G_NUMBER">3.8 to 4.8 hours (P =.0013)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(trimethoprim, rosiglitazone, ADDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_MECHANISM">formation</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="M_1">N-desmethylrosiglitazone</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, rosiglitazone, DDI)">
<sentence>In study 2, <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> and <cons sem="G_IVIVPARA">C max</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> by <cons sem="G_NUMBER">54% (range, 46% to 63%; P &lt;.0001)</cons> and <cons sem="G_NUMBER">28% (range,2% to 56%; P =.0003)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin, rosiglitazone, DDI)">
<sentence>The <cons sem="G_IVIVPARA">t 1/2</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> was shortened from <cons sem="G_NUMBER">3.8 to 1.9 hours ( P &lt;.0001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, rosiglitazone, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_MECHANISM">formation</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="M_1">N-desmethylrosiglitazone</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(trimethoprim, rosiglitazone, DDI)(rifampin, rosiglitazone, DDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> <cons sem="G_CHANGE">raises</cons> and <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem ="G_CHANGE">reduces</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> by <cons sem="G_MECHANISM">inhibiting</cons> and <cons sem="G_MECHANISM">inducing</cons>, respectively, the <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>-<cons sem="G_MECHANISM">catalyzed</cons> biotransformation of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15289787</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of the <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> genotype on the pharmacokinetics of intravenous <cons lex="midazolam" sem="G_DRUG">midazolam</cons> during <cons sem="G_MECHANISM">inhibited</cons> and <cons sem="G_MECHANISM">induced</cons> metabolic states.</sentence>
</title>
<abstract>
<sentence>Our objective was to investigate the effect of the <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> genotype on the systemic <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> in constitutive, <cons sem="G_MECHANISM">inhibited</cons>, and <cons sem="G_MECHANISM">induced</cons> metabolic conditions.</sentence>
<sentence>Nineteen healthy volunteers were grouped with regard to the <cons sem="G_CYP">CYP3A5*3 allele</cons>, into homozygous wild-type (<cons sem="G_CYP">CYP3A5*1/*1</cons>, n = 6), heterozygous (<cons sem="G_CYP">CYP3A5*1/*3</cons>, n = 6), and homozygous variant-type (<cons sem="G_CYP">CYP3A5*3/*3</cons>, n = 7) subject groups.</sentence>
<sentence>The pharmacokinetic profile of intravenous <cons lex="midazolam" sem="G_DRUG">midazolam</cons> was characterized before and after <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> administration (<cons sem="G_NUMBER">200 mg</cons> once daily for 4 days) and also after <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (INN, <cons sem="G_DRUG">rifampicin</cons>) pretreatment (<cons sem="G_NUMBER">600 mg</cons> once daily for 10 days), with a washout period of 2 weeks in between.</sentence>
<sentence>The pharmacokinetic profiles of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and of its hydroxy metabolites did <cons sem="G_NEGATIVEEFFECT">not</cons> show differences between the genotype groups under basal and <cons sem="G_MECHANISM">induced</cons> metabolic conditions.</sentence>
<sentence>However, during the <cons sem="G_MECHANISM">inhibited</cons> metabolic state, the <cons sem="G_CYP">CYP3A5*3/*3</cons> group showed a <cons sem = "G_CHANGE">greater</cons> <cons sem="G_CHANGE">decrease</cons> in systemic <cons sem="G_IVIVPARA">clearance</cons> than was seen in the <cons sem="G_CYP">CYP3A5*1/*1</cons> group (<cons sem="G_NUMBER">8.5 +/- 3.8 L. h(-1).70 kg(-1) versus 13.5 +/- 2.7 L. h(-1).70 kg(-1), P =.027</cons>).</sentence>
<sentence>The 1'-hydroxymidazolam-to-<cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_IVIVPARA">area under the plasma concentration-time curve ratio</cons> was also <cons sem="G_CHANGE">significantly</cons> lower in the <cons sem="G_CYP">CYP3A5*3/*3</cons> group (<cons sem="G_NUMBER">0.58 +/- 0.35 versus 1.09 +/- 0.37</cons> for the homozygous wild-type group, <cons sem="G_NUMBER">P =.026</cons>).</sentence>
<sentence>The <cons lex="cyp3a5" sem="G_CYP">CYP3A5</cons> genotype did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affect</cons> the pharmacokinetics of intravenous <cons lex="midazolam" sem="G_DRUG">midazolam</cons> in the basal or <cons sem="G_MECHANISM">induced</cons> states.</sentence>
<sentence>However, during cytochrome P450 (CYP) <cons lex="3a" sem="G_CYP">3A</cons> <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, individuals carrying the <cons sem="G_CYP">CYP3A5*1 allele</cons> were found to be less susceptible to <cons sem ="G_CHANGE">changes</cons> in systemic <cons sem="G_IVIVPARA">clearance</cons> and showed higher 1'-hydroxymidazolam-to-<cons lex="midazolam" sem="G_DRUG">midazolam</cons> <cons sem="G_IVIVPARA">area under the plasma concentration-time curve ratios</cons>, <cons sem = "G_CHANGE">probably</cons> resulting from the relatively <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-specific <cons sem="G_MECHANISM">inhibition</cons> caused by <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15285851</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> and <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> on <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> pharmacokinetics in healthy volunteers with <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> mutations.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to investigate the effects of the proton pump <cons sem="G_MECHANISM">inhibitors</cons> (PPIs), <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> and <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons>, on <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> pharmacokinetics in healthy volunteers with mutations in the cytochrome P450 (CYP) <cons lex="2c19" sem="G_CYP">2C19</cons> gene (<cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>).</sentence>
<sentence>An open-label crossover study was performed with 19 healthy subjects.</sentence>
<sentence><cons lex="tacrolimus" sem="G_DRUG">Tacrolimus</cons> (<cons sem="G_NUMBER">2 mg</cons>) was administered orally with and <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> (<cons sem="G_NUMBER">30 mg</cons> per day for 4 days) or <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> (10 mg per day for 4 days).</sentence>
<sentence>Blood concentrations of <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> were determined before and 1, 2, 4 and 8 h after dosing.</sentence>
<sentence>Genotyping for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> was conducted by a polymerase chain reaction-restriction fragment length polymorphism method.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(lansoprazole, tacrolimus, DDI)">
<sentence>Coadministration of <cons lex="lansoprazole" sem="G_DRUG" type="inhibitor_1">lansoprazole</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">oral <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> clearance</cons>, resulting in an <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">area under the blood concentration-time curve (AUC0-8)</cons> (control vs with <cons sem="G_DRUG" type="inhibitor_1">lansoprazole</cons>: <cons sem="G_NUMBER">29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P &lt; 0.05</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(lansoprazole, tacrolimus, DDI)">
<sentence>Large individual variation was observed in the effects of <cons lex="lansoprazole" sem="G_DRUG" type="inhibitor_1">lansoprazole</cons> on <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> <cons sem="G_IVIVPARA">AUC0-8</cons> owing to <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotype status.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(lansoprazole, tacrolimus, DDI)">
<sentence>The percent <cons sem = "G_CHANGE">change</cons> for <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> <cons sem="G_IVIVPARA">AUC0-8</cons> in subjects with and <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> mutant alleles was <cons sem="G_NUMBER">81%</cons> and <cons sem="G_NUMBER">29%</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rabeprazole, tacrolimus, NDDI)">
<sentence>Coadministration of <cons lex="rabeprazole" sem="G_DRUG" type="inhibitor_2">rabeprazole</cons> also <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">AUC0-8</cons> of <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons>, but the difference was <cons sem="G_NEGATIVEEFFECT">not</cons> statistically <cons sem="G_CHANGE">significant</cons>.</sentence>
</annotation>
<sentence>These observations suggest that drug interaction between <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> and <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> occurs in subjects with higher <cons lex="lansoprazole" sem="G_DRUG">lansoprazole</cons> blood concentrations corresponding to <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genetic status.</sentence>
<sentence>In contrast, <cons lex="rabeprazole" sem="G_DRUG">rabeprazole</cons> has minimal effect on <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> pharmacokinetics regardless of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotype status.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15229464</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons sem="G_DRUG">grapefruit juice</cons> on the pharmacokinetics of the enantiomers of <cons lex="methadone" sem="G_DRUG">methadone</cons>.</sentence>
</title>
<abstract>
<sentence>Cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons> is the main CYP isozyme involved in <cons lex="methadone" sem="G_DRUG">methadone</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>We investigated the influence of <cons sem="G_DRUG">grapefruit juice</cons>, which contains <cons sem="G_MECHANISM">inhibitors</cons> of intestinal <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, on the steady-state pharmacokinetics of <cons lex="methadone" sem="G_DRUG">methadone</cons>.</sentence>
<sentence>For 5 days, 8 patients undergoing <cons lex="methadone" sem="G_DRUG">methadone</cons> maintenance treatment received <cons sem="G_NUMBER">200 mL</cons> water or <cons sem="G_DRUG">grapefruit juice</cons> 30 minutes before and again together with their daily dose of <cons lex="methadone" sem="G_DRUG">methadone</cons>.</sentence>
<sentence>Blood sampling for R-, S-, and R,S-<cons lex="methadone" sem="G_DRUG">methadone</cons> plasma determination was performed over a 24-hour period.</sentence>
<sentence><cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity was determined by measuring the plasma 1'-hydroxymidazolam/midazolam ratio.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice, midazolam  , ADDI)">
<sentence>A <cons sem="G_CHANGE">decrease</cons> in the <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> ratio was measured in all patients after <cons sem="G_DRUG">grapefruit juice</cons> <cons sem="G_NUMBER">(mean +/- SD before grapefruit juice, 9.3 +/- 5.9; mean +/- SD after grapefruit juice, 3.9 +/- 1.2; P &lt;.05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice, methadone , ADDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">Grapefruit juice</cons> led to a mean <cons sem="G_NUMBER">17%</cons> <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">area under the curve extrapolated to 24 hours</cons> for both enantiomers of <cons lex="methadone" sem="G_DRUG" type="inhibitor_2">methadone</cons> <cons sem="G_NUMBER">(range, 3% to 29%  [P &lt;.005]; range, -4% to 37%  [P &lt;.05]; and range, 1% to 32%  [P &lt;.01]</cons>; for R-, S-, and R,S-<cons lex="methadone" sem="G_DRUG" type="inhibitor_2">methadone</cons>, respectively).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice, methadone , ADDI)">
<sentence>A similar <cons sem="G_CHANGE">increase</cons> in peak level and <cons sem="G_CHANGE">decrease</cons> in apparent <cons sem="G_IVIVPARA">clearance</cons> were measured with <cons sem="G_DRUG" type="inhibitor_1">grapefruit juice</cons>, whereas time to peak level, <cons sem="G_IVIVPARA">terminal half-life</cons>, and apparent volume during the terminal phase of R-, S-, and R,S-<cons lex="methadone" sem="G_DRUG" type="inhibitor_2">methadone</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affected</cons> by <cons sem="G_DRUG" type="inhibitor_1">grapefruit juice</cons>.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> symptom of overmedication was either detected by the clinical staff or reported by the patients.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice, methadone , ADDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">Grapefruit juice</cons> administration is associated with a <cons sem = "G_CHANGE">modest</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="methadone" sem="G_DRUG" type="inhibitor_2">methadone</cons> <cons sem="G_IVIVPARA">bioavailability</cons>, which is <cons sem="G_NEGATIVEEFFECT">not</cons> expected to endanger patients.</sentence>
</annotation>
<sentence>However, it cannot be excluded that a much stronger effect <cons sem = "G_CHANGE">may</cons> occur in some patients, and thus <cons sem="G_DRUG">grapefruit juice</cons> intake is <cons sem="G_NEGATIVEEFFECT">not</cons> recommended during <cons lex="methadone" sem="G_DRUG">methadone</cons> maintenance treatment, in particular in patients initiating such a treatment.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15138710</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic interaction between <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="imatinib" sem="G_DRUG">imatinib</cons> mesylate (Glivec) in healthy subjects.</sentence>
</title>
<abstract>
<sentence>The study under discussion was a drug-drug interaction study in which the effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, a potent CYP450 <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, on the pharmacokinetics of Glivec (<cons lex="imatinib" sem="G_DRUG">imatinib</cons>) was investigated.</sentence>
<sentence>A total of 14 healthy subjects (13 male, 1 female) were enrolled in this study.</sentence>
<sentence>Each subject received a single oral dose of <cons lex="imatinib" sem="G_DRUG">imatinib</cons> <cons sem="G_NUMBER">200 mg</cons> alone, and a single oral dose of <cons lex="imatinib" sem="G_DRUG">imatinib</cons> <cons sem="G_NUMBER">200 mg</cons> coadministered with a single oral dose of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">400 mg</cons> according to a two-period crossover design.</sentence>
<sentence>The treatment sequence was randomly allocated.</sentence>
<sentence>Subtherapeutic <cons lex="imatinib" sem="G_DRUG">imatinib</cons> doses and a short exposure were tested in order <cons sem="G_NEGATIVEEFFECT">not</cons> to overexpose the healthy volunteers.</sentence>
<sentence>There was a minimum 7-day washout period between the two sequences.</sentence>
<sentence>Blood samples for determination of <cons sem="G_IVIVPARA">plasma concentrations</cons> were taken up to 96 h after dosing.</sentence>
<sentence><cons lex="imatinib" sem="G_DRUG">Imatinib</cons> and <cons lex="imatinib" sem="G_DRUG" type="M_1">CGP74588</cons> (main metabolite of <cons lex="imatinib" sem="G_DRUG">imatinib</cons>) concentrations were measured using LC/MS/MS method and pharmacokinetic parameters were estimated by a non-compartmental analysis.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, imatinib, ADDI)">
<sentence>Following <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> coadministration, the mean <cons lex="imatinib" sem="G_DRUG" type="substrate_1">imatinib</cons> <cons sem="G_IVIVPARA">C(max)</cons>, <cons sem="G_IVIVPARA">AUC((0-24))</cons> and <cons sem="G_IVIVPARA">AUC((0- infinity ))</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_CHANGE">significantly</cons> by <cons sem="G_NUMBER">26% ( P&lt;0.005)</cons>, <cons sem="G_NUMBER">40% ( P&lt;0.0005)</cons> and <cons sem="G_NUMBER">40% ( P &lt;0.0005)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, imatinib, ADDI)">
<sentence>There was a statistically <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">decrease</cons> in apparent <cons sem="G_IVIVPARA">clearance (CL/F)</cons> of <cons lex="imatinib" sem="G_DRUG" type="substrate_1">imatinib</cons> with a mean <cons sem ="G_CHANGE">reduction</cons> of <cons sem="G_NUMBER">28.6% ( P&lt;0.0005)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, imatinib, ADDI)">
<sentence>The mean <cons sem="G_IVIVPARA">C(max)</cons> and <cons sem="G_IVIVPARA">AUC((0-24))</cons> of the metabolite <cons lex="imatinib" sem="G_DRUG" type="M_1">CGP74588</cons> <cons sem="G_CHANGE">decreased</cons> <cons sem="G_CHANGE">significantly</cons> by <cons sem="G_NUMBER">22.6% ( P&lt;0.005)</cons> and <cons sem="G_NUMBER">13% ( P&lt;0.05)</cons> after <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> treatment, although the <cons sem="G_IVIVPARA">AUC((0- infinity))</cons> of <cons lex="imatinib" sem="G_DRUG" type="M_1">CGP74588</cons> only <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">5% ( P=0.28)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, imatinib, ADDI)">
<sentence>Coadministration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> and <cons lex="imatinib" sem="G_DRUG" type="substrate_1">imatinib</cons> caused a <cons sem="G_NUMBER">40%</cons> <cons sem="G_CHANGE">increase</cons> in exposure to <cons lex="imatinib" sem="G_DRUG" type="substrate_1">imatinib</cons> in healthy volunteers.</sentence>
</annotation>
<sentence>Given its previously demonstrated safety profile, this <cons sem="G_CHANGE">increased</cons> exposure to <cons lex="imatinib" sem="G_DRUG">imatinib</cons> is likely to be clinically <cons sem="G_CHANGE">significant</cons> only at high doses.</sentence>
<sentence>This interaction should be considered when administering <cons sem="G_MECHANISM">inhibitors</cons> of the <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> family in combination with <cons lex="imatinib" sem="G_DRUG">imatinib</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15116057</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> on the pharmacokinetics of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons>.</sentence>
</title>
<abstract>
<sentence>In vitro studies indicate that the anticancer drug <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> is primarily eliminated by cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Coadministration of drugs that modulate the activity of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is, therefore, likely to have undesirable clinical consequences.</sentence>
<sentence>We investigated the effects of the potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the pharmacokinetics of <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> in patients with cancer.</sentence>
<sentence>Seven patients were treated in a randomized crossover design with <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> (<cons sem="G_NUMBER">100 mg/m(2)</cons>), followed 3 weeks later by <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> (<cons sem="G_NUMBER">10 mg/m(2)</cons>) given in combination with orally administered <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">200 mg</cons> once daily for 3 days), or the reverse sequence.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentration</cons>-time data were analyzed by noncompartmental analysis.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, docetaxel, ADDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">Ketoconazole</cons> coadministration resulted in a <cons sem="G_NUMBER">49%</cons> <cons sem="G_CHANGE">decrease</cons> in <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="docetaxel" sem="G_DRUG" type="substrate_1">docetaxel</cons> (<cons sem="G_NUMBER">P =.018</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, docetaxel, DDI)">
<sentence>The mean (+/-SD) <cons sem="G_IVIVPARA">clearance</cons> values were <cons sem="G_NUMBER">35.0 +/- 11.8 L/h (95% confidence interval, 24.1-45.9 L/h)</cons> for <cons lex="docetaxel" sem="G_DRUG" type="substrate_1">docetaxel</cons> alone and <cons sem="G_NUMBER">18.2 L/h (95% confidence interval, 9.22-27.1 L/h)</cons> in the presence of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, docetaxel, DDI)">
<sentence>The <cons lex="docetaxel" sem="G_DRUG" type="substrate_1">docetaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> ratio in the presence and absence of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> was weakly related to the <cons sem="G_IVIVPARA">area under the curve</cons> of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> (<cons sem="G_NUMBER">R(2) = 0.529, P =.064</cons>).</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> in vivo results in <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> <cons sem="G_IVIVPARA">clearance</cons> values that have previously been shown to be associated with a several-fold <cons sem="G_CHANGE">increase</cons> in the odds for febrile neutropenia at standard doses.</sentence>
<sentence>Caution should be taken and substantial dose <cons sem ="G_CHANGE">reduction</cons>s are required if <cons lex="docetaxel" sem="G_DRUG">docetaxel</cons> has to be administered together with potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15060511</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="fluvoxamine" sem="G_DRUG">Fluvoxamine</cons> drastically <cons sem="G_CHANGE">increases</cons> concentrations and effects of tizanidine: a potentially hazardous interaction.</sentence>
</title>
<abstract>
<sentence>Our objective was to study the effect of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>, a centrally acting skeletal muscle relaxant.</sentence>
<sentence>In a double-blind, randomized, 2-phase crossover study, 10 healthy volunteers took <cons sem="G_NUMBER">100 mg</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> or placebo orally once daily for 4 days.</sentence>
<sentence>On day 4, each ingested a single <cons sem="G_NUMBER">4-mg</cons> dose of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> and <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and pharmacodynamic variables were measured.</sentence>
<sentence>A <cons lex="caffeine" sem="G_DRUG">caffeine</cons> test was performed on day 3 to examine the role of cytochrome P450 (CYP) <cons lex="1a2" sem="G_CYP">1A2</cons> in <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> pharmacokinetics.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, tizanidine, DDI)">
<sentence>On average, <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> <cons sem="G_CHANGE">increased</cons> the total <cons sem="G_IVIVPARA">area under the concentration-time curve  [AUC(0- infinity )]</cons> of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> <cons sem="G_NUMBER">33-fold (range, 14-fold to 103-fold; P =.000002)</cons> and the <cons sem="G_IVIVPARA">peak plasma concentration</cons> <cons sem="G_NUMBER">12-fold (range, 5-fold to 32-fold; P =.000001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, tizanidine, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> was prolonged from <cons sem="G_IVIVPARA">1.5 to 4.3 hours (P =.00004)</cons> by <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, tizanidine, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC(0- infinity)</cons> of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> and its <cons sem="G_CHANGE">increase</cons> by <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> <cons sem="G_MECHANISM">correlated</cons> with the caffeine/paraxanthine ratio and its <cons sem="G_CHANGE">increase</cons>, respectively (<cons sem="G_NUMBER">P &lt;.03</cons>).</sentence>
</annotation>
<sentence>All pharmacodynamic variables revealed a <cons sem="G_CHANGE">significant</cons> difference between the <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and placebo phases, eg, in the maximal effects on systolic blood pressure (<cons sem="G_NUMBER">-35 mm Hg, P =.000009</cons>), diastolic blood pressure (<cons sem="G_NUMBER">-20 mm Hg, P =.00002</cons>), heart rate (<cons sem="G_NUMBER">-4 beats/min, P =.007</cons>), Digit Symbol Substitution Test (<cons sem="G_NUMBER">P =.0003</cons>), subjective drug effect (<cons sem="G_NUMBER">P =.0000001</cons>), and drowsiness (<cons sem="G_NUMBER">P =.0002</cons>).</sentence>
<sentence>In particular, the <cons sem="G_CHANGE">decrease</cons> in systolic blood pressure, to the level of <cons sem="G_NUMBER">80 mm Hg</cons> or even less, was an alarming finding.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, tizanidine, DDI)">
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> seriously affects the pharmacokinetics of <cons lex="tizanidine" sem="G_DRUG" type="substrate_1">tizanidine</cons> and <cons sem="G_CHANGE">increases</cons> the intensity and duration of its effects.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons>-metabolizing enzyme(s), mainly <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, by <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> seems to explain the observed interaction.</sentence>
<sentence>Because of the potentially hazardous consequences, the concomitant use of <cons lex="tizanidine" sem="G_DRUG">tizanidine</cons> with <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>, or other potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, should be avoided.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15034704</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">rifampicin</cons> seems to act as both an <cons sem="G_MECHANISM">inducer</cons> and an <cons sem="G_MECHANISM">inhibitor</cons> of the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
</title>
<abstract>
<sentence>To investigate if <cons sem="G_DRUG">rifampicin</cons> is both an <cons sem="G_MECHANISM">inducer</cons> and an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons>, it was determined whether the timing of <cons sem="G_DRUG">rifampicin</cons> co-administration influences the pharmacokinetics of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
<sentence>Male volunteers ( n=12) participated in a randomised, two-period, crossover trial evaluating the effect of multiple doses of <cons sem="G_NUMBER">600 mg</cons> <cons sem="G_DRUG">rifampicin</cons> once daily for 7 days on <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Subjects were, after baseline measurements of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> pharmacokinetics, randomised to receive, on either day 7 or day 8 of the <cons sem="G_DRUG">rifampicin</cons> administration period, a single dose of <cons sem="G_NUMBER">4 mg</cons> <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> and vice versa in the following period.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, repaglinide, DDI)">
<sentence>When <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> was given, together with the last <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> dose, on day 7, an almost <cons sem="G_NUMBER">50%</cons> <cons sem ="G_CHANGE">reduction</cons> of the median <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> was observed.</sentence>
</annotation>
<sentence>Neither the <cons sem="G_IVIVPARA">peak plasma concentration (C(max))</cons>, <cons sem="G_IVIVPARA">time to reach C(max) (t(max))</cons> nor <cons sem="G_IVIVPARA">terminal half-life (t1/2)</cons> was statistically <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affected</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, repaglinide, DDI)">
<sentence>When <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> was given on day 8, 24 h after the last <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> dose, an almost <cons sem="G_NUMBER">80%</cons> <cons sem ="G_CHANGE">reduction</cons> of the median <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> <cons sem="G_IVIVPARA">AUC</cons> was observed.</sentence>
</annotation>
<sentence>The median <cons sem="G_IVIVPARA">C(max)</cons> was now statistically <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> from <cons sem="G_NUMBER">35 ng/ml to 7.5 ng/ml</cons>.</sentence>
<sentence>Neither <cons sem="G_IVIVPARA">t(max)</cons> nor <cons sem="G_IVIVPARA">t(1/2)</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affected</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, repaglinide, ADDI)">
<sentence>When <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> and <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> are administered concomitantly, <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> seems to act as both an <cons sem="G_MECHANISM">inducer</cons> and an <cons sem="G_MECHANISM">inhibitor</cons> of the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons>.</sentence>
</annotation>
<sentence>After discontinuing <cons sem="G_DRUG">rifampicin</cons> administration, while the <cons sem="G_MECHANISM">inductive</cons> effect on <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons sem = "G_CHANGE">probably</cons> also <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> is still present, an even more <cons sem = "G_CHANGE">marked</cons> <cons sem ="G_CHANGE">reduction</cons> in the <cons sem="G_IVIVPARA">plasma concentration</cons> of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> was observed.</sentence>
<sentence>Our results suggest that concomitant administration of <cons sem="G_DRUG">rifampicin</cons> and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> <cons sem = "G_CHANGE">may</cons> cause a clinically relevant <cons sem="G_CHANGE">decrease</cons> in the glucose-lowering effect of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>, in particular when <cons sem="G_DRUG">rifampicin</cons> treatment is discontinued or if the drugs are <cons sem="G_NEGATIVEEFFECT">not</cons> administered simultaneously or within a few hours of each other.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15025747</bibliomisc>
</articleinfo>
<title>
<sentence>Different <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> on <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_MECHANISM">metabolism</cons> between <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotypes.</sentence>
</title>
<abstract>
<sentence><cons lex="omeprazole" sem="G_DRUG">Omeprazole</cons> is mainly <cons sem="G_MECHANISM">metabolized</cons> by the polymorphic cytochrome P450 (CYP) <cons lex="2c19" sem="G_CYP">2C19</cons>.</sentence>
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> as well as <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, on the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> was compared between different genotypes for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>.</sentence>
<sentence>Eighteen volunteers, of whom six were homozygous extensive <cons sem="G_MECHANISM">metabolizers</cons> (EMs), six were heterozygous EMs and six were poor <cons sem="G_MECHANISM">metabolizers</cons> (PMs) for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, participated in the study.</sentence>
<sentence>A randomized double-blind, placebo-controlled crossover study was performed.</sentence>
<sentence>All subjects received two six-day courses of either daily <cons sem="G_NUMBER">50 mg</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> or placebo in a randomized fashion with a single oral <cons sem="G_NUMBER">40 mg</cons> dose of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> on day six in both cases.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and its metabolites, 5-hydroxyomeprazole, <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulphone, and <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> were monitored up to 8 h after the dosing.</sentence>
<sentence>During placebo administration, geometric means of <cons sem="G_IVIVPARA">peak concentration (C(max))</cons>, <cons sem="G_IVIVPARA">under the plasma concentration-time curve from 0 to 8 h (AUC(0,8 h))</cons> and <cons sem="G_IVIVPARA">elimination half-life (t(1/2))</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> were <cons sem="G_NUMBER">900 ng ml(-1), 1481 ng ml(-1) h, and 0.6 h</cons> in homozygous EMs, <cons sem="G_NUMBER">1648 ng ml(-1), 4225 ng ml(-1) h, and 1.1 h</cons> in heterozygous EMs, and <cons sem="G_NUMBER">2991 ng ml(-1), 11537 ng ml(-1) h, and 2.8 h</cons> in PMs, respectively.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, omeprazole, DDI)">
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> treatment <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> by <cons sem="G_NUMBER">3.7-fold (95%CI, 2.4, 5.0-fold, P &lt; 0.01)</cons> and <cons sem="G_NUMBER">2.0-fold (1.4, 2.6-fold, P &lt; 0.01)</cons>, <cons sem="G_IVIVPARA">AUC(0,8 h)</cons> by <cons sem="G_NUMBER">6.0-fold (3.3, 8.7-fold, P &lt; 0.001) and 2.4-fold (1.7, 3.2-fold, P &lt; 0.01)</cons>, <cons sem="G_IVIVPARA">AUC(0, infinity)</cons> by <cons sem="G_NUMBER">6.2-fold (3.0, 9.3-fold, P &lt; 0.01) and 2.5-fold (1.6, 3.4-fold, P &lt; 0.001)</cons> and prolonged <cons sem="G_IVIVPARA">t((1/2))</cons> by <cons sem="G_NUMBER">2.6-fold (1.9, 3.4-fold, P &lt; 0.001) and 1.4-fold (1.02, 1.7-fold, P &lt; 0.05)</cons>, respectively.</sentence>
</annotation>
<sentence>However, <cons sem="G_NEGATIVEEFFECT">no</cons> pharmacokinetic parameters were <cons sem="G_CHANGE">changed</cons> in PMs.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, omeprazole, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC(0,8 h) ratios</cons> of <cons lex="omeprazole" sem="G_DRUG" type="M_1">5-hydroxyomeprazole</cons> to <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> were <cons sem="G_CHANGE">decreased</cons> with <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> in homozygous EMs (<cons sem="G_NUMBER">P &lt; 0.05</cons>) and heterozygous EMs (<cons sem="G_NUMBER">P &lt; 0.01</cons>).</sentence>
</annotation>
<sentence>Even a low dose of <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> exposure in EMs, but did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">increase</cons> <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> exposure in PMs after a single oral dose of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons>.</sentence>
<sentence>These findings confirm a potent <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> on <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, omeprazole, DDI)">
<sentence>The <cons sem="G_IVIVPARA">bioavailability</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> <cons sem = "G_CHANGE">might</cons>, to some extent, be <cons sem="G_CHANGE">increased</cons> through <cons sem="G_MECHANISM">inhibition</cons> of P-glycoprotein during <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> treatment.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15025742</bibliomisc>
</articleinfo>
<title>
<sentence>The <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> <cons sem="G_CHANGE">increases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence>Our aim was to investigate the effect of the <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> on the pharmacokinetics and pharmacodynamics of the antidiabetic drug <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>, and to examine the influence of the former on the <cons sem="G_MECHANISM">metabolism</cons> of the latter in vitro.</sentence>
<sentence>In a randomized, double-blind, crossover study with two phases, nine healthy volunteers took <cons sem="G_NUMBER">160 mg</cons> <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> or placebo orally twice daily for 3 days.</sentence>
<sentence>On day 3, 1 h after the last dose of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> or placebo, they ingested a single <cons sem="G_NUMBER">0.25 mg</cons> dose of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
<sentence>Plasma <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> and blood glucose concentrations were measured for up to 7 h post-dose.</sentence>
<sentence>In addition, the effect of <cons lex="trimethoprim" sem="G_DRUG">trimethoprim</cons> on the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> by human liver microsomes was investigated.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Trimethoprim, repaglinide, DDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> <cons sem="G_CHANGE">raised</cons> the <cons sem="G_IVIVPARA">AUC(0, infinity)</cons> and <cons sem="G_IVIVPARA">C(max)</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> by <cons sem="G_NUMBER">61% (range, 30-117%; P= 0.0008)</cons> and <cons sem="G_NUMBER">41% (P = 0.005.)</cons>, respectively, and prolonged the <cons sem="G_IVIVPARA">t((1/2))</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> from <cons sem="G_NUMBER">0.9 to 1.1 h (P = 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Trimethoprim, repaglinide, DDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on the pharmacokinetics of its aromatic amine metabolite (M1), but <cons sem="G_CHANGE">decreased</cons> the M1 : <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> <cons sem="G_IVIVPARA">AUC(0, infinity ) ratio</cons> by <cons sem="G_NUMBER">38% (P = 0.0005)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Trimethoprim, repaglinide, NDDI)">
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> effect of <cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">trimethoprim</cons> on the blood glucose-lowering effect of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> was detectable.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Trimethoprim, repaglinide, DDI)">
<sentence>In vitro, <cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">trimethoprim</cons> <cons sem="G_MECHANISM">inhibited</cons> the <cons sem="G_MECHANISM">metabolism</cons> of (<cons sem="G_NUMBER">220 nm</cons>) <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> in a concentration-dependent manner.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Trimethoprim, repaglinide, DDI)">
<sentence><cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">Trimethoprim</cons> <cons sem="G_CHANGE">raised</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> <cons sem = "G_CHANGE">probably</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>-mediated biotransformation.</sentence>
</annotation>
<sentence>Although the interaction did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> enhance the effect of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> on blood glucose concentration at the drug doses used, the possibility of an <cons sem="G_CHANGE">increased</cons> risk of hypoglycaemia should be considered during concomitant use of <cons lex="trimethoprim" sem="G_DRUG" type="inhibitor_1">trimethoprim</cons> and <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> in patients with diabetes.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:15001966</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin (INN, rifampicin)</cons> causes several drug interactions with coadministered antidiabetic drugs.</sentence>
<sentence><cons lex="rosiglitazone" sem="G_DRUG">Rosiglitazone</cons> is a novel thiazolidinedione antidiabetic drug, but <cons sem = "G_CHANGE">little</cons> is known about the drug interaction between <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons>.</sentence>
<sentence>Our objective was to investigate the effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics of <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> in humans.</sentence>
<sentence>In an open-label, randomized, 2-way crossover study, 10 healthy Korean male subjects were treated once daily for 6 days with <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or with placebo.</sentence>
<sentence>On day 7, a single dose of <cons sem="G_NUMBER">8 mg</cons> <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> was administered orally.</sentence>
<sentence>Plasma <cons lex="rosiglitazone" sem="G_DRUG">rosiglitazone</cons> concentrations were measured.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, rosiglitazone, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> the mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> for <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> by <cons sem="G_NUMBER">65% (2947.9 ng.h/mL versus 991.5 ng.h/mL, P &lt;.001)</cons> and the mean <cons sem="G_IVIVPARA">elimination half-life</cons> from <cons sem="G_NUMBER">3.9 to 1.5 hours (P &lt;.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, rosiglitazone, DDI)">
<sentence>The <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> (<cons sem="G_NUMBER">537.7 ng/mL versus 362.3 ng/mL, P &lt;.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, rosiglitazone, DDI)">
<sentence>The apparent <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> <cons sem="G_CHANGE">increased</cons> about <cons sem="G_NUMBER">3-fold</cons> after <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> treatment (<cons sem="G_NUMBER">2.8 L/h versus 8.5 L/h, P &lt;.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, rosiglitazone, DDI)">
<sentence>This study showed that <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">affected</cons> the disposition of <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons> in humans, <cons sem = "G_CHANGE">probably</cons> by the <cons sem="G_MECHANISM">induction</cons> of cytochrome P450 (CYP) <cons lex="2c8" sem="G_CYP">2C8</cons> and, to a lesser extent, <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
</annotation>
<sentence>Therefore caution should be exercised during the coadministration of <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> and <cons lex="rosiglitazone" sem="G_DRUG" type="substrate_1">rosiglitazone</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14998561</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic interactions between omeprazole/pantoprazole and <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> in health volunteers.</sentence>
</title>
<abstract>
<sentence>The association omeprazole/clarithromycin is of current wide use in the treatment of Helicobacter pylori associated gastroduodenal ulcer.</sentence>
<sentence>This combination <cons sem = "G_CHANGE">may</cons> result in <cons sem="G_CHANGE">increased</cons> levels of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> with potential interactions with commonly associated drugs.</sentence>
<sentence>Kinetic/metabolic <cons sem ="G_CHANGE">changes</cons> occurring after <cons sem ="G_DRUG">omeprazole</cons>/<cons sem ="G_DRUG">clarithromycin</cons> were compared to those occurring after <cons sem ="G_DRUG">pantoprazole</cons>/<cons sem ="G_DRUG">clarithromycin</cons> in healthy volunteers.</sentence>
<sentence>Eight healthy volunteers, all males, age 25-34 years, all EM for <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, participated in a randomized, double blind crossover study in two periods of 7 days, separated by a 14-day washout.</sentence>
<sentence>In each treatment period, subjects took either <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_NUMBER">20mg b.i.d.</cons> together with <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> <cons sem="G_NUMBER">500 mg b.i.d.</cons>, or <cons lex="pantoprazole" sem="G_DRUG">pantoprazole</cons> <cons sem="G_NUMBER">40 mg b.i.d.</cons> with the same dose of the antibiotic.</sentence>
<sentence>The pharmacokinetic parameters of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and <cons lex="pantoprazole" sem="G_DRUG">pantoprazole</cons> were compared to those after intake of both agents alone.</sentence>
<sentence>Kinetics of <cons sem="G_NEGATIVEEFFECT">unchanged</cons> <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> was evaluated at the end of the two periods.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, omeprazole, ADDI)">
<sentence>The mean value of the <cons sem="G_IVIVPARA">area under the plasma concentration versus time curve (AUC)</cons> of <cons sem="G_NEGATIVEEFFECT">unchanged</cons> <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_CHANGE">increased</cons> almost <cons sem="G_NUMBER">two-fold</cons> after concomitant administration of <cons sem="G_DRUG" type="inhibitor_1">clarithromycin</cons>; the average <cons lex="omeprazole" sem="G_DRUG" type="M_1">5-OH-omeprazole</cons> <cons sem="G_IVIVPARA">AUC</cons> was instead <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">42%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, omeprazole, DDI)">
<sentence><cons lex="omeprazole" sem="G_DRUG">Omeprazole</cons> <cons sem="G_IVIVPARA">clearance</cons> and volume of distribution were <cons sem="G_CHANGE">reduced</cons> <cons sem="G_CHANGE">significantly</cons> by <cons sem="G_NUMBER">75</cons> and <cons sem="G_NUMBER">56%</cons>, respectively, after administration of the drug with <cons sem="G_DRUG" type="inhibitor_1">clarithromycin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(clarithromycin, pantoprazole, NDDI)">
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> of the kinetic of <cons lex="pantoprazole" sem="G_DRUG">pantoprazole</cons> and metabolites were observed.</sentence>
</annotation>
<sentence>Kinetics of <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> differ after the two associated treatments.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, omeprazole, DDI)(clarithromycin, pantoprazole, NDDI)">
<sentence>The administration of <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> with two different proton pump <cons sem="G_MECHANISM">inhibitors</cons> indicates that the antibiotic can <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increase</cons> <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="pantoprazole" sem="G_DRUG" type="inhibitor_2">pantoprazole</cons>, levels.</sentence>
</annotation>
<sentence>This observation <cons sem = "G_CHANGE">may</cons> result in a better therapeutic response to <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons>, but it <cons sem = "G_CHANGE">may</cons> also potentially <cons sem="G_CHANGE">affect</cons> either the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrates or interfere with the absorption of drugs requiring an intact gastric digestion system.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14768975</bibliomisc>
</articleinfo>
<title>
<sentence>Influence of <cons sem="G_DRUG">rifampicin</cons> pretreatment on the pharmacokinetics of <cons lex="celecoxib" sem="G_DRUG">celecoxib</cons> in healthy male volunteers.</sentence>
</title>
<abstract>
<sentence>The effect of <cons sem="G_DRUG">rifampicin</cons> pretreatment on the pharmacokinetics of <cons lex="celecoxib" sem="G_DRUG">celecoxib</cons> was investigated in 12 healthy male human volunteers.</sentence>
<sentence>After an overnight fast, <cons lex="celecoxib" sem="G_DRUG">celecoxib</cons> <cons sem="G_NUMBER">200 mg</cons> was administered to the volunteers, either alone or after 5 days pretreatment with once daily dose of <cons sem="G_NUMBER">600 mg</cons> <cons sem="G_DRUG">rifampicin</cons>.</sentence>
<sentence>Serum concentrations of <cons lex="celecoxib" sem="G_DRUG">celecoxib</cons> were estimated by reverse phase HPLC.</sentence>
<sentence>Pharmacokinetic parameters were determined based on non-compartmental model analysis using the computer program KINETICA.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, celecoxib, DDI)">
<sentence>A <cons sem="G_CHANGE">significant</cons> difference was observed in <cons sem="G_IVIVPARA">AUC(0-1)</cons> <cons sem="G_NUMBER">(4531.28 +/- 2147 vs 1629.1 +/- 1006 ng x h x ml(-1), p &lt; 0.0001)</cons>, <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> <cons sem="G_NUMBER">(4632.42 +/- 2221.75 vs 1629.46 +/- 1012.61 ng x h x ml(-1), p = 0.0006)</cons>, <cons sem="G_IVIVPARA">Cmax</cons> <cons sem="G_NUMBER">(544.89 +/- 273.91 vs 238.61 +/- 146.34 ng/ml, p = 0.04)</cons>, <cons sem="G_IVIVPARA">t(1/2)</cons> <cons sem="G_NUMBER">(9.3 +/- 3.58 vs 4.0 +/- 1.43 h, p = 0.0317)</cons> and <cons sem="G_IVIVPARA">CL/F</cons> <cons sem="G_NUMBER">(43.14 +/- 36.23 vs 122.85 +/- 95 l x h(-1), p &lt; 0.0001)</cons> of <cons lex="celecoxib" sem="G_DRUG" type="substrate_1">celecoxib</cons> administered before and after <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> pretreatment.</sentence>
</annotation>
<sentence>However, <cons sem="G_IVIVPARA">time to reach peak concentration, tmax</cons> (<cons sem="G_NUMBER">4 +/- 0.88 vs 4 +/- 0.83 h</cons>) and volume of distribution <cons sem="G_IVIVPARA">Vd/f</cons> (<cons sem="G_NUMBER">583 +/- 251 vs 710 +/- 690 l/kg</cons>) were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affected</cons> <cons sem="G_CHANGE">significantly</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, celecoxib, DDI)">
<sentence><cons sem="G_DRUG" type="inducer_1">rifampicin</cons> pretreatment <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="celecoxib" sem="G_DRUG" type="substrate_1">celecoxib</cons> by <cons sem="G_NUMBER">64%</cons> and <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">clearance</cons> by <cons sem="G_NUMBER">185%</cons>.</sentence>
</annotation>
<sentence>This <cons sem = "G_CHANGE">may</cons> be due to <cons sem="G_CHANGE">increased</cons> <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="celecoxib" sem="G_DRUG">celecoxib</cons> due to the <cons sem="G_MECHANISM">induction</cons> of cytochrome <cons sem="G_CYP">P4502C9 (CYP2C9)</cons> in liver.</sentence>
<sentence>This interaction has a <cons sem="G_CHANGE">significant</cons> clinical relevance and <cons sem = "G_CHANGE">may</cons> warrant dosage adjustment when <cons lex="celecoxib" sem="G_DRUG">celecoxib</cons> is co-administered with <cons sem="G_DRUG">rifampicin</cons> in chronic treatment conditions, such as tuberculosis, leprosy and other infections of joints, bones, etc.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14730412</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of the novel anxiolytic drug <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons> on cytochrome P(450) <cons lex="2d6" sem="G_CYP">2D6</cons> activity as measured by <cons lex="desipramine" sem="G_DRUG">desipramine</cons> pharmacokinetics.</sentence>
</title>
<abstract>
<sentence>In vitro findings have indicated that the novel anxiolytic drug, <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons>, is an <cons sem="G_MECHANISM">inhibitor</cons> of the cytochrome P(450) (CYP) <cons lex="2d6" sem="G_CYP">2D6</cons> enzyme and co-administration of <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons> and the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> probe drug <cons lex="desipramine" sem="G_DRUG">desipramine</cons> is possible in clinical practice.</sentence>
<sentence>To evaluate the effects of <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons> on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity as measured by <cons lex="desipramine" sem="G_DRUG">desipramine</cons> pharmacokinetics and pharmacodynamics using <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> as a positive control for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibition</cons>.</sentence>
<sentence>Fifteen healthy subjects received either <cons sem="G_NUMBER">60 mg</cons> <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons>, <cons sem="G_NUMBER">20 mg</cons> <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> or matched placebo for 8 days in randomized order in this double-blind, cross-over study.</sentence>
<sentence>On day 8 of each study phase, the subjects received a <cons sem="G_NUMBER">100-mg</cons> single dose of <cons lex="desipramine" sem="G_DRUG">desipramine</cons>.</sentence>
<sentence><cons lex="desipramine" sem="G_DRUG">Desipramine</cons> and its <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-dependent metabolite, <cons lex="desipramine" sem="G_DRUG" type="M_1">2-OH-desipramine</cons>, concentrations were measured for 240 h. Measurement of secretion of saliva, Visual Analogue Scale assessment of dryness of mouth and tiredness were carried out on day 7 and day 8 to assess the pharmacodynamic consequences of <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons> or <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> co-administration with <cons lex="desipramine" sem="G_DRUG">desipramine</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(deramciclane, desipramine, DDI)(paroxetine, desipramine, DDI)">
<sentence>Repeated administration of <cons lex="deramciclane" sem="G_DRUG" type="inhibitor_1">deramciclane</cons> <cons sem = "G_CHANGE">doubled</cons> the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> ( <cons sem="G_NUMBER">P&lt;0.001</cons>), while <cons lex="paroxetine" sem="G_DRUG" type="inhibitor_2">paroxetine</cons> caused a <cons sem="G_NUMBER">4.8-fold</cons> <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> ( <cons sem="G_NUMBER">P&lt;0.001</cons>).</sentence>
</annotation>
<sentence><cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">correlations</cons> were observed with <cons lex="paroxetine" sem="G_DRUG" type="inhibitor_2">paroxetine</cons> (<cons sem="G_NUMBER">r(s)=0.84, P&lt;0.001</cons>) and <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons> (<cons sem="G_NUMBER">r(s)=0.51, P=0.0498</cons>) concentrations and the magnitude of <cons sem="G_CHANGE">increase</cons> of <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> <cons sem="G_IVIVPARA">AUC</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(deramciclane, desipramine, ADDI)(paroxetine, desipramine, DDI)">
<sentence>Both <cons lex="deramciclane" sem="G_DRUG" type="inhibitor_1">deramciclane</cons> and <cons lex="paroxetine" sem="G_DRUG" type="inhibitor_2">paroxetine</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_MECHANISM">formation</cons> of <cons lex="desipramine" sem="G_DRUG" type="M_1">2-OH-desipramine</cons> in the first-pass phase.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(deramciclane, desipramine, ADDI)(paroxetine, desipramine, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC ratio</cons> of <cons lex="desipramine" sem="G_DRUG" type="M_1">2-OH-desipramine</cons>/<cons sem ="G_DRUG" type="substrate_1">desipramine</cons> was <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">39% ( P&lt;0.001)</cons> by <cons lex="deramciclane" sem="G_DRUG" type="inhibitor_1">deramciclane</cons> and by <cons sem="G_NUMBER">74% ( P&lt;0.001)</cons> by <cons lex="paroxetine" sem="G_DRUG" type="inhibitor_2">paroxetine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(deramciclane, desipramine, NDDI)">
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem ="G_CHANGE">changes</cons> in the secretion of saliva during co-administration of <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> with <cons lex="deramciclane" sem="G_DRUG" type="inhibitor_1">deramciclane</cons> compared with placebo.</sentence>
</annotation>
<sentence>Although <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons> seems to be a weaker <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> than <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>, dose adjustment of drugs <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem = "G_CHANGE">may</cons> be needed when used concomitantly with <cons lex="deramciclane" sem="G_DRUG">deramciclane</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14624194</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="nefazodone" sem="G_DRUG">Nefazodone</cons> <cons sem="G_MECHANISM">inhibits</cons> <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> disposition and enhances its adrenal-suppressant effect.</sentence>
</title>
<abstract>
<sentence><cons lex="nefazodone" sem="G_DRUG">Nefazodone</cons> is a potent and selective <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4 (CYP3A4)</cons>, an enzyme pathway responsible for the biotransformation of a number of steroid compounds.</sentence>
<sentence>The potential therefore exists that <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons> <cons sem="G_MECHANISM">inhibits</cons> the disposition of <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons>.</sentence>
<sentence>In this open label, repeated measures study, the effect of 9 days of <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons> administration on the pharmacokinetic disposition of a single <cons sem="G_NUMBER">0.6 mg/kg</cons> intravenous dose of <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> was assessed.</sentence>
<sentence>Additionally the effect of concomitant <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons> use on duration of <cons lex="cortisol" sem="G_DRUG">cortisol</cons> <cons sem = "G_MECHANISM">suppression</cons> after <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> administration was assessed.</sentence>
<sentence>Eight healthy volunteers completed the study.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(nefazodone, methylprednisolone, DDI)">
<sentence>Following <cons lex="nefazodone" sem="G_DRUG" type="inhibitor_1">nefazodone</cons> administration, the mean (+/-SD) <cons sem="G_IVIVPARA">area under the <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> concentration-time curve</cons> was <cons sem="G_CHANGE">significantly</cons> higher <cons sem="G_NUMBER">(1393 +/- 343 vs. 2966 +/- 928 ug*h/L; P &lt; 0.005)</cons>, apparent <cons sem="G_IVIVPARA">clearance</cons> was lower <cons sem="G_NUMBER">(28.7 +/- 7.2 vs. 14.6 +/- 7.8 L/h; P &lt; 0.02)</cons> and the <cons sem="G_IVIVPARA">terminal elimination half-life</cons> was longer <cons sem="G_NUMBER">(2.28 +/- 0.49 vs. 3.32 +/- 0.95 hours; P &lt; 0.02)</cons>.</sentence>
</annotation>
<sentence>The duration of <cons lex="cortisol" sem="G_DRUG">cortisol</cons> <cons sem = "G_MECHANISM">suppression</cons> after <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> administration was longer (<cons sem="G_NUMBER">&gt; or =32 vs. 23.3 +/- 3.43 hours</cons>) during <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons> administration.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14551182</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic and pharmacodynamic interactions of oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>, <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>, and <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons>.</sentence>
</title>
<abstract>
<sentence>The objective of this study was to investigate pharmacokinetic and pharmacodynamic interactions between <cons lex="midazolam" sem="G_DRUG">midazolam</cons> and <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons>, <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>, <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons>, and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
<sentence>Forty healthy subjects were randomized to receive one of the four study drugs for 12 days in a parallel study design: <cons lex="fluoxetine" sem="G_DRUG">fluoxetine</cons> <cons sem="G_NUMBER">60 mg</cons> per day for 5 days, followed by <cons sem="G_NUMBER">20 mg</cons> per day for 7 days; <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> titrated to a daily dose of <cons sem="G_NUMBER">200 mg</cons>; <cons lex="nefazodone" sem="G_DRUG">nefazodone</cons> titrated to a daily dose of <cons sem="G_NUMBER">400 mg</cons>; or <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">200 mg</cons> per day.</sentence>
<sentence>All 40 subjects received oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> solution before and after the 12-day study drug regimen.</sentence>
<sentence>Blood samples for determination of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> concentrations were drawn for 24 hours after each <cons lex="midazolam" sem="G_DRUG">midazolam</cons> dose and used for the calculation of pharmacokinetic parameters.</sentence>
<sentence>The effects of the study drugs on <cons lex="midazolam" sem="G_DRUG">midazolam</cons> pharmacodynamics were assessed using the symbol digit modalities test (SDMT).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, midazolam, DDI)(nefazodone, midazolam, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">area under the curve (AUC)</cons> for <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">771.9%</cons> by <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> and <cons sem="G_NUMBER">444.0%</cons> by <cons lex="nefazodone" sem="G_DRUG" type="inhibitor_2">nefazodone</cons> administration.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluoxetine, midazolam, ADDI)(fluvoxamine , midazolam, ADDI)">
<sentence>However, there was <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> <cons sem = "G_CHANGE">change</cons> in <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">AUC</cons> as a result of <cons lex="fluoxetine" sem="G_DRUG" type="inducer_1">fluoxetine</cons> (<cons sem="G_NUMBER">13.4%</cons> <cons sem="G_CHANGE">decrease</cons>) and a statistical trend for <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_3">fluvoxamine</cons> (<cons sem="G_NUMBER">66.1%</cons> <cons sem="G_CHANGE">increase</cons>) administration.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, midazolam, DDI)(nefazodone, midazolam, DDI)">
<sentence>Pharmacodynamic data are consistent with pharmacokinetic data indicating that <cons lex="nefazodone" sem="G_DRUG" type="inhibitor_2">nefazodone</cons> and <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> resulted in <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> in <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons>-related cognition impairment.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, midazolam, DDI)(nefazodone, midazolam, DDI)">
<sentence>The <cons sem="G_CHANGE">significant</cons> impairment in subjects' cognitive function reflects the <cons sem ="G_CHANGE">changes</cons> in <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">clearance</cons> after treatment with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> and <cons lex="nefazodone" sem="G_DRUG" type="inhibitor_2">nefazodone</cons>.</sentence>
</annotation>
<sentence>These results suggest that caution with the use of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> is warranted with potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:14517191</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons sem="G_DRUG">mibefradil</cons> on <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in vivo.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">mibefradil</cons>, a calcium channel blocker, was removed from the market because of adverse drug interactions with coadministered <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrates.</sentence>
<sentence>This study examined the effect of <cons sem="G_DRUG">mibefradil</cons> on the activity of hepatic and intestinal <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in vivo, employing the <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> breath test (EBT) and oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> pharmacokinetics.</sentence>
<sentence>This was a two-period, single-blind, placebo-controlled crossover study in which 8 male volunteers were randomized to the order of receiving placebo and a single <cons sem="G_NUMBER">100-mg</cons> oral dose of <cons sem="G_DRUG">mibefradil</cons>.</sentence>
<sentence>Oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> was coadministered with intravenous  [14C N-methyl] <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> 1 hour after <cons sem="G_DRUG">mibefradil</cons>/placebo administration.</sentence>
<sentence>The EBT was performed 20 minutes following <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> administration.</sentence>
<sentence>Blood and urine were collected during the 36 hours following probe drug administration for analysis of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> pharmacokinetics.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(mibefradil, midazolam, DDI)">
<sentence>Coadministration of <cons sem="G_DRUG" type="inhibitor_1">mibefradil</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_NUMBER">3-fold</cons>, the <cons sem="G_IVIVPARA">AUC</cons> <cons sem="G_NUMBER">8- to 9-fold</cons>, and the <cons sem="G_IVIVPARA">t1/2</cons> <cons sem="G_NUMBER">4-fold</cons>.</sentence>
</annotation>
<sentence><cons sem="G_DRUG">mibefradil</cons> coadministration <cons sem="G_CHANGE">decreased</cons> the amount of exhaled 14CO2 in 6 of 8 subjects, with a mean <cons sem="G_CHANGE">decrease</cons> of <cons sem="G_NUMBER">25%</cons>.</sentence>
<sentence>It was concluded that a single oral dose of <cons sem="G_DRUG">mibefradil</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">inhibits</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in intestine and liver.</sentence>
<sentence>These data support that adverse drug interactions involving <cons sem="G_DRUG">mibefradil</cons> reflect <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in intestine and liver.</sentence>
<sentence>Also, they suggest that the EBT, while a valid probe of in vivo hepatic <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, is a single time point measurement and <cons sem = "G_CHANGE">may</cons> be less sensitive than oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> pharmacokinetics in detecting <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:13129991</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons sem="G_DRUG">St John's wort</cons> on drug <cons sem="G_MECHANISM">metabolism</cons> by <cons sem="G_MECHANISM">induction</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> enzyme.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">St John's wort</cons> is a popular herbal product used to treat depression but it has been implicated in drug interactions.</sentence>
<sentence>To assess the potential of <cons sem="G_DRUG">St John's wort</cons> administration to alter the activity of the cytochrome P450 (CYP) enzymes extensively involved in drug <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Open-label crossover study with fixed treatment order conducted March 2002 to February 2003 in a US general clinical research center involving 12 healthy volunteers (6 men and 6 women) aged 22 to 38 years before and after 14 days of administration of <cons sem="G_DRUG">St John's wort</cons>.</sentence>
<sentence>Participants were given probe drugs (<cons sem="G_NUMBER">30 mg</cons> of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> and <cons sem="G_NUMBER">2 mg</cons> of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons>) to establish baseline CYP <cons lex="3a4" sem="G_CYP">3A4</cons> and CYP <cons lex="2d6" sem="G_CYP">2D6</cons> activity.</sentence>
<sentence>After a minimum 7-day washout period, participants began taking one <cons sem="G_NUMBER">300-mg</cons> tablet 3 times per day.</sentence>
<sentence>After 14 days of <cons sem="G_DRUG">St John's wort</cons> administration, participants were given the probe drugs along with 1 <cons sem="G_DRUG">St John's wort</cons> tablet to establish postadministration CYP activity; the <cons sem="G_DRUG">St John's wort</cons> dosing regimen was continued for 48 hours.</sentence>
<sentence><cons sem ="G_CHANGE">Changes</cons> in plasma pharmacokinetics of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> as a probe for CYP <cons lex="3a4" sem="G_CYP">3A4</cons> activity and the ratio of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> to its metabolite, dextrorphan, in urine as a probe for CYP <cons lex="2d6" sem="G_CYP">2D6</cons> activity.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort, alprazolam, DDI)">
<sentence>A <cons sem="G_NUMBER">2-fold</cons> <cons sem="G_CHANGE">decrease</cons> in the <cons sem="G_IVIVPARA">area under the curve for <cons lex="alprazolam" sem="G_DRUG" type="substrate_1">alprazolam</cons> <cons sem="G_IVIVPARA">plasma concentration</cons> vs time</cons> (<cons sem="G_NUMBER">P&lt;.001</cons>) and a <cons sem="G_NUMBER">2-fold</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="alprazolam" sem="G_DRUG" type="substrate_1">alprazolam</cons> <cons sem="G_IVIVPARA">clearance</cons> (<cons sem="G_NUMBER">P&lt;.001</cons>) were observed following <cons sem="G_DRUG" type="inhibitor_1">St John's wort</cons> administration.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(St John's wort, alprazolam, DDI)">
<sentence><cons lex="alprazolam" sem="G_DRUG" type="substrate_1">Alprazolam</cons> <cons sem="G_IVIVPARA">elimination half-life</cons> was shortened from <cons sem="G_NUMBER">a mean (SD) of 12.4 (3.9) hours to 6.0 (2.4) hours (P&lt;.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort, dextromethorphan, ADDI)">
<sentence>The mean (SD) urinary ratio of <cons lex="dextromethorphan" sem="G_DRUG" type="substrate_2">dextromethorphan</cons> to its metabolite was <cons sem="G_NUMBER">0.006 (0.010)</cons> at baseline and <cons sem="G_NUMBER">0.014 (0.025)</cons> after <cons sem="G_DRUG" type="inhibitor_1">St John's wort</cons> administration (<cons sem="G_NUMBER">P =.26</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(St John's wort, alprazolam, DDI)">
<sentence>A 14-day course of <cons sem="G_DRUG" type="inhibitor_1">St John's wort</cons> administration <cons sem="G_CHANGE">significantly</cons> <cons sem="G_MECHANISM">induced</cons> the activity of CYP <cons lex="3a4" sem="G_CYP">3A4</cons> as measured by <cons sem ="G_CHANGE">changes</cons> in <cons lex="alprazolam" sem="G_DRUG" type="substrate_1">alprazolam</cons> pharmacokinetics.</sentence>
</annotation>
<sentence>This suggests that long-term administration of <cons sem="G_DRUG">St John's wort</cons> <cons sem = "G_CHANGE">may</cons> result in diminished clinical effectiveness or <cons sem="G_CHANGE">increased</cons> dosage requirements for all CYP <cons lex="3a4" sem="G_CYP">3A4</cons> substrates, which represent at least <cons sem="G_NUMBER">50%</cons> of all marketed medications.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12898080</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> in extensive and poor metabolisers of <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons>.</sentence>
</title>
<abstract>
<sentence>To study the influence of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the disposition of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> in individuals with different <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> pheno- and genotypes.</sentence>
<sentence>In an open two-phase study, 21 healthy volunteers with known <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> pheno- and genotype  [14 extensive metabolisers (EMs), 7 poor metabolisers (PMs)] were given a single oral dose of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> (<cons sem="G_NUMBER">50 mg</cons> to EMs and <cons sem="G_NUMBER">25 mg</cons> to PMs).</sentence>
<sentence>Plasma and urine levels of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> and its three metabolites were measured and the pharmacokinetics of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> were determined.</sentence>
<sentence>After a 2-week washout period, subjects were treated for 2 days with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">100 mg</cons> twice daily) starting 1 day before the administration of venlafaxine; and the same parameters as for the administration of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> only were measured.</sentence>
<sentence>Data were evaluated from 20 subjects (14 EMs and 6 PMs) who completed the study.</sentence>
<sentence>The dose-corrected <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> was on average 2.3 times higher ( <cons sem="G_NUMBER">P&lt;0.01</cons>) and that of its active metabolite <cons lex="venlafaxine" sem="G_DRUG" type="M_1">O-desmethylvenlafaxine</cons> 3.4 times lower ( <cons sem="G_NUMBER">P&lt;0.0001</cons>) in PMs than EMs.</sentence>
<sentence>There was a good <cons sem="G_MECHANISM">correlation</cons> between the <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons> metabolic ratio and the ratio between the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> and that of <cons lex="venlafaxine" sem="G_DRUG" type="M_1">O-desmethylvenlafaxine</cons> ( <cons sem="G_NUMBER">Rs=0.93, P&lt;0.002</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, venlafaxine, DDI)">
<sentence>The majority of subjects showed higher plasma levels of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> and <cons lex="venlafaxine" sem="G_DRUG" type="M_1">O-desmethylvenlafaxine</cons> upon co-administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, venlafaxine, ADDI)">
<sentence><cons sem="G_IVIVPARA">AUC</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">36%</cons> and that of <cons lex="venlafaxine" sem="G_DRUG" type="M_1">O-desmethylvenlafaxine</cons> by <cons sem="G_NUMBER">26% ( P&lt;0.01)</cons>.</sentence>
</annotation>
<sentence><cons sem="G_IVIVPARA">C(max)</cons> values <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">32%</cons> and <cons sem="G_NUMBER">18%</cons>, respectively.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, venlafaxine, NDDI)">
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> was <cons sem="G_NEGATIVEEFFECT">unaltered</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(ketoconazole, venlafaxine, NDDI)">
<sentence>Three of the PMs displayed <cons sem = "G_CHANGE">marked</cons> <cons sem="G_CHANGE">increases</cons> in <cons sem="G_IVIVPARA">AUC</cons> (<cons sem="G_NUMBER">81, 126 and 206%</cons>) and <cons sem="G_IVIVPARA">C(max)</cons> (<cons sem="G_NUMBER">60, 72, 119%</cons>) of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> while the other three showed small or <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem ="G_CHANGE">changes</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, venlafaxine, DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">Ketoconazole</cons> consistently <cons sem="G_CHANGE">affected</cons> the disposition of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> in EMs of <cons lex="debrisoquine" sem="G_DRUG">debrisoquine</cons> while the response in PMs was erratic.</sentence>
</annotation>
<sentence>The precise mechanisms underlying this interaction remain to be elucidated.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12891225</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="aprepitant" sem="G_DRUG">aprepitant</cons> on cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> activity using <cons lex="midazolam" sem="G_DRUG">midazolam</cons> as a probe.</sentence>
</title>
<abstract>
<sentence><cons lex="aprepitant" sem="G_DRUG">Aprepitant</cons> is a neurokinin(1) receptor antagonist that enhances prevention of chemotherapy-<cons sem="G_MECHANISM">induced</cons> nausea and vomiting when added to conventional therapy with a corticosteroid and a 5-hydroxytryptamine(3) (5-HT(3)) antagonist.</sentence>
<sentence>Because <cons lex="aprepitant" sem="G_DRUG">aprepitant</cons> <cons sem = "G_CHANGE">may</cons> be used with a variety of chemotherapeutic agents and ancillary support drugs, which <cons sem = "G_CHANGE">may</cons> be substrates of cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>, assessment of the potential of this drug to <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in vivo is important.</sentence>
<sentence>The effect of <cons lex="aprepitant" sem="G_DRUG">aprepitant</cons> on in vivo <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in humans with oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> used as a sensitive probe of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity was evaluated in this study.</sentence>
<sentence>In this open-label, randomized, single-period study, 16 healthy male subjects were enrolled.</sentence>
<sentence>Subjects received one of two oral <cons lex="aprepitant" sem="G_DRUG">aprepitant</cons> regimens for 5 days (8 subjects per regimen): (1) <cons sem="G_NUMBER">125 mg</cons> <cons lex="aprepitant" sem="G_DRUG">aprepitant</cons> on day 1 and then <cons sem="G_NUMBER">80 mg/d</cons> on days 2 to 5 or (2) <cons sem="G_NUMBER">40 mg</cons> <cons lex="aprepitant" sem="G_DRUG">aprepitant</cons> on day 1 and then <cons sem="G_NUMBER">25 mg/d</cons> on days 2 to 5.</sentence>
<sentence>All subjects also received a single oral dose of <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, <cons sem="G_NUMBER">2 mg</cons>, at prestudy (3 to 7 days before <cons lex="aprepitant" sem="G_DRUG">aprepitant</cons> treatment) and on days 1 and 5 (1 hour after <cons lex="aprepitant" sem="G_DRUG">aprepitant</cons> administration).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(aprepitant, midazolam, DDI)">
<sentence>Coadministration of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> and <cons sem="G_NUMBER">125/80 mg</cons> <cons lex="aprepitant" sem="G_DRUG" type="inhibitor_1">aprepitant</cons> <cons sem="G_CHANGE">increased</cons> the <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> by <cons sem="G_NUMBER">2.3-fold</cons> on day 1 (<cons sem="G_NUMBER">P &lt;.01</cons>) and by <cons sem="G_NUMBER">3.3-fold</cons> on day 5 (<cons sem="G_NUMBER">P &lt;.01</cons>), as compared with <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> alone (prestudy).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(aprepitant, midazolam, DDI)">
<sentence>The <cons sem="G_NUMBER">125/80-mg</cons> regimen of <cons lex="aprepitant" sem="G_DRUG" type="inhibitor_1">aprepitant</cons> also <cons sem="G_CHANGE">increased</cons> the <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">maximum observed concentration</cons> by <cons sem="G_NUMBER">1.5-fold</cons> on day 1 (<cons sem="G_NUMBER">P &lt;.05</cons>) and by <cons sem="G_NUMBER">1.9-fold</cons> on day 5 (<cons sem="G_NUMBER">P &lt;.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(aprepitant, midazolam, DDI)">
<sentence>The <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">half-life</cons> values <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">1.7 hours (prestudy) to 3.3 hours</cons> on both day 1 and day 5.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(aprepitant, midazolam, NDDI)">
<sentence>Coadministration of <cons sem="G_NUMBER">40/25 mg</cons> <cons lex="aprepitant" sem="G_DRUG" type="inhibitor_1">aprepitant</cons> and <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> result in <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> in the <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons>, <cons sem="G_IVIVPARA">maximum observed concentration</cons>, and <cons sem="G_IVIVPARA">half-life</cons> at either day 1 or day 5.</sentence>
</annotation>
<sentence>The 5-day <cons sem="G_NUMBER">125/80-mg</cons> regimen of <cons lex="aprepitant" sem="G_DRUG" type="inhibitor_1">aprepitant</cons> produced <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in humans, as measured with the use of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> as a probe drug.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12723463</bibliomisc>
</articleinfo>
<title>
<sentence>Interaction between <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="almotriptan" sem="G_DRUG">almotriptan</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>The interaction between <cons lex="almotriptan" sem="G_DRUG">almotriptan</cons>, a 5-HT1B/1D agonist, and the potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> was examined in 16 healthy volunteers.</sentence>
<sentence>Subjects received (A) <cons sem="G_NUMBER">12.5 mg</cons> <cons lex="almotriptan" sem="G_DRUG">almotriptan</cons> orally on Day 2 of a 3-day regimen of <cons sem="G_NUMBER">400 mg</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> once daily and (B) 12.5 mg <cons lex="almotriptan" sem="G_DRUG">almotriptan</cons> in a crossover design.</sentence>
<sentence>Plasma and urine concentrations of <cons lex="almotriptan" sem="G_DRUG">almotriptan</cons> were measured by HPLC.</sentence>
<sentence>Treatment effects on <cons lex="almotriptan" sem="G_DRUG">almotriptan</cons> pharmacokinetics were assessed by analysis of variance.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, almotriptan, DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">Ketoconazole</cons> coadministration <cons sem="G_CHANGE">increased</cons> mean <cons lex="almotriptan" sem="G_DRUG" type="substrate_1">almotriptan</cons> <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">Cmax</cons> from <cons sem="G_NUMBER">312 to 490 ng h/mL and 52.6 to 84.5 ng/mL</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, almotriptan, ADDI)">
<sentence>Mean <cons sem="G_IVIVPARA">oral clearance</cons> was <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">40.7 to 26.2 L/h</cons> by <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>, with an accompanying <cons sem="G_CHANGE">increase</cons> in the fraction of <cons lex="almotriptan" sem="G_DRUG" type="substrate_1">almotriptan</cons> excreted <cons sem="G_NEGATIVEEFFECT">unchanged</cons> in the urine (<cons sem="G_NUMBER">40.6% to 53.3%</cons>) and a <cons sem="G_CHANGE">decrease</cons> in <cons sem="G_IVIVPARA">renal clearance</cons> (<cons sem="G_NUMBER">16.4 to 13.8 L/h</cons>).</sentence>
</annotation>
<sentence>These effects were statistically <cons sem="G_CHANGE">significant</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, almotriptan, DDI)">
<sentence>The effects of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> on <cons lex="almotriptan" sem="G_DRUG" type="substrate_1">almotriptan</cons> <cons sem="G_IVIVPARA">clearance</cons> were consistent with <cons sem="G_MECHANISM">inhibition</cons> of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> and a <cons sem="G_CHANGE">slight</cons> effect on the active tubular secretion of <cons lex="almotriptan" sem="G_DRUG" type="substrate_1">almotriptan</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12687332</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
</title>
<abstract>
<sentence>Our aim was to investigate possible interactions of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, and their combination with <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
<sentence>In a randomised crossover study, 12 healthy volunteers received twice daily for 3 days either 600 mg <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, <cons sem="G_NUMBER">100 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> (first dose <cons sem="G_NUMBER">200 mg</cons>), both <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, or placebo.</sentence>
<sentence>On day 3 they ingested a <cons sem="G_NUMBER">0.25 mg</cons> dose of <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
<sentence>Plasma drug and blood glucose concentrations were followed for 7 h and serum insulin and C-peptide concentrations for 3 h postdose.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, repaglinide, DDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> <cons sem="G_CHANGE">raised</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> <cons sem="G_NUMBER">8.1-fold (range 5.5- to 15.0-fold; p&lt;0.001)</cons> and prolonged its <cons sem="G_IVIVPARA">half-life (t(1/2))</cons> from <cons sem="G_NUMBER">1.3 to 3.7 h (p&lt;0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, repaglinide, ADDI)(gemfibrozil-itraconazole, repaglinide, DDI)">
<sentence>Although <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> alone <cons sem="G_CHANGE">raised</cons> <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> <cons sem="G_IVIVPARA">AUC</cons> only <cons sem="G_NUMBER">1.4-fold (1.1- to 1.9-fold; p&lt;0.001)</cons>, the <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons>-<cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> combination <cons sem="G_CHANGE">raised</cons> it <cons sem="G_NUMBER">19.4-fold (12.9- to 24.7-fold)</cons> and prolonged the <cons sem="G_IVIVPARA">t(1/2)</cons> of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> to <cons sem="G_NUMBER">6.1 h (<cons sem="G_NUMBER">p&lt;0.001</cons>)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, repaglinide, DDI)(gemfibrozil-itraconazole, repaglinide, DDI)">
<sentence><cons sem="G_IVIVPARA">Plasma <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> concentration</cons> at 7 h was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">28.6-fold</cons> by <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> and <cons sem="G_NUMBER">70.4-fold</cons> by the <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons>-<cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> combination (<cons sem="G_NUMBER">p&lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, repaglinide, DDI)(gemfibrozil-itraconazole, repaglinide, DDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> alone and in combination with <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> considerably enhanced and prolonged the blood glucose-lowering effect of <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons>; i.e., <cons lex="repaglinide" sem="G_DRUG" type="substrate_1">repaglinide</cons> became a long-acting and stronger antidiabetic.</sentence>
</annotation>
<sentence>Clinicians should be aware of this previously unrecognised and potentially hazardous interaction between <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons>.</sentence>
<sentence>Concomitant use of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> and <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> is best avoided.</sentence>
<sentence>If the combination is considered necessary, <cons lex="repaglinide" sem="G_DRUG">repaglinide</cons> dosage should be <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">reduced</cons> and blood glucose concentrations carefully monitored.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12621382</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="duloxetine" sem="G_DRUG">Duloxetine</cons> is both an <cons sem="G_MECHANISM">inhibitor</cons> and a substrate of cytochrome <cons sem="G_CYP">P4502D6</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="duloxetine" sem="G_DRUG">Duloxetine</cons>, a potent dual reuptake <cons sem="G_MECHANISM">inhibitor</cons> of serotonin and <cons lex="norepinephrine" sem="G_DRUG">norepinephrine</cons> currently undergoing clinical investigation for treatment of depression and stress urinary incontinence, has the potential to act as both a substrate and an <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome <cons sem="G_CYP">P4502D6</cons> (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>).</sentence>
<sentence>Our objectives were to determine the effect of <cons lex="duloxetine" sem="G_DRUG">duloxetine</cons> on the pharmacokinetics of <cons lex="desipramine" sem="G_DRUG">desipramine</cons>, a tricyclic antidepressant <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> (study 1), and the effect of <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>, a potent <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>, on <cons lex="duloxetine" sem="G_DRUG">duloxetine</cons> pharmacokinetics (study 2).</sentence>
<sentence>Subjects were healthy men and women between 21 and 63 years old.</sentence>
<sentence>All subjects were genotypically <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> extensive <cons sem="G_MECHANISM">metabolizers</cons>.</sentence>
<sentence>In study 1, <cons sem="G_NUMBER">50 mg</cons> of <cons lex="desipramine" sem="G_DRUG">desipramine</cons> was administered as a single dose alone and in the presence of steady-state <cons lex="duloxetine" sem="G_DRUG">duloxetine</cons> <cons sem="G_NUMBER">60 mg</cons> twice daily.</sentence>
<sentence>In study 2, steady-state pharmacokinetics of <cons lex="duloxetine" sem="G_DRUG">duloxetine</cons> <cons sem="G_NUMBER">40 mg</cons> once daily were determined in the presence and absence of steady-state <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> <cons sem="G_NUMBER">20 mg</cons> once daily.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Duloxetine, desipramine, DDI)">
<sentence><cons lex="duloxetine" sem="G_DRUG" type="inhibitor_1">Duloxetine</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">maximum plasma concentration</cons> of <cons lex="desipramine" sem="G_DRUG" type="substrate_1">desipramine</cons> <cons sem="G_NUMBER">1.7-fold</cons> and the <cons sem="G_IVIVPARA">area under the concentration-time curve</cons> <cons sem="G_NUMBER">2.9-fold</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Paroxetine, duloxetine, DDI)">
<sentence><cons lex="paroxetine" sem="G_DRUG" type="inhibitor_2">Paroxetine</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">maximum plasma concentration</cons> of <cons lex="duloxetine" sem="G_DRUG" type="substrate_2">duloxetine</cons> and the <cons sem="G_IVIVPARA">area under the concentration-time curve</cons> at steady state <cons sem="G_NUMBER">1.6-fold</cons>.</sentence>
</annotation>
<sentence>Reports of adverse events were similar whether <cons lex="duloxetine" sem="G_DRUG">duloxetine</cons> was administered alone or in combination with <cons lex="desipramine" sem="G_DRUG">desipramine</cons> or <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons>.</sentence>
<sentence><cons lex="duloxetine" sem="G_DRUG">Duloxetine</cons> <cons sem="G_NUMBER">60 mg</cons> twice daily is a <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderately</cons></cons> potent <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons>, intermediate between <cons lex="paroxetine" sem="G_DRUG">paroxetine</cons> and <cons lex="sertraline" sem="G_DRUG">sertraline</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(paroxetine, duloxetine, ADDI)">
<sentence>The potent <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="paroxetine" sem="G_DRUG" type="inhibitor_2">paroxetine</cons> has a <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> effect on <cons lex="duloxetine" sem="G_DRUG" type="substrate_2">duloxetine</cons> concentrations.</sentence>
</annotation>
<sentence>The results of these 2 studies suggest that caution should be used when <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> substrates and <cons sem="G_MECHANISM">inhibitors</cons> are coadministered with <cons lex="duloxetine" sem="G_DRUG">duloxetine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:12544511</bibliomisc>
</articleinfo>
<title>
<sentence>Role of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in the stereoselective disposition of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> in humans.</sentence>
</title>
<abstract>
<sentence><cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is involved in the O-demethylation metabolic pathway of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> in humans.</sentence>
<sentence>In this study, we investigated whether this isozyme is stereoselective.</sentence>
<sentence>Plasma samples from seven <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> extensive <cons sem="G_MECHANISM">metabolizers</cons> (EMs) and five <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> poor <cons sem="G_MECHANISM">metabolizers</cons> (PMs), collected during a period <cons sem="G_NEGATIVEEFFECT">without</cons> and with coadministration of <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, were analysed.</sentence>
<sentence>Subjects were administered <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> hydrochloride <cons sem="G_NUMBER">18.75 mg</cons> orally every 12 h for 48 h on two occasions (1 week apart); once alone and once during the concomitant administration of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> sulphate every 12 h. Blood and urine samples were collected under steady-state conditions over one dosing interval (12 h).</sentence>
<sentence>The present results show that, although <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> catalyses the O-demethylation of both enantiomers of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons>, it displays a <cons sem = "G_CHANGE">marked</cons> stereoselectivity towards the (R)-enantiomer.</sentence>
<sentence>The <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="venlafaxine" sem="G_DRUG">(R)-venlafaxine</cons> was found to be <cons sem="G_NUMBER">nine-fold</cons> higher in EMs compared to PMs  [<cons sem="G_NUMBER">median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P &lt; 0.005</cons>], while it was <cons sem="G_NUMBER">two-fold</cons> higher for <cons lex="venlafaxine" sem="G_DRUG">(S)-venlafaxine</cons>  [<cons sem="G_NUMBER">73 (32-130) l/h versus 37 (21-44) l/h, P &lt; 0.05</cons>].</sentence>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, (S)-venlafaxine, DDI)(quinidine, (R)-venlafaxine, DDI)">
<sentence>In EMs, <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> <cons sem="G_CHANGE">decreased</cons> <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">(R)-</cons> and <cons lex="venlafaxine" sem="G_DRUG" type="substrate_2">(S)-venlafaxine</cons> <cons sem="G_IVIVPARA">oral clearance</cons> by <cons sem="G_NUMBER">12-fold ( 0.05)</cons> and <cons sem="G_NUMBER">four-fold ( 0.05)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, (S)-venlafaxine, NDDI)(quinidine, (S)-venlafaxine, NDDI)">
<sentence>In contrast, <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> have any effects on <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">(R)-venlafaxine</cons>  [<cons sem="G_NUMBER">4 (2-10) l/h</cons> for <cons lex="venlafaxine" sem="G_DRUG" type="substrate_3">venlafaxine</cons> alone versus <cons sem="G_NUMBER">5 (0.6-7) l/h</cons> for <cons lex="venlafaxine" sem="G_DRUG" type="substrate_3">venlafaxine</cons> + <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons>] and of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_2">(S)-venlafaxine</cons>  [<cons sem="G_NUMBER">4 (1-7) l/h</cons> for <cons lex="venlafaxine" sem="G_DRUG" type="substrate_3">venlafaxine</cons> alone versus <cons sem="G_NUMBER">3 (0.4-6) l/h</cons> for <cons lex="venlafaxine" sem="G_DRUG" type="substrate_3">venlafaxine</cons> + <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons>].</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, (S)-venlafaxine, DDI)(quinidine, (R)-venlafaxine, DDI)">
<sentence>The coadministration of <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> to EMs resulted in an almost complete <cons sem="G_MECHANISM">inhibition</cons> of the partial metabolic <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">(R)-venlafaxine</cons> to O-demethylated metabolites  [<cons sem="G_NUMBER">127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05</cons>], while a <cons sem="G_NUMBER">seven-fold</cons> <cons sem ="G_CHANGE">reduction</cons> was measured for <cons lex="venlafaxine" sem="G_DRUG" type="substrate_2">(S)-venlafaxine</cons>  [<cons sem="G_NUMBER">47 (14-94) l/h versus 7 (1-19) l/h, 0.05</cons>].</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, (S)-venlafaxine, NDDI)(quinidine, (R)-venlafaxine, NDDI)">
<sentence>In PMs, coadministration of <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem = "G_CHANGE">change</cons> <cons sem="G_IVIVPARA">oral clearance</cons> and partial metabolic <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">(R)-</cons> and <cons lex="venlafaxine" sem="G_DRUG" type="substrate_2">(S)-venlafaxine</cons> to its various metabolites.</sentence>
</annotation>
<sentence>In contrast, data obtained on the partial metabolic <cons sem="G_IVIVPARA">clearance</cons> of (R)- and (S)-<cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> to N-demethylated metabolites, a reaction which is mediated by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, suggest a lack of stereoselectivity of this enzyme.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11103751</bibliomisc>
</articleinfo>
<title>
<sentence>The cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons> and enhances its adrenal-suppressant effect.</sentence>
</title>
<abstract>
<sentence>To examine the possible interaction of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> with orally and intravenously administered <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons>.</sentence>
<sentence>In a randomized, double-blind, placebo-controlled crossover study with four phases, eight healthy subjects took either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> (in two phases) or placebo (in two phases) orally once daily for 4 days.</sentence>
<sentence>On day 4 each subject received an oral dose of <cons sem="G_NUMBER">4.5 mg</cons> <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons> or an intravenous dose of <cons sem="G_NUMBER">5.0 mg</cons> <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons> sodium phosphate during both <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and placebo phases.</sentence>
<sentence>Plasma <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons> and <cons lex="cortisol" sem="G_DRUG">cortisol</cons> concentrations were determined by HPLC up to 71 hours, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and hydroxyitraconazole up to 23 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, dexamethasone, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">decreased</cons> the systemic <cons sem="G_IVIVPARA">clearance</cons> of intravenously administered <cons lex="dexamethasone" sem="G_DRUG" type="substrate_1">dexamethasone</cons> by <cons sem="G_NUMBER">68% (P &lt; .001)</cons>, <cons sem="G_CHANGE">increased</cons> the total <cons sem="G_IVIVPARA">area under the plasma <cons lex="dexamethasone" sem="G_DRUG" type="substrate_1">dexamethasone</cons> concentration-time curve  [AUC(0-infinity)]</cons> <cons sem="G_NUMBER">3.3-fold (P &lt; .001)</cons>, and prolonged the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="dexamethasone" sem="G_DRUG" type="substrate_1">dexamethasone</cons> <cons sem="G_NUMBER">3.2-fold (P &lt; .001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, dexamethasone, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of oral <cons lex="dexamethasone" sem="G_DRUG" type="substrate_1">dexamethasone</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">3.7-fold (P &lt; .001)</cons>, the <cons sem="G_IVIVPARA">peak plasma concentration</cons> <cons sem="G_NUMBER">1.7-fold (P &lt; .001)</cons>, and the <cons sem="G_IVIVPARA">elimination half-life</cons> <cons sem="G_NUMBER">2.8-fold (P &lt; .001)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<sentence>The morning plasma <cons lex="cortisol" sem="G_DRUG">cortisol</cons> concentrations measured 47 and 71 hours after administration of <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons> were substantially lower after exposure to <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> than to placebo (<cons sem="G_NUMBER">P &lt; .001</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, dexamethasone, DDI)">
<sentence>Accordingly, the adrenal-suppressant effect of <cons lex="dexamethasone" sem="G_DRUG" type="substrate_1">dexamethasone</cons> was <cons sem = "G_CHANGE">greatly</cons> enhanced during the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phases.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, dexamethasone, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increases</cons> the systemic exposure to and effects of <cons lex="dexamethasone" sem="G_DRUG" type="substrate_1">dexamethasone</cons>.</sentence>
</annotation>
<sentence>A careful follow-up is recommended when <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or other potent <cons sem="G_MECHANISM">inhibitors</cons> of the cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> are added to the drug regimen of patients receiving <cons lex="dexamethasone" sem="G_DRUG">dexamethasone</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11092571</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="mefloquine" sem="G_DRUG">Mefloquine</cons> is a 4-quinolinemethanol compound structurally related to <cons lex="quinine" sem="G_DRUG">quinine</cons>.</sentence>
<sentence><cons lex="quinine" sem="G_DRUG">Quinine</cons> is mainly <cons sem="G_MECHANISM">metabolized</cons> by the cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4 isozyme (CYP3A4)</cons>, whereas <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, a potent <cons sem="G_MECHANISM">inducer</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, is known to <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">decrease</cons> plasma <cons lex="quinine" sem="G_DRUG">quinine</cons> concentration.</sentence>
<sentence>Our aim was to study the effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics of <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons>, and explore a possible role of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> on <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>In an open, two-phase crossover study, seven healthy Thai male volunteers received a single oral dose of <cons sem="G_NUMBER">500 mg</cons> <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> alone, or <cons sem="G_NUMBER">500 mg</cons> <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> plus a long-term administration of <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<sentence>Blood samples were collected at specific time points over a 56-day period.</sentence>
<sentence>Plasma <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> and its carboxylic acid metabolite were measured by HPLC for pharmacokinetic analysis.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, mefloquine, DDI)">
<sentence>The results indicate that <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC0 - infinity)</cons> of <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> by <cons sem="G_NUMBER">68% (P &lt; 0.01)</cons>, <cons sem="G_IVIVPARA">maximum plasma concentration (Cmax)</cons> by <cons sem="G_NUMBER">19% (P &lt; 0.001)</cons>, and <cons sem="G_IVIVPARA">elimination half-life (t1/2)</cons> by <cons sem="G_NUMBER">63% (P &lt; 0.01)</cons>, whereas <cons sem="G_IVIVPARA">the time to reach Cmax (t(max))</cons> of <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> was <cons sem="G_NEGATIVEEFFECT">unaffected</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin, mefloquine, DDI)">
<sentence>The apparent <cons sem="G_IVIVPARA">oral clearance (CL)</cons> of <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">281% (P &lt; 0.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, mefloquine, DDI)">
<sentence>After administration of <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>, the <cons sem="G_IVIVPARA">Cmax</cons> of the <cons lex="mefloquine" sem="G_DRUG" type="M_1">carboxylic acid metabolite of mefloquine</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">47% (P &lt; 0.05)</cons>, whereas the <cons sem="G_IVIVPARA">t1/2</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">39% (P &lt; 0.01)</cons>, and <cons sem="G_IVIVPARA">t(max)</cons> by <cons sem="G_NUMBER">76% (P &lt; 0.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin, mefloquine, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC0 - infinity</cons> and <cons sem="G_IVIVPARA">CL</cons> of the <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> metabolite were <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">30% and 25%</cons>, respectively, but were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> different from the control phase.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, mefloquine, DDI)">
<sentence>The results indicate that <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem ="G_CHANGE">reduces</cons> the <cons sem="G_IVIVPARA">plasma concentration</cons> of a single oral dose of <cons sem="G_NUMBER">500 mg</cons> <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> by <cons sem="G_CHANGE">increasing</cons> <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="mefloquine" sem="G_DRUG" type="substrate_1">mefloquine</cons> in the liver and gut wall.</sentence>
</annotation>
<sentence>The <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> isozyme most likely plays an important role in the enhanced <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons>.</sentence>
<sentence>Simultaneous use of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> should be avoided to optimize the therapeutic efficacy of <cons lex="mefloquine" sem="G_DRUG">mefloquine</cons> and prevent the risk of Plasmodium falciparum resistance in malarial treatment.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11061579</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> alters the pharmacokinetics of <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> to a <cons sem = "G_CHANGE">greater</cons> extent than either <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons> or <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons>.</sentence>
</title>
<abstract>
<sentence>3-Hydroxy-3-methylglutaryl coenzyme A reductase <cons sem="G_MECHANISM">inhibitors</cons> (statins) are <cons sem="G_MECHANISM">metabolized</cons> by distinct pathways that <cons sem = "G_CHANGE">may</cons> alter the extent of drug-drug interactions.</sentence>
<sentence><cons lex="cerivastatin" sem="G_DRUG">Cerivastatin</cons> is <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 <cons sem="G_CYP">(CYP)3A4</cons> and <cons lex="cyp2c8" sem="G_CYP">CYP2C8</cons>.</sentence>
<sentence><cons lex="atorvastatin" sem="G_DRUG">Atorvastatin</cons> is <cons sem="G_MECHANISM">metabolized</cons> solely by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> <cons sem="G_MECHANISM">metabolism</cons> is <cons sem="G_NEGATIVEEFFECT">not</cons> well defined.</sentence>
<sentence>Coadministration of higher doses of these statins with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> has the potential for eliciting adverse drug-drug interactions.</sentence>
<sentence>To determine the comparative effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, on the pharmacokinetics of <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons>, <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons>, and <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons>.</sentence>
<sentence>In this single-site, randomized, three-way crossover, open-labeled study, healthy subjects (n = 18) received single doses of <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons> <cons sem="G_NUMBER">0.8 mg</cons>, <cons lex="atorvastatin" sem="G_DRUG">atorvastatin</cons> <cons sem="G_NUMBER">20 mg</cons>, or <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> <cons sem="G_NUMBER">40 mg</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> and with <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem="G_NUMBER">200 mg</cons>.</sentence>
<sentence>Pharmacokinetic parameters  [<cons sem="G_IVIVPARA">AUC(0-infinity)</cons>, <cons sem="G_IVIVPARA">AUC(0-tn)</cons>, <cons sem="G_IVIVPARA">peak concentration (Cmax)</cons>, <cons sem="G_IVIVPARA">time to reach Cmax (tmax)</cons>, and <cons sem="G_IVIVPARA">half-life (t1/2)</cons>] were determined for parent statins and major metabolites.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, cerivastatin, ADDI)">
<sentence>Concomitant <cons lex="cerivastatin" sem="G_DRUG" type="substrate_1">cerivastatin</cons>/<cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> treatment produced small elevations in the <cons lex="cerivastatin" sem="G_DRUG" type="substrate_1">cerivastatin</cons> <cons sem="G_IVIVPARA">AUC(0-infinity)</cons>, <cons sem="G_IVIVPARA">Cmax</cons>, and <cons sem="G_IVIVPARA">t1/2</cons> (<cons sem="G_NUMBER">27%</cons>, <cons sem="G_NUMBER">25%</cons>, and <cons sem="G_NUMBER">19%</cons>, respectively; <cons sem="G_NUMBER">P &lt; .05</cons> versus <cons lex="cerivastatin" sem="G_DRUG" type="substrate_1">cerivastatin</cons> alone).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, pravastatin, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> coadministration produced similar <cons sem ="G_CHANGE">changes</cons> in <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> pharmacokinetics  [<cons sem="G_IVIVPARA">AUC</cons> elevated <cons sem="G_NUMBER">51%</cons> (<cons sem="G_NUMBER">P &lt; .05</cons> versus <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> alone), <cons sem="G_NUMBER">24%</cons> (<cons sem="G_IVIVPARA">Cmax</cons>), and <cons sem="G_NUMBER">23%</cons> (<cons sem="G_IVIVPARA">t1/2</cons>), respectively].</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, atorvastatin, DDI)">
<sentence>However, <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> dramatically <cons sem="G_CHANGE">increased</cons> <cons lex="atorvastatin" sem="G_DRUG" type="substrate_3">atorvastatin</cons> <cons sem="G_IVIVPARA">AUC</cons> (<cons sem="G_NUMBER">150%</cons>), <cons sem="G_IVIVPARA">Cmax</cons> (<cons sem="G_NUMBER">38%</cons>), and <cons sem="G_IVIVPARA">t1/2</cons> <cons sem="G_NUMBER">(30%) (P &lt; .05)</cons>.</sentence>
</annotation>
<sentence>The elevation in <cons lex="atorvastatin" sem="G_DRUG" type="substrate_3">atorvastatin</cons> <cons sem="G_IVIVPARA">AUC</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem = "G_CHANGE">greater</cons> than that of <cons lex="cerivastatin" sem="G_DRUG" type="substrate_1">cerivastatin</cons> (<cons sem="G_NUMBER">P &lt; .005</cons>) or <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> (<cons sem="G_NUMBER">P &lt; .005</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, atorvastatin, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem = "G_CHANGE">markedly</cons> elevated <cons lex="atorvastatin" sem="G_DRUG" type="substrate_3">atorvastatin</cons> plasma levels (<cons sem="G_NUMBER">2.5-fold</cons>) after <cons sem="G_NUMBER">20 mg</cons> dosing, suggesting that concomitant <cons sem="G_DRUG" type="inhibitor_1">itraconazole</cons>/<cons sem="G_DRUG" type="inhibitor_3">atorvastatin</cons> therapy be carefully considered.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, cerivastatin, ADDI)(itraconazole, pravastatin, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> produced <cons sem = "G_CHANGE">modest</cons> elevations in the plasma levels of <cons lex="cerivastatin" sem="G_DRUG" type="substrate_1">cerivastatin</cons> <cons sem="G_NUMBER">0.8 mg</cons> or <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> <cons sem="G_NUMBER">40 mg</cons> (<cons sem="G_NUMBER">1.3-fold</cons> and <cons sem="G_NUMBER">1.5-fold</cons>, respectively), indicating that combination treatment with <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> with <cons lex="cerivastatin" sem="G_DRUG" type="substrate_1">cerivastatin</cons> or <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons> <cons sem = "G_CHANGE">may</cons> be preferable.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:11049910</bibliomisc>
</articleinfo>
<title>
<sentence>The effect of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>, and their combination on the pharmacokinetics of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons>.</sentence>
</title>
<abstract>
<sentence>We studied the effect of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> on the pharmacokinetics of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons> in a double-blinded, randomized, four-way cross-over study.</sentence>
<sentence>Eight healthy volunteers ingested daily <cons sem="G_NUMBER">1500 mg</cons> <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> for 6 days, <cons sem="G_NUMBER">100 mg</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> for 5 days (Days 2-6), both <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons>, or placebo.</sentence>
<sentence>On Day 6, each subject received a single dose of <cons sem="G_NUMBER">0.6 mg/kg</cons> <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons> IV over 30 min.</sentence>
<sentence><cons lex="ropivacaine" sem="G_DRUG">Ropivacaine</cons>, 3-hydroxyropivacaine, and 2',6'-pipecoloxylidide in venous plasma and urine samples were measured for up to 12 h and 24 h, respectively.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, ropivacaine, DDI)">
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the drug plasma concentration-time curve (AUC)</cons> of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> <cons sem="G_NUMBER">3.7-fold (P: &lt; 0.001)</cons>, prolonged the <cons sem="G_IVIVPARA">elimination half-life (t(1/2))</cons> from <cons sem="G_NUMBER">2.3 to 7.4 h (P: &lt; 0.01)</cons>, and <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">clearance</cons> by <cons sem="G_NUMBER">77% (P: &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Erythromycin, ropivacaine, NDDI)">
<sentence><cons lex="erythromycin" sem="G_DRUG" type="inhibitor_2">Erythromycin</cons> alone had only a <cons sem = "G_CHANGE">minor</cons> effect on the pharmacokinetics of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine + erythromycin, ropivacaine, DDI)">
<sentence>However, when compared with <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> alone, the combination of <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> and <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_2">erythromycin</cons> further <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the drug plasma concentration-time curve</cons> and <cons sem="G_IVIVPARA">t(1/2)</cons> of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> by <cons sem="G_NUMBER">50% (P: &lt; 0.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine, ropivacaine, DDI)">
<sentence>We conclude that <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> by <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> considerably <cons sem ="G_CHANGE">reduces</cons> elimination of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Fluvoxamine + erythromycin, ropivacaine, DDI)">
<sentence>Concomitant use of <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_2">erythromycin</cons> further <cons sem="G_CHANGE">increases</cons> plasma <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> concentration by decreasing its <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
</annotation>
<sentence>Implications: Clinicians should be aware of the possibility of <cons sem="G_CHANGE">increased</cons> toxicity of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> when used together with <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>.</sentence>
<sentence>Concomitant use of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> further <cons sem="G_CHANGE">increases</cons> <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> concentration.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10976543</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of active <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> acid are <cons sem="G_CHANGE">increased</cons> by <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>.</sentence>
</title>
<abstract>
<sentence>Concomitant treatment with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>, two lipid-lowering drugs, has been associated with occurrence of myopathy in case reports.</sentence>
<sentence>The aim of this study was to determine whether <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> affects the pharmacokinetics of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and whether it affects <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity in vitro.</sentence>
<sentence>A double-blind, randomized crossover study with two phases (placebo and <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons>) was carried out.</sentence>
<sentence>Ten healthy volunteers were given <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> (<cons sem="G_NUMBER">600 mg</cons> twice daily) or placebo orally for 3 days.</sentence>
<sentence>On day 3 they ingested a single <cons sem="G_NUMBER">40-mg</cons> dose of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> acid were measured up to 12 hours.</sentence>
<sentence>In addition, the effect of <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> (<cons sem="G_NUMBER">0 to 1,200 micromol/L</cons>) on <cons lex="midazolam" sem="G_DRUG">midazolam</cons> 1'-hydroxylation, a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> model reaction, was investigated in human liver microsomes in vitro.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, simvastatin, ADDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> <cons sem="G_CHANGE">increased</cons> the mean total <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons>  [<cons sem="G_IVIVPARA">AUC(0-infinity)</cons>] by <cons sem="G_NUMBER">35% (P &lt; .01)</cons> and the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="simvastatin" sem="G_DRUG" type="M_2">simvastatin acid</cons> by <cons sem="G_NUMBER">185% (P &lt; .001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, simvastatin, DDI)">
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">74% (P &lt; .05)</cons>, and that of <cons lex="simvastatin" sem="G_DRUG" type="M_2">simvastatin acid</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">51% (P &lt; .01)</cons> by <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Gemfibrozil, simvastatin, DDI)">
<sentence>The <cons sem="G_IVIVPARA">peak concentration</cons> of <cons lex="simvastatin" sem="G_DRUG" type="M_2">simvastatin acid</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">112%, from 3.20 +/- 2.73 ng/mL to 6.78 +/- 4.67 ng/mL (mean +/- SD; P &lt; .01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, midazolam , NDDI)">
<sentence>In vitro, <cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">gemfibrozil</cons> showed <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="midazolam" sem="G_DRUG" type="M_1">midazolam 1'-hydroxylation</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Gemfibrozil, simvastatin, DDI)">
<sentence><cons lex="gemfibrozil" sem="G_DRUG" type="inhibitor_1">Gemfibrozil</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> and, in particular, its active form, <cons lex="simvastatin" sem="G_DRUG" type="M_2">simvastatin acid</cons>, suggesting that the <cons sem="G_CHANGE">increased</cons> risk of myopathy in combination treatment is, at least partially, of a pharmacokinetic origin.</sentence>
</annotation>
<sentence>Because <cons lex="gemfibrozil" sem="G_DRUG">gemfibrozil</cons> does <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in vitro, the mechanism of the pharmacokinetic interaction is <cons sem = "G_CHANGE">probably</cons> <cons sem="G_MECHANISM">inhibition</cons> of non-<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> acid.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10952477</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> on plasma <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> and <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> concentrations.</sentence>
</title>
<abstract>
<sentence>To study the effects of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> on the pharmacokinetics of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> and <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons>, two <cons sem="G_MECHANISM">inhibitors</cons> of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase.</sentence>
<sentence>Two separate randomised, double-blind, two-phase, crossover studies with identical study design were carried out.</sentence>
<sentence>In each study, 12 healthy volunteers were given a 4-day pretreatment with oral <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> (<cons sem="G_NUMBER">400 mg</cons> on day 1 and <cons sem="G_NUMBER">200 mg</cons> on days 2-4) or placebo, according to a randomisation schedule.</sentence>
<sentence>On day 4, a single oral dose of <cons sem="G_NUMBER">40 mg</cons> <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> (study I) or <cons sem="G_NUMBER">40 mg</cons> <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> (study II) was administered orally.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons>, <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> were measured over 24 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluconazole, fluvastatin, DDI)">
<sentence>In study 1, <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">area under the plasma <cons lex="fluvastatin" sem="G_DRUG" type="substrate_1">fluvastatin</cons> concentration-time curve (AUC0-infinity)</cons> by <cons sem="G_NUMBER">84% (P &lt; 0.01)</cons>, the mean <cons sem="G_IVIVPARA">elimination half-life (t1/2)</cons> of <cons lex="fluvastatin" sem="G_DRUG" type="substrate_1">fluvastatin</cons> by <cons sem="G_NUMBER">80% (P &lt; 0.01)</cons> and its mean <cons sem="G_IVIVPARA">peak plasma concentration (Cmax)</cons> by <cons sem="G_NUMBER">44% (P &lt; 0.05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluconazole, pravastatin, NDDI)">
<sentence>In study II, <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on the pharmacokinetics of <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluconazole, fluvastatin, DDI)">
<sentence><cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">Fluconazole</cons> has a <cons sem="G_CHANGE">significant</cons> interaction with <cons lex="fluvastatin" sem="G_DRUG" type="substrate_1">fluvastatin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluconazole, fluvastatin, ADDI)">
<sentence>The mechanism of the <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> and prolonged elimination of <cons lex="fluvastatin" sem="G_DRUG" type="substrate_1">fluvastatin</cons> is <cons sem = "G_CHANGE">probably</cons> <cons sem="G_MECHANISM">inhibition</cons> of the <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> by <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons>.</sentence>
</annotation>
<sentence>Care should be taken if <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> or other potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> are prescribed to patients using <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons>.</sentence>
<sentence>However, <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> is <cons sem="G_NEGATIVEEFFECT">not</cons> susceptible to interactions with <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> or other potent <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10930961</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacokinetic interactions between <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> and saquinavir/ritonavir.</sentence>
</title>
<abstract>
<sentence>To investigate the effect of the antiretroviral protease <cons sem="G_MECHANISM">inhibitors</cons> <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> (soft gelatin capsule) and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> on the pharmacokinetic properties and tolerability of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> and to investigate the effect of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> on the steady-state pharmacokinetics of <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
<sentence>Two independent, 8 day, open, randomized, placebo-controlled, parallel-group studies (containing a double-blind crossover phase) were conducted at Pfizer Clinical research units (Canterbury, UK.</sentence>
<sentence>and Brussels, Belgium).</sentence>
<sentence>Twenty-eight healthy male volunteers entered each study.</sentence>
<sentence>In each study, volunteers were randomized (n = 14 per group) to receive <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> on day 1 followed by a 7-day treatment period (days 2-8) with <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> or placebo (Study I) or <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> or placebo (Study II).</sentence>
<sentence><cons lex="sildenafil" sem="G_DRUG">Sildenafil</cons> or placebo (Study I and Study II) was administered alternately on day 7 or day 8, depending on initial randomization.</sentence>
<sentence>The effect of <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> on the pharmacokinetics of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> and its primary circulating metabolite (<cons  sem="G_DRUG">UK-103, 320</cons>) and the effect of single-dose <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> on the steady-state pharmacokinetics of <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> (<cons sem="G_NUMBER">1200 mg</cons> three times daily) and <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> (<cons sem="G_NUMBER">500 mg</cons> twice daily) were determined.</sentence>
<sentence>The safety and tolerability of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> coadministered with <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> or <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> were also assessed.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(Ritonavir, sildenafil, DDI)(saquinavir, sildenafil, DDI)">
<sentence>Both protease <cons sem="G_MECHANISM">inhibitors</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">Cmax</cons>, <cons sem="G_IVIVPARA">AUC</cons>, <cons sem="G_IVIVPARA">tmax</cons> and <cons sem="G_IVIVPARA">t(1/2)</cons> values for both <cons lex="sildenafil" sem="G_DRUG" type="substrate_1">sildenafil</cons> and <cons lex="sildenafil" sem="G_DRUG" type="M_1">UK-103, 320</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, sildenafil, DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inhibitor_2">Ritonavir</cons> showed a <cons sem="G_CHANGE">significantly</cons> <cons sem = "G_CHANGE">greater</cons> effect than <cons lex="saquinavir" sem="G_DRUG" type="inhibitor_1">saquinavir</cons> with <cons sem="G_CHANGE">increases</cons> in <cons lex="sildenafil" sem="G_DRUG" type="substrate_1">sildenafil</cons> <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">Cmax</cons> of <cons sem="G_NUMBER">11-fold (95% CI: 9.0, 12.0)</cons> and <cons sem="G_NUMBER">3.9-fold (95% CI: 3.2, 4.9)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(saquinavir, sildenafil, DDI)">
<sentence>This compared with <cons sem="G_CHANGE">increases</cons> of <cons sem="G_NUMBER">3.1-fold (95% CI: 2.5, 4.0)</cons> and <cons sem="G_NUMBER">2.4-fold (95% CI: 1.8, 3.3)</cons> for coadministration with <cons lex="saquinavir" sem="G_DRUG" type="inhibitor_1">saquinavir</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(sildenafil, saquinavir, NDDI)(sildenafil, ritonavir, NDDI)">
<sentence>In contrast, the steady-state pharmacokinetics of <cons lex="saquinavir" sem="G_DRUG" type="substrate_2">saquinavir</cons> and <cons lex="ritonavir" sem="G_DRUG" type="substrate_3">ritonavir</cons> were <cons sem="G_NEGATIVEEFFECT">unaffected</cons> by <cons lex="sildenafil" sem="G_DRUG" type="inhibitor_3">sildenafil</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_CHANGE">increases</cons> in systemic exposure to <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> and <cons lex="sildenafil" sem="G_DRUG" type="M_1">UK-103, 320</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> associated with an <cons sem="G_CHANGE">increased</cons> incidence of adverse events or clinically <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> in blood pressure, heart rate or ECG parameters.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, sildenafil, DDI)(saquinavir, sildenafil, DDI)">
<sentence>These results indicate that both <cons lex="saquinavir" sem="G_DRUG" type="inhibitor_1">saquinavir</cons> and <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_2">ritonavir</cons> modify the pharmacokinetics of <cons lex="sildenafil" sem="G_DRUG" type="substrate_1">sildenafil</cons> presumably through <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
<sentence>The more <cons sem = "G_CHANGE">pronounced</cons> effect of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem = "G_CHANGE">may</cons> be attributed to its additional potent <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>.</sentence>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem = "G_CHANGE">change</cons> in safety or tolerability was observed when <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> was coadministered with either protease <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
<sentence>However, given the extent of the interactions, a lower <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> starting dose (<cons sem="G_NUMBER">25 mg</cons>) should be considered for patients receiving <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> and it is recommended <cons sem="G_NEGATIVEEFFECT">not</cons> to exceed a maximum single dose of <cons sem="G_NUMBER">25 mg</cons> in a 48 h period for patients receiving <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10853878</bibliomisc>
</articleinfo>
<title>
<sentence>The effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics and pharmacodynamics of oral <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons>.</sentence>
</title>
<abstract>
<sentence>To examine the possible effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics and pharmacodynamics of orally administered <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons>.</sentence>
<sentence>In this double-blind, randomised, two-phase cross-over study, ten healthy subjects received either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo orally once a day for 4 days.</sentence>
<sentence>On day 4, <cons sem="G_NUMBER">20 mg</cons> <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons> was given orally.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons>, <cons lex="cortisol" sem="G_DRUG">cortisol</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, and hydroxyitraconazole were determined by means of high-performance liquid chromatography up to 47 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, prednisolone, ADDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the total <cons sem="G_IVIVPARA">area under the plasma <cons lex="prednisolone" sem="G_DRUG" type="substrate_1">prednisolone</cons> concentration-time curve</cons> by <cons sem="G_NUMBER">24% (P &lt; 0.001)</cons> and the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="prednisolone" sem="G_DRUG" type="substrate_1">prednisolone</cons> by <cons sem="G_NUMBER">29% (P &lt; 0.001)</cons> compared with placebo.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, prednisolone, NDDI)">
<sentence>The <cons sem="G_IVIVPARA">peak plasma concentration</cons> and <cons sem="G_IVIVPARA">time to the peak</cons> of <cons lex="prednisolone" sem="G_DRUG" type="substrate_1">prednisolone</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affected</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, prednisolone, ADDI)">
<sentence>The mean morning plasma <cons lex="cortisol" sem="G_DRUG">cortisol</cons> concentration, measured 23 h after the ingestion of <cons lex="prednisolone" sem="G_DRUG" type="substrate_1">prednisolone</cons>, during the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phase was <cons sem="G_NUMBER">73%</cons> of that during the placebo phase (<cons sem="G_NUMBER">P &lt; 0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, prednisolone, ADDI)">
<sentence>The observed <cons sem = "G_CHANGE">minor</cons> interaction between <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> and oral <cons lex="prednisolone" sem="G_DRUG" type="substrate_1">prednisolone</cons> is <cons sem = "G_CHANGE">probably</cons> of limited clinical <cons sem = "G_CHANGE">significance</cons>.</sentence>
</annotation>
<sentence>The susceptibility of <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons> to interact with <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> is considerably smaller than that of <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons>, and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and <cons sem = "G_CHANGE">probably</cons> also other <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> can be used concomitantly with <cons lex="prednisolone" sem="G_DRUG">prednisolone</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> <cons sem = "G_CHANGE">marked</cons> <cons sem ="G_CHANGE">changes</cons> in the effects of this corticosteroid.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10848718</bibliomisc>
</articleinfo>
<title>
<sentence>Influence of <cons lex="hydroxychloroquine" sem="G_DRUG">hydroxychloroquine</cons> on the <cons sem="G_IVIVPARA">bioavailability</cons> of oral <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="hydroxychloroquine" sem="G_DRUG">Hydroxychloroquine (HCQ)</cons> is used widely in the treatment of chronic inflammatory diseases such as rheumatoid arthritis.</sentence>
<sentence>Since there is <cons sem = "G_CHANGE">great</cons> interindividual variability in the pharmacokinetics of <cons lex="hydroxychloroquine" sem="G_DRUG">HCQ</cons> and <cons lex="chloroquine" sem="G_DRUG">chloroquine</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-catalysed pathways in vitro, we wished to study the interaction of <cons lex="hydroxychloroquine" sem="G_DRUG">HCQ</cons> with <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of other drugs in vivo.</sentence>
<sentence><cons lex="metoprolol" sem="G_DRUG">Metoprolol</cons> and <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> (DM) were selected as probe drugs because they are well-studied and widely used test substrates of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>In this randomized, double-blind crossover study, seven healthy volunteers with extensive <cons sem="G_MECHANISM">metabolizer</cons> phenotype for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> ingested either <cons sem="G_NUMBER">400 mg</cons> <cons lex="hydroxychloroquine" sem="G_DRUG">hydroxychloroquine</cons> or placebo daily for 8 days after which single oral dose pharmacokinetics of <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> were investigated.</sentence>
<sentence><cons lex="dextromethorphan" sem="G_DRUG">Dextromethorphan</cons> metabolic ratio (DM-MR) was also determined at baseline and after the ingestion of <cons lex="hydroxychloroquine" sem="G_DRUG">HCQ</cons> or placebo.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(HCQ, metoprolol, DDI)">
<sentence>Concomitant administration of <cons lex="hydroxychloroquine" sem="G_DRUG" type="inhibitor_1">HCQ</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">bioavailability</cons> of <cons lex="metoprolol" sem="G_DRUG" type="substrate_1">metoprolol</cons>, as indicated by <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> in the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve</cons> (<cons sem="G_NUMBER">65 +/- 4.6%</cons>) and <cons sem="G_IVIVPARA">maximal plasma concentrations</cons> (<cons sem="G_NUMBER">72 +/- 6.9%</cons>) of <cons lex="metoprolol" sem="G_DRUG" type="substrate_1">metoprolol</cons>.</sentence>
</annotation>
<sentence>While the DM-MR values were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">changed</cons>, the phenotypic classification of one individual, who was heterozygous for a mutant <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> allele, was converted to a poor <cons sem="G_MECHANISM">metabolizer</cons> by <cons lex="hydroxychloroquine" sem="G_DRUG" type="inhibitor_1">HCQ</cons> administration.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(HCQ, metoprolol, ADDI)">
<sentence><cons lex="hydroxychloroquine" sem="G_DRUG" type="inhibitor_1">HCQ</cons> <cons sem="G_MECHANISM">inhibits</cons> <cons lex="metoprolol" sem="G_DRUG" type="substrate_1">metoprolol</cons> <cons sem="G_MECHANISM">metabolism</cons> most <cons sem = "G_CHANGE">probably</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its <cons sem="G_IVIVPARA">biotransformation</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(HCQ, dextromethorphan, NDDI)">
<sentence>The <cons sem="G_MECHANISM">inhibitory</cons> effect of <cons lex="hydroxychloroquine" sem="G_DRUG" type="inhibitor_1">HCQ</cons> on <cons lex="dextromethorphan" sem="G_DRUG" type="substrate_2">dextromethorphan</cons> <cons sem="G_MECHANISM">metabolism</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> apparent when DM-MR was used as an indicator, except in an individual with limited <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> capacity.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10780263</bibliomisc>
</articleinfo>
<title>
<sentence>Influence of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity on the disposition and cardiovascular toxicity of the antidepressant agent <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> in humans.</sentence>
</title>
<abstract>
<sentence>According to in-vitro studies with microsomes from human livers and from yeast expression systems with high <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity, the major <cons sem="G_MECHANISM">oxidation</cons> pathway of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> is catalysed by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>In this study, we investigated the role of the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> polymorphism and the effects of low-dose <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, a selective <cons sem="G_MECHANISM">inhibitor</cons> of, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, on the disposition of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons>.</sentence>
<sentence>Fourteen healthy men, eight with the extensive <cons sem="G_MECHANISM">metabolizer</cons> and six with the poor <cons sem="G_MECHANISM">metabolizer</cons> phenotype were administered <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> hydrochloride <cons sem="G_NUMBER">18.75 mg</cons> orally every 12 h for 48 h on two occasions (1 week apart); once alone and once during the concomitant administration of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> sulfate <cons sem="G_NUMBER">100 mg</cons> every 12 h. Blood and urine samples were collected under steady-state conditions over one dosing interval (12 h).</sentence>
<sentence>When <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> was administered alone, the <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> was more than fourfold less in poor <cons sem="G_MECHANISM">metabolizers</cons> compared to extensive <cons sem="G_MECHANISM">metabolizers</cons> (<cons sem="G_NUMBER">P &lt; 0.05</cons>).</sentence>
<sentence>This was mainly due to a <cons sem="G_CHANGE">decreased</cons> capability of poor <cons sem="G_MECHANISM">metabolizers</cons> to form O-desmethylated metabolites at the position 4 of the aromatic moiety.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, venlafaxine, DDI)">
<sentence>In extensive <cons sem="G_MECHANISM">metabolizers</cons>, <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> <cons sem="G_CHANGE">decreased</cons> <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> <cons sem="G_IVIVPARA">oral clearance</cons> from <cons sem="G_NUMBER">100 +/- 62 l/h to 17 +/- 5 l/h (mean +/- SD; P &lt; 0.05)</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> any effects on <cons sem="G_IVIVPARA">renal clearance</cons> (<cons sem="G_NUMBER">4 +/- 1 l/h</cons> during <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> alone and <cons sem="G_NUMBER">4 +/- 1 l/h</cons> during <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> plus <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, venlafaxine, DDI)">
<sentence>In these individuals, the sequential <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> to <cons lex="venlafaxine" sem="G_DRUG" type="M_1">O-desmethylvenlafaxine</cons> and to <cons lex="venlafaxine" sem="G_DRUG" type="M_2">N,O-didesmethylvenlafaxine</cons> was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> coadministration so that metabolic <cons sem="G_IVIVPARA">clearances</cons> to O-desmethylated metabolites <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">43 +/- 32 l/h to 2 +/- 1 l/h (P &lt; 0.05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, venlafaxine, NDDI)">
<sentence>In poor <cons sem="G_MECHANISM">metabolizers</cons>, coadministration of <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> cause <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> in <cons sem="G_IVIVPARA">oral clearance</cons> and partial metabolic <cons sem="G_IVIVPARA">clearances</cons> of <cons lex="venlafaxine" sem="G_DRUG" type="substrate_1">venlafaxine</cons> to its various metabolites.</sentence>
</annotation>
<sentence><cons sem="G_CHANGE">decreased</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity could also be associated with cardiovascular toxicity as observed in four patients during treatment with the drug.</sentence>
<sentence>Thus, genetically determined or pharmacologically <cons sem="G_CHANGE">altered</cons> <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity represents a major determinant of <cons lex="venlafaxine" sem="G_DRUG">venlafaxine</cons> disposition in humans.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10771458</bibliomisc>
</articleinfo>
<title>
<sentence>The effects of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on <cons lex="ziprasidone" sem="G_DRUG">ziprasidone</cons> pharmacokinetics--a placebo-controlled crossover study in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>To assess the effects of multiple oral doses of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the single-dose pharmacokinetics of oral <cons lex="ziprasidone" sem="G_DRUG">ziprasidone</cons> HCl.</sentence>
<sentence>This was a 14-day, open-label, randomized, crossover study in 14 healthy subjects aged 18-31 years.</sentence>
<sentence>Group 1 received oral <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">400 mg</cons> once daily for 6 days, followed by a 2 day wash-out period and 6 days of placebo administration.</sentence>
<sentence>Group 2 received placebo followed by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>.</sentence>
<sentence>Single oral doses of <cons lex="ziprasidone" sem="G_DRUG">ziprasidone</cons> HCl <cons sem="G_NUMBER">40 mg</cons> were administered on days 5 and 13 in both groups.</sentence>
<sentence><cons lex="ziprasidone" sem="G_DRUG">Ziprasidone</cons> pharmacokinetic parameters were compared between placebo and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> administration periods.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, ziprasidone, ADDI)">
<sentence>Co-administration of <cons lex="ziprasidone" sem="G_DRUG" type="substrate_1">ziprasidone</cons> with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> was associated with a <cons sem = "G_CHANGE">modest</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="ziprasidone" sem="G_DRUG" type="substrate_1">ziprasidone</cons> exposure; mean <cons lex="ziprasidone" sem="G_DRUG" type="substrate_1">ziprasidone</cons> <cons sem="G_IVIVPARA">AUC(0,infinity)</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">33%</cons>, from <cons sem="G_NUMBER">899 ng ml(-1) h with placebo to 1199 ng ml(-1) h</cons> with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>.</sentence>
</annotation>
<sentence>Mean <cons sem="G_IVIVPARA">Cmax</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">34%</cons>, from <cons sem="G_NUMBER">89 ng ml(-1) to 119 ng ml(-1)</cons>, respectively.</sentence>
<sentence>The treatment effect on both of these parameters was statistically <cons sem="G_CHANGE">significant</cons> (<cons sem="G_NUMBER">P&lt;0.02</cons>).</sentence>
<sentence>Most adverse events were of mild intensity.</sentence>
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> serious adverse events, laboratory abnormalities, abnormal ECGs, or clinically <cons sem="G_CHANGE">significant</cons> alterations in vital signs throughout the study.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, ziprasidone, ADDI)">
<sentence>The concurrent administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> and <cons lex="ziprasidone" sem="G_DRUG" type="substrate_1">ziprasidone</cons> led to <cons sem = "G_CHANGE">modest</cons>, statistically <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">increases</cons> in <cons lex="ziprasidone" sem="G_DRUG" type="substrate_1">ziprasidone</cons> exposure, although the <cons sem ="G_CHANGE">changes</cons> seen were <cons sem="G_NEGATIVEEFFECT">not</cons> considered clinically relevant.</sentence>
</annotation>
<sentence>This suggests that other <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are unlikely to <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affect</cons> the pharmacokinetics of <cons lex="ziprasidone" sem="G_DRUG">ziprasidone</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10702887</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> on the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons>.</sentence>
</title>
<abstract>
<sentence>In vitro results suggest that <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons> is <cons sem="G_MECHANISM">metabolised</cons> by cytochrome P450 (CYP) isoforms <cons lex="1a2" sem="G_CYP">1A2</cons>, <cons lex="2d6" sem="G_CYP">2D6</cons>, <cons lex="3a4" sem="G_CYP">3A4</cons> and <cons lex="2c19" sem="G_CYP">2C19</cons>.</sentence>
<sentence>This study was designed to evaluate the effect of concomitant administration of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> (a <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> <cons sem="G_MECHANISM">inhibitor</cons>) on the pharmacokinetics of a single <cons sem="G_NUMBER">100 mg</cons> oral dose of <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons>.</sentence>
<sentence>This study was conducted as a single-centre, open-label, nonrandomised, 2-period, crossover pharmacokinetic trial.</sentence>
<sentence>A single <cons sem="G_NUMBER">100 mg</cons> dose of <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons> was administered orally on days 0 and 14.</sentence>
<sentence>Oral <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> (<cons sem="G_NUMBER">40 mg</cons> every day) was administered on days 7 to 18.</sentence>
<sentence>20 healthy nonsmoking male and female volunteers.</sentence>
<sentence>Serial blood samples were collected before and after <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons> administration to characterise the pharmacokinetics of <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons> and its metabolites.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(omeprazole, cilostazol, ADDI)">
<sentence>Following <cons lex="omeprazole" sem="G_DRUG" type="inhibitor_1">omeprazole</cons> coadministration, the <cons sem="G_CHANGE">increases</cons> in <cons lex="cilostazol" sem="G_DRUG" type="substrate_1">cilostazol</cons> <cons sem="G_IVIVPARA">maximum plasma concentration (Cmax)</cons> and <cons sem="G_IVIVPARA">area under the plasma concentration-time curve at time t (AUCt)</cons> were <cons sem="G_NUMBER">18% (p = 0.062)</cons> and <cons sem="G_NUMBER">26% (p &lt; 0.001)</cons>, respectively.</sentence>
</annotation>
<sentence>For the 2 major circulating metabolites, OPC-13015 and OPC-13213, the OPC-13015 <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUCt</cons> <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">29</cons> and <cons sem="G_NUMBER">69%</cons>, respectively (<cons sem="G_NUMBER">p &lt; 0.001</cons>).</sentence>
<sentence>However, for OPC-13213, the <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUCt</cons> <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">22</cons> and <cons sem="G_NUMBER">31%</cons>, respectively (<cons sem="G_NUMBER">p &lt; 0.001</cons>).</sentence>
<sentence>The plasma protein binding of <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons> was <cons sem="G_NEGATIVEEFFECT">unaffected</cons> by coadministration of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(omeprazole, cilostazol, ADDI)">
<sentence>Coadministration of <cons lex="cilostazol" sem="G_DRUG" type="substrate_1">cilostazol</cons> with <cons lex="omeprazole" sem="G_DRUG" type="inhibitor_1">omeprazole</cons> resulted in an <cons sem="G_CHANGE">increase</cons> in the systemic exposure of <cons lex="cilostazol" sem="G_DRUG" type="substrate_1">cilostazol</cons> and its active metabolite, <cons lex="cilostazol" sem="G_DRUG" type="M_1">OPC-13015</cons>, by <cons sem="G_NUMBER">26</cons> and <cons sem="G_NUMBER">69%</cons>, respectively.</sentence>
</annotation>
<sentence>For the other active metabolite, OPC-13213, systemic exposure <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">31%</cons> because of <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons> <cons sem="G_MECHANISM">metabolism</cons> to this metabolite.</sentence>
<sentence>These <cons sem ="G_CHANGE">changes</cons> in systemic exposure were well tolerated.</sentence>
<sentence>A dose of <cons sem="G_NUMBER">50 mg</cons> <cons lex="cilostazol" sem="G_DRUG">cilostazol</cons> twice a day should be considered during coadministration of <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons>, such as <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10683007</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="indinavir" sem="G_DRUG">Indinavir</cons> concentrations and <cons sem="G_DRUG">St John's wort</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">St John's wort</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">area under the curve</cons> of the HIV-1 protease <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="indinavir" sem="G_DRUG">indinavir</cons> by a mean of <cons sem="G_NUMBER">57% (SD 19)</cons> and <cons sem="G_CHANGE">decreased</cons> the extrapolated 8-h <cons lex="indinavir" sem="G_DRUG">indinavir</cons> trough by <cons sem="G_NUMBER">81% (16)</cons> in healthy volunteers.</sentence>
<sentence>A <cons sem ="G_CHANGE">reduction</cons> in <cons lex="indinavir" sem="G_DRUG">indinavir</cons> exposure of this magnitude could lead to the development of drug resistance and treatment failure.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10634135</bibliomisc>
</articleinfo>
<title>
<sentence>Simultaneous assessment of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity in vivo with <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> and <cons lex="caffeine" sem="G_DRUG">caffeine</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="alprazolam" sem="G_DRUG">Alprazolam (ALP)</cons> and <cons lex="caffeine" sem="G_DRUG">caffeine (CAF)</cons> were suggested as probe drugs for the activities of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, respectively.</sentence>
<sentence>We investigated the disposition of oral <cons lex="alprazolam" sem="G_DRUG">ALP</cons> (<cons sem="G_NUMBER">1 mg</cons>) and <cons lex="caffeine" sem="G_DRUG">CAF</cons> (<cons sem="G_NUMBER">100 mg</cons>) in 17 normal volunteers to establish and validate a procedure for the simultaneous assessment of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> enzyme activity.</sentence>
<sentence>Nine received <cons lex="alprazolam" sem="G_DRUG">ALP</cons> alone, <cons lex="alprazolam" sem="G_DRUG">ALP</cons> and <cons lex="caffeine" sem="G_DRUG">CAF</cons> and <cons lex="caffeine" sem="G_DRUG">CAF</cons> alone in an open three-way crossover study to test for pharmacokinetic interaction.</sentence>
<sentence>Four received <cons lex="alprazolam" sem="G_DRUG">ALP</cons> after a 2-day pretreatment with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, and four normal volunteers received <cons sem="G_DRUG">ALP</cons> after 4 days of <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, an <cons sem="G_MECHANISM">inducer</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">AUC</cons> values of <cons lex="alprazolam" sem="G_DRUG">ALP</cons> and <cons lex="caffeine" sem="G_DRUG">CAF</cons> administered alone were <cons sem="G_NEGATIVEEFFECT">not</cons> different from <cons sem="G_IVIVPARA">AUC</cons> values when both drugs were administered combined, indicating that there is <cons sem="G_NEGATIVEEFFECT">no</cons> metabolic interaction.</sentence>
<sentence>The ratio <cons sem="G_MECHANISM">formed</cons> of paraxanthine and <cons lex="caffeine" sem="G_DRUG">CAF</cons> <cons sem="G_MECHANISM">correlated</cons> <cons sem="G_CHANGE">significantly</cons> with systemic <cons lex="caffeine" sem="G_DRUG">CAF</cons> <cons sem="G_IVIVPARA">clearance</cons> at 3, 4, 6, 8, 10 and 24 h. There was a <cons sem="G_CHANGE">strong</cons> <cons sem="G_MECHANISM">correlation</cons> between <cons sem="G_IVIVPARA">AUC</cons> values of <cons lex="alprazolam" sem="G_DRUG">ALP</cons> and <cons sem="G_DRUG">CAF</cons> and the <cons sem="G_IVIVPARA">plasma concentration</cons> obtained 6, 8, 10, or 24 h after ingestion of the drug.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, ALP, DDI)(rifampin, ALP, DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and <cons lex="rifampin" sem="G_DRUG">rifampin</cons> pretreatment <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">changed</cons> <cons sem="G_IVIVPARA">AUC</cons> values of <cons lex="alprazolam" sem="G_DRUG">ALP</cons> (mean <cons sem="G_IVIVPARA">AUC</cons> values in microg/l h:  <cons lex="alprazolam" sem="G_DRUG">ALP</cons> =  <cons  sem="G_NUMBER">242.2</cons>,  <cons lex="alprazolam" sem="G_DRUG">ALP</cons> + <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> = <cons sem="G_NUMBER">426.2</cons>, <cons sem="G_DRUG">ALP</cons> + <cons lex="rifampin" sem="G_DRUG">rifampin</cons> = <cons sem="G_NUMBER">28.4</cons>, <cons sem="G_NUMBER">ANOVA F = 17.7, P &lt; 0.001)</cons>.</sentence>
</annotation>
<sentence>We conclude that <cons lex="alprazolam" sem="G_DRUG">ALP</cons> and <cons lex="caffeine" sem="G_DRUG">CAF</cons> can be administered simultaneously for the assessment of CYP activity.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> 6, 8, 10, and 24 h after drug ingestion reflect <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="alprazolam" sem="G_DRUG">ALP</cons> and <cons lex="caffeine" sem="G_DRUG">CAF</cons> and therefore in-vivo <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> activity, respectively.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10546924</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">mibefradil</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="isradipine" sem="G_DRUG">isradipine</cons> substantially elevates the <cons sem="G_IVIVPARA">plasma concentrations</cons> of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrate <cons lex="triazolam" sem="G_DRUG">triazolam</cons>.</sentence>
</title>
<abstract>
<sentence>The calcium channel blockers <cons sem="G_DRUG">mibefradil</cons> and <cons lex="isradipine" sem="G_DRUG">isradipine</cons> <cons sem="G_MECHANISM">inhibit</cons> <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in vitro.</sentence>
<sentence>However, their in vivo <cons sem="G_MECHANISM">inhibitory</cons> effects on <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are <cons sem="G_NEGATIVEEFFECT">not</cons> known in detail, although <cons sem="G_DRUG">mibefradil</cons> was recently withdrawn from the market because of serious drug interactions.</sentence>
<sentence>The effects of <cons sem="G_DRUG">mibefradil</cons> and <cons lex="isradipine" sem="G_DRUG">isradipine</cons> on the pharmacokinetics and pharmacodynamics of oral <cons lex="triazolam" sem="G_DRUG">triazolam</cons>, a model substrate of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, were studied in a randomized, double-blind crossover study with three phases.</sentence>
<sentence>Nine healthy subjects took <cons sem="G_NUMBER">50 mg</cons> <cons sem="G_DRUG">mibefradil</cons>, <cons sem="G_NUMBER">5 mg</cons> <cons lex="isradipine" sem="G_DRUG">isradipine</cons>, or placebo orally once a day for 3 days.</sentence>
<sentence>On day 3, each subject received a single <cons sem="G_NUMBER">0.25 mg</cons> oral dose of <cons lex="triazolam" sem="G_DRUG">triazolam</cons>.</sentence>
<sentence>Thereafter, blood samples were collected up to 18 hours, and pharmacodynamic effects of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> were measured up to 8 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Mibefradil, triazolam, DDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">mibefradil</cons> <cons sem="G_CHANGE">increased</cons> the total <cons sem="G_IVIVPARA">area under the plasma <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> concentration-time curve  [AUC(0 - infinity)]</cons> <cons sem="G_NUMBER">9-fold compared with placebo (P &lt; .001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Mibefradil, triazolam, DDI)">
<sentence>The <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">1.8-fold (3.4+/-0.1 ng/mL versus 1.8+/-0.2 ng/mL  [mean +/- SEM]; P &lt; .001)</cons>, and the <cons sem="G_IVIVPARA">elimination half-life (t 1/2)</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">4.9-fold (18.5+/-1.9 hours versus 4.0+/-0.5 hours; P &lt; .001)</cons> by <cons sem="G_DRUG" type="inhibitor_1">mibefradil</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Mibefradil, triazolam, DDI)">
<sentence>In addition, <cons sem="G_DRUG" type="inhibitor_1">mibefradil</cons> was associated with <cons sem="G_CHANGE">increased</cons> pharmacodynamic effects of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(isradipine, triazolam, ADDI)">
<sentence>In contrast to <cons sem="G_DRUG" type="inhibitor_1">mibefradil</cons>, <cons lex="isradipine" sem="G_DRUG" type="inducer_1">isradipine</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">AUC(0 - infinity)</cons> and <cons sem="G_IVIVPARA">t 1/2</cons> of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> by about <cons sem="G_NUMBER">20% (P &lt; .05)</cons> and had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effects on the pharmacodynamics of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Mibefradil, triazolam, DDI)(isradipine, triazolam, NDDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">mibefradil</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="isradipine" sem="G_DRUG" type="inducer_1">isradipine</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> and thereby enhances and prolongs its pharmacodynamic effects, consistent with potent <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10546921</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> <cons sem="G_MECHANISM">inhibits</cons> the <cons sem="G_IVIVPARA">clearance</cons> of the enantiomers of the antidepressant <cons lex="reboxetine" sem="G_DRUG">reboxetine</cons> in humans.</sentence>
</title>
<abstract>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of the cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> enzyme.</sentence>
<sentence><cons lex="reboxetine" sem="G_DRUG">Reboxetine</cons>, a selective <cons lex="norepinephrine" sem="G_DRUG">norepinephrine</cons> reuptake <cons sem="G_MECHANISM">inhibitor</cons>, is <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons>.</sentence>
<sentence>The potential interaction of <cons lex="reboxetine" sem="G_DRUG">reboxetine</cons> with this representative from the azole derivative class was examined.</sentence>
<sentence>Eleven healthy volunteers received (1) <cons sem="G_NUMBER">4 mg</cons> <cons lex="reboxetine" sem="G_DRUG">reboxetine</cons> orally on the second day of a 5-day regimen of <cons sem="G_NUMBER">200 mg</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> once daily and (2) <cons sem="G_NUMBER">4 mg</cons> <cons lex="reboxetine" sem="G_DRUG">reboxetine</cons> orally in a crossover design.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="reboxetine" sem="G_DRUG">reboxetine</cons> enantiomers  [R,R(-)-<cons lex="reboxetine" sem="G_DRUG">reboxetine</cons> and the more active S,S(+)-<cons lex="reboxetine" sem="G_DRUG">reboxetine</cons>] were measured by high-performance liquid chromatography-tandem mass spectrometry.</sentence>
<sentence>Effects of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on enantiomer pharmacokinetics were assessed by ANOVA.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, R,R(-)-reboxetine, DDI)(Ketoconazole, S,S(+)-reboxetine, ADDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="reboxetine" sem="G_DRUG" type="substrate_1">R,R(-)-reboxetine</cons> and <cons lex="reboxetine" sem="G_DRUG" type="substrate_2">S,S(+)-reboxetine</cons> mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curves (AUC)</cons> by <cons sem="G_NUMBER">58%</cons> and <cons sem="G_NUMBER">43%</cons>, respectively (<cons sem="G_NUMBER">P &lt; .02</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Ketoconazole, R,R(-)-reboxetine, ADDI)(Ketoconazole, S,S(+)-reboxetine, ADDI)">
<sentence><cons sem="G_IVIVPARA">Oral clearance</cons> of both enantiomers was consequently <cons sem="G_CHANGE">decreased</cons> <cons sem="G_NUMBER">34%</cons> and <cons sem="G_NUMBER">24%</cons>, respectively, by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">P &lt; .005</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Ketoconazole, reboxetine, ADDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affect</cons> maximal plasma concentrations (<cons sem="G_NUMBER">P &gt; .1</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, reboxetine, ADDI)">
<sentence>Mean <cons sem="G_IVIVPARA">terminal half-life</cons> after administration of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">21.5 hours and 18.9 hours</cons>) was <cons sem="G_CHANGE">significantly</cons> longer than after <cons lex="reboxetine" sem="G_DRUG" type="substrate_3">reboxetine</cons> alone (<cons sem="G_NUMBER">14.8 hours and 14.4 hours; P &lt; or = .005</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, reboxetine, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC ratio</cons> for <cons lex="reboxetine" sem="G_DRUG" type="substrate_1">R,R(-)-reboxetine</cons> to <cons lex="reboxetine" sem="G_DRUG" type="substrate_2">S,S(+)-reboxetine</cons> was <cons sem="G_CHANGE">reduced</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> administration (<cons sem="G_NUMBER">2.76 after <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> versus 2.39; P &lt; .003</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, reboxetine, DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> <cons sem="G_CHANGE">decreases</cons> <cons sem="G_IVIVPARA">clearance</cons> of both <cons lex="reboxetine" sem="G_DRUG" type="substrate_3">reboxetine</cons> enantiomers.</sentence>
</annotation>
<sentence>Although the adverse effect profile for <cons lex="reboxetine" sem="G_DRUG">reboxetine</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">altered</cons> by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, the results of this study suggest that caution should be used and that a <cons sem ="G_CHANGE">reduction</cons> in <cons lex="reboxetine" sem="G_DRUG">reboxetine</cons> dose should be considered when the two are coadministered.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10546919</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">Grapefruit juice</cons> has minimal effects on <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</title>
<abstract>
<sentence>To evaluate the effect of regular-strength <cons sem="G_DRUG">grapefruit juice</cons>, a cytochrome <cons sem="G_CYP">P4503A4 (CYP3A4)</cons> <cons sem="G_MECHANISM">inhibitor</cons>, on the pharmacokinetics of a commonly prescribed regimen of oral <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>.</sentence>
<sentence>In a randomized crossover study, 16 healthy subjects received a single <cons sem="G_NUMBER">40 mg</cons> dose of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> in the evening after each consumed an 8-ounce glass of regular-strength <cons sem="G_DRUG">grapefruit juice</cons> or water with breakfast for 3 consecutive days.</sentence>
<sentence>The effect of the same <cons sem="G_DRUG">grapefruit juice</cons> and water regimen on the pharmacokinetics of <cons lex="midazolam" sem="G_DRUG">midazolam</cons> (<cons sem="G_NUMBER">2 mg</cons> oral dose given 1 hour after the third day of <cons sem="G_DRUG">grapefruit juice</cons> and water) was used as a positive control in the same subjects.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase <cons sem="G_MECHANISM">inhibitors</cons> were determined by an enzyme <cons sem="G_MECHANISM">inhibition</cons> assay, and concentrations of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>, <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> acid, and <cons lex="midazolam" sem="G_DRUG">midazolam</cons> were determined by liquid chromatography-tandem mass spectrometry.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(grapefruit juice, HMG-CoA reductase inhibitors, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">area under the plasma concentration-time profiles (AUC)</cons> and <cons sem="G_IVIVPARA">maximum plasma concentrations (Cmax)</cons> of HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_CHANGE">slightly</cons> (<cons sem="G_NUMBER">-30%</cons> for each) after consumption of <cons sem="G_DRUG" type="inhibitor_1">grapefruit juice</cons>.</sentence>
</annotation>
<sentence>Similar effects on <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">Cmax</cons> (approximately <cons sem="G_NUMBER">40%</cons> <cons sem="G_CHANGE">increase</cons> for each) were noted after analysis of samples of hydrolyzed plasma (which converts inactive lactones to active hydroxy acid species).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice, lovastatin, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">Cmax</cons> values for <cons lex="lovastatin" sem="G_DRUG" type="substrate_1">lovastatin</cons> approximately <cons sem = "G_CHANGE">doubled</cons> in the presence of <cons sem="G_DRUG" type="inhibitor_1">grapefruit juice</cons>, whereas the same parameters for <cons lex="lovastatin" sem="G_DRUG" type="M_1">lovastatin acid</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">1.6-fold</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(grapefruit juice, midazolam, DDI)">
<sentence><cons sem="G_DRUG" type="inhibitor_1">Grapefruit juice</cons> caused the <cons sem="G_IVIVPARA">AUC</cons> for <cons lex="midazolam" sem="G_DRUG" type="substrate_2">midazolam</cons> to <cons sem="G_CHANGE">increase</cons> by a factor of approximately <cons sem="G_NUMBER">2.4</cons>.</sentence>
</annotation>
<sentence>Daily consumption of a glass of regular-strength <cons sem="G_DRUG">grapefruit juice</cons> has a minimal effect on <cons sem="G_IVIVPARA">plasma concentrations</cons> of HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons> (approximately <cons sem="G_NUMBER">30% to 40%</cons> <cons sem="G_CHANGE">increase</cons>) after a <cons sem="G_NUMBER">40 mg</cons> evening dose of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10546851</bibliomisc>
</articleinfo>
<title>
<sentence>Interaction of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> and <cons lex="indinavir" sem="G_DRUG">indinavir</cons> when co-administered to HIV-positive patients.</sentence>
</title>
<abstract>
<sentence>The prevalence of erectile dysfunction in HIV-infected men is estimated to be <cons sem="G_NUMBER">33%</cons>.</sentence>
<sentence><cons lex="sildenafil" sem="G_DRUG">Sildenafil</cons> citrate (Viagra; Pfizer Ltd, Sandwich, Kent, UK) is the first oral drug for this condition.</sentence>
<sentence>Since <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> and the protease <cons sem="G_MECHANISM">inhibitors</cons> are both <cons sem="G_MECHANISM">metabolized</cons> by, and act as <cons sem="G_MECHANISM">inhibitors</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons>, we evaluated the pharmacokinetics of the combination <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> plus <cons lex="indinavir" sem="G_DRUG">indinavir</cons> in HIV-infected patients.</sentence>
<sentence>Six patients at steady state in treatment with <cons lex="indinavir" sem="G_DRUG">indinavir</cons> participated in the study.</sentence>
<sentence>On the first day blood samples for <cons lex="indinavir" sem="G_DRUG">indinavir</cons> assay were drawn at times 0, 1, 2, 3, 4, 6 and 8 h after dosing.</sentence>
<sentence>On the second study day patients received a single dose of <cons sem="G_NUMBER">25 mg</cons> of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> in addition to their routine morning medication.</sentence>
<sentence>Blood samples were taken as described.</sentence>
<sentence>Separated plasma was stored at -80 degrees C until analysis by high performance liquid chromatography.</sentence>
<sentence>In a parallel study, the effect of <cons lex="indinavir" sem="G_DRUG">indinavir</cons>, <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons>, <cons lex="saquinavir" sem="G_DRUG">saquinavir</cons> and <cons lex="nelfinavir" sem="G_DRUG">nelfinavir</cons> on the in vitro hepatic <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> was assessed.</sentence>
<sentence>The geometric mean <cons sem="G_IVIVPARA">area under the concentration curve for 0-8 h (AUC0-8h)</cons> and <cons sem="G_IVIVPARA">maximum plasma concentration (Cmax)</cons> for <cons lex="indinavir" sem="G_DRUG">indinavir</cons> were <cons sem="G_NUMBER">19.69 microg/ml h (range, 9.19-31.99 microg/ml h)</cons> and <cons sem="G_NUMBER">7.02 microg/ml (range, 2.33-16.17 microg/ml)</cons>, respectively, on the first study day.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(sildenafil, indinavir, ADDI)">
<sentence>In the presence of <cons lex="sildenafil" sem="G_DRUG" type="inhibitor_1">sildenafil</cons>, the mean <cons sem="G_IVIVPARA">AUC0-8h</cons> and <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="indinavir" sem="G_DRUG" type="substrate_1">indinavir</cons> were <cons sem="G_NUMBER">22.37 microg/ml h  [range, 10.08-37.25 microg/ml h; 95% confidence interval (CI) for difference between means, -15 to 13.25)</cons> and <cons sem="G_NUMBER">9.11 microg/ml (range, 3.41-22.78 microg/ml; 95% CI, -13 to 6.37)</cons>, respectively.</sentence>
</annotation>
<sentence>The geometric mean <cons sem="G_IVIVPARA">AUC0-8h</cons> and <cons sem="G_IVIVPARA">Cmax</cons> for <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> were <cons sem="G_NUMBER">1631 ng/ml h (range, 643-2970 ng/ml h)</cons> and <cons sem="G_NUMBER">384 ng/ml (range, 209-766 ng/ml)</cons> respectively.</sentence>
<sentence>The <cons sem="G_IVIVPARA">AUC</cons> for <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> was 4.4 times higher than data from historical controls given either <cons sem="G_NUMBER">50 mg or 100 mg</cons> of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> and dose normalized to <cons sem="G_NUMBER">25 mg</cons>.</sentence>
<sentence><cons lex="indinavir" sem="G_DRUG">Indinavir</cons> was a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> hepatic <cons sem="G_MECHANISM">metabolism</cons> in vitro  [concentration producing <cons sem="G_NUMBER">50%</cons> <cons sem="G_MECHANISM">inhibition</cons> of control enzyme activity (<cons sem="G_INVITPARA">IC50</cons>) = <cons sem="G_NUMBER">0.39 +/- 0.17 microM, mean +/- SD</cons>].</sentence>
<annotation sem="INVIVOCDDIS" ddi="(sildenafil, indinavir, NDDI)">
<sentence>Co-administration of <cons lex="sildenafil" sem="G_DRUG" type="inhibitor_1">sildenafil</cons> <cons sem="G_NUMBER">25 mg</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> alter the plasma <cons lex="indinavir" sem="G_DRUG" type="substrate_1">indinavir</cons> levels.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(indinavir, sildenafil, DDI)">
<sentence>However, plasma <cons lex="sildenafil" sem="G_DRUG" type="inhibitor_1">sildenafil</cons> <cons sem="G_IVIVPARA">AUC</cons> was <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">increased</cons> in the presence of <cons lex="indinavir" sem="G_DRUG" type="substrate_1">indinavir</cons> compared with historical controls.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(indinavir, sildenafil, DDI)">
<sentence>From the in vitro data, the mechanism of <cons sem="G_CHANGE">increase</cons> is <cons lex="indinavir" sem="G_DRUG" type="substrate_1">indinavir</cons> <cons sem="G_MECHANISM">inhibition</cons> of the hepatic <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="sildenafil" sem="G_DRUG" type="inhibitor_1">sildenafil</cons>.</sentence>
</annotation>
<sentence>The magnitude of this interaction suggests a lower starting dose of <cons lex="sildenafil" sem="G_DRUG">sildenafil</cons> <cons sem = "G_CHANGE">may</cons> be more appropriate in this clinical setting.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10516944</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_CHANGE">altered</cons> pharmacokinetics of <cons lex="indinavir" sem="G_DRUG">indinavir</cons> by a novel nonnucleoside reverse transcriptase <cons sem="G_MECHANISM">inhibitor</cons> (<cons sem="G_DRUG">HBY-097</cons>): a pharmacokinetic evaluation in HIV-positive patients.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">HBY-097 (HBY)</cons>, an investigational nonnucleoside reverse transcriptase <cons sem="G_MECHANISM">inhibitor</cons> (NNRTI), and <cons lex="indinavir" sem="G_DRUG">indinavir (IDV)</cons> share a common metabolic pathway, cytochrome P4503A4 (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), and <cons sem = "G_CHANGE">may</cons> clinically be used together as well as with <cons lex="zidovudine" sem="G_DRUG">zidovudine (ZDV)</cons>.</sentence>
<sentence>Thus, the potential pharmacokinetic (PK) interaction between these drugs was evaluated.</sentence>
<sentence><cons sem="G_DRUG">HBY</cons> (<cons sem="G_NUMBER">500 mg</cons> Q8H), <cons lex="indinavir" sem="G_DRUG">IDV</cons> (<cons sem="G_NUMBER">800 mg</cons> Q8H), and <cons lex="zidovudine" sem="G_DRUG">ZDV</cons> (<cons sem="G_NUMBER">200 mg</cons> Q8H) were given to 8 HIV-infected subjects.</sentence>
<sentence>Serial plasma samples were collected at baseline (<cons lex="zidovudine" sem="G_DRUG">ZDV</cons> and <cons lex="indinavir" sem="G_DRUG">IDV</cons> alone) and day 11 (all 3 drugs) to determine PK parameters using noncompartmental analysis.</sentence>
<sentence>PK parameters for <cons lex="zidovudine" sem="G_DRUG">ZDV</cons> in the presence and absence of <cons sem="G_DRUG">HBY</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> appreciably different.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(HBY, IDV, DDI)">
<sentence>However, both the maximum (<cons sem="G_IVIVPARA">Cmax</cons>) and minimum (<cons sem="G_IVIVPARA">Cmin</cons>) concentrations of <cons lex="indinavir" sem="G_DRUG" type="substrate_1">IDV</cons> were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons>, from <cons sem="G_NUMBER">a mean of 7514 +/- 1636 and 146 +/- 81 mcg/L to 4725 +/- 2494 mcg/L and 54 +/- 24 mcg/L (p &lt; .05)</cons> after addition of <cons sem="G_DRUG" type="inhibitor_1">HBY</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(HBY, IDV, DDI)">
<sentence>Furthermore, apparent <cons sem="G_IVIVPARA">clearance (CL/F)</cons> of <cons lex="indinavir" sem="G_DRUG" type="substrate_1">IDV</cons> before and after 11 days of concomitant <cons sem="G_DRUG" type="inhibitor_1">HBY</cons> administration was <cons sem="G_CHANGE">significantly</cons> higher, from <cons sem="G_NUMBER">0.69 +/- 0.14 to 1.94 +/- 0.63 L/h/kg (p &lt; .05)</cons> with an associated <cons sem ="G_CHANGE">reduction</cons> in <cons sem="G_IVIVPARA">area under the curve (AUC0-8)</cons> from <cons sem="G_NUMBER">16,034 +/- 4903 to 6134 +/- 2701 mg/L/h (p &lt; .05)</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_CHANGE">increase</cons> in <cons lex="indinavir" sem="G_DRUG">IDV</cons> <cons sem="G_IVIVPARA">CL/F</cons> is consistent with the observed metabolic <cons sem="G_MECHANISM">induction</cons> effects of other NNRTIs.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(HBY, IDV, DDI)">
<sentence>The results of this trial showed that <cons sem="G_DRUG" type="inhibitor_1">HBY</cons> <cons sem="G_CHANGE">significantly</cons> alters the pharmacokinetic parameters of <cons lex="indinavir" sem="G_DRUG" type="substrate_1">IDV</cons> at the dose studied.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10511062</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> on the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> in relation to <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotype status in humans.</sentence>
</title>
<abstract>
<sentence>A triple therapy with <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons lex="amoxicillin" sem="G_DRUG">amoxicillin</cons> (INN, amoxicilline), and <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> is widely used for the eradication of Helicobacter pylori.</sentence>
<sentence><cons lex="omeprazole" sem="G_DRUG">Omeprazole</cons> and <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> are <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>This study aimed to elucidate whether <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> affects the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>.</sentence>
<sentence>After administration of placebo or <cons sem="G_NUMBER">400 mg</cons> <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> twice a day for 3 days, <cons sem="G_NUMBER">20 mg</cons> <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and placebo or <cons sem="G_NUMBER">400 mg</cons> <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> were administered to 21 healthy volunteers.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> and <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> and their metabolites were determined before and 1, 2, 3, 5, 7, 10, and 24 hours after dosing.</sentence>
<sentence><cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> genotype status was determined by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.</sentence>
<sentence>Subjects were classified into three groups on the basis of PCR-RFLP analyses for <cons sem="G_CYP">CYP2C19</cons>: homozygous extensive <cons sem="G_MECHANISM">metabolizer</cons> group (n = 6), heterozygous extensive <cons sem="G_MECHANISM">metabolizer</cons> group (n = 11), and poor <cons sem="G_MECHANISM">metabolizer</cons> group (n = 4).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, omeprazole, DDI)">
<sentence>Mean <cons sem="G_IVIVPARA">area under the plasma concentration-time curves from 0 to 24 hours (AUC)</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> in the homozygous extensive <cons sem="G_MECHANISM">metabolizer</cons>, heterozygous extensive <cons sem="G_MECHANISM">metabolizer</cons>, and poor <cons sem="G_MECHANISM">metabolizer</cons> groups were <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> by <cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">clarithromycin</cons> from <cons sem="G_NUMBER">383.9 to 813.1</cons>, from <cons sem="G_NUMBER">1001.9 to 2110.4</cons>, and from <cons sem="G_NUMBER">5589.7 to 13098.6 ng x h/mL</cons>, respectively.</sentence>
</annotation>
<sentence>There were <cons sem="G_CHANGE">significant</cons> differences in the mean <cons sem="G_IVIVPARA">AUC</cons> values of <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> among the three groups.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(clarithromycin, omeprazole, DDI)">
<sentence><cons lex="clarithromycin" sem="G_DRUG" type="inhibitor_1">Clarithromycin</cons> <cons sem="G_MECHANISM">inhibits</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons>.</sentence>
</annotation>
<sentence>Drug interaction between <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons> and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem = "G_CHANGE">may</cons> underlie high eradication rates achieved by triple therapy with <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, <cons lex="amoxicillin" sem="G_DRUG">amoxicillin</cons>, and <cons lex="clarithromycin" sem="G_DRUG">clarithromycin</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10490907</bibliomisc>
</articleinfo>
<title>
<sentence>Duration of cytochrome P-450 <cons lex="2e1" sem="G_CYP">2E1 (CYP2E1)</cons> <cons sem="G_MECHANISM">inhibition</cons> and estimation of functional <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> enzyme <cons sem="G_IVIVPARA">half-life</cons> after single-dose <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons> administration in humans.</sentence>
</title>
<abstract>
<sentence><cons lex="disulfiram" sem="G_DRUG">Disulfiram (DSF)</cons> is a mechanism-based <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P-450 <cons lex="2e1" sem="G_CYP">2E1 (CYP2E1)</cons>, resulting in loss of <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> protein and activity, which <cons sem = "G_CHANGE">may</cons> be useful in preventing <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>-mediated xenobiotic toxicity.</sentence>
<sentence>The duration of <cons sem="G_MECHANISM">inhibition</cons> after a single DSF dose is, however, unknown.</sentence>
<sentence>The purpose of this investigation was to determine this duration, and <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> <cons sem="G_MECHANISM">formation</cons> and degradation rates, in humans.</sentence>
<sentence>Oral <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone (CLZ)</cons> was used as the selective in vivo probe for <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>.</sentence>
<sentence>Healthy subjects received <cons lex="chlorzoxazone" sem="G_DRUG">CLZ</cons> to determine baseline <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> activity ( <cons lex="chlorzoxazone" sem="G_DRUG">CLZ</cons> plasma <cons sem="G_IVIVPARA">clearance</cons> and 6-hydroxychlorzoxazone fractional metabolic <cons sem="G_IVIVPARA">clearance</cons>).</sentence>
<sentence>One week later, <cons lex="disulfiram" sem="G_DRUG">DSF</cons> (<cons sem="G_NUMBER">500 mg</cons> orally) was administered at bedtime, and <cons lex="chlorzoxazone" sem="G_DRUG">CLZ</cons> administered the following morning and 3, 6, 8, 10, and 13 days after DSF.</sentence>
<sentence>A terminal DSF metabolite, 2-thiothiazolidine-4 carboxylic acid, was also measured in each 24-h urine sample.</sentence>
<sentence>The mean <cons lex="chlorzoxazone" sem="G_DRUG">CLZ</cons> <cons sem="G_IVIVPARA">clearance</cons> and 6-hydroxychlorzoxazone fractional metabolic <cons sem="G_IVIVPARA">clearance</cons> on the first day declined to <cons sem="G_NUMBER">10.2 and 5.5%</cons> of baseline values, indicating rapid and profound <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> <cons sem="G_MECHANISM">inhibition</cons>.</sentence>
<sentence><cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> activity returned to half that of control on day 3, and to baseline values on day 8.</sentence>
<sentence>Assuming zero-order synthesis and first-order degradation, the in vivo <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> synthesis rate and degradation <cons sem="G_IVIVPARA">half-life</cons> was estimated to be <cons sem="G_NUMBER">11 +/- 5 nmol/h and 50 +/- 19 h</cons>, respectively.</sentence>
<sentence><cons sem="G_CHANGE">significant</cons> amounts of 2-thiothiazolidine-4 carboxylic acid were present only on day 1, suggesting that the return of in vivo <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> activity was <cons sem="G_NEGATIVEEFFECT">not</cons> caused by <cons sem="G_MECHANISM">inhibitor</cons> washout, but by enzyme resynthesis.</sentence>
<sentence>Results regarding <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> disposition <cons sem = "G_CHANGE">may</cons> be useful for modeling the effects of <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons> <cons sem="G_MECHANISM">inducers</cons> and <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
<sentence>For prevention of <cons lex="cyp2e1" sem="G_CYP">CYP2E1</cons>-mediated bioactivation, depending on protoxicant disposition, a second DSF dose <cons sem = "G_CHANGE">might</cons> be necessary to completely prevent toxicity.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10485779</bibliomisc>
</articleinfo>
<title>
<sentence>Ritonavir's role in <cons sem ="G_CHANGE">reducing</cons> <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> <cons sem="G_IVIVPARA">clearance</cons> and prolonging its <cons sem="G_IVIVPARA">half-life</cons>.</sentence>
</title>
<abstract>
<sentence>The human immunodeficiency virus protease <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of the cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> enzyme, and ritonavir's concomitant administration with the substrates of this enzyme <cons sem = "G_CHANGE">may</cons> lead to dangerous drug interactions.</sentence>
<sentence>The authors investigated possible interactions between <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> and intravenously administered <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> in a double-blind, placebo-controlled, cross-over study in two phases.</sentence>
<sentence>Twelve healthy volunteers received orally <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> or placebo for 3 days; the dose of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> was <cons sem="G_NUMBER">200 mg</cons> three times on the first day and <cons sem="G_NUMBER">300 mg</cons> three times on the second.</sentence>
<sentence>The last dose of <cons lex="ritonavir" sem="G_DRUG">ritonavir</cons> <cons sem="G_NUMBER">300 mg</cons> or placebo was given on the morning of the third day.</sentence>
<sentence>On the second day, 2 h after the afternoon pretreatment dose, <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> <cons sem="G_NUMBER">5 microg/kg</cons> was injected intravenously in 2 min with <cons lex="naloxone" sem="G_DRUG">naloxone</cons> to <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> its effects, and 15 timed venous blood samples were collected for 18 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, fentanyl, DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">Ritonavir</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="fentanyl" sem="G_DRUG" type="substrate_1">fentanyl</cons> by <cons sem="G_NUMBER">67% from 15.6+/-8.2 to 5.2+/-2.0 ml x min(-1) x kg(-1) (P&lt;0.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, fentanyl, DDI)">
<sentence>The <cons sem="G_IVIVPARA">area under the <cons lex="fentanyl" sem="G_DRUG" type="substrate_1">fentanyl</cons> plasma concentration-time curve from 0 to 18 h</cons> was <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">4.8+/-2.7 to 8.8+/-2.3 ng x ml(-1) x h(-1)</cons> by <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> (<cons sem="G_NUMBER">P&lt;0.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, fentanyl, NDDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">Ritonavir</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affect</cons> the initial concentrations and the steady-state volume of distribution of <cons lex="fentanyl" sem="G_DRUG" type="substrate_1">fentanyl</cons>.</sentence>
</annotation>
<sentence>One subject discontinued participation before <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> administration because of severe side effects, and during the study 8 of the remaining 11 subjects reported nausea.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ritonavir, fentanyl, DDI)">
<sentence><cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">Ritonavir</cons> can <cons sem="G_MECHANISM">inhibit</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="fentanyl" sem="G_DRUG" type="substrate_1">fentanyl</cons> <cons sem="G_CHANGE">significantly</cons>, so caution should be exercised if <cons lex="fentanyl" sem="G_DRUG">fentanyl</cons> is given to patients receiving <cons lex="ritonavir" sem="G_DRUG" type="inhibitor_1">ritonavir</cons> medication.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10456487</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="fluvoxamine" sem="G_DRUG">Fluvoxamine</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="tacrine" sem="G_DRUG">tacrine</cons> <cons sem="G_MECHANISM">metabolism</cons> in vivo.</sentence>
</title>
<abstract>
<sentence>In vitro studies have shown that <cons lex="tacrine" sem="G_DRUG">tacrine</cons> is <cons sem="G_MECHANISM">metabolized</cons> by cytochrome <cons sem="G_CYP">P4501A2 (CYP1A2)</cons>.</sentence>
<sentence>One of the monohydroxy-metabolites has been incriminated with <cons lex="tacrine" sem="G_DRUG">tacrine</cons>-<cons sem="G_MECHANISM">induced</cons> hepatotoxicity.</sentence>
<sentence>The aim of this study was to establish whether the potent <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> in clinically relevant doses could <cons sem="G_MECHANISM">inhibit</cons> <cons lex="tacrine" sem="G_DRUG">tacrine</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Eighteen healthy young men were enrolled in an open, randomized crossover study.</sentence>
<sentence>In the first study period a single oral dose of <cons lex="tacrine" sem="G_DRUG">tacrine</cons> <cons sem="G_NUMBER">40 mg</cons> was given.</sentence>
<sentence>In the second period the volunteers were randomized to maintenance doses of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> <cons sem="G_NUMBER">50 or 100 mg</cons> per day, and a single oral dose of <cons lex="tacrine" sem="G_DRUG">tacrine</cons> <cons sem="G_NUMBER">20 mg</cons> was given.</sentence>
<sentence><cons lex="fluvoxamine" sem="G_DRUG">Fluvoxamine</cons> was found to be a very potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="tacrine" sem="G_DRUG">tacrine</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, tacrine, DDI)">
<sentence>A fractional decrement in <cons lex="tacrine" sem="G_DRUG" type="substrate_1">tacrine</cons> <cons sem="G_IVIVPARA">clearance</cons> of approximately <cons sem="G_NUMBER">85%</cons> was found with both <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> doses, which was in good agreement with a prediction based on in vitro data.</sentence>
</annotation>
<sentence>The medians of the steady-state concentration of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> were <cons sem="G_NUMBER">43 nM (range 25-49) and 70 nM (range 44-124)</cons> in the <cons sem="G_NUMBER">50 mg</cons> per day and <cons sem="G_NUMBER">100 mg</cons> per day groups, respectively.</sentence>
<sentence>The steady-state concentration of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> <cons sem="G_MECHANISM">correlated</cons> with the fractional decrement in <cons lex="tacrine" sem="G_DRUG">tacrine</cons> <cons sem="G_IVIVPARA">clearance</cons> (Spearman <cons sem="G_NUMBER">Rs = 0.53, P &lt; 0.05</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, tacrine, DDI)">
<sentence><cons sem = "G_CHANGE">Modest</cons>, but statistically <cons sem="G_CHANGE">significant</cons>, <cons sem ="G_CHANGE">reduction</cons>s in the <cons sem="G_MECHANISM">formation</cons> of the metabolites <cons lex="tacrine" sem="G_DRUG" type="M_1">1- and 2-hydroxytacrine</cons> were found during concomitant <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> treatment.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, tacrine, DDI)" >
<sentence><cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">Fluvoxamine</cons> at clinically relevant doses is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="tacrine" sem="G_DRUG" type="substrate_1">tacrine</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>This interaction is very likely to have clinical relevance.</sentence>
<sentence>Whether concomitant <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> treatment <cons sem ="G_CHANGE">reduces</cons> <cons lex="tacrine" sem="G_DRUG">tacrine</cons>-<cons sem="G_MECHANISM">induced</cons> hepatotoxicity needs further study.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10426160</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem="G_CHANGE">decreases</cons> the <cons sem="G_IVIVPARA">clearance</cons> and enhances the effects of intravenously administered <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> in healthy volunteers.</sentence>
</title>
<abstract>
<sentence>A possible interaction of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, with intravenously administered <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons>, was examined.</sentence>
<sentence>In this double-blind, randomized, two-phase cross-over study, 9 healthy volunteers received either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or matched placebo orally once a day for 4 days.</sentence>
<sentence>On day 4, a dose of 16 mg <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> as sodium succinate was administered intravenously.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons>, <cons lex="cortisol" sem="G_DRUG">cortisol</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, and hydroxyitraconazole were determined up to 24 hr.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, methylprednisolone, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the total <cons sem="G_IVIVPARA">area under the plasma <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> concentration-time curve (AUC(0-infinity)</cons> <cons sem="G_NUMBER">2.6-fold) (P&lt;0.001)</cons>, while the <cons sem="G_IVIVPARA">AUC (12-24)</cons> of <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">12.2-fold (P&lt;0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, methylprednisolone, DDI)">
<sentence>The systemic <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> during the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phase was <cons sem="G_NUMBER">40%</cons> of that during the placebo phase (<cons sem="G_NUMBER">P&lt;0.01</cons>).</sentence>
</annotation>
<sentence>The volume of distribution of <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">affected</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, methylprednisolone, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> was <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">2.1+/-0.3 hr to 4.8+/-0.8 hr (P&lt;0.001)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, methylprednisolone, DDI)">
<sentence>The mean morning plasma <cons lex="cortisol" sem="G_DRUG">cortisol</cons> concentration during the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phase, measured 24 hr after the administration of <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons>, was only about <cons sem="G_NUMBER">9%</cons> of that during the placebo phase (<cons sem="G_NUMBER">11.0+/-9.0 ng/ml versus 117+/-49.2 ng/ml; P&lt;0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, methylprednisolone, DDI)">
<sentence>In conclusion, <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> <cons sem="G_CHANGE">decreases</cons> the <cons sem="G_IVIVPARA">clearance</cons> and <cons sem="G_CHANGE">increases</cons> the <cons sem="G_IVIVPARA">elimination half-life</cons> of intravenously administered <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons>, resulting in <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increased</cons> exposure to <cons lex="methylprednisolone" sem="G_DRUG" type="substrate_1">methylprednisolone</cons> during the night time and in enhanced adrenal <cons sem = "G_MECHANISM">suppression</cons>.</sentence>
</annotation>
<sentence>Care should be taken when <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or other potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> are used concomitantly with <cons lex="methylprednisolone" sem="G_DRUG">methylprednisolone</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10223773</bibliomisc>
</articleinfo>
<title>
<sentence>The effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics of oral and intravenous <cons lex="ondansetron" sem="G_DRUG">ondansetron</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="ondansetron" sem="G_DRUG">Ondansetron</cons> is an antiemetic agent <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 (CYP) enzymes.</sentence>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin (INN, rifampicin)</cons> is a potent <cons sem="G_MECHANISM">inducer</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and some other CYP enzymes.</sentence>
<sentence>We examined the possible effect of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics of orally and intravenously administered <cons lex="ondansetron" sem="G_DRUG">ondansetron</cons>.</sentence>
<sentence>In a randomized crossover study with 4 phases and a washout of 4 weeks, 10 healthy volunteers took either <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (in 2 phases) or placebo (in 2 phases) once a day for 5 days.</sentence>
<sentence>On day 6, <cons sem="G_NUMBER">8 mg</cons> <cons lex="ondansetron" sem="G_DRUG">ondansetron</cons> was administered either orally (after <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and placebo) or intravenously (after <cons lex="rifampin" sem="G_DRUG">rifampin</cons> and placebo).</sentence>
<sentence><cons lex="ondansetron" sem="G_DRUG">Ondansetron</cons> concentrations in plasma were measured up to 12 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, ondansetron, DDI)">
<sentence>The mean total <cons sem="G_IVIVPARA">area under the plasma concentration-time curve  [AUC(0-infinity)]</cons> of orally administered <cons lex="ondansetron" sem="G_DRUG" type="substrate_1">ondansetron</cons> after <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> pretreatment was <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">65%</cons> compared with placebo (<cons sem="G_NUMBER">P &lt; .001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, ondansetron, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">peak plasma concentration</cons> of oral <cons lex="ondansetron" sem="G_DRUG" type="substrate_1">ondansetron</cons> by about <cons sem="G_NUMBER">50% (from 27.2+/-3.0 to 13.8+/-1.5 ng/mL  [mean +/- SEM]; P &lt; .001])</cons> and the <cons sem="G_IVIVPARA">elimination half-life (t1/2)</cons> by <cons sem="G_NUMBER">38% (P &lt; .01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, ondansetron, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">bioavailability</cons> of oral <cons lex="ondansetron" sem="G_DRUG" type="substrate_1">ondansetron</cons> was <cons sem="G_CHANGE">reduced</cons> from <cons sem="G_NUMBER">60% to 40% (P &lt; .01)</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, ondansetron, DDI)">
<sentence>The <cons sem="G_IVIVPARA">clearance</cons> of intravenous <cons lex="ondansetron" sem="G_DRUG" type="substrate_1">ondansetron</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">83% (from 440+/-38.4 to 805+/-44.6 mL/min  [P &lt; .001])</cons> by <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, ondansetron, ADDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">t1/2</cons> of intravenously administered <cons lex="ondansetron" sem="G_DRUG" type="substrate_1">ondansetron</cons> by <cons sem="G_NUMBER">46% (P &lt; .001)</cons> and the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> by <cons sem="G_NUMBER">48% (P &lt; .001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, ondansetron, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> considerably <cons sem="G_CHANGE">decreases</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="ondansetron" sem="G_DRUG" type="substrate_1">ondansetron</cons> after both oral and intravenous administration.</sentence>
</annotation>
<sentence>The interaction is most likely the result of <cons sem="G_MECHANISM">induction</cons> of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="ondansetron" sem="G_DRUG">ondansetron</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, ondansetron, DDI)">
<sentence>Concomitant use of <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> or other potent <cons sem="G_MECHANISM">inducers</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> with <cons lex="ondansetron" sem="G_DRUG" type="substrate_1">ondansetron</cons> <cons sem = "G_CHANGE">may</cons> result in a <cons sem="G_CHANGE">reduced</cons> antiemetic effect, particularly after oral administration of <cons lex="ondansetron" sem="G_DRUG" type="substrate_1">ondansetron</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10206086</bibliomisc>
</articleinfo>
<title>
<sentence>The effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the pharmacokinetics, pharmacodynamics and safety of <cons lex="nisoldipine" sem="G_DRUG">nisoldipine</cons>.</sentence>
</title>
<abstract>
<sentence>The primary aim of the present study was to investigate the effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the pharmacokinetics of <cons lex="nisoldipine" sem="G_DRUG">nisoldipine</cons>.</sentence>
<sentence>A single dose of <cons lex="nisoldipine" sem="G_DRUG">nisoldipine</cons> <cons sem="G_NUMBER">5 mg</cons> immediate-release tablet was administered either alone or in combination with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> <cons sem="G_NUMBER">200 mg</cons> (4 days pretreatment and concomitant administration) in a randomized crossover trial in seven healthy male caucasian volunteers.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentration</cons>-versus-time profiles of <cons lex="nisoldipine" sem="G_DRUG">nisoldipine</cons> and its metabolite M9 were determined.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, nisoldipine, DDI)">
<sentence>Pre-treatment with and concomitant administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> resulted in a <cons sem="G_NUMBER">24-fold</cons> and <cons sem="G_NUMBER">11-fold</cons>, <cons sem="G_CHANGE">increase</cons> in mean <cons sem="G_IVIVPARA">AUC</cons> and <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="nisoldipine" sem="G_DRUG" type="substrate_1">nisoldipine</cons>, respectively, compared with treatment with <cons lex="nisoldipine" sem="G_DRUG">nisoldipine</cons> <cons sem="G_NUMBER">5 mg</cons> alone.</sentence>
</annotation>
<sentence>The <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>-<cons sem="G_MECHANISM">induced</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">plasma concentration</cons> of the metabolite M9 was of similar magnitude.</sentence>
<sentence>The interaction is attributed to <cons sem="G_MECHANISM">inhibition</cons> of cytochrome <cons lex="3a4" sem="G_CYP">3A4</cons>-mediated first-pass <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and other antifungal drugs of the substituted <cons lex="imidazole" sem="G_DRUG">imidazole</cons> type as well as other potent <cons sem="G_MECHANISM">inhibitors</cons> of cytochrome <cons lex="3a4" sem="G_CYP">3A4</cons> should <cons sem="G_NEGATIVEEFFECT">not</cons> be used concomitantly with <cons lex="nisoldipine" sem="G_DRUG">nisoldipine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10193676</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics of oral <cons sem="G_DRUG">lignocaine</cons>.</sentence>
</title>
<abstract>
<sentence><cons sem="G_DRUG">Lignocaine</cons> is <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> enzyme (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), and has a <cons sem="G_CHANGE"><cons sem = "G_CHANGE">moderate</cons></cons> to high extraction ratio resulting in <cons sem="G_IVIVPARA">oral bioavailability</cons> of <cons sem="G_NUMBER">30%</cons>.</sentence>
<sentence>We have studied the possible effect of two <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, on the pharmacokinetics of oral <cons sem="G_DRUG">lignocaine</cons> in nine volunteers using a cross-over study design.</sentence>
<sentence>The subjects were given <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> orally (<cons sem="G_NUMBER">500 mg</cons> three times a day), <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> (<cons sem="G_NUMBER">200 mg</cons> once a day) or placebo for four days.</sentence>
<sentence>On day 4, each subject ingested a single dose of <cons sem="G_NUMBER">1 mg/kg</cons> of oral <cons sem="G_DRUG">lignocaine</cons>.</sentence>
<sentence>Plasma samples were collected until 10 hr and concentrations of <cons lex="lignocaine" sem="G_DRUG">lignocaine</cons> and its major metabolite, <cons lex="lignocaine" sem="G_DRUG" type="M_1">monoethylglycinexylidide</cons> were measured by gas chromatography.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin, lignocaine, DDI)(itraconazole, lignocaine, DDI)">
<sentence>Both <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the <cons sem="G_DRUG" type="substrate_1">lignocaine</cons> plasma concentration-time curve  [AUC(0-infinity)]</cons> and <cons sem="G_DRUG" type="substrate_1">lignocaine</cons> <cons sem="G_IVIVPARA">peak concentrations</cons> by <cons sem="G_NUMBER">40-70% (P&lt;0.05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin, lignocaine, DDI)(itraconazole, lignocaine, DDI)">
<sentence>Compared to placebo and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons>, <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="lignocaine" sem="G_DRUG" type="M_1">monoethylglycinexylidide</cons> <cons sem="G_IVIVPARA">peak concentrations</cons> by approximately <cons sem="G_NUMBER">40% (P&lt;0.01)</cons> and <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> by <cons sem="G_NUMBER">60% (P&lt;0.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin, lignocaine, DDI)(itraconazole, lignocaine, DDI)">
<sentence>The clinical implication of this study is that <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increase</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> and toxicity of oral <cons sem="G_DRUG" type="substrate_1">lignocaine</cons>.</sentence>
</annotation>
<sentence>The extent of the interaction of <cons sem="G_DRUG">lignocaine</cons> with these <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons> was, however, less than that of, e.g. <cons lex="midazolam" sem="G_DRUG">midazolam</cons> or <cons lex="buspirone" sem="G_DRUG">buspirone</cons>, and it did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_MECHANISM">correlate</cons> with the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibiting</cons> potency of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:10027660</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons> pharmacokinetics.</sentence>
</title>
<abstract>
<sentence>To determine the effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, on the pharmacokinetics of <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons>, a competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
<sentence>A randomized, double-blind, cross-over study design with two phases, which were separated by a washout period of 4 weeks, was used.</sentence>
<sentence>In each phase ten healthy volunteers took <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or matched placebo orally once daily for 4 days according to a randomization schedule.</sentence>
<sentence>On day 4, <cons sem="G_NUMBER">0.3 mg</cons> <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons> was administered orally.</sentence>
<sentence>Serum concentrations of <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons>, its major metabolites, active and total HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and hydroxyitraconazole were measured up to 24 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, cerivastatin, ADDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the concentration-time curve from time zero to infinity (AUC(0-infinity))</cons> of the parent <cons lex="cerivastatin" sem="G_DRUG" type="substrate_1">cerivastatin</cons> by <cons sem="G_NUMBER">15% (P &lt; 0.05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, cerivastatin, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">peak serum concentration (Cmax)</cons> of <cons lex="cerivastatin" sem="G_DRUG" type="M_1">cerivastatin lactone</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">1.8-fold (range 1.1-fold to 2.4-fold, P &lt; 0.001)</cons> and the <cons sem="G_IVIVPARA">AUC(0-24h)</cons> <cons sem="G_NUMBER">2.6-fold (range 2.0-fold to 3.6-fold, P &lt; 0.001)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Itraconazole, cerivastatin, DDI)">    
<sentence>The <cons sem="G_IVIVPARA">elimination half-life (t1/2)</cons> of <cons lex="cerivastatin" sem="G_DRUG" type="M_1">cerivastatin lactone</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">3.2-fold (P &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, cerivastatin, ADDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">AUC(0-24h)</cons> of the <cons lex="cerivastatin" sem="G_DRUG" type="M_1">active M-1 metabolite of cerivastatin</cons> by <cons sem="G_NUMBER">28% (P &lt; 0.05)</cons>, whereas the <cons sem="G_IVIVPARA">AUC(0- 24h)</cons> of the more active metabolite, <cons lex="cerivastatin" sem="G_DRUG" type="M_2">M-23</cons>, was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">36% (P &lt; 0.05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Itraconazole, cerivastatin, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC(0-24h)</cons> and <cons sem="G_IVIVPARA">t1/2</cons> of active HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons> were <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">27% (P &lt; 0.05)</cons> and <cons sem="G_NUMBER">40% (P &lt; 0.05)</cons>, respectively, by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, cerivastatin, ADDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> has a <cons sem = "G_CHANGE">modest</cons> interaction with <cons lex="cerivastatin" sem="G_DRUG" type="substrate_1">cerivastatin</cons>.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated M-1 metabolic pathway leads to elevated serum concentrations of <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons>, <cons lex="cerivastatin" sem="G_DRUG">cerivastatin</cons> lactone and metabolite M-23, resulting in <cons sem="G_CHANGE">increased</cons> concentrations of active HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9987705</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> pharmacokinetics in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="tacrolimus" sem="G_DRUG">Tacrolimus</cons> is a marketed immunosuppressant used in liver and kidney transplantation.</sentence>
<sentence>It is subject to extensive <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and is a substrate for P-glycoprotein-mediated transport.</sentence>
<sentence>A pharmacokinetic interaction with <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, an antituberculosis agent and potent <cons sem="G_MECHANISM">inducer</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> and P-glycoprotein, and <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> was evaluated in six healthy male volunteers.</sentence>
<sentence><cons lex="tacrolimus" sem="G_DRUG">Tacrolimus</cons> was administered at doses of <cons sem="G_NUMBER">0.1 mg/kg</cons> orally and <cons sem="G_NUMBER">0.025 mg/kg/4 hours</cons> intravenously.</sentence>
<sentence>The pharmacokinetics of <cons lex="tacrolimus" sem="G_DRUG">tacrolimus</cons> were obtained from serial blood samples collected over 96 hours, after single oral and intravenous administration prior to and during an 18-day concomitant <cons lex="rifampin" sem="G_DRUG">rifampin</cons> dosing phase.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, tacrolimus, ADDI)">
<sentence>Coadministration of <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> <cons sem="G_IVIVPARA">clearance</cons> (<cons sem="G_NUMBER">36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03</cons>) and <cons sem="G_CHANGE">decreased</cons> <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons> <cons sem="G_IVIVPARA">bioavailability</cons> (<cons sem="G_NUMBER">14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, tacrolimus, ADDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> appears to <cons sem="G_MECHANISM">induce</cons> both intestinal and hepatic <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="tacrolimus" sem="G_DRUG" type="substrate_1">tacrolimus</cons>, most likely through <cons sem="G_MECHANISM">induction</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> and P-glycoprotein in the liver and small bowel.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9871429</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="tamoxifen" sem="G_DRUG">Tamoxifen</cons> and <cons lex="toremifene" sem="G_DRUG">toremifene</cons> concentrations in plasma are <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">decreased</cons> by <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin (INN, rifampicin)</cons> is a potent <cons sem="G_MECHANISM">inducer</cons> of cytochrome P450 (CYP) enzymes involved in drug <cons sem="G_MECHANISM">metabolism</cons> and therefore causes many drug interactions.</sentence>
<sentence>The effects of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on the pharmacokinetics of <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> (study I) and <cons lex="toremifene" sem="G_DRUG">toremifene</cons> (study II) were examined in 2 randomized, placebo-controlled crossover studies.</sentence>
<sentence>Ten (study I) or 9 (study II) healthy male volunteers took either <cons sem="G_NUMBER">600 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or placebo orally once a day for 5 days.</sentence>
<sentence>On the sixth day, <cons sem="G_NUMBER">80 mg</cons> <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> or <cons sem="G_NUMBER">120 mg</cons> <cons lex="toremifene" sem="G_DRUG">toremifene</cons> was administered orally.</sentence>
<sentence>Blood samples were collected up to 336 hours after drug administration.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, tamoxifen, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">area under the plasma concentration-time curve (AUC)</cons> of <cons lex="tamoxifen" sem="G_DRUG" type="substrate_1">tamoxifen</cons> by <cons sem="G_NUMBER">86% (P &lt; .001)</cons>, <cons sem="G_IVIVPARA">peak plasma concentration (Cmax)</cons> by <cons sem="G_NUMBER">55% (P &lt; .001)</cons>, and <cons sem="G_IVIVPARA">elimination half-life (t1/2)</cons> by <cons sem="G_NUMBER">44% (P &lt; .001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, toremifene, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="toremifene" sem="G_DRUG" type="substrate_2">toremifene</cons> was <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_NUMBER">87% (P &lt; .001)</cons>, <cons sem="G_IVIVPARA">Cmax</cons> by <cons sem="G_NUMBER">55% (P &lt; .001)</cons>, and <cons sem="G_IVIVPARA">t1/2</cons> by <cons sem="G_NUMBER">44% (P &lt; .01)</cons> with <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, tamoxifen, ADDI)(rifampin, toremifene, ADDI)">
<sentence>During the <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> phase, the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="tamoxifen" sem="G_DRUG" type="M_1">N-demethyltamoxifen</cons> was <cons sem="G_NUMBER">38% (P &lt; .001)</cons> and the <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="toremifene" sem="G_DRUG" type="M_2">N-demethyltoremifene</cons> was <cons sem="G_NUMBER">20% (P &lt; .01)</cons> of that during the placebo phase.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, tamoxifen, DDI)(rifampin, toremifene, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem ="G_CHANGE">reduces</cons> the <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="tamoxifen" sem="G_DRUG" type="substrate_1">tamoxifen</cons> and <cons lex="toremifene" sem="G_DRUG" type="substrate_2">toremifene</cons> by <cons sem="G_MECHANISM">inducing</cons> their <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>Concomitant use of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> or other potent <cons sem="G_MECHANISM">inducers</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> with <cons lex="tamoxifen" sem="G_DRUG">tamoxifen</cons> and <cons lex="toremifene" sem="G_DRUG">toremifene</cons> <cons sem = "G_CHANGE">may</cons> <cons sem="G_CHANGE">reduce</cons> the efficacy of these antiestrogens.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9839763</bibliomisc>
</articleinfo>
<title>
<sentence>Concurrent administration of <cons lex="donepezil" sem="G_DRUG">donepezil</cons> HCl and ketoconazole: assessment of pharmacokinetic <cons sem ="G_CHANGE">changes</cons> following single and multiple doses.</sentence>
</title>
<abstract>
<sentence>The aim of this study was to examine the pharmacokinetics of <cons lex="donepezil" sem="G_DRUG">donepezil</cons> HCl and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> separately, and in combination, following administration of single and multiple oral doses.</sentence>
<sentence>This was an open-label, randomized, three-period crossover study in healthy volunteers (n=21).</sentence>
<sentence>During each treatment period, subjects received single daily doses of either <cons lex="donepezil" sem="G_DRUG">donepezil</cons> HCl (<cons sem="G_NUMBER">5 mg</cons>), <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">200 mg</cons>), or a combination of both drugs for 7 consecutive days.</sentence>
<sentence>Pharmacokinetic comparisons were made between treatment groups for the day 1 and day 7 profiles.</sentence>
<sentence>Each treatment period was followed by a 3-week, drug-free washout period.</sentence>
<sentence>On both day 1 and day 7, a statistically <cons sem="G_CHANGE">significant</cons> difference was observed between the <cons lex="donepezil" sem="G_DRUG">donepezil</cons> and the <cons lex="donepezil" sem="G_DRUG">donepezil</cons> + <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> treatment groups in terms of <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUC(0-24)</cons> of <cons lex="donepezil" sem="G_DRUG">donepezil</cons>.</sentence>
<sentence>The concurrent administration of both drugs resulted in a <cons sem="G_NUMBER">12%</cons> <cons sem = "G_CHANGE">greater</cons> <cons sem="G_IVIVPARA">Cmax</cons> (<cons sem="G_NUMBER">9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01</cons>) and a <cons sem="G_NUMBER">12%</cons> <cons sem = "G_CHANGE">greater</cons> <cons sem="G_IVIVPARA">AUC(0-24)</cons> (<cons sem="G_NUMBER">135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001</cons>) than <cons lex="donepezil" sem="G_DRUG">donepezil</cons> alone on day 1, and a <cons sem="G_NUMBER">26.8%</cons> <cons sem = "G_CHANGE">greater</cons> <cons sem="G_IVIVPARA">Cmax</cons> (<cons sem="G_NUMBER">37.7 ng ml(-1) versus 27.6 ng ml(-1); P &lt; 0.0001</cons>) and a <cons sem="G_NUMBER">26.4%</cons> <cons sem = "G_CHANGE">greater</cons> <cons sem="G_IVIVPARA">AUC(0-24)</cons> (<cons sem="G_NUMBER">680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P&lt;0.0001</cons>) than <cons lex="donepezil" sem="G_DRUG">donepezil</cons> alone on day 7.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(donepezil, ketoconazole, NDDI)">
<sentence>In contrast, <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> were <cons sem="G_NEGATIVEEFFECT">unaffected</cons> by the concurrent administration of <cons lex="donepezil" sem="G_DRUG" type="substrate_1">donepezil</cons>, and there were <cons sem="G_NEGATIVEEFFECT">no</cons> statistically <cons sem="G_CHANGE">significant</cons> differences in <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> pharmacokinetics when <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> administered alone was compared with <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> administered with <cons lex="donepezil" sem="G_DRUG" type="substrate_1">donepezil</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(donepezil, ketoconazole, NDDI)(ketoconazole, donepezil, DDI)">
<sentence>The concurrent administration of <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> and <cons lex="donepezil" sem="G_DRUG" type="substrate_1">donepezil</cons> produces <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem = "G_CHANGE">change</cons> in <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>, but a statistically <cons sem="G_CHANGE">significant</cons> change in <cons lex="donepezil" sem="G_DRUG" type="substrate_1">donepezil</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons>.</sentence>
</annotation>
<sentence>These observed <cons sem ="G_CHANGE">changes</cons>, which are smaller than those produced by <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> for other agents sharing the CYP-<cons lex="3a4" sem="G_CYP">3A4</cons> pathway, are most likely the result of <cons lex="donepezil" sem="G_DRUG">donepezil</cons> also being <cons sem="G_MECHANISM">metabolized</cons> by CYP-<cons lex="2d6" sem="G_CYP">2D6</cons>, as well as its slow rate of <cons sem="G_IVIVPARA">clearance</cons> from plasma.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9834040</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_MECHANISM">Metabolism</cons> of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons> in humans is mediated by <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and to a <cons sem = "G_CHANGE">minor</cons> extent by <cons sem="G_CYP">CYP3A4</cons>: an interaction study with <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> and <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> as in vivo <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</title>
<abstract>
<sentence>Potential drug-drug interactions can be identified in vitro by exploring the importance of specific cytochrome P450 (CYP) isozymes for drug <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>The <cons sem="G_MECHANISM">metabolism</cons> of the local anesthetic <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons> to 3-hydroxyropivacaine and (S)-2',6'-pipecoloxylidide was shown in vitro to be dependent on <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> and <cons lex="3a4" sem="G_CYP">3A4</cons>, respectively.</sentence>
<sentence>In this in vivo model study we quantitated the role of these 2 isozymes for the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons>.</sentence>
<sentence>In a randomized, 3-way crossover study, 12 healthy subjects received a single dose of <cons sem="G_NUMBER">40 mg</cons> <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons> intravenously alone or combined either with 25 mg <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> as a <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> <cons sem="G_MECHANISM">inhibitor</cons> or with <cons sem="G_NUMBER">100 mg</cons> <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> as a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> twice daily for 2 days.</sentence>
<sentence>Venous plasma and urine samples were collected over 10 hours and 24 hours, respectively.</sentence>
<sentence>The samples were analyzed for <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons> base, 3-hydroxyropivacaine, and (S)-2',6'-pipecoloxylidide.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, ropivacaine , DDI)(ketoconazole, ropivacaine, ADDI)">
<sentence>Coadministration with <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> <cons sem="G_CHANGE">decreased</cons> the mean total plasma <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> from <cons sem="G_NUMBER">354 to 112 mL/min (68%)</cons>, whereas <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_2">ketoconazole</cons> <cons sem="G_CHANGE">decreased</cons> plasma <cons sem="G_IVIVPARA">clearance</cons> to <cons sem="G_NUMBER">302 mL/min (15%)</cons>.</sentence>
</annotation>
<sentence>The relative <cons sem ="G_CHANGE">changes</cons> in unbound plasma <cons sem="G_IVIVPARA">clearance</cons> were similar to the <cons sem ="G_CHANGE">changes</cons> in total plasma <cons sem="G_IVIVPARA">clearance</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, ropivacaine, DDI)(ketoconazole, ropivacaine, NDDI)">
<sentence>The <cons lex="ropivacaine" sem="G_DRUG" type="substrate_1">ropivacaine</cons> <cons sem="G_IVIVPARA">half-life (t1/2)</cons> of <cons sem="G_NUMBER">1.9 hours</cons> was almost <cons sem = "G_CHANGE">doubled</cons> during <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> administration and the <cons sem="G_IVIVPARA">plasma concentration</cons> at the end of infusion <cons sem="G_CHANGE">increased</cons> <cons sem="G_CHANGE">slightly</cons>, whereas the corresponding parameters after <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_2">ketoconazole</cons> administration remained <cons sem="G_NEGATIVEEFFECT">unchanged</cons>.</sentence>
</annotation>
<sentence>Coadministration with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> almost abolished the (S)-2',6'-pipecoloxylidide concentrations in plasma, whereas <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> administration <cons sem="G_CHANGE">increased</cons> the (S)-2',6'-pipecoloxylidide levels.</sentence>
<sentence>The fraction of dose excreted as 3-hydroxyropivacaine in urine <cons sem="G_CHANGE">decreased</cons> during <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> administration from <cons sem="G_NUMBER">39% to 13%</cons>.</sentence>
<sentence><cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons> is the most important isozyme for the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="ropivacaine" sem="G_DRUG">ropivacaine</cons>.</sentence>
<sentence>Drug-drug interactions with <cons sem="G_CHANGE">strong</cons> <cons sem="G_MECHANISM">inhibitors</cons> of this isozyme could be of clinical relevance during repeated administration.</sentence>
<sentence>A potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> causes a <cons sem = "G_CHANGE">minor</cons> <cons sem="G_CHANGE">decrease</cons> in <cons sem="G_IVIVPARA">clearance</cons>, which should be of <cons sem="G_NEGATIVEEFFECT">no</cons> clinical relevance.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9832299</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics of intravenous <cons sem="G_DRUG">lignocaine</cons>.</sentence>
</title>
<abstract>
<sentence>We have studied the possible interaction of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, both <cons sem="G_MECHANISM">inhibitors</cons> of cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> isoenzyme (<cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>), with intravenous <cons sem="G_DRUG">lignocaine</cons> in nine healthy volunteers using a randomized cross-over study design.</sentence>
<sentence>The subjects were given oral placebo, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> (<cons sem="G_NUMBER">500 mg</cons> three times a day) or <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> (<cons sem="G_NUMBER">200 mg</cons> once a day) for 4 days.</sentence>
<sentence>Intravenous <cons sem="G_DRUG">lignocaine</cons> <cons sem="G_NUMBER">1.5 mg x kg(-1)</cons> was given with an infusion for 60 min on the fourth day of pretreatment with placebo, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> or <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
<sentence>Timed plasma samples were collected until 11 h. The concentrations of <cons sem="G_DRUG">lignocaine</cons> and its metabolite <cons sem="G_DRUG">monoethylglycinexylidide (MEGX)</cons> were measured by gas chromatography.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin, lignocaine, ADDI)">
<sentence>The <cons sem="G_IVIVPARA">area under the <cons sem="G_DRUG" type="substrate_1">lignocaine</cons> concentration-time curve</cons> was similar during all three phases but <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons sem="G_DRUG" type="substrate_1">lignocaine</cons> from <cons sem="G_NUMBER">2.5 to 2.9 (0.7) h</cons> compared with placebo.</sentence>
</annotation>
<sentence>Following <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> administration, <cons sem="G_IVIVPARA">t1/2</cons> was 2.6 h. The values for plasma <cons sem="G_IVIVPARA">clearance</cons> and volume of distribution at steady state were similar during all the phases.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin, MEGX, DDI)">
<sentence>Compared with placebo and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> <cons lex="lignocaine" sem="G_DRUG" type="M_1">MEGX</cons> <cons sem="G_IVIVPARA">peak concentrations</cons> by approximately <cons sem="G_NUMBER">40%</cons> and <cons sem="G_IVIVPARA">AUC(0-11 h)</cons> by <cons sem="G_NUMBER">45-60%</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin + itraconazole, lignocaine, NDDI)">
<sentence>The plasma decay of <cons sem="G_DRUG" type="substrate_1">lignocaine</cons> administered intravenously is virtually <cons sem="G_NEGATIVEEFFECT">unaffected</cons> by the concomitant administration of <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin, MEGX, DDI)(erythromycin, lignocaine, DDI)">
<sentence>However, <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> <cons sem="G_CHANGE">increases</cons> the concentrations of <cons lex="lignocaine" sem="G_DRUG" type="M_1">MEGX</cons>, which indicates that <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> either <cons sem="G_CHANGE">increases</cons> the relative amount of <cons sem="G_DRUG" type="substrate_1">lignocaine</cons> <cons sem="G_MECHANISM">metabolized</cons> via N-de-ethylation or <cons sem="G_CHANGE">decreases</cons> the further <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="lignocaine" sem="G_DRUG" type="M_1">MEGX</cons>.</sentence>
</annotation>
<sentence>Further studies are necessary to elucidate the clinical <cons sem = "G_CHANGE">significance</cons> of the <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>-<cons sem="G_MECHANISM">induced</cons> elevated concentrations of <cons sem="G_DRUG">MEGX</cons> during prolonged intravenous infusions of <cons sem="G_DRUG">lignocaine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9784084</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the single oral dose pharmacokinetics and pharmacodynamics of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons>.</sentence>
</title>
<abstract>
<sentence>To assess the effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>, on the single oral dose pharmacokinetics and pharmacodynamics of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons>, the study was conducted in a double-blind randomized crossover manner with two phases of treatment with <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>-placebo or placebo-<cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
<sentence>Ten healthy male subjects receiving <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem="G_NUMBER">200 mg/day</cons> or matched placebo orally for 6 days took an oral <cons sem="G_NUMBER">0.8 mg</cons> dose of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> on day 4 of each treatment phase.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentration</cons> of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> was measured up to 48 h after <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> dosing, together with the assessment of psychomotor function by the Digit Symbol Substitution Test, Visual Analog Scale and Udvalg for kliniske undersgelser side effect rating scale.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, alprazolam, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">P &lt; 0.01</cons>) <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the concentration-time curves from 0 h to infinity</cons> (<cons sem="G_NUMBER">252 +/- 47 versus 671 +/- 205 ng h/ml</cons>), <cons sem="G_CHANGE">decreased</cons> the apparent <cons sem="G_IVIVPARA">oral clearance</cons> (<cons sem="G_NUMBER">0.89 +/- 0.21 versus 0.35+/-0.10 ml/min per kg</cons>) and prolonged the <cons sem="G_IVIVPARA">elimination half-life</cons> (<cons sem="G_NUMBER">15.7 +/- 4.1 versus 40.3 +/- 13.5 h</cons>) of <cons lex="alprazolam" sem="G_DRUG" type="substrate_1">alprazolam</cons>.</sentence>
</annotation>
<sentence>The test performed during <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> treatment showed <cons sem="G_CHANGE">significantly</cons> depressed psychomotor function.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, alprazolam, DDI)">
<sentence>It is suggested that <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>, a potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>, <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentration</cons> of <cons lex="alprazolam" sem="G_DRUG" type="substrate_1">alprazolam</cons> via its <cons sem="G_MECHANISM">inhibitory</cons> effects on <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>Thus, this study supports previous studies suggesting that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> is the major enzyme <cons sem="G_MECHANISM">catalyzing</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, alprazolam, DDI)">
<sentence>Enhanced side effects of <cons lex="alprazolam" sem="G_DRUG" type="substrate_1">alprazolam</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> coadministration were <cons sem = "G_CHANGE">probably</cons> reflected by these pharmacokinetic <cons sem ="G_CHANGE">changes</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9757149</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> therapy on the activities of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> as determined by phenotyping.</sentence>
</title>
<abstract>
<sentence>To determine the effect of <cons sem="G_NUMBER">150 mg/day</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> on the activities of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with <cons lex="caffeine" sem="G_DRUG">caffeine</cons>, <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>, and <cons lex="midazolam" sem="G_DRUG">midazolam</cons>.</sentence>
<sentence>Oral <cons lex="caffeine" sem="G_DRUG">caffeine</cons> (<cons sem="G_NUMBER">2 mg/kg</cons>), oral <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> (<cons sem="G_NUMBER">30 mg</cons>), and intravenous <cons lex="midazolam" sem="G_DRUG">midazolam</cons> (<cons sem="G_NUMBER">0.025 mg/kg</cons>) were administered to 10 white male volunteers every 14 days for 4 months and to 10 white premenopausal female volunteers during the midfollicular and midluteal phases of the menstrual cycle for 4 complete cycles (8 total phenotyping measures).</sentence>
<sentence>The first 6 phenotyping measures were used to establish baseline activity.</sentence>
<sentence>Subjects were given <cons sem="G_NUMBER">150 mg/day</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> for the fourth month or cycle of the study.</sentence>
<sentence>Enzyme activity for <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, NAT2, and XO was expressed as urinary metabolite ratios.</sentence>
<sentence><cons lex="midazolam" sem="G_DRUG">Midazolam</cons> plasma <cons sem="G_IVIVPARA">clearance</cons> was used to express <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity.</sentence>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> difference between baseline and weeks 2 and 4 of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> therapy was observed for NAT2 or XO metabolite ratios.</sentence>
<sentence>For <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> phenotypes, <cons sem="G_CHANGE">significant</cons> differences existed between baseline and <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> therapy.</sentence>
<sentence>For <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, the mean urinary metabolite ratio (+/-SD) was <cons sem="G_NUMBER">7.53 +/- 7.44</cons> at baseline and <cons sem="G_NUMBER">4.30 +/- 2.82</cons> with <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> ( <cons sem="G_NUMBER">P = .012</cons>).</sentence>
<sentence>Mean <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> molar urinary <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons> ratios before and after <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> therapy were <cons sem="G_NUMBER">0.00780 +/- 0.00694 and 0.0153 +/- 0.0127, respectively (<cons sem="G_NUMBER">P = .011</cons>)</cons>.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(fluvoxamine , midazolam, DDI)">
<sentence><cons lex="midazolam" sem="G_DRUG" type="substrate_1">Midazolam</cons> <cons sem="G_IVIVPARA">clearance</cons> <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">0.0081 +/ 0.0024 L/min/kg</cons> at baseline to <cons sem="G_NUMBER">0.0054 +/- 0.0021 L/min/kg</cons> with therapy (<cons sem="G_NUMBER">P = .0091</cons>).</sentence>
</annotation>
<sentence>For <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>, <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> therapy <cons sem="G_CHANGE">changed</cons> the phenotyping measures by a median of <cons sem="G_NUMBER">-44.4%, 123.5%, and -34.4%</cons>, respectively.</sentence>
<sentence>We concluded that <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> <cons sem = "G_CHANGE">may</cons> cause <cons sem="G_CHANGE">significant</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp1a2" sem="G_CYP">CYP1A2</cons>, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> activity.</sentence>
<sentence>This metabolic <cons sem="G_MECHANISM">inhibition</cons> <cons sem = "G_CHANGE">may</cons> have serious implications for a variety medications.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9728898</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="erythromycin" sem="G_DRUG">Erythromycin</cons> and <cons lex="verapamil" sem="G_DRUG">verapamil</cons> considerably <cons sem="G_CHANGE">increase</cons> serum <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> acid concentrations.</sentence>
</title>
<abstract>
<sentence>To study the effects of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="verapamil" sem="G_DRUG">verapamil</cons> on the pharmacokinetics of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>, an <cons sem="G_MECHANISM">inhibitor</cons> of 3-hydroxy-3-methylglutaryl coenzyme A reductase.</sentence>
<sentence>A randomized, double-blind crossover study was performed with three phases separated by a washout period of 3 weeks.</sentence>
<sentence>Twelve young, healthy volunteers took orally either <cons sem="G_NUMBER">1.5 gm/day</cons> <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons sem="G_NUMBER">240 mg/day</cons> <cons lex="verapamil" sem="G_DRUG">verapamil</cons>, or placebo for 2 days.</sentence>
<sentence>On day 2, <cons sem="G_NUMBER">40 mg</cons> <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> was administered orally.</sentence>
<sentence>Serum concentrations of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>, <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> acid, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="verapamil" sem="G_DRUG">verapamil</cons>, and norverapamil were measured for up to 24 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Erythromycin, simvastatin, DDI)(verapamil, simvastatin, DDI)">
<sentence><cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">Erythromycin</cons> and <cons lex="verapamil" sem="G_DRUG" type="inhibitor_2">verapamil</cons> <cons sem="G_CHANGE">increased</cons> mean <cons sem="G_IVIVPARA">peak serum concentration (Cmax)</cons> of <cons sem="G_NEGATIVEEFFECT">unchanged</cons> <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> <cons sem="G_NUMBER">3.4-fold (p &lt; 0.001)</cons> and <cons sem="G_NUMBER">2.6-fold (p &lt; 0.05)</cons> and the <cons sem="G_IVIVPARA">area under the serum <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> concentration-time curve from time zero to 24 hours  [AUC(0-24)]</cons> <cons sem="G_NUMBER">6.2-fold(p &lt; 0.001)</cons> and <cons sem="G_NUMBER">4.6-fold (p &lt; 0.01)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Erythromycin, simvastatin, DDI)">
<sentence><cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">Erythromycin</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">Cmax</cons> of active <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> <cons sem="G_NUMBER">fivefold (p &lt; 0.001)</cons> and the <cons sem="G_IVIVPARA">AUC(0-24)</cons> <cons sem="G_NUMBER">3.9-fold (p &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Verapamil, simvastatin, DDI)">
<sentence><cons lex="verapamil" sem="G_DRUG" type="inhibitor_2">Verapamil</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> <cons sem="G_NUMBER">3.4-fold (p &lt; 0.001)</cons> and the <cons sem="G_IVIVPARA">AUC(0-24)</cons> <cons sem="G_NUMBER">2.8-fold (p &lt; 0.001)</cons>.</sentence>
</annotation>
<sentence>There was more than tenfold interindividual variability in the extent of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> interaction with both <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> and <cons lex="verapamil" sem="G_DRUG">verapamil</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Erythromycin, simvastatin, DDI)(verapamil, simvastatin, DDI)">
<sentence>Both <cons lex="erythromycin" sem="G_DRUG" type="inhibitor_1">erythromycin</cons> and <cons lex="verapamil" sem="G_DRUG" type="inhibitor_2">verapamil</cons> interact considerably with <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons>, <cons sem = "G_CHANGE">probably</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>Concomitant administration of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="verapamil" sem="G_DRUG">verapamil</cons>, or other potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> should be avoided.</sentence>
<sentence>As an alternative, the dosage of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> should be <cons sem="G_CHANGE">reduced</cons> considerably, that is, by about <cons sem="G_NUMBER">50% to 80%</cons>, at least when a <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> dosage higher than <cons sem="G_NUMBER">20 mg/day</cons> is used.</sentence>
<sentence>Possible adverse effects, such as elevation of <cons lex="creatine" sem="G_DRUG">creatine</cons> kinase level and muscle tenderness, should be closely monitored when such combinations are used.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9728896</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="artemisinin" sem="G_DRUG">Artemisinin</cons> <cons sem="G_MECHANISM">induces</cons> <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_MECHANISM">metabolism</cons> in human beings.</sentence>
</title>
<abstract>
<sentence>This study investigated whether time-dependent <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> pharmacokinetics <cons sem="G_MECHANISM">correlated</cons> to <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> or <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity in vivo.</sentence>
<sentence><cons lex="artemisinin" sem="G_DRUG">Artemisinin</cons> (two oral doses per day of <cons sem="G_NUMBER">250 mg</cons>) was given to nine healthy Vietnamese subjects for 7 days (day 1 to day 7).</sentence>
<sentence>Single <cons sem="G_NUMBER">20 mg</cons> doses of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> were given orally on day -7, day 1, and day 7.</sentence>
<sentence>Single doses of <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> were given in combination on day 14 after a 6-day washout period.</sentence>
<sentence>The pharmacokinetics of <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons>, <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons>, hydroxyomeprazole, and <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulfone were evaluated on days -7, 1, 7, and 14.</sentence>
<sentence>On the same days urine was collected for the determination of 6beta-hydroxycortisol and <cons lex="cortisol" sem="G_DRUG">cortisol</cons> excretion.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(artemisinin , omeprazole , DDI)">
<sentence><cons sem="G_IVIVPARA">Areas under plasma concentration-time curves (AUC)</cons> for <cons lex="artemisinin" sem="G_DRUG" type="inducer_1">artemisinin</cons> and <cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> <cons sem="G_CHANGE">decreased</cons> on day 7 to <cons sem="G_NUMBER">20% (95% confidence intervals, 13%, 28%)</cons> and <cons sem="G_NUMBER">35% (25%, 46%)</cons>, respectively, compared with values on day 1.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(artemisinin , omeprazole , DDI)">
<sentence><cons sem="G_IVIVPARA">AUC</cons> ratios for <cons lex="omeprazole" sem="G_DRUG" type="M_1">hydroxyomeprazole</cons>/<cons lex="omeprazole" sem="G_DRUG" type="substrate_1">omeprazole</cons> <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">2.2-fold (1.7, 2.7)</cons> on day 7 compared with values on day 1.</sentence>
</annotation>
<sentence>All values were normalized at day 14.</sentence>
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> in the <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> sulfone/omeprazole ratio or in the 6beta-hydroxycortisol/cortisol ratio between the study days.</sentence>
<sentence>In one subject found to have poor <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> metabolization, the elimination of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> <cons sem="G_CHANGE">increased</cons> after <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> exposure, with <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem = "G_CHANGE">change</cons> in the hydroxyomeprazole/omeprazole <cons sem="G_IVIVPARA">AUC</cons> ratio.</sentence>
<sentence><cons lex="artemisinin" sem="G_DRUG">Artemisinin</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> alter <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> activity, whereas an <cons sem="G_CHANGE">increase</cons> in <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> activity was observed.</sentence>
<sentence>The <cons sem="G_CHANGE">increased</cons> elimination of <cons lex="omeprazole" sem="G_DRUG">omeprazole</cons> in both poor and extensive <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> <cons sem="G_MECHANISM">metabolizers</cons> suggests <cons lex="artemisinin" sem="G_DRUG">artemisinin</cons> <cons sem="G_MECHANISM">induces</cons> both <cons lex="cyp2c19" sem="G_CYP">CYP2C19</cons> and another enzyme.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9690949</bibliomisc>
</articleinfo>
<title>
<sentence>Different effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> and <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>.</sentence>
</title>
<abstract>
<sentence>The effects of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the pharmacokinetics of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> and <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>, two <cons sem="G_MECHANISM">inhibitors</cons> of HMG-CoA reductase with different pharmacokinetic properties, were studied.</sentence>
<sentence>Two separate randomized, placebo-controlled, cross-over studies, each involving 10 healthy volunteers, were carried out.</sentence>
<sentence>The general design was identical in both studies.</sentence>
<sentence>The subjects took either <cons sem="G_NUMBER">100 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or matched placebo orally once daily for 4 days.</sentence>
<sentence>On day 4, <cons sem="G_NUMBER">40 mg</cons> <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons> or <cons sem="G_NUMBER">40 mg</cons> <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> was administered orally.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="fluvastatin" sem="G_DRUG">fluvastatin</cons>, <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>, <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> acid, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and hydroxyitraconazole were determined up to 24 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, fluvastatin, ADDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> had <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on the <cons sem="G_IVIVPARA">Cmax</cons> (<cons sem="G_NUMBER">190 +/- 124 ng ml(-1) vs 197 +/- 189 ng ml(-1) (mean +/- s.d.)</cons>) or total <cons sem="G_IVIVPARA">AUC</cons> (<cons sem="G_NUMBER">368 +/- 153 ng ml(-1) h vs 324 +/- 155 ng ml(-1) h</cons>) of <cons lex="fluvastatin" sem="G_DRUG" type="substrate_1">fluvastatin</cons> compared with placebo.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Itraconazole, fluvastatin, ADDI)">
<sentence>However, the <cons sem="G_IVIVPARA">t1/2</cons>,z of <cons lex="fluvastatin" sem="G_DRUG" type="substrate_1">fluvastatin</cons> was <cons sem="G_CHANGE">slightly</cons> prolonged by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> (<cons sem="G_NUMBER">2.8 +/- 0.49 h vs 2.4 +/- 0.51 h; P &lt; 0.05</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, lovastatin, DDI)">
<sentence>The <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="lovastatin" sem="G_DRUG" type="substrate_2">lovastatin</cons> was <cons sem="G_CHANGE">increased</cons> about <cons sem="G_NUMBER">15-fold (P &lt; 0.01)</cons> and the total <cons sem="G_IVIVPARA">AUC</cons> more than <cons sem="G_NUMBER">15-fold (P &lt; 0.01)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, lovastatin, DDI)">
<sentence>Similarly, the <cons sem="G_IVIVPARA">Cmax</cons> and total <cons sem="G_IVIVPARA">AUC</cons> of <cons lex="lovastatin" sem="G_DRUG" type="M_1">lovastatin acid</cons> were <cons sem="G_CHANGE">increased</cons> about <cons sem="G_NUMBER">12-fold (95% CI, 5.3 to 17.7-fold; P &lt; 0.01)</cons> and <cons sem="G_NUMBER">15-fold (95% CI, 4.6 to 26.2-fold; P &lt; 0.01)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>, respectively.</sentence>
</annotation>
<sentence>The <cons sem="G_IVIVPARA">t1/2</cons>,z of <cons lex="lovastatin" sem="G_DRUG" type="substrate_2">lovastatin</cons> averaged <cons sem="G_NUMBER">3.7 +/- 3.8 h</cons> and that of <cons lex="lovastatin" sem="G_DRUG" type="M_1">lovastatin acid</cons> <cons sem="G_NUMBER">4.7 +/- 4.0 h</cons> during the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phase; these variables could <cons sem="G_NEGATIVEEFFECT">not</cons> be determined in all subjects during the placebo phase.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, lovastatin, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons>, even at a small dosage of <cons sem="G_NUMBER">100 mg</cons> daily, <cons sem = "G_CHANGE">greatly</cons> elevated <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="lovastatin" sem="G_DRUG" type="substrate_2">lovastatin</cons> and its active metabolite, <cons lex="lovastatin" sem="G_DRUG" type="M_1">lovastatin acid</cons>.</sentence>
</annotation>
<sentence><cons lex="lovastatin" sem="G_DRUG">Lovastatin</cons> should therefore <cons sem="G_NEGATIVEEFFECT">not</cons> be used concomitantly with <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and other potent <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>, or the dosage of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> should be <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">reduced</cons> while using a <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, fluvastatin, ADDI)(itraconazole, lovastatin, DDI)">
<sentence>In contrast, <cons lex="fluvastatin" sem="G_DRUG" type="substrate_1">fluvastatin</cons> concentrations were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>, indicating that <cons lex="fluvastatin" sem="G_DRUG" type="substrate_1">fluvastatin</cons> has much less potential than <cons lex="lovastatin" sem="G_DRUG" type="substrate_2">lovastatin</cons> for clinically <cons sem="G_CHANGE">significant</cons> interactions with <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> and other <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitors</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9663178</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="buspirone" sem="G_DRUG">buspirone</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="buspirone" sem="G_DRUG">Buspirone</cons> has an extensive first-pass <cons sem="G_MECHANISM">metabolism</cons>, which makes it potentially susceptible to drug interactions.</sentence>
<sentence>The aim of this study was to investigate possible interactions of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> with <cons lex="verapamil" sem="G_DRUG">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons>.</sentence>
<sentence>In a randomized, placebo-controlled, three-phase crossover study, nine healthy volunteers received either <cons sem="G_NUMBER">80 mg</cons> <cons lex="verapamil" sem="G_DRUG">verapamil</cons>, <cons sem="G_NUMBER">60 mg</cons> <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons>, or placebo orally three times a day.</sentence>
<sentence>On day 2, after the fifth dose, <cons sem="G_NUMBER">10 mg</cons> <cons lex="buspirone" sem="G_DRUG">buspirone</cons> was given orally.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="buspirone" sem="G_DRUG">buspirone</cons>, <cons lex="verapamil" sem="G_DRUG">verapamil</cons>, and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> were determined up to 18 hours, and the effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> were measured up to 8 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Verapamil, buspirone, DDI)(diltiazem, buspirone, DDI)">
<sentence><cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">Verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG" type="inhibitor_2">diltiazem</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> plasma concentration-time curve  [AUC (0-infinity)]</cons> <cons sem="G_NUMBER">3.4-fold (p &lt; 0.001)</cons> and <cons sem="G_NUMBER">5.5-fold (p &lt; 0.001)</cons>, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Verapamil, buspirone, DDI)(diltiazem, buspirone, DDI)">
<sentence>The <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">3.4-fold (p &lt; 0.001)</cons> and <cons sem="G_NUMBER">4.1-fold (p &lt; 0.001)</cons> by <cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG" type="inhibitor_2">diltiazem</cons>, respectively.</sentence>
</annotation>
<sentence>The effect of <cons lex="diltiazem" sem="G_DRUG" type="inhibitor_2">diltiazem</cons> on the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> was <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">p &lt; 0.05</cons>) <cons sem = "G_CHANGE">greater</cons> than that of <cons lex="verapamil" sem="G_DRUG">verapamil</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Verapamil, buspirone, NDDI)(diltiazem, buspirone, NDDI)">
<sentence>The <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">changed</cons> by <cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG" type="inhibitor_2">diltiazem</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Verapamil, buspirone, DDI)(diltiazem, buspirone, DDI)">
<sentence>Of the six pharmacodynamic variables, only the subjective overall drug effect of <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> was <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> with <cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">verapamil</cons> (<cons sem="G_NUMBER">p &lt; 0.05</cons>) and <cons lex="diltiazem" sem="G_DRUG" type="inhibitor_2">diltiazem</cons> (<cons sem="G_NUMBER">p &lt; 0.05</cons>).</sentence>
</annotation>
<sentence>Side effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> occurred more often (<cons sem="G_NUMBER">p &lt; 0.05</cons>) with <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> than with placebo.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Verapamil, buspirone, DDI)(diltiazem, buspirone, DDI)">
<sentence>Both <cons lex="verapamil" sem="G_DRUG" type="inhibitor_1">verapamil</cons> and <cons lex="diltiazem" sem="G_DRUG" type="inhibitor_2">diltiazem</cons> considerably <cons sem="G_CHANGE">increase</cons> plasma <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> concentrations, <cons sem = "G_CHANGE">probably</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated first-pass <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>Thus enhanced effects and side effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> are possible when it is used with <cons lex="verapamil" sem="G_DRUG">verapamil</cons>, <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons>, or other <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9578186</bibliomisc>
</articleinfo>
<title>
<sentence>Concentrations and effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> are considerably <cons sem="G_CHANGE">reduced</cons> by <cons sem="G_DRUG">rifampicin</cons>.</sentence>
</title>
<abstract>
<sentence>The effects of <cons sem="G_DRUG">rifampicin</cons> on the pharmacokinetics and pharmacodynamics of <cons lex="buspirone" sem="G_DRUG">buspirone</cons>, a non-benzodiazepine anxiolytic agent, were investigated.</sentence>
<sentence>In a randomized, placebo-controlled cross-over study with two phases, 10 young healthy volunteers took either <cons sem="G_NUMBER">600 mg</cons> <cons sem="G_DRUG">rifampicin</cons> or matched placebo once daily for 5 days.</sentence>
<sentence>On day 6, <cons sem="G_NUMBER">30 mg</cons> <cons lex="buspirone" sem="G_DRUG">buspirone</cons> was administered orally.</sentence>
<sentence>Plasma <cons lex="buspirone" sem="G_DRUG">buspirone</cons> concentrations and effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> were measured up to 10 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, buspirone, DDI)">
<sentence>The total <cons sem="G_IVIVPARA">area under the plasma <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> concentration-time curve</cons> after <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> was <cons sem="G_NUMBER">10.4% (95% CI, 6.3-14.5%)</cons> of that after placebo (<cons sem="G_NUMBER">1.64+/-0.35 ng ml(-1) h vs 22.0+/-15.1 ng ml(-1) h (mean+/-s.d.); P&lt; 0.01</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, buspirone, DDI)">
<sentence><cons sem="G_DRUG" type="inducer_1">rifampicin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> from <cons sem="G_NUMBER">6.6+/-3.7 ng ml(-1) to 0.84+/-0.23 ng ml(-1) (P&lt; 0.01)</cons> and the <cons sem="G_IVIVPARA">half-life</cons> from <cons sem="G_NUMBER">2.8+/-0.7 h to 1.3+/-0.5 h (P&lt; 0.01)</cons>.</sentence>
</annotation>
<sentence>A <cons sem="G_CHANGE">significant</cons> (<cons sem="G_NUMBER">P&lt;0.05</cons>) <cons sem ="G_CHANGE">reduction</cons> in the effects of <cons lex="buspirone" sem="G_DRUG">buspirone</cons> was observed in three of the six psychomotor tests employed (postural sway test with eyes closed, subjective drowsiness and overall drug effect) after <cons sem="G_DRUG">rifampicin</cons> pretreatment.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampicin, buspirone, DDI)">
<sentence>The <cons sem="G_CHANGE">strong</cons> interaction between <cons sem="G_DRUG" type="inducer_1">rifampicin</cons> and <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons> is <cons sem = "G_CHANGE">probably</cons> mostly due to enhanced <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated first-pass <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="buspirone" sem="G_DRUG" type="substrate_1">buspirone</cons>.</sentence>
</annotation>
<sentence><cons lex="buspirone" sem="G_DRUG">Buspirone</cons> will most likely show a <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">reduced</cons> anxiolytic effect when used together with <cons sem="G_DRUG">rifampicin</cons> or other potent <cons sem="G_MECHANISM">inducers</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> such as <cons lex="phenytoin" sem="G_DRUG">phenytoin</cons> and <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9542475</bibliomisc>
</articleinfo>
<title>
<sentence>Effects of <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> or <cons lex="rifampin" sem="G_DRUG">rifampin</cons> on <cons lex="losartan" sem="G_DRUG">losartan</cons> pharmacokinetics in healthy volunteers.</sentence>
</title>
<abstract>
<sentence><cons lex="losartan" sem="G_DRUG">Losartan</cons> is <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons> and <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> to an active metabolite, E3174, which has <cons sem = "G_CHANGE">greater</cons> antihypertensive activity than the parent compound.</sentence>
<sentence>Coadministered drugs that <cons sem="G_MECHANISM">inhibit</cons> or <cons sem="G_MECHANISM">induce</cons> metabolic processes <cons sem = "G_CHANGE">may</cons> therefore alter the pharmacokinetics and pharmacologic response of <cons lex="losartan" sem="G_DRUG">losartan</cons> and E3174.</sentence>
<sentence>Ten healthy volunteers were studied to assess the effects of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibition</cons> and nonspecific P450 enzyme <cons sem="G_MECHANISM">induction</cons> on the pharmacokinetics of <cons lex="losartan" sem="G_DRUG">losartan</cons> and E3174.</sentence>
<sentence>Subjects completed three 1-week phases separated by 6 days: <cons sem="G_NUMBER">50 mg</cons> <cons lex="losartan" sem="G_DRUG">losartan</cons> every morning, <cons lex="losartan" sem="G_DRUG">losartan</cons> plus <cons sem="G_NUMBER">500 mg</cons> <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons> four times a day, and <cons lex="losartan" sem="G_DRUG">losartan</cons> plus <cons sem="G_NUMBER">300 mg</cons> <cons lex="rifampin" sem="G_DRUG">rifampin</cons> (INN, <cons sem="G_DRUG">rifampicin</cons>) twice a day.</sentence>
<sentence>On the eighth day of each phase, serial <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="losartan" sem="G_DRUG">losartan</cons> and E3174 were obtained over 32 hours and steady-state pharmacokinetics were determined.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, losartan, ADDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">area under the concentration-time curve from time zero to 24 hours after the dose (AUC [0-24])</cons> of <cons lex="losartan" sem="G_DRUG" type="substrate_1">losartan</cons> by <cons sem="G_NUMBER">35% (349 +/- 246 versus 225 +/- 130; p = 0.0001)</cons> and <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">AUC(0-24)</cons> of <cons lex="losartan" sem="G_DRUG" type="M_1">E3174</cons> by <cons sem="G_NUMBER">40% (1336 +/- 445 versus 792 +/- 302; p &lt; 0.005)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Rifampin, losartan, DDI)">
<sentence><cons lex="losartan" sem="G_DRUG" type="substrate_1">Losartan</cons> <cons sem="G_IVIVPARA">oral clearance</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">44% (p = 0.0001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Rifampin, losartan, DDI)">
<sentence>The <cons sem="G_IVIVPARA">half-life</cons> values of both compounds were <cons sem="G_CHANGE">decreased</cons> by <cons sem="G_NUMBER">50% (p &lt; 0.005)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(erythromycin, losartan, NDDI)">
<sentence>In contrast, <cons lex="erythromycin" sem="G_DRUG" type="inducer_2">erythromycin</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">affect</cons> the <cons sem="G_IVIVPARA">AUC(0-24)</cons> or <cons sem="G_IVIVPARA">half-life</cons> of either <cons lex="losartan" sem="G_DRUG" type="substrate_1">losartan</cons> or <cons lex="losartan" sem="G_DRUG" type="M_1">E3174</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Rifampin, losartan, DDI)(Rifampin, E3174, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> is a potent <cons sem="G_MECHANISM">inducer</cons> of <cons lex="losartan" sem="G_DRUG" type="substrate_1">losartan</cons> and <cons lex="losartan" sem="G_DRUG" type="M_1">E3174</cons> elimination.</sentence>
</annotation>
<sentence>Given the magnitude of the effect, this interaction is likely to be clinically <cons sem="G_CHANGE">significant</cons>.</sentence>
<sentence>On the basis of the minimal <cons sem="G_MECHANISM">inhibitory</cons> effects observed with <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> appears to play a <cons sem = "G_CHANGE">minor</cons> role in the in vivo <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="losartan" sem="G_DRUG">losartan</cons> to <cons lex="losartan" sem="G_DRUG" type="M_1">E3174</cons>.</sentence>
<sentence>Further studies are needed to define the contribution of other isozymes, particularly <cons lex="cyp2c9" sem="G_CYP">CYP2C9</cons>, to the pharmacokinetics of <cons lex="losartan" sem="G_DRUG">losartan</cons> and E3174.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9542477</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="simvastatin" sem="G_DRUG">Simvastatin</cons> but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> is very susceptible to interaction with the <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem="G_CHANGE">increases</cons> the risk of skeletal muscle toxicity of some 3-hydroxy-3-methylglutaryl coenzyme A' (HMG-CoA) reductase <cons sem="G_MECHANISM">inhibitors</cons> by increasing their serum concentrations.</sentence>
<sentence>We studied possible interactions of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> and <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons>.</sentence>
<sentence>Two randomized, double-blind, two-phase crossover studies were performed with use of an identical design, one with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> (study I) and one with <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> (study II).</sentence>
<sentence>In both studies, 10 healthy volunteers received either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo orally once a day for 4 days.</sentence>
<sentence>On day 4, each subject ingested a single <cons sem="G_NUMBER">40 mg</cons> dose of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> (study I) or <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons> (study II).</sentence>
<sentence>Serum concentrations of <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons>, <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> acid, <cons lex="pravastatin" sem="G_DRUG">pravastatin</cons>, HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, and hydroxyitraconazole were determined.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, simvastatin, DDI)">
<sentence>In study I, <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak serum concentrations (Cmax)</cons> and the <cons sem="G_IVIVPARA">areas under the serum concentration-time curve  [AUC(0-infinity)]</cons> of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons> and <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons>  <cons sem="G_NUMBER">at least tenfold (p &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(itraconazole, simvastatin, DDI)">
<sentence>The <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of total <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> (naive <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons> plus that derived by hydrolysis of the lactone) were <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">17-fold</cons> and <cons sem="G_NUMBER">19-fold (p &lt; 0.001)</cons>, respectively, and the <cons sem="G_IVIVPARA">half-life (t1/2)</cons> was <cons sem="G_CHANGE">increased</cons> by <cons sem="G_NUMBER">25% (p &lt; 0.05)</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> of HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons> was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">fivefold (p &lt; 0.001)</cons> and the <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">t1/2</cons> were <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">threefold (p &lt; 0.001)</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, pravastatin, NDDI)">
<sentence>In study II, <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> <cons sem="G_CHANGE">slightly</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> and <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons>, but the <cons sem ="G_CHANGE">changes</cons> were statistically nonsignificant (<cons sem="G_NUMBER">p = 0.052 and 0.172</cons>, respectively).</sentence>
</annotation>
<sentence>The <cons sem="G_IVIVPARA">t1/2</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">altered</cons>.</sentence>
<sentence>The <cons sem="G_IVIVPARA">AUC(0-infinity)</cons> and <cons sem="G_IVIVPARA">Cmax</cons> of HMG-CoA reductase <cons sem="G_MECHANISM">inhibitors</cons> were <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">less than twofold (p &lt; 0.05 and p = 0.063</cons>, respectively) by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
<sentence>There were <cons sem="G_NEGATIVEEFFECT">no</cons> differences in the serum concentrations of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and hydroxyitraconazole between studies I and II.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, simvastatin, DDI)(itraconazole, HMG CoA reductase inhibitors, DDI)(itraconazole, pravastatin, NDDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increased</cons> serum concentrations of <cons lex="simvastatin" sem="G_DRUG" type="substrate_1">simvastatin</cons>, <cons lex="simvastatin" sem="G_DRUG" type="M_1">simvastatin acid</cons>, and HMG CoA reductase <cons sem="G_MECHANISM">inhibitors</cons>, <cons sem = "G_CHANGE">probably</cons> by <cons sem="G_MECHANISM">inhibiting</cons> <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons>, but it had only a <cons sem = "G_CHANGE">minor</cons> effect on <cons lex="pravastatin" sem="G_DRUG" type="substrate_2">pravastatin</cons>.</sentence>
</annotation>
<sentence>Concomitant use of potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> with <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> should be avoided or its dosage should be <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">reduced</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9536449</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> on the single oral dose pharmacokinetics of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons>.</sentence>
</title>
<abstract>
<sentence>The effect of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons>, an <cons sem="G_MECHANISM">inducer</cons> of cytochrome P450 (CYP) <cons lex="3a4" sem="G_CYP">3A4</cons>, on the single oral dose pharmacokinetics of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> was examined in a double-blind, randomized crossover study with two phases.</sentence>
<sentence>Seven healthy male subjects took <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> <cons sem="G_NUMBER">300 mg/day</cons> or matched placebo orally for 10 days, and on the 8th day they took a single oral <cons sem="G_NUMBER">0.8 mg</cons> dose of <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons>.</sentence>
<sentence>Blood samples were taken and psychomotor function was assessed by the Digit Symbol Substitution Test, Visual Analog Scale, and UKU Side Effect Rating Scale up to 48 h after <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> dosing.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Carbamazepine, alprazolam, DDI)">
<sentence><cons lex="carbamazepine" sem="G_DRUG" type="inducer_1">Carbamazepine</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">p &lt; .01 to .001</cons>) <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_IVIVPARA">plasma <cons lex="alprazolam" sem="G_DRUG" type="substrate_1">alprazolam</cons> concentrations</cons> during the elimination phase.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Carbamazepine, alprazolam, DDI)">
<sentence><cons lex="carbamazepine" sem="G_DRUG" type="inducer_1">Carbamazepine</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">p &lt; .001</cons>) <cons sem="G_CHANGE">increased</cons> the apparent <cons sem="G_IVIVPARA">oral clearance</cons> (<cons sem="G_NUMBER">0.90 +/- 0.21 vs. 2.13 +/- 0.54 ml/min/kg</cons>) and shortened the <cons sem="G_IVIVPARA">elimination half-life</cons> (<cons sem="G_NUMBER">17.1 +/- 4.9 vs. 7.7 +/- 1.7 h</cons>), with <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> effect on the <cons sem="G_IVIVPARA">peak plasma concentration</cons> (<cons sem="G_NUMBER">11.7 +/- 1.5 vs. 13.0 +/- 3.5 ng/ml</cons>).</sentence>
</annotation>
<sentence>The majority of psychomotor function parameters during the <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> treatment were <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> different from those during the placebo treatment, <cons sem = "G_CHANGE">probably</cons> because of the sedative effect of <cons lex="carbamazepine" sem="G_DRUG">carbamazepine</cons> itself.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Carbamazepine, alprazolam, DDI)">
<sentence>The present study suggests that <cons lex="carbamazepine" sem="G_DRUG" type="inducer_1">carbamazepine</cons> <cons sem="G_CHANGE">decreases</cons> <cons sem="G_IVIVPARA">plasma concentration</cons> of <cons lex="alprazolam" sem="G_DRUG" type="substrate_1">alprazolam</cons> by <cons sem="G_MECHANISM">inducing</cons> its <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
<sentence>It also supports the previous studies, suggesting that <cons lex="alprazolam" sem="G_DRUG">alprazolam</cons> is <cons sem="G_MECHANISM">metabolized</cons> predominantly by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9421099</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem="G_CHANGE">decreases</cons> <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="digoxin" sem="G_DRUG">digoxin</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem="G_CHANGE">strongly</cons> interacts with some drugs <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons>, for example, <cons lex="felodipine" sem="G_DRUG">felodipine</cons> and <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>, by <cons sem="G_MECHANISM">inhibiting</cons> their <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>A concomitant use of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem="G_CHANGE">increases</cons> the serum concentrations of <cons lex="digoxin" sem="G_DRUG">digoxin</cons>, although <cons lex="digoxin" sem="G_DRUG">digoxin</cons> is excreted mainly <cons sem="G_NEGATIVEEFFECT">unchanged</cons> in urine.</sentence>
<sentence>To reveal the mechanism of the <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>-<cons lex="digoxin" sem="G_DRUG">digoxin</cons> interaction, the effect of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> on the serum concentrations and urinary excretion of <cons lex="digoxin" sem="G_DRUG">digoxin</cons> was studied.</sentence>
<sentence>Ten healthy volunteers in a double-blind, randomized, two-phase crossover study received either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo orally once a day for 5 days.</sentence>
<sentence>On day 3, each volunteer ingested a single <cons sem="G_NUMBER">0.5-mg</cons> oral dose of <cons lex="digoxin" sem="G_DRUG">digoxin</cons>.</sentence>
<sentence>The serum concentrations of <cons lex="digoxin" sem="G_DRUG">digoxin</cons> and its excretion into urine as well as <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> were determined up to 72 hours after dosing.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, digoxin, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">area under the serum <cons lex="digoxin" sem="G_DRUG" type="substrate_1">digoxin</cons> concentration-time curve, AUC(0-72),</cons> was approximately <cons sem="G_NUMBER">50% higher (P &lt; 0.001)</cons> during the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phase than during the placebo phase.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, digoxin, ADDI)">
<sentence>In addition, the <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="digoxin" sem="G_DRUG" type="substrate_1">digoxin</cons> <cons sem="G_CHANGE">decreased</cons> about <cons sem="G_NUMBER">20% (P &lt; 0.01)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, digoxin, NDDI)">
<sentence>The <cons sem="G_CHANGE">increases</cons> in <cons lex="digoxin" sem="G_DRUG" type="substrate_1">digoxin</cons> <cons sem="G_IVIVPARA">Cmax</cons> and <cons sem="G_IVIVPARA">t(1/2)</cons> by <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> were <cons sem="G_NEGATIVEEFFECT">not</cons> statistically <cons sem="G_CHANGE">significant</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, digoxin, ADDI)">
<sentence>The <cons sem="G_CHANGE">decreased</cons> <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="digoxin" sem="G_DRUG" type="substrate_1">digoxin</cons> during the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phase partially explains <cons sem="G_CHANGE">increased</cons> concentrations of <cons lex="digoxin" sem="G_DRUG" type="substrate_1">digoxin</cons> during their concomitant use and <cons sem = "G_CHANGE">may</cons> be caused by the <cons sem="G_MECHANISM">inhibition</cons> of P-glycoprotein-mediated <cons lex="digoxin" sem="G_DRUG" type="substrate_1">digoxin</cons> secretion in the renal tubular cells.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9146848</bibliomisc>
</articleinfo>
<title>
<sentence>Enhanced effect of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> with <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="triazolam" sem="G_DRUG">Triazolam</cons>, a triazolobenzodiazepine hypnotic agent, is <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence><cons lex="diltiazem" sem="G_DRUG">Diltiazem</cons> is an <cons sem="G_MECHANISM">inhibitor</cons> of this isozyme.</sentence>
<sentence>The aim of this study was to determine if <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> affects <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> in humans.</sentence>
<sentence>We investigated the interaction between <cons lex="triazolam" sem="G_DRUG">triazolam</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> in a randomized, three-phase crossover study.</sentence>
<sentence>Seven healthy male volunteers received orally either a single <cons sem="G_NUMBER">0.25 mg</cons> dose of <cons lex="triazolam" sem="G_DRUG">triazolam</cons>, a <cons sem="G_NUMBER">0.25 mg</cons> dose of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> after a 3-day treatment of <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> (<cons sem="G_NUMBER">180 mg day-1</cons>), or a placebo.</sentence>
<sentence>Plasma samples were collected to determine <cons lex="triazolam" sem="G_DRUG">triazolam</cons> concentration over a 24 h period.</sentence>
<sentence>The pharmacodynamic effects of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> were investigated using the peak saccadic velocity of eye movements (PSV), electroencephalogram (EEG), and visual analogue scale (VAS) through 8 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(Diltiazem, triazolam, DDI)">
<sentence><cons lex="diltiazem" sem="G_DRUG" type="inhibitor_1">Diltiazem</cons> pretreatment <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> concentration-time curve</cons> (<cons sem="G_NUMBER">8.0 +/- 2.4 to 18.2 +/- 3.1 ng ml-1 h; P &lt; 0.001; mean +/- s.d.</cons>).</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(Diltiazem, triazolam, DDI)">
<sentence><cons sem="G_IVIVPARA">Peak <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> concentration</cons> was <cons sem="G_CHANGE">increased</cons> (<cons sem="G_NUMBER">2.1 +/- 0.7 to 3.6 +/- 1.0 ng ml-1, P &lt; 0.05</cons>) and the <cons sem="G_IVIVPARA">elimination half-life</cons> prolonged (<cons sem="G_NUMBER">4.1 +/- 2.1 to 7.6 +/- 1.9 h; P &lt; 0.01</cons>).</sentence>
</annotation>
<sentence>The PSV, EEG, and VAS of the <cons lex="triazolam" sem="G_DRUG">triazolam</cons> plus <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> group revealed <cons sem="G_CHANGE">significant</cons> differences from the <cons lex="triazolam" sem="G_DRUG">triazolam</cons> alone group or the control placebo group.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Diltiazem, triazolam, DDI)">
<sentence><cons lex="diltiazem" sem="G_DRUG" type="inhibitor_1">Diltiazem</cons> <cons sem="G_CHANGE">markedly</cons> affects the pharmacokinetics of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> and <cons sem="G_CHANGE">increases</cons> the intensity of its sedative effects.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons> isozyme by <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> <cons sem = "G_CHANGE">may</cons> explain the observed pharmacokinetic interaction.</sentence>
<sentence>Therefore, <cons lex="triazolam" sem="G_DRUG">triazolam</cons> should be avoided when patients are using <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9129558</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> and effects of <cons lex="felodipine" sem="G_DRUG">felodipine</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="felodipine" sem="G_DRUG">Felodipine</cons>, a dihydropyridine calcium antagonist, is extensively <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> <cons sem="G_CHANGE">strongly</cons> interacts with some of the substrates of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (e.g., <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons>, <cons lex="triazolam" sem="G_DRUG">triazolam</cons> and <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>); hence it is important to uncover the possible interaction of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> with <cons lex="felodipine" sem="G_DRUG">felodipine</cons>.</sentence>
<sentence>A double-blind, randomized, two-phase crossover design was used to investigate the interaction between <cons lex="felodipine" sem="G_DRUG">felodipine</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
<sentence>Nine healthy volunteers received either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo orally once a day for 4 days.</sentence>
<sentence>On day 4, each ingested a single <cons sem="G_NUMBER">5 mg</cons> oral dose of <cons lex="felodipine" sem="G_DRUG">felodipine</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="felodipine" sem="G_DRUG">felodipine</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> were determined and systolic and diastolic blood pressures and heart rate were measured up to 32 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, felodipine, DDI)">
<sentence>On average, <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak plasma concentration</cons> (<cons sem="G_IVIVPARA">Cmax</cons>) of <cons lex="felodipine" sem="G_DRUG" type="substrate_1">felodipine</cons> nearly <cons sem="G_NUMBER">eightfold (p &lt; 0.001)</cons>, the <cons sem="G_IVIVPARA">areas under the <cons lex="felodipine" sem="G_DRUG" type="substrate_1">felodipine</cons> concentration-time curve  [AUC(0-32) and <cons sem="G_IVIVPARA">AUC</cons>(0-infinity)]</cons> about <cons sem="G_NUMBER">sixfold (p &lt; 0.001)</cons>, and the <cons sem="G_IVIVPARA">elimination half-life</cons> <cons sem="G_NUMBER">twofold (p &lt; 0.05)</cons>.</sentence>
</annotation>
<sentence>In seven of the nine subjects, even the <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="felodipine" sem="G_DRUG">felodipine</cons> was lower <cons sem="G_NEGATIVEEFFECT">without</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> than the 32-hour concentrations during the <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> phase.</sentence>
<sentence>The <cons sem="G_CHANGE">decreases</cons> in blood pressure and the <cons sem="G_CHANGE">increases</cons> in heart rate were <cons sem="G_CHANGE">significantly</cons> <cons sem = "G_CHANGE">greater</cons> during the <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> phase than during the placebo phase.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, felodipine, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> and effects of oral <cons lex="felodipine" sem="G_DRUG" type="substrate_1">felodipine</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> during the first-pass and elimination phases of <cons lex="felodipine" sem="G_DRUG">felodipine</cons> seems to be the mechanism of the observed interaction.</sentence>
<sentence>The concomitant use of <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> and some other azole antifungals with <cons lex="felodipine" sem="G_DRUG">felodipine</cons> and other dihydropyridine calcium antagonists should be avoided or their doses should be <cons sem="G_CHANGE">reduced</cons> accordingly.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9088587</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> on the pharmacokinetics of <cons lex="imipramine" sem="G_DRUG">imipramine</cons> and <cons lex="desipramine" sem="G_DRUG">desipramine</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence>The aim of the study was to characterize further the role of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> in the <cons sem="G_MECHANISM">metabolism</cons> of tricyclic antidepressants.</sentence>
<sentence>The effect of oral <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> (<cons sem="G_NUMBER">200 mg day-1</cons> for 14 days) on the kinetics of a single oral dose of <cons lex="imipramine" sem="G_DRUG">imipramine</cons> (<cons sem="G_NUMBER">100 mg</cons>) and <cons lex="desipramine" sem="G_DRUG">desipramine</cons> (<cons sem="G_NUMBER">100 mg</cons>) was evaluated in two groups of six healthy male subjects.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, imipramine, ADDI)(Ketoconazole, desipramine , DDI)">
<sentence><cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">Ketoconazole</cons> administration was associated with a <cons sem="G_CHANGE">decrease</cons> in <cons lex="imipramine" sem="G_DRUG" type="substrate_1">imipramine</cons> apparent <cons sem="G_IVIVPARA">oral clearance</cons> (from <cons sem="G_NUMBER">1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P &lt; 0.02</cons>), a prolongation in <cons lex="imipramine" sem="G_DRUG" type="substrate_1">imipramine</cons> <cons sem="G_IVIVPARA">half-life</cons> (from <cons sem="G_NUMBER">16.7 +/- 3.3 to 19.2 +/- 5.4 h, P &lt; 0.05</cons>) and a <cons sem="G_CHANGE">decrease</cons> in <cons sem="G_IVIVPARA">area under the curve</cons> of metabolically derived <cons lex="desipramine" sem="G_DRUG" type="substrate_2">desipramine</cons> (from <cons sem="G_NUMBER">3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P &lt; 0.05)</cons>, whereas concentrations of <cons lex="imipramine" sem="G_DRUG" type="M_1">2-hydroxy-imipramine</cons> were <cons sem="G_NEGATIVEEFFECT">unaffected</cons>.</sentence>
</annotation>
<sentence>In the subjects given <cons lex="desipramine" sem="G_DRUG">desipramine</cons>, <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> in <cons lex="desipramine" sem="G_DRUG">desipramine</cons> and <cons lex="imipramine" sem="G_DRUG" type="M_1">2-hydroxy-desipramine</cons> kinetics were observed during <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> treatment.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Ketoconazole, imipramine, DDI)(Ketoconazole, desipramine , DDI)">
<sentence>These findings indicate that <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons>, a relatively specific <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, <cons sem="G_MECHANISM">inhibits</cons> the N-demethylation of <cons lex="imipramine" sem="G_DRUG" type="substrate_1">imipramine</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> affecting the 2-hydroxylation of <cons lex="imipramine" sem="G_DRUG" type="substrate_1">imipramine</cons> and <cons lex="desipramine" sem="G_DRUG" type="substrate_2">desipramine</cons>.</sentence>
</annotation>
<sentence>This interaction, confirms that <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> plays a role in the demethylation of tricyclic antidepressants.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9068933</bibliomisc>
</articleinfo>
<title>
<sentence>A study of the potential effect of <cons lex="sertraline" sem="G_DRUG">sertraline</cons> on the pharmacokinetics and protein binding of <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons>.</sentence>
</title>
<abstract>
<sentence>The effect of the selective serotonin reuptake <cons sem="G_MECHANISM">inhibitor</cons> (SSRI) <cons lex="sertraline" sem="G_DRUG">sertraline</cons> <cons sem="G_NUMBER">200 mg/day</cons> on the <cons sem="G_MECHANISM">metabolism</cons> of intravenously administered <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons> was examined in a randomised nonblinded parallel-group study in 25 healthy male volunteers.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(sertraline, tolbutamide, ADDI)">
<sentence>There was a small but statistically <cons sem="G_CHANGE">significant</cons> <cons sem="G_CHANGE">decrease</cons> (<cons sem="G_NUMBER">16%</cons>) in the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="tolbutamide" sem="G_DRUG" type="substrate_1">tolbutamide</cons> in patients receiving the maximum recommended dosage of <cons lex="sertraline" sem="G_DRUG" type="inhibitor_1">sertraline</cons>.</sentence>
</annotation>
<sentence>The terminal elimination rate constant was also <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons>, corresponding to the <cons sem="G_CHANGE">increase</cons> in the <cons sem="G_IVIVPARA">terminal elimination half-life</cons> (from <cons sem="G_NUMBER">6.9 to 8.6 hours</cons>).</sentence>
<sentence>The <cons sem="G_CHANGE">decrease</cons> in <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> associated with any <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> in plasma protein binding or in the apparent volume of distribution of <cons lex="tolbutamide" sem="G_DRUG">tolbutamide</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(sertraline, tolbutamide, ADDI)">
<sentence>This suggests that the <cons sem = "G_CHANGE">change</cons> in <cons lex="tolbutamide" sem="G_DRUG" type="substrate_1">tolbutamide</cons> <cons sem="G_IVIVPARA">clearance</cons> <cons sem = "G_CHANGE">may</cons> be due to a <cons sem="G_CHANGE">slight</cons> <cons sem="G_MECHANISM">inhibition</cons> of the cytochrome P450 (CYP) isoenzyme <cons sem="G_CYP">CYP2C9/10</cons> when <cons lex="sertraline" sem="G_DRUG" type="inhibitor_1">sertraline</cons> was administered in its maximum recommended dosage.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(sertraline, tolbutamide, NDDI)">
<sentence>However, the small <cons sem ="G_CHANGE">changes</cons> in the volume of distribution and plasma binding of <cons lex="tolbutamide" sem="G_DRUG" type="substrate_1">tolbutamide</cons> after <cons lex="sertraline" sem="G_DRUG" type="inhibitor_1">sertraline</cons> treatment indicate that there is a minimal interaction between <cons lex="sertraline" sem="G_DRUG" type="inhibitor_1">sertraline</cons> and <cons lex="tolbutamide" sem="G_DRUG" type="substrate_1">tolbutamide</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:9049584</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of route of administration of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> on the interaction between <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> and <cons lex="midazolam" sem="G_DRUG">midazolam</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="midazolam" sem="G_DRUG">Midazolam</cons> is a short-acting benzodiazepine hypnotic extensively <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> enzyme.</sentence>
<sentence>Orally ingested azole antimycotics, including <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons>, interfere with the <cons sem="G_MECHANISM">metabolism</cons> of oral <cons lex="midazolam" sem="G_DRUG">midazolam</cons> during its absorption and elimination phases.</sentence>
<sentence>We compared the effect of oral and intravenous <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> on the pharmacokinetics and pharmacodynamics of orally ingested <cons lex="midazolam" sem="G_DRUG">midazolam</cons>.</sentence>
<sentence>A double-dummy, randomized, cross-over study in three phases was performed in 9 healthy volunteers.</sentence>
<sentence>The subjects were given orally <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> <cons sem="G_NUMBER">400 mg</cons> and intravenously saline within 60 min; orally placebo and intravenously <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> <cons sem="G_NUMBER">400 mg</cons>; and orally placebo and intravenously saline.</sentence>
<sentence>An oral dose of <cons sem="G_NUMBER">7.5 mg</cons> <cons lex="midazolam" sem="G_DRUG">midazolam</cons> was ingested 60 min after oral intake of fluconazole/placebo, i.e. at the end of the corresponding infusion.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, <cons lex="midazolam" sem="G_DRUG" type="M_1">alpha-hydroxymidazolam</cons> and <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> were determined and pharmacodynamic effects were measured up to 17 h. </sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluconazole, midazolam, DDI)">
<sentence>Both oral and intravenous <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> plasma concentration-time curve (AUC0-3, AUC0-17)</cons> <cons sem="G_NUMBER">2- to 3-fold</cons>, the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> <cons sem="G_NUMBER">2.5-fold</cons> and its <cons sem="G_IVIVPARA">peak concentration (Cmax)</cons> <cons sem="G_NUMBER">2- to 2.5-fold</cons> compared with placebo.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluconazole, midazolam, DDI)">
<sentence>The <cons sem="G_IVIVPARA">AUC0-3</cons> and the <cons sem="G_IVIVPARA">Cmax</cons> of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> were <cons sem="G_CHANGE">significantly</cons> higher after oral than after intravenous administration of <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluconazole, midazolam, DDI)">
<sentence>Both oral and intravenous <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons> <cons sem="G_CHANGE">increased</cons> the pharmacodynamic effects of <cons lex="midazolam" sem="G_DRUG" type="substrate_1">midazolam</cons> but <cons sem="G_NEGATIVEEFFECT">no</cons> differences were detected between the <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons> phases.</sentence>
</annotation>
<sentence>We conclude that the <cons sem="G_MECHANISM">metabolism</cons> of orally administered <cons lex="midazolam" sem="G_DRUG">midazolam</cons> was more <cons sem="G_CHANGE">strongly</cons> <cons sem="G_MECHANISM">inhibited</cons> by oral than by intravenous administration of <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8894514</bibliomisc>
</articleinfo>
<title>
<sentence>The <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons>-<cons lex="rifampin" sem="G_DRUG">rifampin</cons> interaction. Evidence for <cons sem="G_MECHANISM">induction</cons> of gut wall <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</title>
<abstract>
<sentence>The calcium channel blocker <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> is <cons sem="G_MECHANISM">metabolized</cons> by cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons>, which is present in liver and mucosa of the small bowel.</sentence>
<sentence>Cytochrome P450 <cons lex="3a4" sem="G_CYP">3A4</cons> is <cons sem="G_MECHANISM">inducible</cons> by the tuberculostatic <cons lex="rifampin" sem="G_DRUG">rifampin</cons> in liver and the small bowel.</sentence>
<sentence>The contribution of gut wall <cons sem="G_MECHANISM">metabolism</cons> to total <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> before and during <cons sem="G_MECHANISM">induction</cons> has <cons sem="G_NEGATIVEEFFECT">not</cons> been determined in detail.</sentence>
<sentence>We therefore investigated the <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons>-<cons lex="rifampin" sem="G_DRUG">rifampin</cons> interaction, with special emphasis on the contribution of gut wall <cons sem="G_MECHANISM">metabolism</cons> to total <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> before and during administration of <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
<sentence>Pharmacokinetics of <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> were studied in six healthy volunteers on separate days by administration of <cons sem="G_NUMBER">20 micrograms/kg</cons> body weight <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> iv and <cons sem="G_NUMBER">20 mg</cons> <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> orally before and after 7 days of <cons lex="rifampin" sem="G_DRUG">rifampin</cons> treatment (<cons sem="G_NUMBER">600 mg/day</cons>).</sentence>
<sentence>Enzyme <cons sem="G_MECHANISM">induction</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> alter pharmacokinetics of <cons lex="nifedipine" sem="G_DRUG">nifedipine</cons> after iv administration.</sentence>
<annotation sem="INVIVOVDDIS" ddi="(rifampin, nifedipine, DDI)">
<sentence>In contrast, <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="nifedipine" sem="G_DRUG" type="substrate_1">nifedipine</cons> <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">1.5 +/- 0.2 liters/min to 20.9 +/- 8.3 liters/min (p &lt; 0.01)</cons> and <cons sem="G_IVIVPARA">bioavailability</cons> <cons sem="G_CHANGE">decreased</cons> from <cons sem="G_NUMBER">41.2 +/- 5.4% to 5.3 +/- 2.7% (p &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(rifampin, nifedipine, DDI)">
<sentence>Although hepatic extraction of <cons lex="nifedipine" sem="G_DRUG" type="substrate_1">nifedipine</cons> was <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">altered</cons> during <cons sem="G_MECHANISM">induction</cons> (<cons sem="G_NUMBER">47.4 +/- 6.6% versus 67.4 +/- 20.2%; ns</cons>), the calculated extraction of <cons lex="nifedipine" sem="G_DRUG" type="substrate_1">nifedipine</cons> in gut wall mucosa <cons sem="G_CHANGE">increased</cons> from <cons sem="G_NUMBER">21.8 +/- 13.3% to 75.8 +/- 28.2% (p &lt; 0.05)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, nifedipine, DDI)">
<sentence>We conclude that there is a relevant interaction between <cons lex="nifedipine" sem="G_DRUG" type="substrate_1">nifedipine</cons> and <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, nifedipine, DDI)">
<sentence>The <cons sem ="G_CHANGE">reduction</cons> of <cons lex="nifedipine" sem="G_DRUG" type="substrate_1">nifedipine</cons> <cons sem="G_IVIVPARA">bioavailability</cons> during enzyme <cons sem="G_MECHANISM">induction</cons> is most likely due to <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons>-<cons sem="G_MECHANISM">induced</cons> gut wall <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8855178</bibliomisc>
</articleinfo>
<title>
<sentence>Differential <cons sem="G_MECHANISM">induction</cons> of prehepatic and hepatic <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> by <cons lex="rifampin" sem="G_DRUG">rifampin</cons>.</sentence>
</title>
<abstract>
<sentence>Cytochrome P450 (CYP) enzymes, which <cons sem="G_MECHANISM">metabolize</cons> numerous drugs, are expressed both in liver and in extrahepatic tissues.</sentence>
<sentence><cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> for example is present and <cons sem="G_MECHANISM">inducible</cons> by <cons lex="rifampin" sem="G_DRUG">rifampin</cons> in epithelial cells of the gastrointestinal tract.</sentence>
<sentence>It has been shown that such prehepatic <cons sem="G_MECHANISM">metabolism</cons> contributes substantially to total <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> substrates (e.g., <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons>) before and even more <cons sem = "G_CHANGE">pronounced</cons> during enzyme <cons sem="G_MECHANISM">induction</cons>.</sentence>
<sentence>We examined the effect of enzyme <cons sem="G_MECHANISM">induction</cons> on prehepatic and hepatic <cons sem="G_MECHANISM">metabolism</cons> of the model compound R/S-<cons lex="verapamil" sem="G_DRUG">verapamil</cons> after simultaneous oral and intravenous administration using a stable isotope technology.</sentence>
<sentence>This approach allows us to exclude intraindividual day-to-day variability and is therefore suitable to quantitatively assess prehepatic extraction of high-<cons sem="G_IVIVPARA">clearance</cons> drugs.</sentence>
<sentence>Moreover, because <cons lex="verapamil" sem="G_DRUG">verapamil</cons> is administered as a race-mate with the S-enantiomer being preferentially <cons sem="G_MECHANISM">metabolized</cons>, we investigated the influence of <cons sem="G_MECHANISM">induction</cons> on stereoselectivity of prehepatic and hepatic <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>Eight male volunteers received <cons sem="G_NUMBER">120 mg</cons> of racemic <cons lex="verapamil" sem="G_DRUG">verapamil</cons> bid for 24 days.</sentence>
<sentence><cons lex="rifampin" sem="G_DRUG">Rifampin</cons> (<cons sem="G_NUMBER">600 mg daily</cons>) was given from day 5 to day 16.</sentence>
<sentence>Systemic <cons sem="G_IVIVPARA">clearance</cons> and <cons sem="G_IVIVPARA">bioavailability</cons> of the <cons lex="verapamil" sem="G_DRUG">verapamil</cons> enantiomers were determined by coadministering deuterated <cons lex="verapamil" sem="G_DRUG">verapamil</cons> intravenously on day 4, on day 16, and on day 24.</sentence>
<sentence>Effects of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> on atrioventricular conduction after oral and intravenous (iv) administration were assessed by measuring the maximum PR-interval prolongation <cons lex="rifampin" sem="G_DRUG">Rifampin</cons> <cons sem="G_CHANGE">increased</cons> the systemic <cons sem="G_IVIVPARA">clearance</cons> of the active <cons lex="verapamil" sem="G_DRUG">S-verapamil</cons> <cons sem="G_NUMBER">1.3-fold (P &lt; .001)</cons>.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin, S-verapamil, DDI)">
<sentence>In contrast, <cons lex="rifampin" sem="G_DRUG" type="inducer_1">rifampin</cons> <cons sem="G_CHANGE">increased</cons> the apparent <cons sem="G_IVIVPARA">oral clearance</cons> of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">S-verapamil</cons> <cons sem="G_NUMBER">32-fold (P &lt; .001)</cons> and <cons sem="G_CHANGE">decreased</cons> its <cons sem="G_IVIVPARA">bioavailability</cons> <cons sem="G_NUMBER">25-fold (P &lt; .001)</cons>, with partial recovery after <cons lex="rifampin" sem="G_DRUG">rifampin</cons> withdrawal (<cons sem="G_NUMBER">P &lt; .01</cons>).</sentence>
</annotation>
<sentence>With <cons lex="rifampin" sem="G_DRUG">rifampin</cons>, the effect of oral <cons lex="verapamil" sem="G_DRUG" >verapamil</cons> on atrioventricular conduction was nearly abolished (<cons sem="G_NUMBER">P &lt; .01</cons>), whereas <cons sem="G_NEGATIVEEFFECT">no</cons> <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> were observed after intravenous administration.</sentence>
<sentence><cons sem="G_MECHANISM">Induction</cons> caused a considerable <cons sem ="G_CHANGE">reduction</cons> of stereoselectivity after both intravenous and oral administration (<cons sem="G_NUMBER">P &lt; .001</cons>).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(rifampin,verapamil, DDI)">
<sentence><cons lex="rifampin" sem="G_DRUG" type="inducer_1">Rifampin</cons> <cons sem="G_CHANGE">altered</cons> the pharmacokinetics and the pharmacological effects of <cons lex="verapamil" sem="G_DRUG" type="substrate_1">verapamil</cons> to a much <cons sem = "G_CHANGE">greater</cons> extent after oral administration compared with intravenous administration.</sentence>
</annotation>
<sentence>These data clearly indicate that prehepatic <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> (presumably in the gut wall) is preferentially <cons sem="G_MECHANISM">induced</cons> compared with hepatic <cons sem="G_MECHANISM">metabolism</cons> and that stereoselectivity of <cons lex="verapamil" sem="G_DRUG">verapamil</cons> <cons sem="G_MECHANISM">metabolism</cons> is <cons sem="G_CHANGE">affected</cons> by <cons sem="G_MECHANISM">induction</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8819499</bibliomisc>
</articleinfo>
<title>
<sentence>Pharmacogenetic determination of the effects of <cons lex="codeine" sem="G_DRUG">codeine</cons> and prediction of drug interactions.</sentence>
</title>
<abstract>
<sentence>To define the differences in <cons lex="codeine" sem="G_DRUG">codeine</cons> pharmacodynamics in extensive (EMs) and poor (PMs) <cons sem="G_MECHANISM">metabolizers</cons> of debrisoquin and to determine whether the <cons sem="G_MECHANISM">inhibition</cons> of codeine's <cons sem="G_MECHANISM">metabolism</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons> produces phenotypically dependent pharmacodynamic <cons sem ="G_CHANGE">changes</cons>, we studied 16 healthy nonsmoking males, 10 EMs and 6 PMs of debrisoquin.</sentence>
<sentence>The subjects received in random double-blind fashion <cons sem="G_NUMBER">120 mg</cons> of <cons lex="codeine" sem="G_DRUG">codeine</cons> plus placebo, <cons sem="G_NUMBER">120 mg</cons> of <cons lex="codeine" sem="G_DRUG">codeine</cons> plus <cons sem="G_NUMBER">100 mg</cons> of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> and <cons sem="G_NUMBER">100 mg</cons> of <cons lex="quinidine" sem="G_DRUG">quinidine</cons> plus placebo.</sentence>
<sentence>Blood was obtained over 24 hr and urine was collected for 48 hr.</sentence>
<sentence>Respiratory, psychomotor and pupillary effects of <cons lex="codeine" sem="G_DRUG">codeine</cons> were <cons sem = "G_CHANGE">greater</cons> in the EMs than in the PMs (<cons sem="G_NUMBER">P &lt; .01</cons>).</sentence>
<sentence><cons lex="morphine" sem="G_DRUG">Morphine</cons> and <cons lex="morphine" sem="G_DRUG">morphine</cons> metabolites were detectable only in plasma from EMs.</sentence>
<sentence><cons lex="codeine" sem="G_DRUG">Codeine</cons> metabolic <cons sem="G_IVIVPARA">clearance</cons> by O-demethylation was almost <cons sem="G_NUMBER">200-fold</cons> <cons sem = "G_CHANGE">greater</cons> in the EMs than in the PMs.</sentence>
<sentence>After coadministration of <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, <cons lex="morphine" sem="G_DRUG">morphine</cons> and <cons lex="morphine" sem="G_DRUG">morphine</cons> metabolites were <cons sem="G_NEGATIVEEFFECT">not</cons> detectable in the plasma of either phenotype and mean (+/- S.E.M.) O-demethylation <cons sem="G_IVIVPARA">clearance</cons> was <cons sem="G_CHANGE">reduced</cons> in the EMs from <cons sem="G_NUMBER">162.7 +/- 36.6 to 17.0 +/- 5.0 ml/min (P &lt; .003)</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> in the PMs.</sentence>
<sentence>The diminished production of <cons lex="morphine" sem="G_DRUG">morphine</cons> in the EMs was associated with <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> respiratory, psychomotor and pupillary effects (<cons sem="G_NUMBER">P &lt; .01</cons>).</sentence>
<sentence>Thus, <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> mediated O-demethylation of <cons lex="codeine" sem="G_DRUG">codeine</cons> to <cons lex="morphine" sem="G_DRUG">morphine</cons> is central to its pharmacodynamic effects.</sentence>
<sentence>Patients who lack <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> or whose <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> is <cons sem="G_MECHANISM">inhibited</cons> would <cons sem="G_NEGATIVEEFFECT">not</cons> be expected to benefit from <cons lex="codeine" sem="G_DRUG">codeine</cons>.</sentence>
<sentence>Thus, phenotyping for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> and the avoidance of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> <cons sem="G_MECHANISM">inhibitors</cons> is justified in patients with chronic path before initiating long-term therapy with analgesics whose in vivo <cons sem="G_MECHANISM">activation</cons> is dependent on <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity (i.e., <cons lex="codeine" sem="G_DRUG">codeine</cons>, <cons lex="hydrocodone" sem="G_DRUG">hydrocodone</cons> and <cons lex="oxycodone" sem="G_DRUG">oxycodone</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8689812</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="itraconazole" sem="G_DRUG">Itraconazole</cons> drastically <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> and <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> acid.</sentence>
</title>
<abstract>
<sentence><cons lex="lovastatin" sem="G_DRUG">Lovastatin</cons> is a <cons lex="cholesterol" sem="G_DRUG">cholesterol</cons>-lowering drug that can cause myopathy as a rare side effect.</sentence>
<sentence>Concomitant use of certain drugs (e.g., <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons>) <cons sem="G_CHANGE">increases</cons> the risk of skeletal muscle toxicity.</sentence>
<sentence><cons lex="lovastatin" sem="G_DRUG">Lovastatin</cons> is <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Because <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>, we wanted to study a possible interaction between these drugs.</sentence>
<sentence>In this double-blind, randomized, two-phase crossover study, 12 healthy volunteers received either <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> or placebo orally once a day for 4 days.</sentence>
<sentence>On day 4, each subject ingested a single <cons sem="G_NUMBER">40 mg</cons> dose of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons>, <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> acid, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, hydroxyitraconazole, and <cons lex="creatine" sem="G_DRUG">creatine</cons> kinase were measured up to 24 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, lovastatin, DDI)">
<sentence>On average, <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">peak concentration (Cmax)</cons> of <cons lex="lovastatin" sem="G_DRUG" type="substrate_1">lovastatin</cons> and the <cons sem="G_IVIVPARA">area under the <cons lex="lovastatin" sem="G_DRUG" type="substrate_1">lovastatin</cons> concentration-time curve (AUC)</cons> <cons sem="G_NUMBER">more than twentyfold (p &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOVDDIS" ddi="(itraconazole, lovastatin, DDI)">
<sentence>The mean <cons sem="G_IVIVPARA">Cmax</cons> of the active metabolite, <cons lex="lovastatin" sem="G_DRUG" type="M_1">lovastatin acid</cons>, was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">13-fold (range, tenfold to 23-fold; p &lt; 0.001)</cons> and the <cons sem="G_IVIVPARA">AUC(0-24)</cons> <cons sem="G_NUMBER">twentyfold (p &lt; 0.001).</cons></sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, lovastatin, DDI)">
<sentence>In one subject plasma <cons lex="creatine" sem="G_DRUG">creatine</cons> kinase was <cons sem="G_CHANGE">increased</cons> <cons sem="G_NUMBER">tenfold</cons> within 24 hours of <cons lex="lovastatin" sem="G_DRUG" type="substrate_1">lovastatin</cons> administration during the <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">itraconazole</cons> phase but <cons sem="G_NEGATIVEEFFECT">not</cons> during the placebo phase.</sentence>
</annotation>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem="G_CHANGE">increase</cons> in <cons lex="creatine" sem="G_DRUG">creatine</cons> kinase was observed in the other subjects.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(itraconazole, lovastatin, DDI)">
<sentence><cons lex="itraconazole" sem="G_DRUG" type="inhibitor_1">Itraconazole</cons> <cons sem = "G_CHANGE">greatly</cons> <cons sem="G_CHANGE">increases</cons> <cons sem="G_IVIVPARA">plasma concentrations</cons> of <cons lex="lovastatin" sem="G_DRUG" type="substrate_1">lovastatin</cons> and <cons lex="lovastatin" sem="G_DRUG" type="M_1">lovastatin acid</cons>.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> <cons sem = "G_CHANGE">probably</cons> explains the <cons sem="G_CHANGE">increased</cons> toxicity of <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> caused <cons sem="G_NEGATIVEEFFECT">not</cons> only by <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> but also by <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons>, <cons lex="erythromycin" sem="G_DRUG">erythromycin</cons>, and other <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence>Their concomitant use with <cons lex="lovastatin" sem="G_DRUG">lovastatin</cons> and <cons lex="simvastatin" sem="G_DRUG">simvastatin</cons> should be avoided, or the dose of 3-hydroxy-3-methylglutaryl coenzyme A reductase <cons sem="G_MECHANISM">inhibitors</cons> should be <cons sem="G_CHANGE">reduced</cons> accordingly.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8730978</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="fluconazole" sem="G_DRUG">Fluconazole</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons lex="terbinafine" sem="G_DRUG">terbinafine</cons>, enhances the effects of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>The interaction between <cons lex="triazolam" sem="G_DRUG">triazolam</cons> and two antifungal agents, <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons> and <cons lex="terbinafine" sem="G_DRUG">terbinafine</cons>, was investigated in a double-blind, randomized crossover study of three phases.</sentence>
<sentence>2.</sentence>
<sentence>Twelve healthy young volunteers received <cons sem="G_NUMBER">100 mg</cons> <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons>, <cons sem="G_NUMBER">250 mg</cons> <cons lex="terbinafine" sem="G_DRUG">terbinafine</cons> or placebo orally once a day for 4 days.</sentence>
<sentence>On day 4 they took a single <cons sem="G_NUMBER">0.25 mg</cons> dose of <cons lex="triazolam" sem="G_DRUG">triazolam</cons>.</sentence>
<sentence>Plasma samples were collected and pharmacodynamic effects were measured up to 17 h after the intake of <cons lex="triazolam" sem="G_DRUG">triazolam</cons>.</sentence>
<sentence>3.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluconazole, triazolam, DDI)">
<sentence><cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">Fluconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> concentration time-curve</cons> more than <cons sem="G_NUMBER">twofold (P &lt; 0.001)</cons> and prolonged the <cons sem="G_IVIVPARA">elimination half-life</cons> of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> nearly <cons sem="G_NUMBER">twofold (P &lt; 0.001)</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Fluconazole, triazolam, DDI)">
<sentence>The <cons sem="G_IVIVPARA">peak concentration</cons> of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> was also <cons sem="G_CHANGE">increased</cons> <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">P &lt; 0.05</cons>) by <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons>.</sentence>
</annotation>
<sentence>4.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Fluconazole, triazolam, DDI)">
<sentence>During the <cons lex="fluconazole" sem="G_DRUG" type="inhibitor_1">fluconazole</cons> phase pharmacodynamic effects of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> (e.g. digit symbol substitution test, body sway and drowsiness) were enhanced <cons sem="G_CHANGE">significantly</cons> (<cons sem="G_NUMBER">P &lt; 0.05</cons>) when compared with the placebo phase.</sentence>
</annotation>
<sentence>5.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Terbinafine , triazolam, NDDI)">
<sentence><cons lex="terbinafine" sem="G_DRUG" type="inhibitor_2">Terbinafine</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem = "G_CHANGE">change</cons> <cons sem="G_CHANGE">significantly</cons> the pharmacokinetics or pharmacodynamics of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons>.</sentence>
</annotation>
<sentence>6.</sentence>
<sentence>Care should be taken when <cons lex="triazolam" sem="G_DRUG">triazolam</cons> is prescribed to patients using <cons lex="fluconazole" sem="G_DRUG">fluconazole</cons>.</sentence>
<sentence>Although the interaction is <cons sem="G_NEGATIVEEFFECT">not</cons> as <cons sem="G_CHANGE">strong</cons> as that of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> with <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> or <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, it is clinically <cons sem="G_CHANGE">significant</cons>.</sentence>
<sentence><cons lex="triazolam" sem="G_DRUG">Triazolam</cons> and <cons sem = "G_CHANGE">probably</cons> other drugs <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> can be used in normal doses with <cons lex="terbinafine" sem="G_DRUG">terbinafine</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8612379</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="diltiazem" sem="G_DRUG">Diltiazem</cons> enhances the effects of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> by <cons sem="G_MECHANISM">inhibiting</cons> its <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="triazolam" sem="G_DRUG">Triazolam</cons> is <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons>.</sentence>
<sentence><cons lex="diltiazem" sem="G_DRUG">Diltiazem</cons> is an <cons sem="G_MECHANISM">inhibitor</cons> of this isozyme and interacts with <cons lex="midazolam" sem="G_DRUG">midazolam</cons>, another substrate of this enzyme.</sentence>
<sentence>Therefore the possible interaction between <cons lex="triazolam" sem="G_DRUG">triazolam</cons> and <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> is worth investigation.</sentence>
<sentence>A balanced, randomized, double-blind crossover study design was used, with an interval of 2 weeks between phases.</sentence>
<sentence>Ten healthy volunteers were given <cons sem="G_NUMBER">60 mg</cons> <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> orally or placebo three times a day for 2 days.</sentence>
<sentence>On the second day they received a single <cons sem="G_NUMBER">0.25 mg</cons> oral dose of <cons lex="triazolam" sem="G_DRUG">triazolam</cons>, after which plasma samples were collected and effects of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> measured for up to 17 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Diltiazem, triazolam, DDI)">
<sentence><cons lex="diltiazem" sem="G_DRUG" type="inhibitor_1">Diltiazem</cons> <cons sem="G_CHANGE">increased</cons> the mean <cons sem="G_IVIVPARA">area under the <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> concentration-time curve</cons> <cons sem="G_NUMBER">threefold (p &lt; 0.001)</cons> and the <cons sem="G_IVIVPARA">elimination half-life</cons> (<cons sem="G_NUMBER">p &lt; 0.001</cons>) and the <cons sem="G_IVIVPARA">peak plasma concentration</cons> of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> <cons sem="G_NUMBER">twofold (p &lt; 0.005)</cons>.</sentence>
</annotation>
<sentence>The <cons sem="G_CHANGE">increased</cons> concentrations of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> during the <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> phase were associated with <cons sem="G_CHANGE">increased</cons> and prolonged pharmacodynamic effects.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Diltiazem, triazolam, DDI)">
<sentence><cons lex="diltiazem" sem="G_DRUG" type="inhibitor_1">Diltiazem</cons> has a clinically <cons sem="G_CHANGE">significant</cons> interaction with oral <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Diltiazem, triazolam, DDI)">
<sentence>The data is highly suggestive that <cons lex="diltiazem" sem="G_DRUG" type="inhibitor_1">diltiazem</cons> <cons sem="G_MECHANISM">inhibits</cons> the <cons sem="G_MECHANISM">metabolism</cons> of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> during the first-pass and elimination phases.</sentence>
</annotation>
<sentence>Prescription of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> should be avoided if a patient is using <cons lex="diltiazem" sem="G_DRUG">diltiazem</cons> or other potent <cons sem="G_MECHANISM">inhibitors</cons> of <cons lex="cyp3a" sem="G_CYP">CYP3A</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8820427</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="metoprolol" sem="G_DRUG">Metoprolol</cons> <cons sem="G_MECHANISM">metabolism</cons> via cytochrome P4502D6 in ethnic populations.</sentence>
</title>
<abstract>
<sentence>The objective of this study was to determine whether <cons sem="G_MECHANISM">metabolism</cons> via cytochrome P4502D6 (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>) was higher in Black subjects than White subjects.</sentence>
<sentence>Ten Black and 10 White healthy male volunteers who were phenotyped <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> extensive <cons sem="G_MECHANISM">metabolizer</cons> phenotypes participated in this randomized, cross-over study in which <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> was used as a model <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> substrate.</sentence>
<sentence>In both study phases, subjects received oral rac-<cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> tartrate (<cons sem="G_NUMBER">200 mg</cons>); during one phase, subjects also took <cons lex="quinidine" sem="G_DRUG">quinidine</cons> sulfate (<cons sem="G_NUMBER">100 mg</cons>) daily beginning 3 days before the dose of <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons>.</sentence>
<sentence>Plasma samples were collected for 12 and 24 hr after the dose in the <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> and <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> plus <cons lex="quinidine" sem="G_DRUG">quinidine</cons> phases, respectively.</sentence>
<sentence><cons lex="metoprolol" sem="G_DRUG">Metoprolol</cons> enantiomer concentrations were determined by chiral HPLC with fluorescence detection.</sentence>
<sentence>S-<cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> areas under the concentration vs. time curves during the <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> phase were <cons sem="G_NUMBER">879 +/- 600 ng/ml*hr</cons> in White subjects vs. <cons sem="G_NUMBER">984 +/- 653 ng/ml*hr</cons> in Black subjects.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, S-metoprolol, DDI)">
<sentence>During <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated <cons sem="G_MECHANISM">metabolism</cons> with <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons>, <cons lex="metoprolol" sem="G_DRUG" type="substrate_1">S-metoprolol</cons> <cons sem="G_IVIVPARA">areas under the concentration vs. time curves</cons> were <cons sem="G_NUMBER">2515 +/- 749</cons> and <cons sem="G_NUMBER">2719 +/- 742</cons> in White and Black subjects, respectively.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, Metoprolol, DDI)">
<sentence><cons lex="metoprolol" sem="G_DRUG" type="substrate_3">Metoprolol</cons> <cons sem="G_IVIVPARA">elimination half-lives</cons> in both groups were approximately <cons sem = "G_CHANGE">doubled</cons> by <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, Metoprolol, DDI)">
<sentence>Mean <cons lex="metoprolol" sem="G_DRUG" type="substrate_1">S-metoprolol</cons>/<cons lex="metoprolol" sem="G_DRUG" type="substrate_2">R-metoprolol</cons> ratios were <cons sem="G_NUMBER">1.39</cons> in both racial groups during the <cons lex="metoprolol" sem="G_DRUG" type="substrate_3">metoprolol</cons> phase, and during the <cons lex="metoprolol" sem="G_DRUG" type="substrate_3">metoprolol</cons> plus <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> phase were <cons sem="G_NUMBER">0.89</cons> and <cons sem="G_NUMBER">1.03</cons> in White subjects and Black subjects, respectively (<cons sem="G_NUMBER">p &lt; 0.05</cons>, Blacks vs. Whites).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, Metoprolol, DDI)">
<sentence>The percentage of <cons lex="metoprolol" sem="G_DRUG" type="substrate_3">metoprolol</cons> <cons sem="G_MECHANISM">metabolism</cons> <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> was similar between Blacks and Whites (e.g., <cons sem="G_NUMBER">66 +/- 15%</cons> and <cons sem="G_NUMBER">64 +/- 25%</cons> of <cons lex="metoprolol" sem="G_DRUG" type="substrate_1">S-metoprolol</cons> apparent <cons sem="G_IVIVPARA">oral clearance</cons> in Blacks and Whites, respectively).</sentence>
</annotation>
<sentence>We conclude that there are <cons sem="G_NEGATIVEEFFECT">no</cons> differences between Black subjects and White subjects in <cons sem="G_MECHANISM">metabolism</cons> via <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
<sentence>There were also <cons sem="G_NEGATIVEEFFECT">no</cons> racial differences in the contribution of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> to overall <cons lex="metoprolol" sem="G_DRUG">metoprolol</cons> <cons sem="G_MECHANISM">metabolism</cons>.</sentence>
<sentence>The results of this study suggest that drugs are primarily <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> will <cons sem="G_NEGATIVEEFFECT">not</cons> exhibit racial differences in their disposition.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7995001</bibliomisc>
</articleinfo>
<title>
<sentence>Oral <cons lex="triazolam" sem="G_DRUG">triazolam</cons> is potentially hazardous to patients receiving systemic antimycotics <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> or <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="triazolam" sem="G_DRUG">Triazolam</cons> is <cons sem="G_MECHANISM">metabolized</cons> by <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> isozyme.</sentence>
<sentence><cons lex="ketoconazole" sem="G_DRUG">Ketoconazole</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> <cons sem = "G_CHANGE">may</cons> seriously interact with some of the substrates of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> (e.g., <cons lex="terfenadine" sem="G_DRUG">terfenadine</cons>); hence their possible interaction with <cons lex="triazolam" sem="G_DRUG">triazolam</cons> in humans is important to uncover.</sentence>
<sentence>In this double-blind, randomized, three-phase crossover study, the interaction between <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, and <cons lex="triazolam" sem="G_DRUG">triazolam</cons> was investigated.</sentence>
<sentence>Nine healthy young volunteers received either 400 mg <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons>, <cons sem="G_NUMBER">200 mg</cons> <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>, or matched placebo (control phase) orally once a day for 4 days.</sentence>
<sentence>On day 4, each ingested a single <cons sem="G_NUMBER">0.25 mg</cons> dose of <cons lex="triazolam" sem="G_DRUG">triazolam</cons>.</sentence>
<sentence><cons sem="G_IVIVPARA">Plasma concentrations</cons> of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> and antimycotics were determined, and pharmacodynamic effects were measured up to 17 hours.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, triazolam, DDI)(itraconazole, triazolam, DDI)">
<sentence>On average, <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> <cons sem="G_CHANGE">increased</cons> the <cons sem="G_IVIVPARA">area under the <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> concentration-time curve  [AUC(0-infinity)]</cons> <cons sem="G_NUMBER">22-fold</cons> and <cons sem="G_NUMBER">27-fold</cons> (<cons sem="G_NUMBER">p &lt; 0.001</cons>), the <cons sem="G_IVIVPARA">peak concentrations</cons> <cons sem="G_NUMBER">threefold (p &lt; 0.001)</cons>, and the <cons sem="G_IVIVPARA">elimination half-life</cons> <cons sem="G_NUMBER">sixfold</cons> and <cons sem="G_NUMBER">sevenfold</cons> (<cons sem="G_NUMBER">p &lt; 0.001</cons>), respectively.</sentence>
</annotation>
<sentence>In seven of the nine subjects, even the maximum concentration of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> in plasma was lower <cons sem="G_NEGATIVEEFFECT">without</cons> the antimycotics than were the 17-hour concentrations during the <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> and <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons> phases.</sentence>
<sentence>All pharmacodynamic effects (e.g., the Digit Symbol Substitution Test) revealed a <cons sem="G_CHANGE">significant</cons> difference between the antimycotic and placebo phases.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(ketoconazole, triazolam, DDI)(itraconazole, triazolam, DDI)">
<sentence>Both <cons lex="ketoconazole" sem="G_DRUG" type="inhibitor_1">ketoconazole</cons> and <cons lex="itraconazole" sem="G_DRUG" type="inhibitor_2">itraconazole</cons> seriously <cons sem="G_CHANGE">affect</cons> the pharmacokinetics of <cons lex="triazolam" sem="G_DRUG" type="substrate_1">triazolam</cons> and <cons sem="G_CHANGE">increase</cons> the intensity and duration of its effects.</sentence>
</annotation>
<sentence><cons sem="G_MECHANISM">Inhibition</cons> of <cons lex="cyp3a4" sem="G_CYP">CYP3A4</cons> during the absorption and elimination phases of <cons lex="triazolam" sem="G_DRUG">triazolam</cons> seems to explain the interaction observed.</sentence>
<sentence>Because of the potentially hazardous consequences of this interaction, <cons lex="triazolam" sem="G_DRUG">triazolam</cons> should be avoided if patients are using <cons lex="ketoconazole" sem="G_DRUG">ketoconazole</cons> or <cons lex="itraconazole" sem="G_DRUG">itraconazole</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:7693389</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> phenotype determines the metabolic conversion of <cons lex="hydrocodone" sem="G_DRUG">hydrocodone</cons> to <cons lex="hydromorphone" sem="G_DRUG">hydromorphone</cons>.</sentence>
</title>
<abstract>
<sentence>The contribution of cytochrome P450 <cons lex="2d6" sem="G_CYP">2D6 (CYP2D6)</cons> to the <cons sem="G_MECHANISM">formation</cons> of hydrocodone's active metabolite, <cons lex="hydromorphone" sem="G_DRUG">hydromorphone</cons>, was examined in vitro and in vivo.</sentence>
<sentence>Human liver microsomes prepared from an individual homozygous for the D6-B mutation of the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> gene <cons sem="G_MECHANISM">catalyzed</cons> this reaction at a <cons sem = "G_CHANGE">negligible</cons> rate.</sentence>
<sentence>Urinary metabolic ratios of hydrocodone/hydromorphone were highly <cons sem="G_MECHANISM">correlated</cons> with O-demethylation ratios for <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>, an established marker drug of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity (<cons sem="G_NUMBER">rs = 0.85; n = 18</cons>).</sentence>
<sentence>The kinetics of <cons lex="hydrocodone" sem="G_DRUG">hydrocodone</cons> after a single oral dose and its partial metabolic <cons sem="G_IVIVPARA">clearance</cons> to <cons lex="hydromorphone" sem="G_DRUG">hydromorphone</cons> were investigated in five extensive <cons sem="G_MECHANISM">metabolizers</cons> of <cons lex="dextromethorphan" sem="G_DRUG">dextromethorphan</cons>, six poor <cons sem="G_MECHANISM">metabolizers</cons>, and four extensive <cons sem="G_MECHANISM">metabolizers</cons> after pretreatment with <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, a selective <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> activity.</sentence>
<sentence>The mean values for partial metabolic <cons sem="G_IVIVPARA">clearance</cons> by O-demethylation in the three groups were <cons sem="G_NUMBER">28.1 +/- 10.3, 3.4 +/- 2.4, and 5.0 +/- 3.6 ml/hr/kg</cons>, respectively.</sentence>
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> statistically <cons sem="G_CHANGE">significant</cons> phenotypic differences in physiologic measures were observed.</sentence>
<sentence>However, over the first hour after dosing, the extensive <cons sem="G_MECHANISM">metabolizers</cons> reported more "good opiate effects" and fewer "bad opiate effects" than poor <cons sem="G_MECHANISM">metabolizers</cons> and extensive <cons sem="G_MECHANISM">metabolizers</cons> in whom <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> was <cons sem="G_MECHANISM">inhibited</cons> by <cons lex="quinidine" sem="G_DRUG">quinidine</cons>.</sentence>
<sentence>These data establish the importance of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> in the <cons sem="G_MECHANISM">formation</cons> of <cons lex="hydromorphone" sem="G_DRUG">hydromorphone</cons> from <cons lex="hydrocodone" sem="G_DRUG">hydrocodone</cons> and suggest that the activity of this enzyme <cons sem = "G_CHANGE">may</cons> limit the abuse liability of <cons lex="hydrocodone" sem="G_DRUG">hydrocodone</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8513656</bibliomisc>
</articleinfo>
<title>
<sentence>Single-dose <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons> <cons sem="G_MECHANISM">inhibition</cons> of <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> <cons sem="G_MECHANISM">metabolism</cons>: a clinical probe for P450 <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
</title>
<abstract>
<sentence><cons lex="disulfiram" sem="G_DRUG">Disulfiram</cons> and its <cons sem="G_CHANGE">reduced</cons> metabolite <cons lex="diethyldithiocarbamate" sem="G_DRUG">diethyldithiocarbamate</cons> have been identified previously as selective mechanism-based <cons sem="G_MECHANISM">inhibitors</cons> of human liver microsomal cytochrome P450 <cons lex="2e1" sem="G_CYP">2E1</cons> in vitro.</sentence>
<sentence>In animals, a single oral dose of <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons> has been shown to produce a rapid and selective <cons sem="G_MECHANISM">inactivation</cons> of hepatic P450 <cons lex="2e1" sem="G_CYP">2E1</cons> content and catalytic activity in vivo.</sentence>
<sentence>This investigation explored the efficacy of single dose <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons> as an <cons sem="G_MECHANISM">inhibitor</cons> of human P450 <cons lex="2e1" sem="G_CYP">2E1</cons> activity in vivo.</sentence>
<sentence>Clinical P450 <cons lex="2e1" sem="G_CYP">2E1</cons> activity was assessed by the 6-hydroxylation of <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons>, a metabolic pathway <cons sem="G_MECHANISM">catalyzed</cons> selectively by P450 <cons lex="2e1" sem="G_CYP">2E1</cons>.</sentence>
<sentence>Six healthy volunteers received <cons sem="G_NUMBER">750 mg</cons> oral <cons lex="chlorzoxazone" sem="G_DRUG">chlorzoxazone</cons> on two occasions in a crossover design, 10 hours after <cons sem="G_NUMBER">500 mg</cons> oral <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons>, or after <cons sem="G_NEGATIVEEFFECT">no</cons> pretreatment (control subjects).</sentence>
<annotation sem="INVIVOCDDIS" ddi="(Disulfiram, chlorzoxazone, DDI)">
<sentence><cons lex="disulfiram" sem="G_DRUG" type="inhibitor_1">Disulfiram</cons> pretreatment <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_CHANGE">decreased</cons> <cons lex="chlorzoxazone" sem="G_DRUG" type="substrate_1">chlorzoxazone</cons> <cons sem="G_IVIVPARA">elimination clearance</cons> to <cons sem="G_NUMBER">15%</cons> of control values (<cons sem="G_NUMBER">from 3.28 +/- 1.40 to 0.49 +/- 0.07 ml/kg/min, p &lt; 0.005</cons>), prolonged the <cons sem="G_IVIVPARA">elimination half-life</cons> (<cons sem="G_NUMBER">from 0.92 +/- 0.32 to 5.1 +/- 0.9 hours, p &lt; 0.001</cons>), and caused a <cons sem="G_NUMBER">twofold</cons> <cons sem="G_CHANGE">increase</cons> in <cons sem="G_IVIVPARA">peak plasma <cons lex="chlorzoxazone" sem="G_DRUG" type="substrate_1">chlorzoxazone</cons> concentrations</cons> (<cons sem="G_NUMBER">20.6 +/- 9.9 versus 38.7 +/- 10.3 micrograms/ml, p &lt; 0.001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(Disulfiram, chlorzoxazone, DDI)">
<sentence><cons lex="disulfiram" sem="G_DRUG" type="inhibitor_1">Disulfiram</cons> also profoundly <cons sem="G_CHANGE">decreased</cons> the <cons sem="G_MECHANISM">formation</cons> <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="chlorzoxazone" sem="G_DRUG" type="M_1">6-hydroxychlorzoxazone</cons>, from <cons sem="G_NUMBER">2.30 +/- 0.93 to 0.17 +/- 0.05 ml/kg/min (p &lt; 0.005)</cons>.</sentence>
</annotation>
<sentence>These findings show that a single dose of <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons> <cons sem="G_CHANGE">significantly</cons> diminishes the activity of human P450 <cons lex="2e1" sem="G_CYP">2E1</cons> in vivo.</sentence>
<sentence>The efficacy of single-dose <cons lex="disulfiram" sem="G_DRUG">disulfiram</cons> as an <cons sem="G_MECHANISM">inhibitor</cons> of human P450 <cons lex="2e1" sem="G_CYP">2E1</cons> suggests that this modality for manipulating clinical P450 <cons lex="2e1" sem="G_CYP">2E1</cons> activity <cons sem = "G_CHANGE">may</cons> provide a useful probe for delineating P450 <cons lex="2e1" sem="G_CYP">2E1</cons> participation in human drug biotransformation or for the treatment of poisoning by P450 <cons lex="2e1" sem="G_CYP">2E1</cons>-<cons sem="G_MECHANISM">activated</cons> toxins.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8333005</bibliomisc>
</articleinfo>
<title>
<sentence>Effect of <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> on the pharmacokinetics of <cons lex="imipramine" sem="G_DRUG">imipramine</cons> and <cons lex="desipramine" sem="G_DRUG">desipramine</cons> in healthy subjects.</sentence>
</title>
<abstract>
<sentence>The effect of the selective serotonin reuptake <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="fluvoxamine" sem="G_DRUG">fluvoxamine</cons> (<cons sem="G_NUMBER">100 mg/day</cons> for 10 consecutive days) on the kinetics of a single oral dose of <cons lex="imipramine" sem="G_DRUG">imipramine</cons> (<cons sem="G_NUMBER">50 mg</cons>) and <cons lex="desipramine" sem="G_DRUG">desipramine</cons> (<cons sem="G_NUMBER">100 mg</cons>) was investigated in 12 healthy subjects.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, imipramine, DDI)">
<sentence>Compared with a control session, treatment with <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> caused a <cons sem="G_CHANGE">significant</cons> prolongation of <cons lex="imipramine" sem="G_DRUG" type="substrate_1">imipramine</cons> <cons sem="G_IVIVPARA">half-life</cons> (from <cons sem="G_NUMBER">22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p &lt; 0.01</cons>) and a <cons sem = "G_CHANGE">marked</cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons></cons> in <cons lex="imipramine" sem="G_DRUG" type="substrate_1">imipramine</cons> apparent <cons sem="G_IVIVPARA">oral clearance</cons> (from <cons sem="G_NUMBER">1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p &lt; 0.0001</cons>).</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, desipramine, DDI)">
<sentence><cons sem="G_NEGATIVEEFFECT">No</cons> <cons sem="G_CHANGE">significant</cons> <cons sem ="G_CHANGE">changes</cons> in <cons lex="desipramine" sem="G_DRUG" type="substrate_2">desipramine</cons> kinetics were observed during <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> treatment.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(fluvoxamine, imipramine, DDI)(fluvoxamine, desipramine, DDI)">
<sentence>These findings indicate that, at the dosage tested, <cons lex="fluvoxamine" sem="G_DRUG" type="inhibitor_1">fluvoxamine</cons> <cons sem = "G_CHANGE">markedly</cons> <cons sem="G_MECHANISM">inhibits</cons> the demethylation of <cons lex="imipramine" sem="G_DRUG" type="substrate_1">imipramine</cons> <cons sem="G_NEGATIVEEFFECT">without</cons> affecting <cons sem="G_CHANGE">significantly</cons> the <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>-mediated hydroxylation of <cons lex="desipramine" sem="G_DRUG">desipramine</cons>.</sentence>
</annotation>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:8451775</bibliomisc>
</articleinfo>
<title>
<sentence><cons sem="G_DRUG">Citalopram</cons>: interaction studies with <cons sem="G_DRUG">levomepromazine</cons>, <cons lex="imipramine" sem="G_DRUG">imipramine</cons>, and <cons lex="lithium" sem="G_DRUG">lithium</cons>.</sentence>
</title>
<abstract>
<sentence>The pharmacokinetic interactions between the selective serotonin reuptake <cons sem="G_MECHANISM">inhibitor</cons> <cons lex="citalopram" sem="G_DRUG">citalopram</cons>, given as an oral dose of 40 mg/day for 10 days, and (1) <cons sem="G_DRUG">levomepromazine</cons> (<cons sem="G_NUMBER">50 mg</cons> single oral dose), (2) <cons lex="imipramine" sem="G_DRUG">imipramine</cons> (<cons sem="G_NUMBER">100 mg</cons> single oral dose), and (3) <cons lex="lithium" sem="G_DRUG">lithium</cons> (<cons sem="G_NUMBER">30 mmol/day</cons> orally for 5 days) were examined in three panels each of 8 healthy young male volunteers (age 20-31).</sentence>
<sentence>All volunteers were classified as extensive <cons sem="G_MECHANISM">metabolizers</cons> of sparteine and <cons lex="mephenytoin" sem="G_DRUG">mephenytoin</cons>.</sentence>
<sentence>Each subject completed three study phases--one with <cons lex="citalopram" sem="G_DRUG">citalopram</cons> alone, one with one of the three other drugs, alone, and one with <cons lex="citalopram" sem="G_DRUG">citalopram</cons> combined with the corresponding other drug.</sentence>
<sentence>For <cons lex="citalopram" sem="G_DRUG">citalopram</cons> and its metabolites, a non-enantioselective analytical method (high-performance liquid chromatography) was used.</sentence>
<sentence>Only two statistically <cons sem="G_CHANGE">significant</cons> interactions were indicated.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(levomepromazine, citalopram, ADDI)">
<sentence>First, <cons sem="G_DRUG" type="inducer_1">levomepromazine</cons> caused a <cons sem="G_NUMBER">10-20%</cons> <cons sem="G_CHANGE">increase</cons> from the initial steady-state levels of the primary <cons lex="citalopram" sem="G_DRUG" type="substrate_1">citalopram</cons> metabolite, <cons lex="citalopram" sem="G_DRUG" type="M_1">desmethylcitalopram</cons>.</sentence>
</annotation>
<annotation sem="INVIVOCDDIS" ddi="(desipramine, citalopram, DDI)">
<sentence>Second, <cons lex="citalopram" sem="G_DRUG" type="inhibitor_1">citalopram</cons> caused approximately <cons sem="G_NUMBER">50%</cons> <cons sem="G_CHANGE">increase</cons> in the single-dose <cons sem="G_IVIVPARA">area under the serum concentration/time curve</cons> of <cons lex="desipramine" sem="G_DRUG" type="substrate_2">desipramine</cons> (primary metabolite or <cons lex="imipramine" sem="G_DRUG" type="substrate_3">imipramine</cons>) and a corresponding <cons sem ="G_CHANGE">reduction</cons> in the level of the subsequently <cons sem="G_MECHANISM">formed</cons> metabolite <cons lex="desipramine" sem="G_DRUG" type="M_2">2-hydroxydesipramine</cons>.</sentence>
</annotation>
<sentence>These findings are in agreement with the recent observations that (1) the demethylation of desmethylcitalopram (to didesmethylcytalopram) is partly mediated via the sparteine/debrisoquine oxygenase (<cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>) and that <cons sem="G_DRUG">levomepromazine</cons> is a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>, and (2) that desmethylcitalopram has a somewhat stronger affinity for <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons> than <cons lex="desipramine" sem="G_DRUG">desipramine</cons>, and therefore <cons sem = "G_CHANGE">may</cons> <cons sem="G_MECHANISM">inhibit</cons> the hydroxylation of <cons lex="desipramine" sem="G_DRUG">desipramine</cons>, which is also a substrate of <cons lex="cyp2d6" sem="G_CYP">CYP2D6</cons>.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:1610865</bibliomisc>
</articleinfo>
<title>
<sentence><cons lex="amiodarone" sem="G_DRUG">Amiodarone</cons>-<cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons> interaction in a heart transplant patient.</sentence>
</title>
<abstract>
<annotation sem="INVIVOCDDIS" ddi="(amiodarone, cyclosporine, DDI)">
<sentence>We report the case of a heart transplant patient whose <cons lex="cyclosporine" sem="G_DRUG" type="substrate_1">cyclosporine</cons> <cons sem="G_IVIVPARA">clearance</cons> <cons sem="G_CHANGE"><cons sem="G_CHANGE">decreased</cons></cons> by more than <cons sem="G_NUMBER">50%</cons> after the institution of <cons lex="amiodarone" sem="G_DRUG" type="inhibitor_1">amiodarone</cons> therapy.</sentence>
</annotation>
<sentence>This interaction necessitated a <cons sem="G_CHANGE">significant</cons> dosage <cons sem ="G_CHANGE">reduction</cons> to maintain <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons> concentrations within the therapeutic range.</sentence>
<sentence>To investigate the mechanism of the interaction, a <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons>-lipoprotein-binding determination was performed.</sentence>
<sentence>The results suggest that drug displacement from competitive lipoprotein-binding sites is <cons sem="G_NEGATIVEEFFECT">not</cons> responsible for the alterations in <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons> pharmacokinetics.</sentence>
<sentence><cons sem="G_IVIVPARA">clearance</cons> data suggests, however, that the primary mechanism for the interaction is the <cons sem="G_MECHANISM">inhibition</cons> <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons> <cons sem="G_MECHANISM">metabolism</cons> by the cytochrome P-450 system.</sentence>
<sentence>This report emphasizes the importance of reevaluating therapeutic drug regimens when new agents are added to prevent complications caused by drug interactions.</sentence>
<sentence>If <cons lex="amiodarone" sem="G_DRUG">amiodarone</cons> and <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons> must be used concomitantly, <cons lex="cyclosporine" sem="G_DRUG">cyclosporine</cons> levels must be monitored frequently, in anticipation of this interaction.</sentence>
</abstract>
</article>
<article>
<articleinfo>
<bibliomisc>MEDLINE:1576047</bibliomisc>
</articleinfo>
<title>
<sentence>Stereoselective genetically-determined interaction between chronic <cons lex="flecainide" sem="G_DRUG">flecainide</cons> and <cons lex="quinidine" sem="G_DRUG">quinidine</cons> in patients with arrhythmias.</sentence>
</title>
<abstract>
<sentence>1.</sentence>
<sentence>Recent reports have indicated a role for the <cons sem="G_CYP">P450IID6</cons> polymorphism in the stereoselective disposition of single doses of the antiarrhythmic <cons lex="flecainide" sem="G_DRUG">flecainide</cons>.</sentence>
<sentence>2.</sentence>
<sentence>In this study, we evaluated the effects of adding low dose <cons lex="quinidine" sem="G_DRUG">quinidine</cons>, a potent <cons sem="G_MECHANISM">inhibitor</cons> of <cons sem="G_CYP">P450IID6</cons>, to chronic <cons lex="flecainide" sem="G_DRUG">flecainide</cons> therapy in patients with arrhythmias.</sentence>
<sentence>3.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, R-(-)-flecainide, ADDI)">
<sentence>In five extensive <cons sem="G_MECHANISM">metabolizer</cons> patients, <cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">quinidine</cons> <cons sem="G_CHANGE">significantly</cons> <cons sem="G_CHANGE">reduced</cons> the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="flecainide" sem="G_DRUG" type="substrate_1">R-(-)-flecainide</cons>, from <cons sem="G_NUMBER">395 +/- 121 (s.d.) to 335 +/- 88 ml min-1</cons>.</sentence>
</annotation>
<sentence>This <cons sem = "G_CHANGE">change</cons> was attributable to a <cons sem="G_CHANGE"><cons sem="G_CHANGE">decrease</cons></cons> in metabolic <cons sem="G_IVIVPARA">clearance</cons>, was accompanied by <cons sem="G_CHANGE">decreased</cons> <cons sem="G_MECHANISM">formation</cons> of the two major metabolites of <cons lex="flecainide" sem="G_DRUG">flecainide</cons> and was <cons sem="G_NEGATIVEEFFECT">not</cons> observed in a poor <cons sem="G_MECHANISM">metabolizer</cons> subject.</sentence>
<sentence>The <cons sem="G_IVIVPARA">renal clearance</cons> of <cons lex="flecainide" sem="G_DRUG">R-(-)-flecainide</cons> rose <cons sem="G_CHANGE">significantly</cons>.</sentence>
<sentence>4.</sentence>
<annotation sem="INVIVOCDDIS" ddi="(quinidine, S-(-)-flecainide, NDDI)">
<sentence><cons lex="quinidine" sem="G_DRUG" type="inhibitor_1">Quinidine</cons> did <cons sem="G_NEGATIVEEFFECT">not</cons> alter the <cons sem="G_IVIVPARA">clearance</cons> of <cons lex="flecainide" sem="G_DRUG" type="substrate_2">S-(+)-flecainide</cons>.</sentence>
</annotation>
<sentence>5.</sentence>
<sentence>The pharmacologic effects of <cons lex="flecainide" sem="G_DRUG">flecainide</cons> therapy (QRS widening, % arrhythmia <cons sem = "G_MECHANISM">suppression</cons>) were <cons sem="G_CHANGE">slightly</cons>, but <cons sem="G_NEGATIVEEFFECT">not</cons> <cons sem="G_CHANGE">significantly</cons>, <cons sem="G_CHANGE">increased</cons>.</sentence>
<sentence>6.</sentence>
<sentence>In extensive <cons sem="G_MECHANISM">metabolizer</cons> patients receiving chronic <cons lex="flecainide" sem="G_DRUG">flecainide</cons>, <cons sem="G_CHANGE">increased</cons> <cons sem="G_IVIVPARA">plasma concentration</cons> will develop if <cons sem="G_CYP">P450IID6</cons> is <cons sem="G_MECHANISM">inhibited</cons>.</sentence>
</abstract>
</article>
</set>
